Developing a bioinformatics framework for proteogenomics by Chapman, Brett
 i 




This thesis was submitted in fulfilment of the requirements for the degree of Doctor of 
Philosophy of Murdoch University 
 
Presented by: 
Brett Steven Chapman 
BSc. (Hons), GradDip 
 
School of Engineering and Information Technology 
Murdoch University 











I declare that this thesis is my own account of my research and it contains as its main 



















In the last 15 years, since the human genome was first sequenced, genome sequencing 
and annotation have continued to improve. However, genome annotation has not kept 
up with the accelerating rate of genome sequencing and as a result there is now a large 
backlog of genomic data waiting to be interpreted both quickly and accurately. Through 
advances in proteomics a new field has emerged to help improve genome annotation, 
termed proteogenomics, which uses peptide mass spectrometry data, enabling the 
discovery of novel protein coding genes, as well as the refinement and validation of 
known and putative protein-coding genes. 
The annotation of genomes relies heavily on ab initio gene prediction programs 
and/or mapping of a range of RNA transcripts. Although this method provides insights 
into the gene content of genomes it is unable to distinguish protein-coding genes from 
putative non-coding RNA genes. This problem is further confounded by the fact that 
only 5% of the public protein sequence repository at UniProt/SwissProt has been 
curated and derived from actual protein evidence. 
This thesis contends that it is critically important to incorporate proteomics data 
into genome annotation pipelines to provide experimental protein-coding evidence. 
Although there have been major improvements in proteogenomics over the last decade 
there are still numerous challenges to overcome. These key challenges include the loss 
of sensitivity when using inflated search spaces of putative sequences, how best to 
interpret novel identifications and how best to control for false discoveries. 
This thesis addresses the existing gap between the use of genomic and proteomic 
sources for accurate genome annotation by applying a proteogenomics approach with a 
customised methodology. This new approach was applied within four case studies: a 
prokaryote bacterium; a monocotyledonous wheat plant; a dicotyledonous grape plant; 
 iv 
and human. The key contributions of this thesis are: a new methodology for 
proteogenomics analysis; 145 suggested gene refinements in Bradyrhizobium 
diazoefficiens (nitrogen-fixing bacteria); 55 new gene predictions (57 protein isoforms) 
in Vitis vinifera (grape); 49 new gene predictions (52 protein isoforms) in Homo sapiens 
(human); and 67 new gene predictions (70 protein isoforms) in Triticum aestivum 
(bread wheat). Lastly, a number of possible improvements for the studies conducted in 
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This PhD thesis consists of chapters that have been accepted for publication (Chapter 4) 
and also in preparation for publication (Chapters 5 to 7), with similar or the same 
applied methods. To reduce repetition between chapters, the core methodology applied 
throughout all chapters is compiled in Chapter 3 and as a result, each of the final 
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Proteogenomics is a multi-omics approach for genome annotation, integrating 
proteomics and genomics, as well as evidence from transcriptomics. Over the last 
decade proteogenomics has become a popular field of research, and is becoming a key 
player in global genome annotation efforts at an accelerating rate. Advances in 
proteogenomics have been driven by the demand to meet the ever-advancing rate of 
genome sequencing technologies, as many diverse species from the tree of life are 
sequenced [1, 2]. Proteogenomics, and other related approaches such as RNA-seq 
technology, are now increasingly being employed in genome annotation efforts. As a 
result, the impact of the “non-model” organism will be significantly reduced or non-
existent in the not too distant future [3], as every genomics study begins to meet the 
same level of annotation as that of model organisms. 
Genome annotation often uses public curated protein sequence repositories such 
as UniProt/SwissProt, however only 5% of the entries are derived from actual protein 
evidence, while the remaining 95% have been inferred from genomics. There are a 
number of challenges that need to be addressed in order to enable proteogenomics to 
resolve such an anomaly and to provide genome annotation with direct protein-coding 
evidence. 
This thesis provides an in-depth review of the main challenges in 
proteogenomics and through the course of this thesis a new methodology evolved to 
improve the peptide identification rate from MS-experiments on large genome and 
transcriptome sequence data. The viability of the new methodology was demonstrated 
through four case studies: Bradyrhizobium diazoefficiens (nitrogen-fixing bacteria), 
Vitis vinifera (grape), Homo sapiens (human) and Triticum aestivum (bread wheat). 
Lastly, from insights gleaned from this thesis, there were considerations for how 
proteogenomics could be conducted in the future, such as using technologies to 
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supplement the database with sequence variants to account for sequence variations 
between the MS/MS spectra and target genome, considerations with the use of top-
down proteomics and multiplexed data-independent acquisition (DIA) to improve depth 
and breadth of coverage, and spectral archives to improve specificity, sensitivity and 
enable a comprehensive screening of annotation events. 
In Chapter 2, an overview of molecular biology, genomics, MS-based 
proteomics, and proteogenomics and bioinformatics workflow environments is 
presented. Within Section 2.1, the basics of molecular biology are covered in detail; 
Section 2.2 encompasses genomics, including the current methods employed in genome 
sequencing and genome annotation; Section 2.3 details MS-based proteomics, which 
includes technologies and tools involved in bottom-up proteomics, top-down 
proteomics, methods of MS/MS spectral interpretation, MS/MS spectral pre-processing 
procedures, database searching and statistical analyses involved in MS/MS spectral and 
peptide identifications, as well as outlining the latest emerging proteomics technologies; 
Section 2.4 provides an in-depth coverage of proteogenomics, which includes current 
trends in methodology, statistical analysis, the level of annotation which can be applied 
in proteogenomics, and the current tools which are available; and lastly in Section 2.5, 
bioinformatics workflow environments are discussed in terms of how they could impact 
analysis across a wide variety of -omics platforms, including proteogenomics, and 
include a range of the current popular workflow environments. 
In Chapter 3, the methodologies employed within the thesis are described in 
detail, which includes pre-processing of datasets, conversion of data formats, RNA-seq 
alignments, database preparation, database searching, optimisation steps, the 
proteogenomics workflow and parameters used, different strategies applied in false 
discovery rate (FDR) filtering, screening of events, and gene prediction. 
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 In Chapter 4, the proteogenomics analysis of Bradyrhizobium diazoefficiens, a 
nitrogen-fixing bacterium, was conducted using the current NCBI genome annotation 
and MS/MS spectra from the studies conducted by Delmotte et al. [4] and Koch et al. 
[5]. A total of 259 novel peptides were identified, contributing to 155 novel annotation 
events consisting of 9 frame shifts, 22 exon boundaries, 19 gene boundaries, 45 reverse 
strands, and 60 novel genes, annotating a total of 145 genes. A two-pass search 
approach to improve on sensitivity of the analysis was also investigated and a possible 
sequencing error was identified. This analysis contributed to a publication in the journal 
Proteomics [6]. 
 In Chapter 5, the proteogenomics analysis of Vitis vinifera (grape) was 
conducted, improving on the current 12Xv2.1 genome annotation from the study 
conducted by Vitulo et al. [7] representing the variety Pinot Noir, an extension of the 
dissertation author’s previous proteogenomics study [8]. A number of datasets were 
utilised, including a large MS/MS spectral dataset from [9], derived from Cabernet 
Sauvignon shoot tips and berry skins from the study in [8], while RNA-seq data was 
obtained from a variety of tissues [10], as well as a large, currently unpublished RNA-
seq dataset from the berry skins of a range of grape varieties. A total of 133 novel 
peptides were identified, contributing to 341 novel annotation events, consisting of 5 
frame shifts, 37 translated UTRs, 16 exon boundaries, 1 novel splice, 9 novel exons, 
160 gene boundaries, 112 reverse strands and 1 novel gene event, annotating a total of 
216 genes and 326 protein isoforms. These annotations led to a total of 110 novel 
peptides which contributed to validate 57 Augustus predicted proteins. In addition, a 
possible over-assembly of the genome and a reduction in sensitivity of analysis 
compared to smaller genomes was identified, indicating a need to further refine the 
method of FDR filtering. 
 
 4 
 In Chapter 6, the proteogenomics analysis of Homo sapiens (Human) was 
conducted, improving on the GENCODE v19 annotation. A large MS/MS spectral 
dataset from the ENCODE study in [11], derived from lymphoblastoid cell line 
GM12878, and RNA-seq data obtained from NCBI GEO accession GSE30567 were 
utilised. A total of 77 novel peptides were identified, contributing to 617 novel 
annotation events, consisting of 7 frame shifts, 4 translated UTRs, 27 exon boundaries, 
23 novel exons, 289 gene boundaries, 262 reverse strands, and 5 novel gene events, 
annotating a total of 147 genes and 609 protein isoforms. These annotations led to a 
total of 66 novel peptides which supported 52 Augustus predicted proteins. In addition, 
a two-pass search approach with improved two-stage FDR strategy was established, 
which was able to identify 35 more novel peptides compared to previous established 
methods, and identified 15,020 more peptides than the previous ENCODE study [11]. 
 In Chapter 7, the proteogenomics analysis of Triticum aestivum (bread wheat) 
was conducted, improving on the Wheat MIPS v2.2 genome annotation and also 
extending the proteogenomics analysis conducted by the dissertation author within the 
study by Mayer and colleagues [12]. A range of MS/MS spectra derived from different 
tissues and protease digests were derived from Wheat flour from cultivar Butte 86 in the 
study from Dupont and colleagues [13], digested with trypsin, chymotrypsin and 
thermolysin and meiotically developing anthers from a cross between rye (Secale 
cereale cultivar Petkus) and wheat (Triticum aestivum cultivar Chinese Spring), 
digested with trypsin and AspN [14]. RNA-seq data were also utilised, derived from 
Chinese Spring from [12, 15], including a range of other cultivars downloaded from the 
Sequence Read Archive (SRA). A total of 290 novel peptides were identified, 
contributing to 189 novel annotation events, consisting of 46 frame shifts, 9 translated 
UTRs, 17 exon boundaries, 39 novel exons, 17 gene boundaries, 24 reverse strands, and 
37 novel gene events, annotating a total of 96 genes and 189 protein isoforms. These 
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annotations identified a total of 180 novel peptides which validated 70 Augustus 
predicted proteins. In addition, a two-pass search approach with improved two-stage 
FDR strategy was also applied, reducing the impact of the inflated search space. Based 
on the methodology applied, and comparing the same dataset, there was an ~8x 
improvement in sensitivity compared to the study reported in [12]. The benefits of 
merging proteogenomics results derived from multiple protease digests was also 
highlighted, as well as the negative impact and resulting difficulties that the highly 
fragmented wheat genome had on the accuracy of proteogenomics analysis. 
 In Chapter 8, the general conclusions outline the findings, caveats and 
conclusions drawn from the case studies, and provide suggestions to revisit some of 
these case studies in the future with more datasets and new methodologies, as well as 
provide suggestions for improvements and future directions that proteogenomics will 
likely take. These new methodologies and suggestions take the form of: 1) improving 
the accuracy of defining annotation events; 2) further refining the search space; 3) the 
addition of multiple other types of annotation events; 4) the use of variant information 
in splice graphs; 5) accounting for missing genomic regions in highly fragmented 
genomes using homologous sequences; 6) leveraging N-terminomics to help define 
events and confidently identify translation initiation start (TIS) sites; 7) ways to more 
accurately discriminate peptides as known and novel; 8) ways to improve the sensitivity 
of event identification with little or no impact to the false positive rate; 9) ways to 
improve the functionality of the proteogenomics workflow; 10) implement new 
technologies such as top-down proteomics and multiplexed data-independent 
acquisition (DIA) to improve depth and breadth of coverage; and finally 11) the use of 
highly specific MS/MS search tools such as spectral library search tools or spectral 
archives to bring proteogenomics into the domain of spectrum-spectrum matching, to 
vastly improve specificity and discrimination between true and false positives. 
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2 LITERATURE REVIEW 
2.1 MOLECULAR BIOLOGY: A PRIMER 
All organisms have a genome, which contains information to construct the 
building blocks of an organism. The genome itself is made up of deoxy-ribose nucleic 
acid (DNA) sequences, which is comprised of Adenine (A), Thyamine (T), Cytosine 
(C), and Guanine (G) nucleotides. Shorter stretches of sequences contained within are 
called genes and are categorized as protein coding and non-protein-coding, which lead 
to the construction of proteins and functional Ribonucleic acid (RNA) molecules, 
respectively. 
The general model of protein production is the same for both eukaryotic and 
prokaryotic organisms, but the structure and organization of genes are quite different. 
Firstly, the genic region of DNA is transcribed or copied into messenger RNA (mRNA), 
also called a transcript, as it is ‘transcribed’ from the gene, and then each transcript is 
‘translated’ by ribosomes into proteins, the functional building blocks of an organism. 
Each gene is also in proximity to a regulatory region, termed ‘enhancer’, ‘promoter’, 
and ‘repressor’ regions, which contain sequences responsible for the regulation of 
transcription of the gene and by extension regulation of the expression of proteins. This 
standard model of molecular biology is also referred to as the “central dogma of 




Figure 2.1 Central dogma of molecular biology 
Genes are transcribed into pre-mRNA, processed by splicesomes into a variety of mature mRNA, which 
are then transported to the cytoplasm where the transcripts are translated into polypeptides, later forming 
into complex protein structures (image courtesy of the Online Computational Biology Textbook at 
PBWorks (http://compbio.pbworks.com/f/central_dogma.jpg)). 
A more detailed examination of the processes highlighted in Figure 2.1, reveals 
a web of complex interactions involving RNA transcription and protein translation. 
These processes differ significantly between eukaryotes and prokaryotes. The protein-
coding genes of eukaryotes are transcribed to a primary transcript or precursor 
messenger RNA (pre-mRNA), which takes place in the nucleus of the cell and is 
produced by an enzyme called RNA polymerase, which synthesizes an RNA strand in a 
5’ to 3’ direction complementary to the DNA strand. The pre-mRNA then has its 5’ end 
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capped with 7-methylguanosine by the enzyme guanylyltransferase which prevents 
degradation during translation, regulates exportation from the nucleus, promotes 
translation and 5’ proximal intron excision [18, 19]. Multiple adenosine 
monophosphates are then added to its 3’ end (poly(A) tail), through a process called 
polyadenylation, catalysed by polyadenylate polymerase. The addition of a poly(A) tail 
to mRNA, occurs in both eukaryotes and prokaryotes, and assists with a number of 
functions, which include transportation from the nucleus into the cytoplasm [20], 
translation [21], stability [22, 23], and conversely, its degradation [24]. 
The resulting polyadenylated RNA strand or premature mRNA consists of long 
stretches of both exons and introns and in eukaryotes the exons are spliced out by an 
enzyme called a spliceosome, which cuts out the introns at specific donor sites at the 5’ 
end of the transcript and at the acceptor site of the 3’ end of the transcript. Donor and 
acceptor sites are commonly of the GU-AG (donor-acceptor) variety, although more 
rarer versions do exist [25]. 
The resulting exons are then reassembled into a variety of different mature 
mRNAs containing one or many exons and in some rare cases introns are retained. The 
final structure of mRNA contains a 5’ un-translated region (UTR) upstream and a 3’ 
untranslated region downstream, flanking a region called an open reading frame (ORF). 
This entire process from precursor mRNA to the wide variety of mature mRNAs, is 
called alternative splicing (AS) [26, 27]. The mature mRNAs are then transported from 
the nucleus into the cytoplasm, in which their ORFs are translated into the final protein 
products. This step is accomplished by the ribosomes, composed of protein and RNA, 
which reads the ORF, three nucleotides at a time, referred to as a triplet codon, and 
translates the codon into an amino acid using different transfer RNAs (tRNAs) 
containing different bound amino acids. The tRNAs bind to three complementary bases 
or the anticodon as they pass through the ribosome, at which point the amino acids 
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ligate, forming a growing polypeptide chain which when complete folds into its 
functional three-dimensional structure and final protein product (Figure 2.1). The 
resulting functional proteins, which originate from the same gene, but are translated 
from different spliced mRNAs are known as protein isoforms, which can differ 
significantly in their sequence structure and biological functions [26]. In the case of 
non-protein coding RNA genes, the protein translations are skipped, and they are simply 
transcribed to RNA molecules. These non-protein-coding RNA molecules have been 
found to outnumber the protein-coding variety by a significant amount in vertebrate 
genomes [28] and are involved in regulatory processes, such as tRNAs important in the 
synthesis of proteins mentioned above and in higher eukaryotes micro RNAs 
(miRNAs), which are involved in the regulation of gene expression through the 
suppression of mRNA translation [29]. The distinction between protein-coding and non-
protein-coding RNA was further explained by the recently completed ENCODE human 
genome project [30], which found that 80% of the human genome which was previously 
classified as “junk DNA”, actually plays a functional role [31]. However, the exact 
proportion, which is functional, is highly debatable and would require further 
investigative analysis. 
In complex organisms, such as humans, AS is clearly the source of such 
complexity and a dominant factor in regulation and function, as well as a source of 
protein diversity and organism complexity in higher eukaryotes [26, 32, 33]. The role 
that AS plays in protein diversity and complexity is illustrated when comparing the 
relatively few genes discovered in the human genome (~23,000 genes), where there are 
approximately 6 or more protein coding transcripts expressed per gene [34-36], to the 
similar number of genes in a simpler organism such as C. elegans (~20,000 genes), 
where there are 1 to 2 protein coding transcripts expressed per gene [37]. 
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In the case of prokaryotes (bacteria), transcription and translation is much 
simpler because AS does not take place, each gene contains only one exon and there is 
no 5’ capping and polyadenylation, with the flow of information from gene, to mRNA, 
to protein being significantly more direct and linear. The differences between the 
‘central dogma’ of a bacterium and a eukaryote are quite apparent (Figure 2.2). 
Figure 2.2 Comparative molecular machinery of a eukaryote and prokaryote 
The differences between the ‘central dogma’ of a prokaryote (bacterium) (A) and a eukaryote (B), 
illustrates the clearer linear relationship between gene and protein product in bacteria, whereas a gene in 
eukaryotes can represent many multiples of protein products (image courtesy of PJ Russell, iGenetics 3rd 
edition [38] (http://www.mun.ca/biology/scarr/iGen3_05-09.html)). 
The genome is considered a relatively static and unchanging component of an 
organism (apart from random mutation and somatic recombination of immunoglobulin 
genes [39]), which comprises all genes (protein and non-protein coding) and regulatory 
micro RNAs, promoter, suppressor, and enhancer regions. The proteome of an organism 
on the other hand is very dynamic, as it represents the complement of all protein-coding 
genes being expressed across different environmental conditions and developmental 
time-points over the organism’s life cycle. 
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Different fields of research have developed around the understanding of each 
step of this “central dogma of molecular biology”, resulting in the field of genomics, 
transcriptomics and proteomics, all of which can feed into each other to provide a better 
understand of the underlying biochemical mechanisms and biological functions of 
genes. It is the interplay between genomics, transcriptomics and proteomics, and how 
they can be combined using cutting edge bioinformatics tools to further genomic 
annotation, which is the focus of this thesis. 
2.2 GENOMICS 
This section provides an in-depth background on genomics, covering genome 
sequencing and genome annotation as in the context of proteogenomics. 
2.2.1 Genome sequencing 
The field of genome sequencing experienced a surge of technological advancement in 
the late 1990s, with the first genome being sequenced, a bacterium called Haemophilus 
influenzae Rd. [40], which was rapidly succeeded by the sequencing of further bacterial 
genomes [41, 42], yeast [43], worm [44], fruit fly [45], plant [46], mouse [47], rat [48] 
and culminated with the sequencing of the complete human genome [35, 49]. Since that 
time many more organisms have been sequenced. 
As of September 2015, 7,256 genome-sequencing projects have been completed 
and 25,173 have permanent drafts, with 32,633 genomes still pending completion 
(http://www.genomesonline.org/). These numbers will continue to increase at an 
exponential rate as more genome sequencing projects begin and as the technologies 
improve to sequence them. 
Sequencing technologies have advanced significantly over the last 38 years 
(Table 2.1). Frederick Sanger pioneered the first technology in 1977, which used a 
chain-termination method (Sanger sequencing) and in that same year Walter Gilbert 
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developed a different technology using chemical modification of DNA sequences and 
subsequent cleavage at specific bases. Sanger sequencing was ultimately adopted as the 
universal standard for DNA sequencing due to its ease of use, efficiency, and its 
capacity to reach sequence lengths of 600 bp with an error rate of only 0.001% and 
yield of 1.9 - 84 Kbp per run [50]. Many automated Sanger sequencers were introduced 
over the years to improve the sequencing speed, and ultimately they were used in the 
sequencing of the human genome [51]. However, it wasn’t until 2005 and later that the 
genome sequencing landscape dramatically changed with the introduction of the 2nd 
generation of sequencing technology, termed “next generation sequencing” (NGS) 
technologies. The first of the NGS technologies to arrive was 454 in 2005 (now Roche 
454), which was initially capable of reaching read lengths of 100 - 150 bp and then later 
upwards of 700 bp with an error rate of 0.1%, but with higher error rates observed with 
polybases of over 6 bp and with a yield of 0.7 Gbp per run [50]. The technology is 
based on pyrosequencing, which detects the pyrophosphate released (detected as light) 
during nucleotide incorporation, as opposed to Sanger sequencing which uses 
dideoxynucleotides to terminate chain amplification. The following year saw the release 
of the Genome Analyzer (GA) by Solexa (now Illumina GA/HiSeq/MiSeq) with a large 
improvement in throughput and yield compared to previous technologies, capable of 
reaching read lengths of 150 bp with <2% error rate and a yield of 30 Gbp per run [50, 
52]. The technology uses a technique termed sequence by synthesis (SBS), which uses a 
library with fixed adapters, denatures them into single strands and attaches them to a 
flowcell, where bridge amplification occurs to create clusters containing clonal DNA 
fragments. The library is then spliced into single fragments using a linearization 
enzyme, dideoxynucleotides (ddATP, ddGTP, ddCTP, ddTTP) containing different 
cleavable fluorescent dyes and a removable blocking group which anneals to a template 
one base at a time, detected by a charge-coupled device (CCD). The same year also saw 
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the development of SOLiD (Sequencing by Oligo Ligation Detection) (now Applied 
Biosystems (AB) SOLiD), initially capable of reaching read lengths of 35 bp and later 
upwards of 85 bp with a 0.01% error rate and a yield of 120 Gbp per run. The 
technology uses a technique termed ligation sequencing, which is a two-base 
sequencing technology. Once the libraries attached to a flowcell they were then 
sequenced by an 8 base-probe ligation, incorporating a fluorescent dye, which produces 
a signal when annealing the last few bases to the template. Collectively these 
technologies, now termed 1st generation NGS technologies have shown improvements 
over the years in throughput, accuracy and cost compared to the now dated Sanger 
technologies [50]. 
A few years later, in 2010 and 2011, saw the arrival of more advanced genome 
sequencing technologies, which straddled the divide between 2nd and 3rd generation 
genome sequencing technologies. The Helicos Genetic Analysis System developed by 
Helicos BioSciences [53] was capable of reaching read lengths of 15 - 50 bp with a 
variable error rate depending on read length: an error rate of 0.60% was achieved at a 
read length of 30 bp and an achieved yield of 35 Gbp per run [54]. The other new 
genome sequencing technology was the Ion Personal Genome Machine (PGM) 
developed by Illumina and Ion Torrent [55] which was capable of reaching read lengths 
of 200 bp, with an error rate of 1.71% [52]. Unfortunately, the Helicos Genetic Analysis 
System was never commercially realised, as Helicos BioSciences was delisted in April 
2010. 
The two main differences in these technologies compared with the previous 
NGS technologies were, in the case of Helicos Genetic Analysis System, the use of a 
form of Single Molecule Sequencing (SMS) called Single Molecule Florescent 
Sequencing (SMFS), which obviated the need for DNA amplification through the 
Polymerase Chain Reaction (PCR) along with its inherent errors and biases’, and in the 
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case of Ion PGM, real time signal detection which provided faster sequencing and 
significantly lower upfront costs [56, 57]. With Ion PGM, each time a nucleotide was 
incorporated onto the end of a DNA strand during DNA synthesis by DNA polymerase, 
a proton was released which altered the pH of the solution, and was subsequently 
detected by a semiconductor [55]. With the Helicos Genetic Analysis System on the 
other hand, DNA molecules were hybridized to a primer and each time a Virtual 
Terminator nucleotide [54] with fluorescent dye was incorporated and the 
complementary strand extended by DNA polymerase an image was taken. The 
fluorescent dye was then cleaved off followed by the addition of another Virtual 
terminator nucleotide with fluorescent dye and DNA polymerase and the process would 
repeat. The process can also be produced in parallel across many different DNA 
fragments, significantly improving the throughput and overall yield compared to 
previous NGS technologies [53]. 
In recent years a number of newer technologies have emerged, termed 3rd 
generation technologies, which were a technological leap forward compared to all the 
previously mentioned NGS technologies. These 3rd generation technologies provide 
both real time sequencing, measuring the incorporation of each nucleotide along the 
strand one at a time, and single molecule sequencing where DNA amplification through 
PCR is not needed. In early 2009 Pacific Bioscience (PacBio) first published their work 
on a single molecule, real time sequencing (SMRT) technology, which could reach read 
lengths ≥3,000 bp, however these were plagued with error rates of around 13% and the 
technology could achieve a yield of 100 Mbp per run [52]. The SMRT technology was 
capable of measuring the incorporation of each fluorescently labelled 
deoxyribonucleoside triphosphate (dNTP) along a template bound DNA fragment. A 
SMRT cell comprises millions of 50 nm wells called zero-mode waveguides (ZMWs), 
consisting of a set of enzymes, a single DNA fragment and a template bound to the 
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bottom. The ZMW allowed for precise detection of nucleotide incorporation each time a 
single fluorophore (fluorescent dye) was excited by a laser by preventing no other 
sources of light into the well. The fluorescent signal was then detected in real-time by a 
camera. The millions of ZMWs running in parallel allowed for very high throughputs 
[50, 58, 59]. 
Another 3rd generation technology, called Nanopore sequencing has been in 
development for most of a decade [60-62] and has matured with the release of the first 
working machine developed by Oxford Nanopore Technologies in 2012 [63], capable of 
reaching read lengths >5,000 bp with speeds of 1 bp per 10 nanoseconds [62]. The 
technology relies on passing a DNA sequence through a nanopore, a biopore with a 
diameter on the nanoscale, in which the sequence is then deduced by measuring changes 
in the ion current as each nucleotide (A, G, C, T) passes through the narrowest 
constriction of the pore. The technology negates the previous requirements for DNA 
amplification by PCR, fluorescent labelling and optical measurements. A number of 
challenges still need to be overcome with this exciting new technology with further 
likely improvements in the foreseeable future [50, 64]. 













20 min - 3 
hours 
0.001 1.9-84 Kbp $2400 1977 
454 100-700 10 hours 0.1 0.7 Gbp $13 2005 
Illumina Genome 
Analyzer 
150 10 days <2.0 30 Gbp $0.02 2006 
SOLiD 85 7 days 0.01 120 Gbp $0.04 2006 
Helicos 15-50 
5 hours - 1 
day 
0.60 35 Gbp NA 2011-2012 
Ion Torrent 100 2 hours 1.70 




PacBio ≥3,000 2 hours 13.0 0.1 Gbp $2 2009 
Nanopore ≥5,000 
1 bp per 10 
nanoseconds 
NA NA NA 2010-2012 
* All costs based on sequencer manufacturer and sequencing provider [50, 52]. 
NA: Not available 
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In recent years, the throughput of next generation sequencing has surpassed the 
speed and cost-benefit barrier, with the sequencing of more than 2 human genomes per 
day, during the 1,000 Genome Project, which sequenced and compared 1,092 human 
genomes [65]. 
Together, these technologies highlight the incredible rate at which genome 
sequencing is progressing. With this progress in mind, the question then needs to be 
posed as to how to process and understand the level of information produced. 
2.2.2 Genome annotation 
The speed at which genomes are now being sequenced and their reduced costs poses a 
problem of how to deal with the large quantities of data being generated. Genomic 
assembly and annotation significantly lags behind the progress that the field of genome 
sequencing has obtained. Many genomes over the last decade have been assembled 
from reads generated using 2nd generation technology, using shorter reads (e.g. 
Illumina), often leading to highly fragmented assemblies, particularly in genomic 
regions containing large numbers of repeat elements [66] or high/low GC content due to 
PCR bias [67, 68]. Depending on the size of the genome, this can result in a highly 
fragmented genome, and in the case of de novo assembly, chimeric scaffolds and 
contigs can form where the de novo algorithm used for the assembly is unable to resolve 
large repeat regions when the read length is equal to or less than the repeat length [69, 
70]. In recent studies it has been shown that using mate-pair information (where a reads 
location is known in relation to another read), can be used to improve the assemblies 
and resolve repeat regions (as long as the insert size between reads is longer than the 
repeat region) [71], and in addition a concept called path extension is able to resolve 
longer repeat regions where the insert sizes are inadequate [72]. Fortunately, smarter 
ways to use short reads is not the only solution, as many of these problems will 
disappear in the coming years as the 3rd generation technologies mature, with longer 
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reads being obtainable (easier to assemble), and with no PCR bias (see previous Section 
2.2.1). 
 As a consequence from the use of shorter sequence reads over the last decade 
and with many larger genomes being sequenced and assembled, genomic annotation, 
which is the act of finding the locations of genes and annotating them with structural 
and biological functional information, has now become more difficult than it has been 
in the past [73]. This is mainly due to the highly fragmented genomes that are now 
being assembled, as a result of short reads and large repeat regions in some genomes, 
such as with the early genome projects, Drosophila melanogaster [74, 75] and the 
human genome project [35, 76]. Additionally, gene finding and annotation isn’t a clear-
cut process, and can often lead to false positives, misannotations or completely missed 
genes [77-84]. In addition, our understanding of what defines a gene is not clear-cut, 
especially since the conclusion on the ENCODE project [30] where it is now understood 
that the boundaries of a gene are poorly defined due to overlapping protein products 
[85]. 
The statement that a genome is “complete” is often misleading, when there is no 
certainty that a genome annotation is truly complete in its entirety. This is certainly 
more true with eukaryotes, due to their complex gene structure as a result of AS. 
Consequently, misannotations are more often found in bacterial genomes where the 
error can be more readily detected. Additionally, misannotations can propagate errors in 
the annotations of other genomes in comparative genomics studies. Using comparative 
genomics to assign annotations to other genomes should be undertaken with caution, as 
errors can be introduced from sequencing errors, alignment errors, and changes in 
nucleotide function and differing biological functions between features such as splice 
donor sites. Iteratively using more genomes in such as study can lead to more noise 
from such errors [86], transferring the error to other genome annotations, termed 
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’transitive disaster’. Therefore, it is best to use at best only a few closely related 
genomes, or one that is much more highly conserved, with the genome of interest. 
 To correct all these genomic misannotations and prevent the scenarios as 
outlined above would be a very large undertaking, incurring high costs and time 
involved. Better genomic annotation practices and standards would result [87-89], but 
the end-product could not completely ensure further errors would not occur, or assist in 
speeding up the annotation process. Therefore, a highly accurate, faster and automated 
approach is needed. 
A number of gene prediction tools have been developed over the years, which 
apply various approaches, classified as: ‘ab initio’, ‘combiner’, and ‘similarity and 
homology’. Ab initio gene prediction tools identify genes by following established 
rules, such as imposed limits on gene size, GC content, transcription start and stop sites 
and also apply mathematical models. A number of approaches include the Generalised 
Hidden-Markov Models (GHMM) [90, 91], machine-learning techniques such as 
support vector machines (SVMs) [92], which were one of the first types of gene 
prediction tools made available [93-96] and a more recent mathematical approach called 
conditional random field (CRF) [97-100]. 
The ab initio tools can provide a fast and easy means to obtain gene predictions 
and their exon-intron structures without necessarily needing any external evidence, 
apart from the use of training parameters to improve the prediction for each specific 
genome, like codon frequency and the distributions of exon-intron lengths, which can 
often be obtained from closely related genomes if available. Ab initio gene predictors 
however only predict the most likely locations of coding DNA sequences (CDS) and are 
unable to detect the locations of untranslated regions (UTRs), sites of AS and they have 
limited accuracy with exon-intron boundaries. A number of ab initio gene prediction 
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tools also include evidence-driven predictions, such as outlined in Table 2.2. By 
providing weighted (i.e. ranking some evidence higher than others) external sources of 
evidence to the ab initio prediction tools, such as sequence alignments from expressed 
sequence tags (ESTs), protein alignments, and RNA-seq alignments, the accuracy of the 
ab initio predictions can be improved. Unfortunately, this requires a great deal of work 
and pre-processing of the data, such as alignment to genomic regions, before being 
presented to the ab initio gene prediction tool. The ‘combiner’-based gene prediction 
tools simply take evidence from multiple different sources, including predictions from 
other prediction tools, and select a prediction based on a consensus of intron-exon 
structure. Examples of such tools are outlined in Table 2.2. The ‘similarity and 
homology’ based gene prediction tools, as the name suggests use similarity and 
homology sequence alignments with known gene sequences from other closely related 
genomic regions, preferentially between conserved genomic regions, potentially 
identifying genes with identical function with the aim of predicting the sites of genes in 
the genome of interest. Examples of such tools are outlined in Table 2.2, all of which 
can also be used to generate evidence for the previously mentioned evidence-driven ab 










Table 2.2 Types of gene prediction tools and their employed method of prediction 
Gene prediction method  Gene prediction tool Reference(s) 
Ab initio 
(evidence-driven) 
Augustus [101, 102] 
TwinScan [103] 
FGENESH  [104] 




JIGSAW, and  [108] 
EVidenceModeler (EVM) [109] 
GAZE  [110] 
Genomix  [111] 
GLEAN  [112] 
Evigan  [113] 
EGPred [114] 
Similarity and homology 
SIM4 [115] 
EST2Genome [116] 
Procrustes  [117] 












Many of the above mentioned gene prediction tools are often incorporated into 
genome annotation pipelines, which can be broken down into a number of different 
types, based on the level of automation: manual, semi-automated, automated and high-
throughput automated. The manual approaches tend towards being highly accurate, 
costly and slow processes, and by contrast, as the annotation pipeline becomes further 
automated with a magnitude of throughput increase, there is often a trade off in the 
accuracy of the annotation, depending on how the annotation pipeline is automated and 
the level of evidence supplied or lack thereof.  
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Sometimes multiple gene predictions tools can be used together, building on 
each of their strengths, with the pipeline taking the consensus predictions, which are 
supported by external evidence from genomic alignments from RNA-seq, ESTs and 
proteins. Other approaches such as combiners, as mentioned above, incorporate multiple 
gene predictions. 
A number of well-known manual, semi-automated, automated and high-
throughput automated genome annotation pipelines, which utilise many of the above 
gene prediction strategies, are pipelines such as those listed in Table 2.3, some of which 
target specific classes of genomes, such as bacterial (IMG, Prokka and RAST) or larger 
complex eukaryotic genomes (NCBI, Ensembl and MIPS), and specifically tailored for 
niche genomes such as large complex plant genomes (TriAnnot and PlandSEED). Other 
genome annotation pipelines are manual efforts, like the HAVANA group who curated 
the human genome and who make their annotations available through the Vertebrate 
Genome Annotation Database (VEGA) [131]. 
The outputs from these pipelines can be used to train and improve the accuracy 
of gene prediction tools, which themselves can be re-used in the pipeline. For example, 
Maker2 can streamline gene prediction tool training, allowing for easy incorporation 
into tools such as Augustus or SNAP. A comprehensive overview of genome annotation 








Table 2.3 Genome annotation pipelines 
Level of automation Annotation pipeline References 
Semi-Automated MIPS [132] 
Semi-Automated IMG [133] 
Automated RAST [134] 
High throughput automated TriAnnot [135] 
High throughput automated PlantSEED [136] 
High throughput automated Maker2 [137] 
High throughput automated Prokka [138] 
Automated AutoFACT [139] 
Automated PASA [140] 
Automated Ensembl [141] 
Automated NCBI [142] 
Manual HAVANA [143] 
Because the genome annotation process often uses ab initio approaches, based 
on pre-defined rules, and consequently due to a limited understanding of gene structure, 
which can vary widely between organisms, such approaches are prone to errors and 
inconsistencies [144]. Even in cases where the evidence is available it may be 
incomplete, such as with transcript-based annotation with un-spliced mRNA or 
nonsense transcripts. The few errors that can be detected are painstakingly corrected 
through manual annotation. As genomic sequencing costs reduce and the rates at which 
they are sequenced increases, the use of a number of genome annotation approaches 
becomes impractical. Therefore, there is now an urgency to produce high throughput 
automated annotation pipelines of higher quality and throughput than before, accepting 
multiple lines of evidence before an annotation is considered “complete” and 
significantly reducing the amount of time and manual annotation required to still 
achieve a high quality level of curation.   
2.3 MASS SPECTROMETRY-BASED PROTEOMICS 
This section provides an in-depth background on MS-based proteomics, covering 
current trends in mass spectrometry technology, proteomics techniques and algorithmic 
approaches to interpret and statistically validate MS/MS spectra. In relevance to 
proteogenomics, of particular interest will be given towards the types of mass 
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spectrometers currently employed in proteomics, as well as the database searching 
methods used in MS/MS spectral interpretation and statistical validation; as such 
strategies are employed throughout this thesis. 
The field of proteomics is focused primarily on the identification of proteins, the 
identification of signal pathways, cellular localization, quantification, their interaction 
in protein-protein networks and complexes and to understand the roles that post-
translational modifications (PTMs) play in these complex networks [145]. 
Mass spectrometry (MS) has been continually improving in throughput, 
specificity, sensitivity, and dynamic range [146] for well over a century since its 
inception, and it has been increasingly used for proteomics, to quantify and identify 
proteins [147-151]. Mass spectrometry has also benefitted greatly from improvements 
in sample handling (generally a clean, dust-free work environment and good sterile 
techniques) and separation techniques (forms of Liquid Chromatography (LC)) and the 
high performance of various MS instruments. 
There are a wide variety of mass spectrometers available, ranging in sensitivity 
and throughput. The most commonly and currently used MS instruments in the field of 
proteomics are ion trap mass spectrometers [152]. These mass spectrometers have high 
data acquisition rates and are known to generate enormous amounts of data of low 
resolution and of low mass accuracy, which affects the level of confidence assigned to 
peptide sequences, with just 10-15% of peptide assignments being regarded as correct 




Figure 2.3 General workflow of MS-based proteomics 
The workflow applied in MS-based proteomics, in this example, with a Quadrupole Time-of-Flight 
(QTOF) mass spectrometer, generally takes the form of: (A) preparing the sample and forming technical 
replicates, running on a SDS-page gel (or taking whole cell lysates); (B) digesting the proteins with a 
protease such as trypsin; (C) followed by injection of the sample onto an LC column followed with 
electro-spray ionisation (ESI) (alternatives being MALDI, with ionisation in a matrix compound), with 
MS1 taking place in the first quadrupole (q1), and MS2 (MS/MS) taking place in the second quadrupole 
(q2), entering the TOF chamber, followed by; (D) detection of the precursor peptide ion mass and; (E) 
fragmented ions masses, where de novo sequencing can take place (modified from [147]). 
A more advanced range of mass spectrometers called hybrid-fourier transform 
(hybrid-FT) mass spectrometers [155, 156] are capable of high mass resolutions of 30-
500 kilodaltons (kDa) and very high mass accuracy within a few parts per million 
(ppm). The throughput and sensitivity is maximized on these mass spectrometers by 
collecting MS data at a higher resolution and accuracy, and recording the MS/MS data 
at a higher speed, but at a lower resolution and accuracy [157]. A higher resolution of 
MS/MS spectra allows for precursor mass ions to have their charge states determined 
[158, 159]. This allows for the detection of higher mass ranges at higher charge states 
and lower cost, with each mass peak having a m/z (mass to charge) ratio, and with a 
higher mass accuracy, coupled with stricter mass tolerance windows allows search 
algorithms to narrow down the number of possible peptide candidates, consequently 
improving the confidence level for peptide matches [160, 161]. 
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2.3.1 Bottom-up proteomics and strategies 
In an MS-based proteomics experiment a number of approaches can be applied 
depending on the desired outcomes. In one approach a protein mixture is first 
fractionated via two-dimensional polyacrylamide gel electrophoresis (2D-PAGE), 
which separates the proteins in two dimensions, by their isoelectric point (pI) and 
molecular mass (MW) [162]. What follows is termed bottom-up proteomics, whereby 
each spot on the gel is excised and the proteins within are then enzymatically digested 
by a protease such as trypsin, chymotrypsin, thermolysin or endopeptidase V8 (Glu-C), 
each of which cleaves proteins at various specific sites. Trypsin is used in most cases, 
producing peptides with a median length of 15 residues with a basic C-terminal end that 
can trap a charge [163] and is approximately 1,600 Daltons (Da) in size, which is well 
within the detectable mass range of most mass spectrometers. 
Once the peptides are ready for analysis, there are a number of options from 
which to choose. Often if all that is desired is protein identification, a technique called 
peptide mass fingerprinting (PMF) can be applied which looks at intact peptides. The 
common approach is to use a time-of-flight mass spectrometer (TOF-MS), which can 
have a High Performance Liquid Chromatography (HPLC) setup with what is termed 
electrospray ionization (ESI). This approach separates peptides according to their 
molecular weight (MW) with a C18 column before the peptides elute off and are ionized 
in a fine spray with an applied electric charge, before entering into a gas phase and 
passing into the mass spectrometer. Alternatively, the TOF-MS can use a Matrix-
assisted laser desorption/ionization (MALDI) setup. Following the extraction of 
digested peptides from the gel pieces, a compound called a matrix is applied to the 
sample, which assists with ionization. This method utilizes a laser to ionize the peptides, 
which then enter the mass spectrometer for analysis. Regardless of the ionization 
method used, the samples now entering the TOF-MS fly to the end of a long cylinder, 
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assisted by large electric fields within a vacuum. The time taken to reach the detector 
and the electric field applied is proportional to the mass of each ionized peptide. The 
larger the electric field, the larger the flight path of each ionized peptide. This 
essentially increases the resolving power of the machine. The process is analogous to 
the length of a C18 column in HPLC: the longer the column, the greater the resolution of 
each mass peak. A similar approach is illustrated in Figure 2.3, applying the use of a 
TOF, however in PMF only the detection of MS1 is carried out with intact peptide ions 
detected. 
The peptide masses obtained from PMF can then be matched to a database with 
a list of peptide masses from known proteins, using search tools such as MOWSE [164], 
Mascot [165], MS-Fit [166], PeptIdent [167], ProFound [168] and Aldente [169]. These 
peptide masses are calculated from protein sequences, digested in silico using a specific 
software program, which cuts the protein sequences at specific cleavage sites based on 
the known specificity of different proteases such as trypsin. However, the actual 
sequences of the peptides in the sample themselves remain unknown. 
Apart from protein identification by PMF, other applications include the varietal 
typing of wheat and barley using pattern matching techniques, where the distinct peaks 
from a PMF between a number of different varieties can readily be identified [170, 
171]. Other applications include a similar concept, using peptide mass values from 
many known samples to train a naïve Bayes classification algorithm, to classify 
unknown samples [172], an analogous concept to biomarker discovery in medicine 
[173], among other similar studies using bottom-up proteomics for understanding 
disease [174-176]. 
The use of a 2D gel at the initial stages, followed by HPLC or MALDI, is 
effective in reducing the sample complexity and purifying the proteins. This method can 
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be relatively low in throughput and the coverage of the resulting proteome also is 
relatively poor. However, the MADLI-TOF stage itself can be quite sensitive and of 
high-throughput, but the use of 2D gel and peptide separation significantly reduces the 
overall proteome coverage and throughput. To overcome this limitation another method 
is available called Multidimensional Protein Identification Technology (MudPIT) [151], 
which makes use of multi-dimensional HPLC and replaces the use of a 2D gel. The 
technique combined with another approach called shotgun proteomics, where whole 
protein samples are first digested by a protease, can significantly improve proteome 
coverage and throughput. Shotgun proteomics is not unlike shotgun genome 
sequencing, in that fragments of the original sequence are created and then reassembled. 
Following protease digestion of the protein the peptide mixture is then separated by 
multidimensional HPLC (2D HPLC), where the peptides are separated by their pI and 
MW using a HPLC column packed with Strong Cation Exchange (SCX) resin and C18 
Reverse Phase (RP) material [151, 154]. The peptides are then eluted off the column 
and ionized, usually by ESI, passed through the mass spectrometer and subsequently 
analysed by the detector. 
Following 2D HPLC in a MudPIT setup, the mass spectrometer normally used is 
a tandem mass spectrometer (MS2 or MS/MS), which can be designed in many formats 
including, but are not limited to quadrupole TOF (QTOF) (Figure 2.3) and quadrupole 
ion trap (QIT), as well as variations on these with additional mass analysers above the 
MS2. For example, TripleTOF or triple quadrupole (QqQ) also referred to as MS3 or 
MS/MS/MS and provides further separation of peptide fragment ions and higher 
resolution. 
Such tandem mass spectrometers are becoming a common method for 
identifying peptides and proteins with high sensitivity, specificity and high throughput 
[177]. Through this method, the precursor ions obtained by the first pass of MS (MS1) 
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at low energy collision-induced dissociation (CID) are fragmented, most commonly 
along the peptide bonds during the second pass of MS (MS2, MS/MS). The resulting 
fragments of a peptide are measured as a mass over charge ratio (m/z), which mirrors 
the overall structure of the peptide ion [178, 179]. According to Roepstorff’s 
nomenclature [179], within the MS/MS spectra at around 10-50 electron volts (eV) 
collision energy the peptide ions are denoted as a, b and c when the charge is on the N-
terminal side of the fragmented peptide, and x, y, z when the charge is on the C-terminal 
side. When the collision energies involved in fragmentation are of orders of magnitude 
greater than around 1 kilo electron volt (keV), the peptide side-chains are broken 
generating side-chain ions, denoted as d, v and w, which can be formed by the loss of 
some or all side-chains [180]. 
The sequence of the fragmented peptides can be calculated through de novo 
sequencing, which uses first principles to determine the amino acid sequence of a 
protein from the MS/MS spectra by looking at the mass differences between peaks [181, 
182]. This was previously conducted manually using a technique called Edman 
degradation [183], requiring chemical labelling of amino acids and the cleavage of each 
amino acid in succession to form amino acid derivatives, followed by electrophoresis to 
identify the amino acids. The procedure was expensive and slow by today’s standards 
using mass spectrometry-based technology which can sequence many hundreds of 
thousands of peptide sequences simultaneously, mapping out the entire proteome within 
a fraction of the time. In addition, the MS/MS spectra can also be matched directly to 
known sequences through the use of MS/MS database search algorithms, discussed in 
detail later on. 
A number of alternatives to the above mentioned MudPIT setup using 2D HPLC 
with SCX and RP, can include other alternative fractionation methods, such as size 
exclusion liquid chromatograph (SEC) [184, 185], capillary electrophoresis (CE) [186, 
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187], capillary isoelectric focusing (CIEF) [188], and gel-based isoelectric focusing 
[189] in the 1st dimension, followed by RP chromatography in the 2nd dimension. 
Another approach called gas-phase fractionation (GPF) [190, 191] can also be applied 
which uses the mass spectrometer to resolve and separate out the different precursor 
ions over a set number of m/z ranges before fragmentation by mass [192, 193] and ion 
intensity (a measure of the number of detected fragments) [194, 195], using iteration 
from different fractions of the same sample by RP chromatography. The proteome 
coverage obtainable with this approach is limited to the number of fractions (m/z 
ranges) applied and the amount of sample available. 
A cost-effective approach to improving proteome coverage is to use a range of 
proteases to digest the sample. In tandem mass spectrometry, peptides of around 7-35 
amino acids (aa), protonated, low charge state (z) and high mass-to-charge ratio (m/z) 
are ideal. Trypsin meets many of these requirements and so has been successful as a 
protease, becoming the common choice. Trypsin cleaves specifically after arginine (R) 
and lysine (K), but not before proline [196] although an absence of proline has recently 
been identified [197]. However, trypsin does have some disadvantages, such as 
autolysis in alkaline pH, requiring that lysine and arginine to be evenly distributed 
across a proteome, which is often not the case, and its thermostability is poor. The use 
of other proteases in conjunction with trypsin would ensure much better coverage of the 
proteome [198]. 
Another approach to improve proteome coverage can be found in the way in 
which mass spectrometry works at the level of precursor ion fragmentation. 
Historically, the majority of MS-based proteomics work has used one fragmentation 
mode, namely CID to derive the MS/MS spectra due to the limitations of the technology 
at the time, and subsequently many MS/MS search tools were optimized solely for CID 
MS/MS spectra. A number of alternative fragmentation methods are now becoming 
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utilized by newer mass spectrometers, such as electron transfer dissociation (ETD), 
higher-energy collisional dissociation (HCD), CID/ETD or HCD/ETD paired MS/MS 
spectra and the less frequently used electron capture dissociation (ECD), used only by a 
few mass spectrometers. The quality and usability of MS/MS spectra depends on the 
fragmentation method used for each precursor ion, which is highly dependent on 
various properties; for example, ETD is more suitable for precursor charge states of >2 
[199-202], acidity due to PTMs such as phosphorylation [203-205], and is more suitable 
for de novo sequencing due to its high levels of fragmentation [206, 207]. Since the 
introduction of hybrid MS/MS machines (QTOF, QIT, TripleTOF etc), which can 
implement a number of fragmentation methods in parallel, an opportunity has arisen to 
use these different methods in a complementary way. The advantages and disadvantages 
of using various fragmentation methods on different precursor ions have been 
thoroughly investigated by Frese et al. 2011 [208]. The combination of these various 
methods has been shown particularly with CID and ETD, which could be used to 
significantly improve proteome sequence coverage [201-203, 205, 206, 209-211]. 
Another approach which leverages mixed CID/ETD MS/MS spectra uses data-
dependent decision tree logic during MS analysis and before MS/MS, while the mass 
spectrometer is running, to determine which fragmentation method is the most 
appropriate to use based on the precursor ion charge state (z) and m/z value. This 
method significantly improves the number of peptide identifications significantly over 
the use of single fragmentation methods alone [206]. 
Shotgun proteomics, which employs a bottom-up proteomics approach, has 
often used a data-dependent acquisition (DDA) method for the selection of precursor 
and fragment ions for analysis.  Briefly, the DDA approach scans for precursor ions 
above certain thresholds for intensity, charge state etc at MS1. The selected precursor 
ions are then sequenced by product ion fragmentation at MS2. Through shotgun 
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proteomics, enough of the sample can be supplied for analysis to improve the number of 
precursor ions passing the selected thresholds, thus improving the overall proteome 
coverage. However this is not ideal and the approach has a number of drawbacks, 
including slow speed [212], random selection of precursor ions, and poor 
reproducibility [213], narrow dynamic range [214], problems with mixture or 
multiplexed MS/MS spectra (co-fragmentation of ≥2 precursor ions within the same 
MS/MS spectra) [215, 216], low reproducibility and others. 
Mass spectrometry has allowed improvements in throughput, the identification 
of proteins, and reliability of inferring protein expression levels, however achieving 
proteome-wide coverage has remained a problem [146, 217]. This is due to different 
protein extraction techniques and the varying conditions under which proteins are 
expressed, as well as the difficulty of detecting lowly expressed proteins in a sea of 
highly abundant proteins. 
One of the more pressing limitations of bottom-up proteomics in terms of 
protein discovery and identification is the ambiguity present with the assignment of 
peptides to proteins, because many proteins share peptide sequences, known as the 
protein inference problem [218-220]. Due to the digestion and fragmentation of intact 
proteins, reassignment back to the proteins becomes problematic if the coverage for a 
particular protein is limited, especially when databases contain multiple isoforms of the 
same protein, or particular peptide sequences are common within protein families. This 
often requires identification of unique peptides or proteotypic peptides, which appear in 
no other isoform to identify the correct protein. However, as is often the case, not every 
protein isoform has an identified unique or proteotypic peptide, limiting its application 
across the whole proteome. 
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2.3.2 Top-down proteomics: A complement to bottom-up proteomics 
A significant development in the field of proteomics, which circumvents the inherent 
problems in bottom-up proteomics, such as the protein inference problem mentioned 
above, is top-down MS proteomics. Top-down proteomics is the MS analysis of intact 
proteins and large peptides [221-232], which is appropriate for the localization of 
multiple PTMs across the entire length of a protein, and the identification of multiple 
proteoforms [233], and is highly suitable for proteotyping of diseases in medicine. 
However, due to the very nature of some proteins that are insoluble, complete analysis 
of all proteins across the whole proteome is not possible. By contrast, traditional 
bottom-up approaches can only provide a limited “fragmented” view across the whole 
proteome, on average, 25% of the full length protein [146], indicating that in a bottom-
up experiment many PTMs are not detected but many more peptides overall can be 
identified due to the higher solubility of smaller peptides and their propensity to ionise. 
The differences between bottom-up and top-down proteomics is illustrated in Figure 2.4 




Figure 2.4 Top-down versus Bottom-up proteomics 
Fragmentation of proteins in top-down proteomics shows more complete coverage of a single protein, and 
unambiguous identification, including more identified PTMs, but lacks coverage across the whole 
proteome. By comparison, bottom-up proteomics shows limited coverage and ambiguous identification of 
a single protein, identifying only some PTMs, and has much wider coverage of the whole proteome 
(modified from [234]). 
Although top-down proteomics is powerful, it has been less commonly used. 
Top-down mass spectrometry has generally been limited with separation strategies for 
whole intact proteins (restricting its capability to single purified proteins), 
fragmentation, computational tools and with upper limits on the detectable protein mass 
with significant impacts on throughput [235-239]. However, top-down proteomics can 
now allow for the analysis of complex mixtures of proteins consisting of many 
hundreds to thousands of proteins, utilizing recent advances in separation techniques, 
fragmentation and improved detection limits (<60 kDa) of the MS instrumentation [232, 
240-245]. To overcome the restrictions current mass spectrometry technologies have 
imposed on the size limits of top-down proteomics, a technique called middle-down 
proteomics was applied, with large peptides generated (<6 kDa) from target specific 
proteases, followed by analysis with the normal top-down approach. This has the 
advantage of identifying proteoforms larger than the top-down limit of ~60 kDa, while 
gaining the sensitivity of bottom-up proteomics [246]. These rapidly changing trends in 
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top-down proteomics have been outlined in a comprehensive review [233] and in a 
clinical setting [247]. 
Top-down proteomics is less sensitive than bottom-up proteomics, due to its 
inherent insolubility and ionization problems. As both approaches further improve in 
terms of throughput, they will ultimately be used as standard in a synergistic manner. 
The use of both approaches can also allow the testing of hypotheses such as the location 
of the N-terminal end of proteins, the presence of N-terminal methionine excision 
(NME) [248] and signal peptide cleavage. In addition, in the future there will likely be a 
merger of multiple approaches, from peptides, whole intact-proteins and whole protein 
complexes [249]. 
2.3.3 Next generation bottom-up proteomics 
Over the last decade there have been substantial improvements in mass spectrometry. A 
number of recently developed techniques have overcome the drawbacks of the 
traditional DDA approaches used in bottom-up proteomics by taking a broader sweep of 
all peptide ions in a sample, thus providing much greater proteome coverage, by 
selecting all precursor masses at MS1, and by extension all possible fragment ions at 
MS2. This approach is known as data-independent acquisition (DIA), originally 
developed in [250], and subsequently improved [251, 252]. A study demonstrating the 
advantages of DIA over DDA was undertaken [253]. The DIA approach allows for MS 
analysis of all precursor ions (no selection process based on intensity etc) in a complex 
mixture of peptides with no loss in detection, resulting in much higher sequence 
coverage, with fewer samples being required and with improved reproducibility 
compared to DDA. 
A number of different approaches based on DIA have emerged, which include 
MSE [254-258], all-ion fragmentation (AIF) [259], Fourier transform-all reaction 
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monitoring (FT-ARM) [260], Sequential Window Acquisition of all THeoretical Mass 
Spectra (SWATH-MS) [261-264], and improvements to this method utilizing 
multiplexed MS/MS [265], to resolve MS/MS spectra containing multiple precursor 
ions and spectra. All of these methods have their individual advantages and 
disadvantages, and by comparison with DDA. In addition, Precursor Acquisition 
Independent From Ion Count (PAcIFIC) [266, 267] is a DIA method that applies small 
precursor windows across a small mass range requiring multiple injections of sample, 
unlike the other DIA methods mentioned. The main advantage over DDA is improved 
proteome coverage and efficiency of sampling the proteome, with the ability to examine 
less abundant proteins. This advantage is, however, also a disadvantage, in that the 
MS/MS spectra are highly complex and noisy, requiring significant pre-processing, and 
since the number of MS/MS spectra is so large, analysing the data becomes a 
computational challenge. The large amount of data also brings up the issue of storage, 
although an advantage of this issue is that it allows further interpretation at a later date 
without having to re-sample and begin a new bottom-up experiment. Comprehensive 
reviews of the different DIA approaches to handle multiplexed and non-multiplexed 
MS/MS spectra can be seen in [268, 269]. A similar problem to multiplexed MS/MS 
spectra is mixture MS/MS spectra. It is often assumed that a single spectrum contains a 
single peptide, but in reality there can be multiple peptides residing in a single 
spectrum, which have the same precursor ion. A number of approaches have been 
developed over the years to identify multiple peptides from a single spectrum, including 
ProbIDTree [270], MSPLIT [271], MixDB [272] and more recently MixGF [273]. 
Approaches to addressing the problem of mixture and multiplexed MS/MS 
spectra will gradually become more mainstream as the tools improve, with an eventual 
integration of DIA with both top-down and bottom-up proteomics, thus opening up MS-
based proteomics to a whole new level and effectively putting it on the same playing 
 
 36 
field as the latest next generation genome sequencing technologies in terms of 
throughput and coverage. 
2.3.4 MS/MS spectral identification strategies 
Over the last 20 years MS/MS search tools have evolved along with the capabilities of 
the mass spectrometers at the time. The vast majority of MS/MS search approaches 
have used CID MS/MS spectra, with data obtained from DDA mass spectrometry 
approaches. Search strategies have since been extended to include other fragmentation 
types, such as ETD and HCD. Search tools have also been developed for MS/MS 
spectra acquired from DIA and also top-down proteomics. 
There are currently a large number of MS/MS identification tools available.  
These tools can be based either on: 1) identification and scoring of peptide-spectrum 
matches (PSMs) through basic database searches; 2) directly identifying sequences by 
de novo sequencing of the MS/MS spectra; 3) a hybrid de novo sequence/database 
search approach; or 4) spectral library searching which identifies MS/MS spectra from 
matches to previously identified MS/MS spectra. 
Database searching and scoring of PSMs has been the most widely used and 
applied method to date for identification of known and novel MS/MS spectra, and 
therefore greater emphasis will be placed on this technique for the remainder of the 
chapter. The methods employed to assign significance or confidence to any matches is, 
however, ubiquitous across many methods. 
2.3.5 MS/MS spectral data formats 
MS/MS spectra in the majority of cases are generated by mass spectrometers in a 
number of different proprietary formats depending on the manufacturer and their 
proprietary software package. To be able to access and mine the MS/MS spectra further 
on a variety of different pre-processing tools and search algorithms, conversion of the 
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proprietary MS/MS spectra to an open format is required. The first two open formats to 
be used in MS-based proteomics were: 1) JCAMP-DX [274], an old format used with 
early small-scale MS/MS spectra and so was unsuitable for today’s large MS/MS 
spectral datasets; and 2) the ANalytical Data Interchange Mass Spectrometry (ANDI-
MS) [275] format which was based on the Network Common Data Form (NetCDF) 
[276] library used for reading and writing common array-oriented scientific data for 
sharing. These older formats were used in the early days of proteomics until the arrival 
of the xml formats. The first xml format to be adopted was mzData [277, 278], 
developed by the Proteomics Standard Initiative (PSI) from the Human Proteome 
Organisation (HUPO), which was tasked with creating a standard format for the 
proteomics community and later was superseded by the mzML and mzXML formats. 
The mzXML format was developed by the Institute for Systems Biology - Seattle 
Proteome Centre (ISB-SPC) contemporary with the development of mzXML by HUPO-
PSI. The mzXML format was based on the eXtensible Markup Language (XML) [279, 
280], and it was later developed as a joint project between the ISB-SPC and HUPO-PSI 
by combining the concepts of mzData and mzXML [281, 282]. Other popular data 
formats include Mascot Generic Format (MGF), DTA (Sequest associated format), PKL 
(Micromass) and MS2 [283]. 
There are a number of tools capable of converting the proprietary formats to 
open formats to allow further analysis, such as ReAdW [284], mzWiff [285], and most 
recently the widely used tool msconvert [286], a part of the Proteowizard tool-kit [287] 
which is now standard with many proteomics analysis pipelines, such as the Trans-
Proteomics Pipeline (TPP) [288]. There have also been a number of new application 
programming interfaces (APIs) to allow the proteomics community to use global 
standard approaches towards the reading and writing of these data formats, to allow 
compatibility of input and output data across different groups, and to allow ease of 
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sharing data and comparing research results. An example of such an API is the 
jmzReader Java API to allow parsing of numerous mass spectrometry data formats 
[289], the jmzML Java API for parsing mzML formats [290], and in addition a new 
format from HUPO-PSI called mzIdentML which is written and read using jmzIdentML 
Java API [291]. MS-GF+ [292] is an example of a search tool already implementing the 
jmzIdentML Java API [292]. 
2.3.6 MS/MS spectra pre-processing 
To improve the confidence of MS/MS spectral identification, it is recommended that the 
MS/MS spectra go through pre-processing steps to improve their overall quality for 
database searching. This is due to a variety of reasons including MS/MS spectral noise, 
which constitutes three types: random noise, chemical noise and non-protein 
contaminant noise. MS/MS spectra can also be of poor quality due to incomplete 
fragmentation patterns and low number and/or intensity of peaks, large redundancies 
within the MS/MS spectra where there are multiple MS/MS spectra for one peptide, the 
presence of multiple mass peak isotopes (isotopomer envelopes) and multiple different 
charge state variations amongst the peptide ions in the analysed sample. There are a 
number of different approaches to address these issues, such as deisotoping, which 
selects the most representative peak from different isotopes and charge state 
deconvolution, which is the determination of the mass at a neutral charge state. 
Additionally, the quality of the MS/MS spectra can be improved by removing noisy 
MS/MS spectra, improving the signal to noise ratio, and also clustering the MS/MS 
spectra. Clustering MS/MS spectra merges similar fragmented MS/MS spectra and has 
the effect of improving the signal to noise ratio, reducing the MS/MS spectral dataset 
size, improving database search speed and reducing the occurrences of false positives. 
Overall, depending on the MS/MS spectral dataset and the type of mass spectrometer 
the MS/MS spectra were generated on, all or a number of these approaches can be used 
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to reduce the complexity of the MS/MS spectra, allowing for easier interpretation, either 
for de novo sequencing or through database searching. Many of the above mentioned 
pre-processing approaches are employed within a wide variety of different tools and 
methods (Table 2.4). 
Table 2.4 MS/MS spectral pre-processing tools and methods 
Type of MS/MS pre-processing MS/MS pre-processing tool / method Reference(s) 




(exclusive to top-down proteomics)   
[295] 




Wavelet transformation [297-299] 
PeakSelect [300] 
Quality filtering 
Binary classification and statistical regression [301] 
PepNovo [302] 
Spectrum quality classifier [303] 
Fisher linear discriminant analysis (FLDA) [304] 
EagleEye  [305] 
ScanRanker  [306] 
Spectral clustering 
MS2Grouper [307, 308] 
Pep-Miner [309] 
Metric space embedding [310, 311] 
MS-Cluster [312] 
2.3.7 MS/MS database searching 
Once MS/MS spectra have been generated and optionally pre-processed, such as by 
clustering and quality filtering, a key step is the ability to interpret the data by searching 
it against a database of known and/or putative proteins. The ability to interpret MS/MS 
spectra has improved over the last 20 years, with the development of various different 
MS/MS search algorithms, employing different searching and PSM scoring strategies to 
assign a best match between a spectrum and peptide sequence. 
One of the first search strategies developed was based on a sequence tag 
approach, which used de novo sequencing of the MS/MS spectra, limited to generating 
short sequence tags of 3-4 residues, called peptide sequence tags (PSTs), flanked by the 
masses of the N- and C- terminals. By combining this information with fragment ion 
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masses, the precursor peptide mass and its enzyme specificity, unambiguous matches 
could be found [313]. Such an approach has seen great improvements over the years in 
terms of the de novo sequencing of the MS/MS spectra [314-322] and its hybrid 
approach with peptide fragment matching [323-332]. 
An advantage of using a sequence tag approach is its ability to filter and reduce 
the size of the database, and by extension reduce the false-positive rate. This also 
improves the ability to detect PTMs, and to conduct mutation-tolerant searches, improve 
search speed, improve the accuracy compared to other popular non-tag based search 
tools [326, 327, 329, 330], as well as to effectively utilise poor quality MS/MS spectra 
with usually short peptide sequences [333]. At the same time the disadvantages of this 
approach include the difficulty of de novo interpretation of the MS/MS spectra. While 
there have been great improvements over the years with the accuracy of PST 
generation, there is still room for MS/MS spectral interpretation to improve. For 
example, with the sequence tag based tool InsPecT [326] a set number of PSTs are 
generated for any given spectrum, even if there are likely many more correct PSTs 
which could be identified. In addition, the ability to generate PSTs is reduced with 
increasing peptide length (>15aa) and poor quality MS/MS spectra, the efficiency of 
filtering large databases with short 3-4 residue PSTs is very limited due to their low 
specificity, particularly when only relatively few PSTs are generated. A similar method 
to the sequence tag approach was that employed by Look-up peaks, which uses both de 
novo sequencing and database searching [323]. 
The concept of the sequence tag approach has since evolved. Where the 
sequence tag approach was limited to a set number of MS/MS spectral interpretations, a 
new approach called spectral dictionaries reconstructs all possible full-length peptide 
sequences from a spectrum to ensure at least one of the peptides is correct. The 
approach sees improvements with efficiency and specificity over the short sequence tag 
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based approach for filtering large databases, due to the longer sequence tags and 
accuracy of the peptide reconstruction. 
The concept of the spectral dictionary was first introduced [182] and later 
implemented in a software tool called Robust Accurate Identification (RAId) [334] that 
performed slow heuristic searches, which reduced its usefulness for larger datasets. 
Recent advances in this area have seen many orders of magnitude reduction in search 
time using the spectral dictionary approach, with the tools MS-Dictionary [324] and its 
successor MS-GappedDictionary [335] (Table 2.5). MS-GappedDictionary is an 
extension to the spectral dictionary approach using gapped peptide sequences 
(substrings substituted with mass values) to resolve poor ambiguous MS/MS spectra, 
different amino acid combinations resulting in the same mass shift, and adaptively 
generating peptide reconstructions for long peptides (>15aa), using forward-backward 
dynamic programming. Applying this approach permits many more peptide 
reconstructions for any given MS/MS spectral dataset and it is amenable to mutation-
tolerant searches and searches of large databases, such as the six-frame translations of 
the human genome in relatively short time frames, compared to other sequence tag 
based and non-sequence tag based search tools [325, 335]. 
The gapped peptide approach has since been extended to interpret other MS/MS 
spectral types (CID, ETD, HCD and MS/MS spectral pairs CID/ETD) in the de novo 
sequencing tool UniNovo [336]. Recent developments have pushed the length of de 
novo peptide reconstructions further to sequence grade levels, using multiple MS/MS 
spectral types (CID, ETD and HCD) in combination with multiple protease digests to 
achieve many more covering peptides, achieving much longer consensus lengths 
between 60 aa and 200 aa of length with 99% sequence accuracy [337, 338]. Another 
development which interprets top-down and bottom-up MS/MS spectra, reconstructs the 
sequences, and uses the top-down longer peptide sequences as scaffolds with the short 
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peptide sequences from bottom-up to improve the coverage across the scaffolds, similar 
to the concept used in genome assembly [339]. 
During the same time that de novo sequencing, the sequence tag approach and 
PMF were being developed, a different database search approach termed Peptide 
Fragment Fingerprinting (PFF) [340] was rapidly evolving in parallel. PFF is an 
analogous concept to PMF, but instead it looks at matching many fragments from a 
parent peptide. This approach did not require interpretation of the MS/MS spectra as 
with de novo sequencing, but instead relied solely on matching the mass values from all 
the MS/MS spectra against all calculated mass values interpreted from the database. The 
basic principle behind the approach is that it mimics the bottom-up experiment by 
digesting the protein sequences in the database in silico with the same protease used in 
the experiment. All the theoretical peptide sequences that match the experimental 
peptide mass within a chosen maximum mass deviation (MMD) are then chosen as 
candidates. Each of these peptide candidates are then investigated further at the MS/MS 
level by comparing the experimental and theoretical peptide fragmentation patterns and 
then ranking/scoring the peptide and peptide fragment matches by the level of 
correlation between the patterns, which often differ between the MS/MS search 
algorithms employed. To account for PTMs, the theoretical MS/MS spectra derived 
from in silico digestion of the sequence include an additional mass shift for each peptide 
fragment corresponding to the mass of all (an exhaustively long ‘blind’ search) or the 
masses of a chosen list of modification(s). 
Yates and Eng first demonstrated the PFF approach for database searching in 
1994, employed in the MS/MS database search tool, Sequest [341, 342]. Since that time 
many similar approaches have been devised, as well as approaches which have 
incorporated sequence tags, spectral dictionaries, gapped peptides, and/or spectral 
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probability (Table 2.5). There have been many other reviews in the literature covering 
other search tools and strategies [343-346]. 
Table 2.5 Types of MS/MS database search tools and their employed methods 
Method MS/MS database search tool Reference(s) 
PFF 











PFF with spectral dictionary RAId [334] 
PFF with spectral dictionary and spectral probability MS-Dictionary [324] 
PFF with gapped peptides, spectral dictionary and 
spectral probability 
MS-GappedDictionary [335] 
PFF with spectral probability and scoring for multiple 
types of spectra 
MS-GF+ [292] 
For a long time the proteomics community has been split on how best to 
interpret MS/MS spectra through database searching and the control of false positives. 
This eventually culminated in a study in 2004, which found many reported results in the 
proteomics community had a very high false discovery rate (FDR). As a result, stricter 
guidelines became required for publication [349], and two years later a study conducted 
by HUPO across a number of laboratories [350, 351] also found widely inconsistent 
results [352], with less than 50% of results in agreement. This illustrates just how 
difficult MS/MS spectral identification is and it highlights a number of challenges 
which still need to be met, including the protein inference problem [220], and the 
inherently poor reproducibility of bottom-up, DDA-based proteomics. As a result of this 
study, HUPO-PSI was formed [353], providing community guidance on the 
standardization and validation of proteomics results. HUPO-PSI further enforced a 
requirement to share all the raw data associated with any publications through public 
repositories such as PeptideAtlas [354], PRoteomics IDEntifications (PRIDE) database 
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[355] and ProteomeXchange [356], and in addition developed standard proteomics data 
formats such as mzXML, mzML and mzIdentML. HUPO-PSI also concluded that there 
was a pressing need for standardization across different studies; concluding that any 
comprehensive proteomics study should endeavour to improve these standards, and 
apply strategies which can better discriminate between true and false positives. Such 
approaches could be a means to combine results from multiple search tools, to provide 
more robust and well-rounded peptide matching strategies, improve search speed and 
improve the number and confidence of matches found. 
To address the needs outlined by HUPO, a number of advances have occurred in 
the development of database search algorithms. Approaches which improve the 
sensitivity, speed and number of peptide identifications, include tools such as MS-
GappedDictionary, outlined previously, addressing the issue of search speed and 
improving the number of identifications compared to other non-gapped peptide 
approaches such as OMSSA, InsPecT and MS-Dictionary (Table 2.5). MS-
GappedDictionary achieved this by generating a spectral dictionary and rigorously 
determining the spectral probabilities (p-values) of each PSM using the generating 
function approach [357]. However, this approach, and other similar full length peptide 
sequence and tag based approaches similar to it, were limited when it came to highly 
charged MS/MS spectra [325]. Approaches that were not limited by MS/MS spectral 
charge included non-tag-based methods such as MS-GF+ (Table 2.5). The MS-GF+ 
search tool uses the MS-GF scoring model first implemented in MS-Dictionary, and is 
able to automatically determine the scoring parameters for a variety of different MS/MS 
spectral types (CID, ETD, and CID/ETD pairs) and proteases (trypsin, LysN etc.).  
Following peptide identification, it is necessary to identify the proteins from 
which the peptides were derived from. However, confident protein identification can be 
hampered by the protein inference problem first mentioned in Section 2.3.1. Although 
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top-down or middle-down proteomics directly addresses the protein inference problem, 
it is not as widely used and does not provide good overall coverage of the entire 
proteome compared to bottom-up mass spectrometry. With the protein inference 
problem still an issue for bottom-up mass spectrometry, algorithmic and database 
construction approaches have arisen [220], such as resorting to infer only a group of 
potential proteins, or infer likely candidates using approaches such as those outlined in 
Table 2.6. 
Table 2.6 Algorithmic and database approaches for the protein inference problem 
Method Protein inference tool/approach Reference(s) 
Expectation-maximization ProteinProphet [219] 
Bayesian Empirical Bayes Protein (EBP) identifier [358] 
Parsimony IDPicker 2.0 [359, 360] 
Deterministic PeptideClassifier [361, 362] 
Graph theory Clique-enrichment approach (CEA) [363] 
Heuristic 
Prediction of proteotypic peptides for protein identification [364] 
Minimum acceptable detectability for identified peptides 
(MDIP) 
[365] 
Minimum protein set with incorporated peptide detectability [366] 
Peptide-centric 
IsoformResolver [367] 
PEPtidomics Protein Isoform (PEPPI) database [368] 
Mass spectrometry-centric sequence database (MScDB) [369] 
The presence of contaminant MS/MS spectra, derived from non-target proteins 
is a problem in proteomics, and can often lead to misidentifications. To account for 
potential contaminants entering a sample it is standard practice to append contaminant 
sequences to the database before searching. Often this consists of human keratin and 
trypsin and other enzymes used in the analysis, as well as any contaminants deemed 
likely to appear due to sampling and handling. MS/MS spectra exclusively matching the 
contaminants can then be removed during the analysis. 
2.3.8 Next generation MS/MS database search technology 
As outlined previously, new approaches for MS/MS database searching for bottom-up 
proteomics are breaking new ground, such as the methods employed by MS-GF+ and 
MS-GappedDictionary. However, other MS/MS database search technologies are 
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beginning to look beyond traditional bottom-up proteomics, to how best to manage and 
interpret the MS/MS spectra from top-down and DIA mass spectrometry. Both 
methods, which have been around for over a decade, are now becoming viable for more 
complex samples and throughputs, opening them up to truly mine the proteome. 
Unfortunately, there has been a lag in the development of MS/MS database search tools 
tailored towards such datasets. 
Top-down MS/MS spectra are highly complex, and to be used in an MS/MS 
database search tool first requires pre-processing to reduce complexity. The MS/MS 
spectra are usually first deconvoluted to their monoisotopic masses (determining the 
mass and charge of the fragment ions from a group of isotope peaks called a isotopomer 
envelope). This can be done via a variety of tools such as Thrash [370], Xtract [371] 
and the more recently MS-Deconv [295]. The spectrum now containing only 
monoisotopic masses is then scored against proteins in a database using a database 
search tool to generate a Protein-Spectrum-Match (PrSM). A number of top-down 
search tools have been developed over the last decade, which include ProSightPC [372, 
373], PIITA [243] and USTag [241], MS-TopDown [374], top-down versions of 
Mascot [375], Sequest [240], and OMSSA [348] search tools and more recently the 
search tools MS-Align+ [376] and its improved version MS-Align-E [377] to identify 
multiple proteoforms from highly modified proteins. Further developments are needed 
in this area to more confidently identify all the various proteoforms in complex samples, 
particularly for large highly modified proteins. In addition there is currently a high-
throughput top-down search strategy in development at Pacific Norwest National 
Laboratories (PNNL) called IQ Top-down, using information from MS1 spectra to 
validate proteoforms [378]. 
The range of MS/MS database search tools to directly interpret DIA MS/MS 
spectra is limited in comparison to those available for DDA. This is because DIA 
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MS/MS spectra requires significant pre-processing (charge/isotopic deconvolution), and 
require conversion into DDA-like MS/MS spectra before interpretation [268]. 
A number of DIA-compatible tools have been developed to meet the need for 
DIA MS/MS spectral interpretation. For example, the MSE approach uses the 
IDENTITYE database search tool [379] but lacks any estimation on FDR, requiring 
validation from conventional DDA approaches [380]. Alternatively, a modified 
approach to MSE, called Ion mobility spectrometry (IMS) assisted MSE (HDMSE) 
[381], applies an additional separation in the gas phase improving proteome coverage 
by up to 60% and then uses a database search tool called Synapter which, unlike 
IDENTITYE, allows control of the FDR [382]. For AIF MS/MS spectra there is an 
MS/MS data processing package called MaxQuant, which in combination with the 
DDA based Andromeda MS/MS database search tool is able to process and interpret 
DIA MS/MS spectra from AIF, and produces pseudo MS/MS spectra before 
interpretation by Andromeda against a database with FDR control [259, 383]. For FT-
ARM MS/MS spectra, there is the FT-ARM analysis tool, which creates hypothetical 
MS/MS spectra from in silico enzymatic digests from a database and scores each 
hypothetical MS/MS spectra against all the acquired multiplexed fragmentation MS/MS 
spectra, and also applies a control on FDR [260]. There are also a number of tools still 
under development, for example, SWATH spectral analysis, which does not currently 
have any established database search tools as it is incompatible with database search 
approaches [268]. However, recently an open-source tool called SWATH-Umpire, 
claimed to extract SWATH signal features from MS1 and MS2 and assemble them into 
pseudo MS/MS spectra compatible with DDA based search tools [384]. Lastly, there are 
other tools under development from Pacific Northwest National Laboratories (PNNL), 
such as IC bottom-up, which is a universal tool for both DIA and DDA, and 
demonstrates improvements over advanced tools such as MS-GF+ [378]. Additionally, 
 
 48 
approaches such as PAcIFIC, generate MS/MS spectra compatible with conventional 
DDA-based search tools, and recent developments have demonstrated how the approach 
can be applied to top-down mass spectrometry by combining the PAcIFIC approach 
with the top-down search tool, PIITA [385]. 
Instead of identifying MS/MS spectra against a database of putative and/or 
known protein sequences resulting in a PSM, an alternative form of database searching 
is to match the MS/MS spectra against a spectral library (database) of other curated 
spectra to identify a spectrum-spectrum match (SSM). The technique is called spectral 
library searching and was first pioneered by Domokos [386], and later adapted for 
peptide mass spectrometry [387]. The concept relies on the previous identification of 
MS/MS spectra to populate the spectral library with identified MS/MS spectra. The 
searching of spectral libraries is fast, precise, has an improved PTM identification rate 
and has fewer false positives, rivalling the majority of conventional database search 
tools and strategies. A number of tools that have been developed to search and identify 
MS/MS spectra in this way are outlined in Table 2.7. Of particular note is the Tremolo 
spectral library search tool, which is a recent advancement, utilizing a spectral library 
generating function approach to identify SSMs. The concept was first demonstrated in 
MS-GF+, a conventional database search tool, which when compared to spectral library 
tools such as SpectraST was comparable in sensitivity indicating a likely route for 
improvement of spectral library searching [292]. A number of spectral libraries have 
been established over the years, which include PeptideAtlas [354], Cardiac Organellar 
Protein Atlas Knowledgebase (COPaKB) [388], NIST Libraries of Peptide Tandem 





Table 2.7 Spectral library search tools 
Search tool Reference(s) 
SpectraST [391] 





MSplit (multiplexed spectral library search) [271] 
MSplit-DIA (multiplexed spectral library search) Currently under review [396] 
Tremolo [397] 
Recently, an approach called Spectral archives [398, 399] was developed, 
expanding on MS-Cluster to generate an archive of many large spectral datasets. With 
this approach the identification of MS/MS spectra becomes rapid, achieves high 
specificity, and is amenable to the identification of novel MS/MS spectra such as 
biomarkers and unknown proteins/genes, which would then contribute to a proteomics 
community consensus of other unidentified MS/MS spectra in the cluster, improving its 
overall representation and confidence of a real identification. Previously, such an 
approach only searched MS/MS spectra against a locally known set of curated MS/MS 
spectra or in the case of a conventional database approach, a protein sequence database. 
The concept of spectral archives was later extended to molecular networks, where any 
class of molecule can be rapidly and confidently identified within both the proteomics 
and metabolomics domains [400]. 
The identification of MS/MS spectra by searching a conventional sequence 
database has a number of caveats when compared to spectral library/archive searching: 
1) the database is often only limited to ‘known’ protein sequences, while adding more 
putative proteins will improve identifications, it will also hamper identifications as the 
database size increases, reducing sensitivity; 2) the database contains many stretches of 
homologous sequences (e.g. larger numbers of isoforms) making identifications, 
particularly of short sequences, difficult; 3) incomplete proteolytic cleavage or 
fragmentation of MS/MS spectra can lead to misidentifications; 4) the presence of 
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unaccounted for PTMs and sequence polymorphisms can lead to misidentifications; 5) 
the potential for erroneous sequences in the database is high, often derived from 
genomic sequences with potential sequencing errors; and 6) usually the search is limited 
to peptides which have been proteolytically cleaved (e.g. tryptic peptides) to reduce the 
occurrence of spurious PSMs and limit the search to only tryptic sequences, improving 
the search speed and sensitivity. 
The sensitivity of a MS/MS spectral identification is inversely proportional to 
the size of the search space. The search space of de novo sequencing is much larger than 
conventional databases, and more so when compared to spectral libraries. This is 
because the number of MS/MS spectral interpretations is far greater when interpreting 
MS/MS spectra into a large number of possible peptides, without being limited to 
matching to a chosen number of sequences (PSMs) or a select number of curated 
MS/MS spectra (SSMs). This indicates that of all the methods of MS/MS spectral 
identification, the spectral library approach is more sensitive, but until the method 
matures and spectral archives are more widely supported by the proteomics community 
for the identification of known and unknown MS/MS spectra, the conventional database 
approach will remain more widely used. 
2.3.9 Statistical approaches for peptide and protein identification 
The search algorithms that MS/MS database search tools employ, use PSM scores to 
determine the confidence of a match between the experimental MS/MS spectra and a 
number of matches to other theoretical MS/MS spectra derived from the protein 
database. Many different scoring systems have been implemented in search tools 





Table 2.8 PSM scoring methods in some common MS/MS database search tools 
Method MS/MS database search tool  Reference(s) 
Cross correlation between theoretical and 
observed MS/MS spectra 
Sequest [341, 342] 
Bayesian probability based on the number of 
ions matching a peptide sequence in the 
protein database 
Mascot [165] 
Dynamic programming using k-similarity 
statistics 
MS-Alignment [401, 402] 
Calculated probability factors PeptideSearch [313] 
Spectral energy (Delta energy between the 





Further scoring of PSMs during post-processing is possible, using a probabilistic 
score (e.g. peptide probability), determined through expectation-maximisation in 
PeptideProphet [403] and iProphet [404], a support vector machine in Percolator [405], 
probabilistic network in PepNovo [302] and generating function in MS-GF [357]. The 
post-processing tool, iProphet, was also able to combine multiple search results, 
applying a protein or peptide probability as a score derived from across all results [406]. 
Other re-scoring tools such as Percolator and MS-GF are also able to achieve this, to 
normalise and combine results. 
Of particular note from Table 2.8, is the MS/MS database search tool MS-GF+ 
(an extension of MS-GF), which when also applying the spectral probability to all 
identified PSMs as a score for FDR filtering, was shown to identify more peptides than 
other well established search tools [292, 407], such as Mascot [165], Sequest [341, 
342], OMSSA [348] or a combination of these, rescored with PeptideProphet [403], 
iProphet [404] or Percolator [405]. 
The scores obtained from various MS/MS database search tools are ranked and 
in most cases the top matching MS/MS spectra are chosen, which are then further 
analysed at the MS/MS level by comparing the theoretical and experimental peptide 
fragmentation patterns. Each match can then also be further ranked by significance 
estimates via the false positive rate (FPR) or p-value and E-value. The p-value is 
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essentially the chance that any individual PSM is incorrect, determined from the 
fraction of all incorrect PSMs above a certain score threshold over all the incorrect 
PSMs, and can be extended to the E-value in multiple hypothesis testing which is the 
product of all p-values and the number of tests, or more simply put, the expected 
number of times that a PSM is observed with a particular score, by chance alone. The p-
value threshold, usually either 5% or 1%, can then be applied, delegating matches as 
significant and rejecting the null hypothesis (all matches known to be incorrect), or in 
agreement with it, delegating the match as incorrect. A number of methods have been 
devised to estimate the p-value over the years, mostly through empirical methods, such 
as those outlined in Table 2.9. 
Table 2.9 Examples of methods employed to estimate the FPR 
Method Description Reference(s) 
Score distribution 
Models the distribution of all scores to determine the 
significance at the tale of the distribution. 
[408, 409] 
Poisson distribution 
Models the distribution of false-positive matches given some 
prior criteria (e.g. peptide length, protein database size etc). 
[351] 
Bayesian probability model 
Probability of the match being correct given certain criteria 
such as fragmentation ion types, prior MS/MS spectra and 
peptide knowledge across an experiment. 
[219, 403, 410] 
Decoy database 
A null hypothesis is generated. This is done by reversing, 
shuffling or randomizing the target sequences. 
[411-415] 
The decoy database mentioned in Table 2.9, is a more common approach due to 
its simplicity, and empirically represents the null hypothesis. Using the decoy database 
approach as an example, the estimated FPR can be calculated by determining the 
number of matches to the decoy database over the number of total decoys. However, 
since the number of matches to the decoy is usually very small or zero, to calculate 
accurate FPRs the decoy database would need to be extremely large, which is 
impractical (and is usually the same size as the target database), so matches need to be 
grouped by the same score to estimate the FPR which tends to be inaccurate [357]. In 
addition, PSM scores from different MS/MS search tools use heuristic methods, which 
do not correlate well with their FPRs, since many search algorithms usually assign 
similar scores to the top-most ranking PSMs. As a consequence, the estimation of their 
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FPRs are more often inaccurate, resulting in an overlap between all correct and 
incorrect identifications above a certain score threshold. To help reduce the number of 
false positives, a variety of different search algorithms employ heuristic measures to 
their scoring, such as taking into consideration the difference between the score of the 
best match and the second best match, the peptide charge state, peak intensity, the 
fraction of b ions, and many other properties. 
As datasets became larger and multiple hypothesis testing increased it soon 
became apparent that control of the number of false positives across all tests was 
needed, which resulted in the now popular approach, called the false discovery rate 
(FDR), first pioneered by Benjamini and Hochberg [416]. A decoy database is a 
common method to determine the FDR, which can be either concatenated with the 
target database and searched or treated as separate databases. Depending on the chosen 
method, the FDR can be calculated, either by counting the number of decoy matches 
above a particular score over all matches to the target above the score or by multiplying 
2 by the number of decoy matches above a particular score over the combined number 
of decoy and target matches above the score [411, 412, 417]. The FDR can then be used 
to remove groups of matches delegated as false, which is usually applied at the PSM-
level, or to be more conservative and reduce false positives the FDR is applied at the 
peptide-level, a common and recommended strategy in proteomics studies. This is due 
to single peptides often being derived from multiple MS/MS spectra, with some 
potentially being spurious, resulting in very different numbers of identified PSMs 
between PSM-level and peptide-level FDRs. 
Strictly applying filters using the p-value, E-value or FDR, runs the risk of either 
being too strict or too lenient, filtering out many true positives or including too many 
false positives, respectively. An approach found to alleviate this problem was adopted 
from genome-wide linkage analysis studies. The use of smaller datasets during the early 
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genomics era, required only p-value cut-offs and they were often made strict to avoid 
any false positives, a valid approach when there are relatively few hypotheses being 
tested in a single small study. In recent times, with larger datasets being generated 
through high-throughput methods, there are now often thousands to millions of multiple 
hypothesis tests being conducted in a study, with many more genomic features now 
being considered significant. As pointed out earlier, a high level of statistical 
significance does not equate to a true positive, and so caution is needed when 
considering every significant feature.  It was found that simply applying strict p-value 
cut-offs across all hypothesis tests runs the risk of removing true positives, and 
therefore further approaches need to be applied to retain as many true positives as 
possible, while minimizing the false positives [418]. 
Although the FDR measures the significance of a group of PSMs, it does not 
provide a level of significance for each PSM, and hence a different approach is 
necessary to improve sensitivity. This can be achieved using the Posterior Error 
Probabilities (PEP) and q-value. The PEP can be considered as a local FDR (lFDR), and 
was coined as such by Efron et al. [419]. When using very large datasets the p-value can 
be very small by chance alone, limiting its use, and hence a different approach is 
required in the form of q-values. The q-value is a p-value analog based on the FDR, 
while the p-value is based on the FPR. The q-value, unlike the p-value, includes 
multiple testing corrections, by determining the minimum FDR of a significant PSM 
score. In other words, the q-value provides the proportion of incorrect identifications 
amongst all those considered significant [418]. The PEP or lFDR is the probability that 
an individual observation (e.g. a single PSM) with a particular score, is found from 
within the null distribution (e.g. a false peptide within a decoy database) [420, 421], and 
by summing all the PEPs/lFDRs of significance and dividing by the total number of 
PEPs/lFDRs, the FDR for that group of PSMs can be determined [422]. The q-value and 
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PEP/lFDR are usually used in a two-tier approach towards PSM validation. The q-value 
estimates the rate of incorrect PSMs from a group, while the PEP/lFDR applies 
significance to whether a particular peptide or protein is present or not. Hence, the first 
pass of assessing PSM significance should be with a q-value threshold to filter out 
likely incorrect PSMs, after which a second pass with the PEP/lFDR is used to 
determine the likelihood of the remaining PSMs being truly present [421]. 
The FPR is a measure of the quality of a single PSM and is the best approach 
towards discriminating true and false positives. Recent approaches to derive the FPR or 
p-value using theoretical means have been developed [357, 423], but they rely on the 
assumption that each peptide derived from the spectrum is equally likely. One of these 
approaches uses the generating function, a commonly used combinatorics approach 
implemented in MS-GF+ [292]. The method determines the spectral probability (p-
value) determined from all theoretically possible peptide reconstructions, and spectral 
energy (score) for each PSM determined from the difference in score between the best 
peptide reconstruction and the best database peptide. The approach theoretically 
determines the FPR or p-value, as opposed to empirically using Bayesian algorithms or 
the use of decoy databases, mentioned previously. The E-value and FDR and 
consequently the q-value and PEP/lFDR can then be determined from the theoretically 
derived FPR, thus avoiding the need for a target-decoy approach (TDA) [357] due to its 
many short comings [424]. The ability to calculate theoretical FPRs, and by association 
theoretical FDRs, is crucial for studies requiring a reliable distinction between true and 
false PSMs, such as in metaproteomics, proteogenomics or with the identification of 
rare PTMs [424]. However, the empirical approach using TDA still remains the 
standard approach undertaken by many studies, with no study conducted thus far using 
the FPR alone. This is a direct result of the limitation of the current available MS/MS 
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database search tools, which still have to rely on empirical approaches to determine an 
approximate FPR for proteomics and proteogenomics studies. 
Recent developments to alleviate this problem eventuated in the study which 
developed MS-GF+ [292], which found that the spectral probability of a spectrum, 
independent of the database, was able to closely predict the FDR with low-low 
precision MS/MS data obtained from LTQ experiments, but produced inaccurate 
predictions with the more commonly used high-low and high-high MS/MS data 
obtained from machines such as LTQ Orbitrap and QTOF respectively. Such 
discrepancies are seen when using high precision MS data with tighter precursor mass 
tolerances (e.g. parts per million (ppm)) compared to wider fixed value precursor mass 
tolerances (e.g. Daltons (Da)) for low-low precision MS data. The tighter tolerances 
reduce the search space and inflates the expected FDR and E-values determined from 
the spectral probability, while loose tolerances with low precision MS/MS data increase 
the search space, reducing the factual FDR and E-values determined from the TDA 
[292]. 
High precision MS/MS data is important to resolve and identify many multiply 
charged peptide ions as mentioned previously, and so even though more peptides can be 
identified with higher precision, at the same time their expected FDRs cannot be 
determined with the same level of precision using the spectral probability or FPR alone. 
Consequently, the TDA is still an essential tool in proteomics, until a more robust 
strategy can be developed to determine the FDR accurately, independent of the 
database. 
Continuing on from the theme of resolving the protein inference problem, 
highlighted in Section 2.3.7. Apart from the algorithmic methods listed in Table 2.6, 
there is a general rule in proteomics, to identify proteins considered statistically valid, 
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by arbitrarily filtering all proteins, which contain at least two identified peptides. This is 
called the “two-peptide rule”, which essentially filters out all single-hit protein matches, 
often referred to as “one-hit-wonders”, and which are considered as potential false 
positives. Another approach that can be combined with the two-peptide rule to further 
improve confidence of protein identification is percent protein coverage. The larger the 
proportion of protein sequence which is covered by identified peptides, the more 
confident that the protein has been identified, and that the peptides have not simply been 
derived from other similar proteins, protein isoforms or paralogs. In cases where 
proteins are small, the percent protein coverage may likely be higher, and the level of 
protein coverage obtainable would also be dependent on the type and number of 
proteases used. 
Other more complex approaches include ProteinProphet [219] mentioned in 
Table 2.6, which uses an expectation-maximization algorithm to derive a minimum 
protein list and assigns a protein probability to each identified protein. 
Although the two-peptide rule and percent protein coverage are capable of 
confidently identifying proteins, these approaches also result in losses due to many 
filtered out one-hit-wonders being real matches. In addition, relying simply on 
maximizing peptide matches does not equate to protein identifications, as many 
peptides can be shared across different protein isoforms, which would result in biases 
skewing the calculated protein FDR. One approach, superior to the two-peptide rule and 
the ProteinProphet approach is the single-peptide rule in combination with a rigorous 
FPR calculation, using the generating function approach, and extending it to protein 
identification to determine the protein FPR. Using this approach Gupta et al. [425] 
found significant improvements compared to ProteinProphet and the two-peptide rule, 
confirming that single-hit peptides in orthologs of other species accounted for an 
additional ~25% of proteins missed by the two-peptide rule. However, to account for 
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protein isoforms, applying a unique peptide rule on the final aggregate of proteins 
identified would remove any potentially incorrectly included protein isoforms. A 
comprehensive review published in 2010, outlines many of the above mentioned 
statistical methods [426]. 
As mentioned earlier in Section 2.3.8, the precursor mass tolerance and the size 
of the database have an effect on the sensitivity of a database search. Adding further 
PTMs to a search also has the same effect [357, 402, 427-429]. The most widely applied 
method to improve on the search space is to reduce the database size where possible and 
to only search for commonly used PTMs such as carbamidomethylation of cysteine, 
oxidation of methionine and protein N-terminal acetylation, and to limit the number of 
modifications per peptide to at least two. Further reduction of the database size is 
possible by applying a two-pass search approach, which was first pioneered by Craig 
and Beavis [430], and can be applied for particular cases where the database size is 
overly large. This can be done by first performing a search with no FDR filtering and no 
decoy database, thus identifying matching protein sequences, and then performing the 
search a second time using the identified sequences as the target database and their 
decoys, followed by FDR filtering. 
All these approaches would maximize the number of matches obtainable, 
compared to the inclusion of further PTMs or additional sequences. The study from 
[427] assessed many of these search strategies and others, and found that for MS-based 






Table 2.10 Optimal methods for proteomics analysis 
Method number Method 
1 Use a reversed decoy database. 
2 Concatenate target and decoy databases. 
3 
Calculate FDR by counting the number of decoy matches over all matches to the target, 
above a score. 
4 Use the smallest possible database. 
5 Filter out of all unidentifiable MS/MS spectra. 
6 Apply tighter parent mass tolerances where possible during the database search. 
7 
Normalise PSM scores when possible. For example use q-values, p-values, local FDRs, 
peptide probability/posterior probability and spectral probability. 
8 
Apply peptide-level FDR filtering for protein identification or accurate PSM-level FDR 
filtering, when warranted, such as with metaproteomics or proteogenomics. 
9 
Apply a two-pass search approach, although the gains could possibly be reduced for 
higher complexity samples. 
10 Carefully select appropriate PTMs. 
11 
Choose an appropriate MS/MS acquisition mode, such as MS/MS and MS/MS/MS for 
higher mass accuracy. 
12 Use spectral library searching when possible. 
All twelve of the above mentioned methods could have a significant impact on 
sensitivity of PSM identification during a MS/MS database search. Other approaches to 
improve upon the sensitivity of a database search include limiting the peptide fractions 
to a particular range of isoelectric points (pIs), predicting the pI of sequences within the 
target database and limiting the search space to the same pI range when performing the 
MS/MS database search [429]. More complicated and extensive proteomics procedures 
can be used to improve the sensitivity and gains from mining the proteome, which 
include multi-stage peptide identification. This involves an exhaustive iterative process 
of performing a general search, further processing of unassigned high quality MS/MS 
spectra, “blind” PTM searches [402, 431], followed by a more focused search for highly 
frequent PTMs, spectral library searching, and then any remaining unassigned MS/MS 
spectra searched against large translated genomic databases [426]. 
It is the searching of large translated genomic databases, and how to manage 
such a search, which is the primary focus of this thesis. The following section outlines 




This section provides an in-depth background on proteogenomics, the focal point of this 
thesis. It provides an overview of the challenges, important dataset considerations, 
methods of statistical analysis, how best to interpret the results, and provides a review 
of a number of proteogenomics tools. 
Proteogenomics is a new genome annotation approach that has emerged over the 
last decade, which merges peptide mass spectrometry with genome and transcriptome 
data. The traditional approach towards genome annotation particularly for the protein-
coding portion of a genome has often been limited to direct protein-level evidence or 
putative translations from gene predictions. A number of annotation strategies, such as 
the automated Ensembl Analysis Pipeline [432], HAVANA analysis pipeline [143] and 
MAKER2 [137], previously mentioned in Section 2.2.2 and Table 2.3, all rely on 
UniProtKB/SwissProt [433, 434] protein sequences, however only 5% of the sequences 
are derived directly from proteins (http://www.uniprot.org/faq/37). These strategies are 
determined from sequencing efforts using Edman degradation or de novo sequencing 
through mass spectrometry, while the majority of remaining protein sequences are 
putative, derived from translations of cDNA and gene predictions which may be 
erroneous. This traditional approach to proteomics follows the assumption that all the 
proteins which make up the protein-coding space are known, and that each protein is 
accurately defined, and are all mirrored in protein sequence databases, such as 
UniProtKB, Ensembl and RefSeq [435]. Any protein identifications and quantifications 
carried out are based on these assumptions. As such, the past few decades of proteomics 
have been skewed to this view and so they ignore the possibility of a hidden proteome. 
In reality, many peptides derived from proteomics experiments are not present in the 
reference database or possibly no known reference database. This is in part due to the 
fact that many MS-derived peptides contain mutations or are derived from novel protein 
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isoforms or proteoforms, as well as many translated gene predictions or cDNA 
sequences. Additionally, many protein sequences populating the databases may be 
incomplete due to gene prediction biases or missing information at the transcriptional 
level. 
Historically, genomics and proteomics have been conducted separately, with the 
proteomics being carried out after genome sequencing, assembly and annotation. In 
recent years a new field has emerged which uses mass spectrometry-based proteomic 
data to annotate a genome with direct peptide evidence, thus complementing current 
annotations by unambiguously determining the reading frame, translation start and stop 
sites, splice boundaries, validation of short ORFs, and the identification of novel genes 
[436-439]. This new genome annotation strategy was first investigated by Jaffe et al. 
[440], who coined it proteogenomics, and it has since been applied to many other 
organisms, such as Drosophila melanogaster [441, 442], Arabidopsis thaliana [81], 
Yersinia pestis [443], Pristionchus pacificus [84], Mus musculus [444], Ruegeria 
pomeroyi [445, 446], Shewanella oneidensis [447, 448], Vitis vinifera [8], Zea mays 
[82], and Homo sapiens [11, 449-451]. 
Proteogenomics is an important new field, because it assists in the improvement 
of gene predictions as well as the direct validation of known genes as protein-coding. 
By approaching genome annotation top-down (genomics) and bottom-up (proteomics) a 
more complete and thorough analysis of gene models can be achieved. Besides the key 
benefits to refining gene models, other benefits include: 1) spectral counting to infer 
expression levels; 2) the discovery of alternative translation initiation start (TIS) sites 
through identification of N-terminal peptides, either through standard identification of 
N-terminal acetylated peptides by MS/MS database search or with a more rigorous 
approach employing the enrichment of N-terminal peptides through N-terminomics 
[452]; and 3) the determination of post-translational/processing modification sites, e.g. 
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to identify signal peptide cleavage sites. Figure 2.5 (modified from [148]), outlines the 
key differences between genomics and proteogenomics approaches. 
Figure 2.5 Genomics versus Proteogenomics 
The (A) genomics approach is linear from gene prediction at the genomics level, with protein coding 
validation of the predictions at the proteomics level. However, the (B) proteogenomics approach utilises 
MS-based proteomics to infer the gene predictions and annotations directly in the genome in a 
complementary way with the genomics approach, iteratively improving the annotations with further 
peptide mass spectrometry evidence (image modified from [148]). 
2.4.1 Defining a proteogenomics search 
The aim of proteogenomics is to identify unknown protein-coding regions, and to 
correct and validate the known gene models. This entails performing database searches 
of MS/MS spectra against the known proteome and a putative search space to identify 
peptides and map them to these regions. These unidentified protein-coding regions 
could identify potential novel protein-coding loci (novel genes), expressed 
pseudogenes/lncRNA, and intergenic regions, such as between genes. Or by extending 
the known gene boundaries within a predefined linkage distance [82], within 
untranslated regions (UTRs), between exons of a gene (i.e. within introns), on different 
frames as those suggested by the known gene, and across splice junctions (Figure 2.6). 
In addition known genes can be further refined through the identification of alternative 
TIS sites inferred from N-terminal peptides to infer over-predicted genes. 
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Figure 2.6 Proteogenomics annotation events 
The range of proteogenomics annotations, which fall outside of the known annotations, can be classified 
as a novel protein-coding locus (novel gene), expressed pseudogene/long non-coding RNA (lncRNA), 
untranslated UTR regions, alternative splice junctions, exon boundaries, novel exons (novel peptides 
mapped within an intron) and alternative frames. In addition, not illustrated in this figure are gene 
boundaries (within predefined boundaries closely flanking the gene region) (image courtesy of [439]). 
Generating databases to reflect all these possible protein-coding regions is not 
trivial. They can be defined by 1): a six-frame translation of the genome, which was 
first pioneered by Yates et al [453] and is usually limited in size to open reading frames 
(ORFs) of around 30-40 amino acids, to reflect the most likely minimum peptide length 
and protein coding portion of the genome and to restrict the extent of the inflated 
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database size. This type of approach is commonly applied in various studies across a 
range of organisms [81, 82, 443, 453-456]. But this does not cater for peptides spanning 
exon-exon junctions. In such situations de novo sequencing of the un-assigned MS/MS 
spectra could account for peptides spanning these exon-exon junctions. However, as 
previously mentioned, de novo sequencing has a larger search space and is highly error-
prone. Other methods are therefore needed to define the exon-exon junction search 
space, such as with 2): ab initio gene predictions, which are able to predict the gene and 
the internal exon-exon junctions using numerous tools (as discussed in Section 2.2.2). 
This limits the size to the most likely coding regions, ORFs and exon-exon junctions 
given some prior evidence, as demonstrated in a previous study [444]. Although this 
limits the search space and includes exon-exon junctions, it biases the search to 
whatever the ab initio method considers being a real gene feature and limits the scope 
for the discovery of novel annotations. Additionally, many incorrect and missing gene 
annotations are a direct result of the limitations of ab initio gene prediction. 
 Previous studies have applied this approach in conjunction with a six-frame 
translation to define a separate exon-exon junction search space, derived from cDNA 
evidence, with each exon represented only once in a compact exon splice graph [81, 82, 
457]. An alternative method is to use 3): a six-frame translation of ESTs, which would 
provide experimental evidence of expressed sequences and limited splicing information 
(due to sequencing bias at the 3’ end), which would include novel splice sites and single 
amino acid polymorphisms (SAPs). Although this has the same limitations as a pure 
six-frame translation of ORFs with its large size, EST datasets can be reduced in size by 
applying a series of stringent criteria to best represent the most likely coding regions 
and representing the sequences in a de Bruijn graph [458], as well as the option to align 
multiple ESTs to genomic regions, and determine exon-intron boundaries which can 
then be represented in a compact exon splice graph [457]. 
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In another alternative method 4): a three-frame translation of curated RNA 
transcripts derived from databases such as Ensembl or RefSeq would allow the 
identification of alternative TIS sites and frame-shifts and since the strand orientation is 
known, it avoids further inflating the search space by not including frames on the 
opposite strand. Sequences of pseudogenes and lncRNAs could also be included to re-
classify such transcripts as coding [459]. A different method is to 5): generate a 
database of splice junctions, derived from RNA-seq reads aligned to a genome [460, 
461] using splice alignment tools such as Bowtie2-TopHat2 [126] and STAR [127], as 
well as a full transcript assembly through de novo methods, or preferably genome-
guided methods using tools such as CuffLinks [462], where high abundant transcripts 
are kept (based on read counts), and a three-frame translation is performed [463]. 
Additionally, a sequencing strategy, called Ribo-seq or Ribosome profiling [464, 465], 
can be used with this method, which is the sequencing of mRNA bound to ribosomes, 
enriched for transcripts destined for translation. This would limit the search space to 
only transcripts coding for protein, allow for easier identification of reading frame, 
frame-shift changes, identification of which transcript isoforms are being expressed, and 
in combination with N-terminomics [452], allow for the identification of alternative 
initiation codons. 
 Various other spliced peptide sequence databases can be generated, using RNA-
seq data with automated approaches from systems such as Galaxy-P, generating novel 
SAPs, splice junctions and sequences from highly expressed transcripts [466]. Other 
tools capable of generating databases from RNA-seq data are customProDB [467], 
which can generate splice variant sequences from public repositories such NCBI dbSNP 
[468], the Online Mendelian Inheritance in Man (OMIM) database [469] and the Protein 
Mutant Database (PMD) [470]. Databases can be generated containing sequences from 
sites of RNA-editing, identifiable from RNA/DNA comparisons with tools such as 
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REDItools [471]. Splice sequences can also be extracted from large RNA-seq datasets 
aligned to the genome and incorporated into a splice graph consisting only of splice 
regions distinct from sequences found in the six-frame translated genome [472]. This 
has been demonstrated to incorporate peptide variants, derived from variant calling 
tools such as the Genome Analysis Toolkit (GATK) [473], in the detection of mutant 
peptides in cancer [474]. This could also be used to generate sequences containing sites 
of RNA-editing. 
Depending on the study or target organism, other approaches could include the 
use of 6): curated databases such as the ECgene database with its large numbers of AS 
sequences [475], the Pseudogene.org database [476], the non-coding RNA sequence 
database NONCODE [477], a database of large intergenic non-coding RNAs 
(lincRNAs) located at Harvard [478] and the ChiTaRS database consisting of chimeric 
RNA transcripts [479]. 
Many of the above approaches assume a completed genome to work from when 
defining the search space, either via six-frame translation, mapped ESTs or RNA-seq. 
However, a complete genome is often not available in the majority of cases, and is only 
available as draft versions, which can be highly fragmented in early draft versions. This 
becomes a problem when assigning MS/MS spectra to a genomic sequence, as the 
MS/MS spectra can potentially be misidentified with a PTM in a different genomic 
location to that originally derived. A potential way to address this problem, would be to 
interpret any unassigned MS/MS spectra of sufficient quality by de novo sequencing 
using tools such as PepNovo [314] and UniNovo [336]. The sequences could then be 
used to search a closely homologous genome sequence or other available sequences, 
using tools such as MS-BLAST [480], which can also interpret raw MS/MS spectra for 
searching. In addition, tools such as InsPecT [326] allow for mutation-tolerant searches 
to find matches within homologous genomes, or to use approaches such as template 
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proteogenomics, with tools such as GenoMS [481] modified for large scale genome 
analysis, to find matches to homologous sequences. Strategies of this type allow the 
assignment of unassigned MS/MS spectra and could also provide a means to assist 
genome assembly by constructing complete proteins independent of the complete 
genome, which could then possibly assist with scaffolding where there is minimal read 
depth or coverage between scaffolds. 
2.4.2 Statistical analysis in proteogenomics 
Despite the differences between proteomics and proteogenomics, there is often common 
ground with the application of statistics, taking what is learnt from proteomics, such as 
FDRs, assignment of FPRs or p-values, and the definition of a null hypothesis through 
decoy databases [411]. In recent years, the repertoire of tools has increased to deal with 
the larger search spaces presented by searching the six-frame translation of a genome 
and addressing the inaccuracies with assigning empirically derived scores and FPRs to 
PSMs. 
In proteogenomics, a PSM level FDR is often chosen as the first step to remove 
spurious identifications. As pointed out in Section 2.3.9, in proteomics a peptide-level 
FDR is applied, as the aim is to identify peptides assigned to proteins. By comparison, 
in proteogenomics, the aim is to identify numerous PSMs across the genome to identify 
new coding regions, which is likely to contain much more spurious than real 
identifications. Applying a peptide-level FDR in a proteogenomics study would be 
overly conservative, and therefore a PSM-level FDR followed with further filtering 
using probabilistic scores, such as the peptide probability or posterior probability [404] 
and spectral probability [357], would be a more appropriate strategy. 
Besides the previously mentioned FPR (p-value) and FDR, derived from the 
empirical approach using the TDA, other statistical methods from proteomics can also 
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be implemented in proteogenomics. Examples of approaches include the q-value [418], 
PEP/local FDR [421], and theoretical as opposed to empirical approaches to calculate 
the score and FPR of each PSM using combinatorics [292], which allows for greater 
discrimination between true and false positives. 
A new statistical technique to contribute to this group of tools, specifically 
developed for proteogenomics, has emerged from concepts in genome linkage analysis 
studies [418]. Unlike other approaches, which simply apply stringent p-value or score 
thresholds on peptide identifications and may greatly improve specificity but with a 
trade off on sensitivity, this approach uses a more holistic approach. Since the aim of 
proteogenomics is genome annotation by identify protein-coding regions, and not 
specifically to identify individual peptides or proteins, this new approach uses the 
annotation event probability (i.e. the probability of being correct), which is based on the 
product of all posterior probabilities or local FDRs of PSMs (1 – local FDR) divided by 
the number of co-locations across the genome. The event probability is assigned to a 
cluster of peptides identified as an annotation event in the context of the known 
annotation. The event probability is employed in the proteogenomics tool, Enosi [81, 
82, 482], which classifies annotation events, such as exon boundaries, novel genes, gene 
boundaries, frame-shifts, reverse strands, translated UTRs, and novel splice junctions. 
The loss in sensitivity with increasing database size has been a challenge in 
proteomics [357, 427], and even more so in proteogenomics, as large numbers of 
putative sequences are added, and with an included decoy database the size of an 
already large database is essentially doubled. Therefore, any increase in database size 
when identifying novel proteins should be undertaken conservatively, by avoiding the 
addition of any unnecessary sequences. 
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The size of the database can significantly affect the scoring schemes used to 
identify PSMs. A number of PSM scoring methods compare the best scoring match and 
the second best, as previously highlighted in Section 2.3.9. As many more sequences 
are added the difference between the best score and second best score reduces and the 
likelihood of the best scoring match being incorrect increases. In addition, the 
significance of any matches which are rare diminish with increased database size, 
making it more difficult to separate out true and false identifications and resulting in 
many true identifications being removed when FDR filtering is applied [426]. While the 
number of identifications to the known proteome is relatively large by comparison to 
the novel identifications from the proteogenomics search, the overall number of 
identifications across both search spaces decreases [483, 484] and has been shown in 
some cases to be between 30% (see Section 4.3.13) and 52% (see Section 5.3.14) with a 
six-frame translation [483]. 
In addition to a reduction in sensitivity the search time is substantially increased. 
This can be addressed by splitting the database into smaller separate databases, and 
searching each one separately, which can become problematic depending on the search 
tool. When results are merged the score of the best matching PSM, second best 
matching PSM, and their difference (delta score), need to be adjusted to reflect 
searching the entire database. This is a necessity for tools such as Sequest [341, 342] 
and InsPecT [326]. Adjusting the scores can be avoided when the search tool uses a 
probabilistic scoring method independent of the database, as with MS-GF+ [292]. Other 
approaches to improve search time include the sequence tag and spectral dictionary 
approaches, mentioned previously in Section 2.3.7. Examples of tools using the 
sequence tag approach include InsPecT [326] and GutenTag [327], with InsPecT being 
demonstrated in proteogenomics studies in Arabidopsis thaliana [81] and Zea mays 
[82], while the spectral dictionary approach implemented in MS-Dictionary (later 
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extended to MS-GappedDictionary [335]) has been demonstrated to quickly search the 
six-frame translated genome of Shewanella oneidensis MR-1 and Homo sapiens and 
was around 40x faster than InsPecT [324]. Other approaches to improve the database 
search time, include database indexing [485-487], algorithmic improvements to utilise 
multi-core and multi-threading of high-performance computers [488], proteomics 
workflows utilising the grid [489], cloud computing [490], as well as other algorithmic 
approaches [310, 311, 491]. 
There have been numerous attempts to improve sensitivity when searching large 
databases used in proteogenomics studies, many of which have previously been 
mentioned for proteomics studies in Section 2.3.9. These strategies include MS-GF+, 
with its rigorous approach to define the score and significance of PSMs to better 
differentiate true and false positives [292], combining database search results from 
multiple different search tools [406], re-scoring database search results using multiple 
sources of information from the PSMs and search parameters, using machine-learning 
approaches such as PeptideProphet [403], iProphet [404] and Percolator [405]. Other 
methods to improve sensitivity in proteogenomics searches, mentioned previously with 
proteomics, are to address the problem at the sampling stage by limiting the peptide 
fractions to a particular range of pIs, or predict the pI of sequences in the database and 
then search only the appropriate fraction of the database with the same pI [429] as these 
peptides will likely be more common. The same principle is applied by searching for 
only tryptic peptides when performing a MS/MS database search using the protease 
trypsin. An additional method, which can be applied at the sampling stage, is Ribo-seq, 
mentioned previously, which can significantly reduce the search space to only 




In addition, the manner in which proteogenomics search results are filtered and 
processed can also improve the sensitivity. Often in the past a single FDR cut-off has 
been applied across all known and novel results [81, 82, 443, 450, 451, 482, 492]. A 
more prudent approach would be to apply FDR cut-offs to the different types of search 
spaces, by first searching the known database and followed by FDR filtering, with any 
remaining unassigned MS/MS spectra used for searching the proteogenomics search 
space for a unified set of novel PSMs [474, 493-495]. This could then have an FDR cut-
off applied across all novel PSMs, or across different classes of novel PSMs [439] (e.g. 
frame-shifts versus novel genes). Control of the FDR across novel PSMs has previously 
been described, after an initial broad 1% PSM level FDR filtering. However, real 
identifications may be missed even before annotation event filtering due to prior 
inaccurate PSM FDR filtering. Such approaches should be applied because different 
genomic regions have their own FPRs, just as different classes of peptides, such as 
tryptic, pI ranged peptides etc have their own likelihood of appearing in a sample, as 
mentioned previously. Compared to a broad FDR cut-off across all known and novel 
PSMs, applying a FDR cut-off separately on the identified known and a unified set of 
novel PSMs, such as those demonstrated in [474], would have the benefit of applying a 
more appropriate threshold for both known and novel PSMs. This would improve FDR 
accuracy, and by applying a more conservative approach by removing MS/MS spectra 
already identified as known, would avoid any possible MS/MS spectral 
misinterpretations among the novel peptides. 
This approach to FDR filtering on known and novel datasets separately, by first 
removing MS/MS spectra assigned to the known proteome before searching the novel 
dataset, is highly presumptuous that the MS/MS spectra was correctly identified in the 
known proteome, which could have also been correctly identified to a novel sequence, 
leading to highly conservative results. However, the approach does have merit when the 
 
 72 
dataset contains numerous variant peptides, as was applicable in a study on cancer 
variant peptides [474], as there would likely be higher numbers of incorrect MS/MS 
spectral interpretations, due to mass shifts as a result of numerous SAPS mistaken as 
PTMs. A similar method is applied in [496], where the sequences from the 
proteogenomics search database are first in silico digested, with any peptides found 
matching known protein databases such as Ensembl, NCBI and UniProt by sub-string 
matching removed from the proteogenomics database leaving only likely novel 
sequences. However, this approach neglects filtering out of spurious MS/MS spectra, 
and assumes that all MS/MS spectra used in a search have no missed cleavages. It also 
limits the analysis to only in vitro protease cleaved peptides, not considering possibly 
interesting in vivo proteolytic peptides which could be included in the analysis. 
Another method, which can be employed to improve the sensitivity of a 
proteogenomics search, is the two-pass search approach, previously mentioned in 
Section 2.3.9. The method can be applied in proteogenomics to improve sensitivity by 
performing an initial search of the six-frame translation or other proteogenomics search 
space, as well as contaminant sequences, to identify putative sequences with high 
scoring PSMs with no FDR filtering and the removal of any MS/MS spectra not 
matching the target database or only matching contaminant sequences. A subsequent 
search is then performed only with sequences identified from the previous search, with 
the target sequences used in the TDA, followed with FDR filtering [428, 483]. This 
approach is able to filter out spurious MS/MS spectra and identify more PSMs by 
reducing the search space, and thereby increasing the significance of rare PSMs. 
Other methods can also be employed to reduce the database size by identifying 
the most optimal sequences to search, e.g. among all frames of a six-frame translation. 
These include ESTScan2 [497], EORF [498], applying homology searches, predicting 
coding potential, and ab initio predictions [483]. But such approaches, particularly those 
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applying predictions, may inadvertently bias the search space, by applying predefined 
assumptions to the data. 
Additional sources of false positives to those from an inflated search space, can 
be derived from random high scoring MS/MS spectra and matches to peptide sequences 
homologous to the real sequences, which may underestimate the FDR [426]. False 
positives may also be derived from chemically modified peptides from the known 
database; with a mass shift matching the unmodified novel peptides [493, 499]. To 
avoid the inclusion of such peptides the identified peptides from the MS/MS database 
search should then be searched, either by a simple sub-string search or using the Basic 
Local Alignment Search Tool (BLAST) against the six-frame and known database, 
which would identify any erroneous sequences. If, however identification of SAPs is 
also an aim of the analysis such sites should be marked and also screened for mass 
shifts explained by selected PTMs during the MS/MS database search, such as 
oxidation of methionine, deamidation, carbamylation, acetylation etc [82, 429, 493, 494, 
499, 500]. If the specific PTMs in a sample are largely unknown, a “blind” search can 
be run to identify the most common PTMs [402]. But the inclusion of multiple PTMs 
within a proteogenomics search can negatively impact the sensitivity by further inflating 
the search space unnecessarily [82, 427], and so it should be done within a proteomics 
context after the proteome has been improved and defined. As pointed out by Tsur et al 
[402], for every protein there is likely at least 1 unmodified peptide, and so adding 
modifications to a proteogenomics search is likely to hamper attempts to discover new 
proteins and novel annotations. 
Once a proteogenomics search is complete with PSMs identified and FDR 
filtering applied, there are other considerations for filtering before final analysis. Due to 
an upper limit on the number of identifiable PSMs imposed in a MS/MS database 
search, identified peptides from a PSM may not be representative across the whole 
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genome. Therefore, any identified peptides require mapping across the whole genome to 
ascertain which of the peptides are shared (co-located) and which are unique, along with 
their respective coordinates. In addition, another filtering consideration is any peptide 
which contains leucine/isoleucine, as mass spectrometers cannot distinguish between 
these amino acids since they are isomers with the same atomic mass, and so requires 
careful interpretation of the fragmentation pattern via multiple MS/MS experiments to 
distinguish one from the other [501]. Thus any sequences identified as 
leucine/isoleucine variants should be removed from the analysis. 
2.4.3 Defining the level of proteogenomics annotation 
In proteomics the level of annotation is at its basic level, with identified proteins and the 
locations of peptides within those identified proteins. In proteogenomics a broader 
annotation is required to characterise locations across the genome, flanking gene 
regions and within genes, such as novel genes, exon boundaries, TIS sites and frame-
shifts, along with their peptide evidence, which should be flagged as unique or shared to 
indicate unambiguously that a particular genomic locus is being expressed [220]. The 
proteogenomics search space has a much higher false positive rate compared to 
proteomics search spaces, and so to identify any annotation events with confidence and 
to unambiguously identify the locus as being expressed, much like in proteomics with 
the two-peptide rule, the parsimonious presence of two or more unique peptides across 
the region should be a requirement, particularly for regions with a higher false positive 
rate, such as intergenic regions – novel genes, translated UTRs and gene boundaries. In 
addition, there can be multiple simultaneous annotation events inferred for the same 
locus, depending on the surrounding known reference annotations. For example a novel 
peptide inferring a frame-shift can also be identified as a novel exon or translated UTR. 
To account for this overlap and simplify proteogenomics annotation, an order of 
precedence as outlined in a previous study [82], is required. 
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To define a peptide as novel relies on the underlying level of completeness of a 
genome annotation, its quality and the underling proteome database. In some cases the 
annotation is lacking and therefore needs to be revisited, requiring ab initio and 
evidence-based predictions, which themselves may be lacking in completeness and 
quality thus introducing errors into the annotation. For example, the protein predictions 
may be incomplete, containing ambiguous residues, gene models may be incomplete, 
such as truncated exons not divisible by 3, the CDS phase information may be incorrect, 
outlining a discontinuity between predicted sequence and entries in the General Feature 
Format (GFF) files etc (for examples see Chapters 4 and 5). For these reasons a highly 
curated annotation, containing only high confidence annotations, and which has 
potentially gone through some manual curation beforehand, is most beneficial to avoid 
any problems further in analysis. After the initial analysis, any novel annotation events 
identified should be screened following consideration of their posterior probabilities 
[404], event probabilities [81, 82, 482], parsimony, and spectral counts [502]. In 
addition, in support of these annotation events or predictions inferred from the 
annotation events, screening can be performed using BLASTP against public 
repositories containing known or predicted sequences from orthologous genomes, to 
confirm the findings, and by identifying orthologous regions or genes in closely related 
genomes, annotation can also be performed on these orthologous genomes, termed 
ortho-proteogenomics [79, 445]. Public repositories may also contain protein sequences 
derived from the target genome, but not currently incorporated into the current 
annotation from the study due to different annotation versions or other not well-known 
parallel genome projects and annotation efforts. 
An approach termed comparative proteogenomics [446, 448] can be used to 
assign confidence to novel annotations, where multiple parallel proteogenomics 
processes using different MS/MS spectral datasets are carried out on closely related 
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species, with cross-validation of any annotations applied. This is useful in the case of 
single peptide hits or “one-hit-wonders”, where the possibility of false positives is more 
likely. However, there is no currently available scoring scheme for comparative 
proteogenomics, and the approach has so far only been limited to bacterial studies, with 
manual inspection and sequence homology searches still necessary to apply confidence 
to proteogenomics annotations across the comparative studies. 
Another approach for conducting proteogenomics is with the annotation of 
metagenomes using metaproteomics, termed metaproteogenomics [503]. The field of 
metagenomics is tasked with the sequencing, assembly and annotation of communities 
of bacterial species, generally from soil samples, which cannot be individually cultured, 
sequenced and studied on a per species basis [504]. Genome annotation in 
metagenomics was performed by comparison with already existing genome annotations 
from individual species [505], however this can heavily bias the annotations and 
potentially introduce errors, as was outlined in Section 2.2.2. Metaproteogenomics 
emerged from the introduction of metaproteomics to provide more direct evidence for 
the expression of proteins across a bacterial community and to an extent indicate the 
functionality of genes and proteins from each species within that community. 
2.4.4 Proteogenomics tools 
The main goal of proteogenomics is to conduct genome annotation. Over the last decade 
the gold standard in genomic annotation involved a concerted effort in manual 
annotation, often referred to as a ‘genome jamboree’, which cost valuable time and 
money. A high-throughput proteogenomics approach, with high specificity and 
sensitivity would alleviate much of the time and financial requirements involved in 
genome annotation efforts. 
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 A number of proteogenomics strategies have been implemented into tools over 
the years, with many more tools becoming available during the last few years, offering 
increased complexity and sophistication. A number of these tools, with their relative 





Table 2.11 Comparison between different proteogenomics tools 
A brief history of proteogenomics is encapsulated in the following twelve tools, developed over the last 
decade. 
Tool Advantages Disadvantages 
PeptideAtlas 
(2004) [354, 506] 
 Uses PeptideProphet. 
 Better specificity due to searching curated 
protein databases. 
 No way to identify unique peptides. 
 No control on FDR. 
 Web-based only lacking flexibility. 
 No six-frame translation search 
(limited novel discoveries). 
 Limited to searching protein 
databases; International Protein Index 
(IPI) [507] (now discontinued), 
Ensembl, Vega, RefSeq and 
UniProtKB. 
 Inferred annotations limited to peptide 
coordinates from known proteins. 
GAPP 
(2006) [508] 
 Downloadable by request, making it more 
flexible than PeptideAtlas. 
 Better specificity due to searching curated 
protein databases. 
 
 Uses Advanced Average Peptide 
Score (Advanced APS) [509] to score 
PSMs when they share a protein 
match that was obtained from within 
the same experiment [510]. Potential 
to identify incorrect proteins and skew 
the FDR when applying the TDA. 
 Limited control on FDR. 
 No measure of significance for each 
PSM. 
 No six-frame translation search 




 De novo peptide sequencing. 
 Maps peptides to six-frame translated 
genome, improving the rate of novel 
identifications. 
 Improved throughput by automation, 
integrating the gene prediction tool 
Augustus. 
 Identification of spliced peptides through 
use of ESTs. 
 
 De novo peptide sequencing of 
MS/MS spectra has a much larger 
search space than other methods of 
MS/MS spectral interpretation, 
impacting sensitivity. 
 No rigorous control on FDR. 
 Limited identification of splice junctions 
using ESTs, as they are limited in 
coverage and are error prone. 
PepLine 
(2008) [512]  
 Maps peptides to six-frame translated 
genome, improving the rate of novel 
identifications. 
 Fast searches of six-frame translated 
genome by mapping peptide sequence 
tags (PSTs) onto genome.  
 PSTs are clustered to identify gene and 
exon-intron boundaries. 
 
 Sensitivity limited due to peptide 
sequence tag approach. 
 Lacks rigorous control on FDR. 
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 Accepts either MS1 or MS2 spectra to 
identify ORFs from a six-frame translation. 
 Flexibility with MS approach: Using MS1, 
the ORFs are in silico digested and 
MS/MS spectra matched to in silico mass 
peaks. Using MS2 the ORFs are matched 
within a precursor mass tolerance, using a 
sequence tag approach or a slower, but 
more accurate GFS HMM_Score 
algorithm. 
 The PSMs are clustered to identify loci. 
 Can be optionally run on a local machine 
or cluster. 
 
 Not optimised for larger genomes. 
 Matches only filtered based on E-
values, with no rigorous control using 
FDR. 
 No discrimination between unique and 
shared peptides. 
 Sensitivity limited due to peptide 
sequence tag approach. 
 No identifications of peptides spanning 
exon-exon junctions. 
 Does not use known protein sequence 





 Flexible and friendly optional graphical 
user interface (GUI). 
 Extends PSMs in a 5’ and 3’ direction from 
start to stop or splice junction to generate 
expressed peptide sequence tags 
(ePSTs), first coined by McCarthy et al 
[515]. 
 Incorporates splicing either using 
canonical acceptor and donor sites or 
using imported splice junctions from 
GeneSplicer [516]. 
 The identified ePSTs can be used to 
confirm transcriptional data and/or used to 
search for homologues in similarly related 
species. 
 
 Not a fully integrated proteogenomics 
tool and no integrated MS/MS 
database search tool. 
 Lacks specificity, sensitivity and 
limited in its application. 
 Does a complete six-frame translation 
of genome. Not segmented into ORFs 
of a limited size, resulting in a far 
larger search space. 
 Can only map previously identified 
peptides given in a FASTA file. 
 No control on FDR or other filtering 
methods. 
Peppy 
(2013) [11, 449] 
 Employed as a proteogenomics tool for 
ENCODE. 
 Uses a newly developed PSM scoring 
approach. 
 Can run on a desktop for relatively smaller 
genomes when compute resources are 
limited. 
 Lacks rigorous control on FDR (only 
1% PSM FDR applied). 
 Performs a separate proteogenomics 
search and proteomics search, 
requiring manual filtering and 
identification of any novel PSMs. 
 All peptides identified. Studies 
indicated that only unique peptides 
were focussed on to identify loci. 









 Employs MS/MS database search against 
six-frame translation, Ensembl and 
RefSeq public repositories. 
 Converts identified PSMs into genomic 
coordinates within a SAM and BED file, 
which can then be viewed in IGV 
alongside RNA-seq read alignment 
results. 
 Integrated into a workflow environment 
(Galaxy) for wider accessibility. 
 Bacterial genomes are sliced into 
segments of a chosen size (e.g. 900 bp) 
and six-frame translation performed. ORFs 
inferred by stitching together sliced 
segments with peptide matches. An 
alternative means to cluster peptides on 
overly long non-genic ORFs due to high 
GC content bacterial genomes. 
 
 Only limited to the MS/MS database 
search tool, Mascot [165]. 
 No rigorous control on FDR, besides 
that employed by Mascot, which is 
known to rapidly lose sensitivity and 
FDR accuracy with larger database 
searches due to its scoring function 
[426]. 
 For eukaryotic genomes, peptides are 
identified against Ensembl and 
RefSeq protein sequences, and then 
mapped onto the genome for 
annotation. 
 MS/MS spectra are not directly 
searched against the RNA-seq data. 
Only co-visualised with mapped 
peptides on the genome. 
Genosuite 
(2013) [502] 
 Combines multiple MS/MS database 
search tools and merges results for 
improved sensitivity, using Combined 
FDRScore [518]. 
 Visualisation of novel peptides mapping to 
genome in HTML file. 
 Visualisation of novel PSMs for manual 
validation in HTML file. 
 High specificity by enforcing ≥2 unique 
peptides, with single peptides ≥5 
significant PSMs. 
 
 Limited to only bacterial genome 
annotation. 
 Only limited to MassWiz [519], 
OMSSA [348], Tandem [347] and 
InsPecT [326] MS/MS database 
search tools. 
 No rigorous control on FDR, besides 
that employed by the MS/MS 
database search tools, and the use of 
a Combined FDRScore [518] when 
merging results. 
 ORF size from six-frame translation 
fixed at ≥50 aa. 
 Any identified leucine and isoleucine 
are considered the same, and mapped 
to the genome/proteome. Could 
introduce ambiguity to identifications. 
 Peptides, which are co-located in the 
genome, are not considered for further 
analysis. Only ≥2 unique peptides, 
with single peptides ≥5 significant 
PSMs, above the desired FDR 
threshold are considered – this 
improves specificity, but reduces 
sensitivity significantly. 
 Limited categorisation of novel 
peptides into Novel Protein Coding 
Region (NPCR) and changes in 
annotated gene models. Manual 
interpretation is then needed via 
comparisons to the NPCRs, ORF and 
other gene predictions. 
 Visual inspection in relation to the 
reference gene model and through 




Tool Advantages Disadvantages 
PGTools 
(2015) [496] 
 Employs MS/MS database search tools 
Tandem [347], Comet [520] and MS-GF+ 
[292]. The results of each can be 
combined using Percolator [405]. 
 Runs on multiple processors and on a 
cluster to enable high-throughput. 
 Modular approach, with some modules 
running as independent tools, allowing for 
flexibility with workflow design. 
 Incorporates OpenMS [521] and 
ProteoWizard [287] msconvert for file 
conversion. 
 Databases accessible from FASTA or 
SQLite formats. 
 Source code is freely available as open-
source allowing for customisation for non-
commercial use. 
 Uses JSON data format for reading and 
writing configuration files. Data outputs are 
in CSV, BED, SVG and HTML format. This 
allows for compatibility with other tools. 
 Usable as an automated pipeline or 
through a simple customisable graphical 
user interface (GUI). 
 Translation possible from 1 to 6 frames, 
not just all 6, for transcripts, ESTs and 
genome. 
 At multiple stages of analysis results are 
reported and data visualised as Venn 
diagrams of unique and shared peptides 
between search results, a zoomable 
treemap showing protein groups, 
chromosome distribution and Circos plots 
of identified mapped novel peptides [522], 
and through tools such as UCSC genome 
browser and the Integrative Genomics 
Viewer (IGV) [523]. 
 Separate modules for a proteomics only 
search with aggregation into protein 
groups based on parsimony and unique 
peptides and a genomics only search for 
proteogenomics annotation. 
 Segregates the novel search space prior 
to searching, by in silico digesting 
sequences from proteogenomics 
databases, filtering peptide lengths 7-36 
aa and removing peptides identified from 
known proteins in Ensembl, NCBI and 
UniProt. 
 Multiple types of annotation events 
detectable; pseudogene, translated non-
coding RNA, novel spliced peptides, 
translated UTR, novel gene, novel exon, 
frame-shift, gene extension, exon 
boundary, mutant peptides (indels) and 
gene fusions. 
 
 Currently only human focused and 
requires a database for different 
annotation event types, such as none 
coding, pseudogene, UTR, mutation 
and fusion databases, which are all 
pre-made and require downloading 
(although scripts for database 
generation are available from the 
authors on request), making it difficult 
to extend to other organisms. 
Algorithmic interpretation of the GFF 
file for these regions from the six-
frame translation, RNA-seq and 
variant calling tools would be more 
efficient and extendable as a general 
approach for proteogenomics. 
 The method employed to split 
databases to known and novel before 
MS/MS database searching, neglects 
filtering out spurious MS/MS spectra, 
assumes no missed cleavages, and is 
limited to in vitro protease cleaved 
peptides, as opposed to the inclusion 
of interesting in vivo proteolytic 
peptides, which could be included in 
the analysis. 
 A splice junction database was 
constructed from exon information 
extracted from a GFF file and donor 
and acceptor sites, joining exons 
together in different arrangements. 
Although this is able to identify 
previously unknown isoforms, it also 
has the potential to inflate the false-
positive rate. A similar approach was 
used in an exon graph from [81], but 
was abandoned in favour of a FASTA 
splice graph database derived from 
RNA-seq read alignments, thus 
reducing the false-positive rate, by 
inclusion of experimental evidence, 
generated with user controlled 
stringencies. 
 Only considers unique peptides 
mapped to genomic coordinates, to 








(2010, 2011, 2014)  
[443, 492, 524]  
 Fast search times with sequence tag 
approach employed by InsPecT. 
 Configured to run MS/MS database search 
on a variety of HPC environments for 
parallel running on a cluster. 
 Uses MS-GF to re-score PSMs with 
MS/MS spectral probability. 
 Clusters PSMs based on a chosen 
interpeptide distance to limit ORF size for 
high GC genomes, which often have long 
–non-genic ORFs. 
 Allows identification of signal peptides. 
 Applies ORF filtering to remove low 
complexity peptides, non-tryptic peptides, 
non-unique peptides, and ORFs 
containing only 1 peptide (one-hit-
wonders). 
 Reports different degrees of conflicting 
overlapping annotations, due to commonly 
overlapping genes in bacteria. 
 
 Limited to only bacterial genome 
annotation. 
 Only limited to the MS/MS database 
search tool, InsPecT [326]. 
 Sensitivity limited due to sequence tag 
approach. 
 Filtering of identified PSMs used high 
stringency of spectral E-values. 
Improved specificity, but reduced 
sensitivity. 
 New annotations only limited to ‘novel 
proteins’, ‘new starts’ and expressed 




Tool Advantages Disadvantages 
Enosi 
(2008, 2012, 2014)  
[81, 82, 472, 482]  
 Integrates different MS/MS database 
search tools, initially with InsPecT [81], 
later used InsPecT with MS-GF to re-score 
PSMs [82], and has most recently been 
updated to MS-GF+ [6, 472]. 
 Two levels of FDR control: 1% PSM level 
FDR and event level with the event 
probability. 
 The use of an event probability is able to 
save single peptide identifications, which 
have often been delegated as “one-hit-
wonders”. 
 The number of unique peptides and the 
size of the peptide linkage distance for 
peptide clusters can be defined by the 
user, providing control on analysis 
stringencies. 
 A minimum stop-to-stop ORF size during 
six-frame translation can be defined, 
giving control on identification of short 
ORFs and database size. 
 Accounts for peptides spanning splice 
junctions using an exon graph [8, 81, 82] 
derived from all previously identified 
exons, later abandoned in favour of a 
FASTA splice graph used in [472, 474], 
derived from large RNA-seq experiments.  
 A larger number of annotation events are 
identifiable; novel genes and distal events: 
reverse strands, translated UTRs and 
gene boundaries and proximal events: 
frame-shifts, exon boundaries, novel 
exons and novel splicing. In the latest 
release through the use of variant 
peptides in a splice graph [474], indels 
and substitutions can be identified. 
 Configurable to run the MS/MS database 
search on a SGE cluster. 
 Reports annotation event types, genomic 
location, event probabilities, and the 
presence of the annotation event directly 
overlapping the gene of interest. All novel 
and known peptide identifications are 
provided in a GFF file, suitable for 
visualisation and as hints for gene 
prediction. 
 Novel peptides are verified as truly novel, 
by searching for those which are 
homeometric, i.e. those indistinguishable 
by mass spectrometry and which may be 
contained in the known proteome, and 
identified as novel my accident. These are 
then removed from the analysis after FDR 
filtering. Such peptides include those 
containing Isoleucine/Leucine 
substitutions and Lysine/Pyroglutamate 
substitutions. 
 
 Many peptide clusters are 
miscategorised as gene boundary and 
reverse strand annotation events as a 
result of a fixed peptide linkage 
distance too large for some genomic 
regions, which would suit a smaller 
linkage distance. This also affects the 
number of novel genes, which can be 
categorised. 
 The latest version 1.0 only runs the 
MS/MS database search on an SGE 
cluster, splitting the database up to run 
on each node, and is not configured 
for other schedulers such as PBS Pro 
and SLURM. Running on these would 
require running the search outside 
Enosi within an in-house script. 
 Pre- and post-processing tasks are not 
multi-threading and do not run on a 
cluster, such as splice graph 
generation and FDR filtering. This 
requires some innovative approaches 
outside of the Enosi tool to process 
particularly large datasets from splice 
graphs and the combined raw results 
from a six-frame translation search. 
 In Enosi version 1.0 when using the 
built-in combined FDR strategy, 
filtering is applied to each result file 
based on the number of split 
databases searched and then merges 
them post-filtering. This introduces 
FDR inaccuracies, but can be avoided 
to a degree by manually combining 
results prior to FDR filtering.  
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Many of the tools mentioned above in Table 2.11 do not scale well for large 
projects, do not easily allow the capture of metadata, offer flexibility to integrate a 
seamless workflow, or the sharing of these workflows with collaborators, and not all of 
them leverage HPC clusters. However, there are a few known exceptions: 1) Enosi uses 
a text file containing parameters which can be shared and reused, is configurable to run 
on an SGE cluster, and is also accessible from ProteoSAFe [525], a web-based 
proteomics analysis suite; 2) the prokaryotic proteogenomics pipeline (PPGP) [524] 
allows the use of high performance computing clusters using InsPecT for MS/MS 
database searching, and using a text file for parameters, similar to Enosi; 3) PG Nexus 
has been integrated into Galaxy, a web-based workflow environment; and 4) the 
recently released PGTools, can run on a HPC cluster, and captures results at each stage 
of analysis in HTML reports and visual aids. 
There is a need for such analysis approaches in proteogenomics, where the 
capture of meta-data is essential and major collaborations in genome annotation will 
benefit from the sharing and re-use of workflows to enable large scale proteogenomics 
efforts. 
2.5 BIOINFORMATICS WORKFLOW ENVIRONMENTS 
This section provides a background on bioinformatics workflow environments and 
outlines the means of enabling the wider uptake of proteogenomics in large 
international and national genomics projects. A number of workflow environments are 
discussed in detail. 
The domains of genomics, transcriptomics, proteomics and proteogenomics all 
mentioned up to this point share a common theme, that of informatics, or more 
precisely, bioinformatics, which details how the processing of biological data and their 
interpretation are conducted. Bioinformatics itself has often been isolated to scientists 
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with information technology (IT) skills, who also frequently have knowledge in a wide 
variety of disciplines, e.g. statistical analysis, proteomics, genomics, transcriptomics 
and metabolomics. The bioinformatics workflow environment is a new tool that 
simplifies the requirements for bioinformatics analysis, allowing anyone access to tools 
with much of their complexity abstracted away, the only requirement being the choice 
of parameters, input and form of workflows. However, many of these prerequisites can 
become standard with particular workflows, which could be set up once by a specialist, 
and then reused with minimal tweaking of parameters by the end user. This paradigm is 
powerful, allowing much broader use of tools with minimal downtime for training. 
For proteogenomics to become more accessible to the wider scientific 
community, anyone who can generate peptide mass spectrometry data, or who has 
recently sequenced a new genome, either themselves or through external sources, 
should be able to bring these datasets together and perform analyses without needing to 
employ the skills of further specialists in bioinformatics. 
A number of bioinformatics workflow environments have emerged over the 
years [526-534], some of which are limited in functionality, flexibility, and user-
friendliness and others breaking those trends and setting new benchmarks for a better 
and useful workflow environment. Three examples of bioinformatics workflow 
environments are detailed below. 
Taverna [529, 530] is a desktop-based workflow environment that is employed 
in a highly configurable graph of interconnected processes. The execution and 
management of each process is written in eXtensible Markup Language (XML) called 
Simple conceptual unified language (Scufl). Each process must be configured in the 
Scufl language with error handling managed by the user, with the various processes 
then chained together into complex workflows with multiple branching or iterative 
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processes running in parallel. Each process can be run on a local machine or submitted 
to a web service for execution (e.g. NCBI and EMBL web services such as BLAST and 
ClustalW), and all actions are saved in a log file. In addition, Taverna has integrated 
workflow saving and offers sharing through myExperiment [535], a web site which 
shares workflow objects between scientists. Taverna is focused towards scientists who 
understand programming and probably are familiar with a command line environment, 
and who essentially become the system administrators of their own workflows. 
Consequently, many scientists not familiar with these necessary skill-sets may shy away 
from using such a workflow environment. 
Galaxy [532] is an internet-based workflow environment, designed with 
genomics [531], and more recently proteomics [466] and proteogenomics [536] 
workflows in mind. Compared to Taverna, the skill requirements are lower and the 
interface is simplified, with no user requirements to have programming or system 
administrative skills, and with the maintenance of tools the responsibility of a separate 
systems administrator. However, adding new tools requires a software developer to 
integrate the tool using JavaScript Object Notation (JSON), which becomes problematic 
when many different tools are needed for various different groups. In addition, as with 
Taverna, all work history is recorded allowing easy access to previous run workflows 
and their use as templates for similar workflows, which can then be processed 
independently or processed together to find their union, intersect, subtraction etc. Also 
similarly to Taverna, Galaxy allows the sharing of workflows through myExperiment 
and Galaxy Published Workflows and, just as Taverna runs on a local computer, Galaxy 
runs on a single server on the Internet with a single location for the storage of data input 
and output of results. The workflow design scheme can be complex, with multiple 
branching and parallel processes, but it is limited by comparison with Taverna, since the 
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user has less control on how to configure the processes, leaving that responsibility to a 
programmer. 
Yabi [533] is an internet-based workflow environment for various domain-
specific tasks, and which uses a three tier system: 1) a frontend web application for the 
user interface, 2) a middleware layer for process management, tool configuration, 
analysis history tracking and user management, and 3) a resource manager that exposes 
data and then compute resources to the middleware. Yabi skill requirements are less 
than both Taverna and Galaxy, with much of the complexity of managing and 
configuring the processes abstracted away from the user and delegated to the systems 
administrator. The display of the workflow scheme is also simplified to a linear form, 
although branching and parallel processing of tasks is still possible. This allows 
complex workflows to be created without the workflow clutter from many multiple 
different processes running in parallel, and provides a more intuitive and easy to 
understand workflow. Yabi separates out roles to the user, systems administrator and 
software developer. This is designed to abstract out the complexities for the user and 
allow the systems administrator to focus on their role without needing to be involved in 
software development. Monitoring the progress of processes through Yabi can be 
followed through a web-browser. Yabi is also able to access data in a heterogeneous 
manner, which distinctly separates it from both Taverna and Galaxy, as the backend 
where data are stored can be in various remote locations, and accessed through SSH 
[537], GridFTP [538], SFTP , Amazon Simple Storage Service (S3) [539] and others. In 
addition, various compute resources can be used, which include Torque [540] and PBS 
Pro [541], residing on HPC, Grid or Cloud based machines. This architecture lends 
itself well to performing tasks across various compute and storage resources for 
analysis, without relying on any one single resource. This capacity is critical when the 
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user has large datasets accessible from a remote site, with the results outputted to a 
different remote site for review. 
Yabi has also been implemented into a command line interface for users who are 
more familiar with the command line, and who do not wish to write scripts in order to 
run jobs on HPC systems. During the design of workflows each process is configured to 
know which types of input and outputs to expect, with an indication to the user when a 
particular input is required from the output of a previous process. In addition, 
workflows in Yabi can be saved and re-used, with plans to make these workflows 
sharable between different installation instances of Yabi.   
All these tools lend themselves well towards proteomics and proteogenomics 
pipelines, which could be easily supplemented with pre-processing and post-processing 
stages. However, to really reach out to the scientific community, tools such as Yabi are 
needed to simplify the tasks by abstracting away the complexities, and allowing 
flexibility to where the tools can be deployed and accessed. This can be done even from 
remotely distant locations, so that scientists can focus on the science, instead of 











This chapter outlines the key Materials and Methods used throughout this thesis and 
culminates in the synthesis of a roadmap for undertaking proteogenomics. 
3.1 DATASETS 
3.1.1 Proteomics and genomics datasets 
The MS/MS spectra and genomic datasets from all four case studies (Chapter 4: 
Bacteria, Chapter 5: Grape, Chapter 6: Human and Chapter 7: Wheat) were obtained 
from a variety of different sources, including research collaborators and publically 
available datasets and generated through prediction tools, as outlined in the Materials 
and Methods sections for each case study. All protein datasets included a common 
source of contaminants downloaded from the Global Proteome Machine (GPM) 
(ftp://ftp.thegpm.org/fasta/cRAP/crap.fasta), comprising a broad range of contaminants 
including keratins, chymotrypsin and trypsin. Other contaminants were added if 
suspected to be in the samples, such as non-target proteins and other uncommon 
proteases if used in the study. These were added to the known protein datasets prior to 
MS/MS database searching. 
Visualization of all gene models and their supporting evidence, including novel 
and known peptides, was done using the Integrative Genomics Viewer (IGV) [523]. For 
illustrative purposes for this thesis, GenomeTools [542] was used. 
When visualizing the MS/MS spectra assigned to the known and novel peptides, 
and for illustration in this thesis, Lorikeet Spectrum Viewer 
(https://code.google.com/p/lorikeet/) was used. 
3.1.2 RNA-seq datasets 
For eukaryote studies, to account for alternatively spliced genes and to define a search 
space for spliced peptides, Illumina RNA-seq data was obtained from the Sequence 
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Read Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra) through DNA Nexus 
(http://sra.dnanexus.com/), and also obtained from collaborators, the details of which 
are highlighted in each respective chapter. 
3.2 DATA FORMATS 
The initial step for any proteogenomics analysis is the conversion of data formats. File 
formats outputted from mass spectrometers are in a proprietary format and before any 
analysis can begin, they require conversion to an open source format such as mzXML, 
mzML and MGF, to be processed by the analysis tools. 
The main workhorse of any MS-based proteomics analysis pipeline is the 
MS/MS database search tool; in this case it is MS-GF+ [407] (version v9949 
2/10/2014). MS-GF+ can accept mzML, mzXML, MGF, MS2, PKL and DTA file 
formats. Due to the pre-processing steps undertaken for clustering and quality filtering, 
for each case study investigated it was necessary to convert the original file format, if 
not already formatted and whether proprietary or open format such as mzXML, to 
MGF. 
The tool msconvert, from the Proteowizard package 
(http://proteowizard.sourceforge.net/), was used for conversion of the MS/MS spectral 
file format. The Windows 32-bit version of msconvert was used, which was the only 
free open source version available that includes vendor reader support. The msconvert 
tool is capable of running on the command line or through a graphical user interface 
(GUI). 
3.3 MS/MS DATABASE SEARCHING 
The MS/MS database search was performed by MS-GF+, which uses the following 
settings: 1) Depending on the source of the MS/MS spectra the protease was either 
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trypsin, chymotrypsin, Aspn or unspecified, 2) a precursor mass tolerance was then 
chosen, which varied depending on the case study and/or dataset used and whether the 
search was for the assessment of optimal precursor mass tolerance, mentioned later in 
Section 3.4.6. 3) The number of allowed modifications per peptide was set to 2, with 
modifications: carbamidomethylation of cysteine (C+57), oxidation of methionine 
(M+16) and protein N-terminal acetylation (+42). 4) The maximum peptide length was 
set to 30 amino acids (aa), 5) the isotope error range was set to “0,2”, 6) the instrument 
was set to either high-res Time-of-Flight (TOF) (e.g. Quadrupole TOF (QTOF)) or low-
res Linear Trap Quadrupole (LTQ) (e.g. Ion Trap) depending on the mass spectrometer 
used to generate the data. 7) The number of tolerable termini was set to 1, 8) the number 
of reported matches per MS/MS spectrum was set to 10, and 9) a reverse sequence 
decoy database was generated. 
In Enosi (version 1.0), some MS-GF+ parameters mentioned above are always on 
by default and are not changeable (i.e. they are hard coded into the tool), such as the 
number of tolerable termini, maximum peptide length, number of reported matches per 
MS/MS spectrum, use of a reversed sequence decoy database and the isotope error 
range. In addition, there are restrictions to parameters such as the number and types of 
modifications and a precursor mass tolerance in Daltons (Da) is restricted to between 
0.0 to 2.0 Da, as a mass window above this would increase search time and reduce the 
sensitivity of the search by considering many more possible precursor masses, which 
becomes a problem and more so in proteogenomics searches. However, due to the 
inaccuracies with low-accuracy mass spectrometers (e.g. LTQ), there is no well-defined 
optimal precursor mass tolerance that can be chosen, as the actual mass of each peptide 
ion may vary widely, resulting in the MS/MS spectra not being identified if the mass 
window is too narrow or too wide. In some situations, going above 2.0 Da, and looking 
at a range of precursor mass tolerances, e.g. up to 3.0 Da may be warranted to improve 
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upon coverage, as demonstrated in a later chapter utilizing low-accuracy MS/MS 
spectra. As a result, the database searches were performed using an in-house script, 
independent of Enosi, with each MS/MS spectral file searched against each database 
file. This step was also taken due to the limitation that Enosi required an SGE cluster for 
scheduling, which was not accessible to the dissertation author. Only access to SLURM 
and PBS Pro schedulers were available, as further explained later in Section 3.5. 
3.4 PROCESSING AND PREPARATION OF DATASETS 
3.4.1 Formatting of gene model and protein sequence datasets 
Datasets from the various case studies required varying degrees of modification 
depending on the state of the publicly available annotations or the output from 
prediction and annotation tools. For the proteogenomics pipeline to be compatible with 
the GFF file an “mRNA” line must be present preceding the “CDS” line, while a “gene” 
line is not critical for processing. In cases where only “gene” and “CDS” lines exist, the 
word “gene” from column three, can be replaced with “mRNA”. Also the protein 
FASTA headers and/or Parent identifiers in the GFF file were modified to ensure that 
they were the same. The “Parent” identifier for mRNA was also required to be the same 
on the corresponding CDS and exon features. Additionally, to assist downstream 
annotation, where the “ID” and “Parent” identifiers were too generic or inconsistent 
across all features, they were modified to include the gene name and/or accession for 
easy identification. 
In some instances, gene feature coordinates were found to be in the wrong 
orientation on the reverse strand (e.g. 5’ to 3’ on the forward strand and 3’ to 5’ on the 
reverse strand). In particular, for Enosi to determine known mapped peptide 
coordinates, CDS and exon coordinates must be in a 5’ to 3’ orientation on the reverse 
strand (i.e. the highest coordinate to lowest coordinate), and the reverse for the forward 
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strand. In instances where GFF files contained CDS and exons in the wrong orientation, 
an in-house script, utilizing GFFutils (https://github.com/daler/gffutils), was used to 
parse the GFF file and to output all gene features in a 5’ to 3’ orientation, regardless of 
which strand was implicated. In addition to the gene feature orientation, modifications 
to the GFF files were carried out with a series of Unix commands. 
3.4.2 Pre-processing of RNA-seq datasets 
All Illumina reads were first checked for quality using FASTQC [543], followed by 
trimming using Trimmomatic [544], with quality score thresholds set to an average of 
20 across a 4 bp window. Minimum length was set to 20 bp and Phred scores were set 
to 33 (Illumina 1.8+) or 64 (Illumina 1.5+) depending on the reads. The first 15 bp of 
the reads were cropped to remove any Illlumina bias present, and the appropriate 
Illumina adapter sequences (either TruSeq2 or TruSeq3) were chosen in each case 
depending on the sequencing method used. All unpaired reads were merged and labelled 
single end (SE). All trimmed reads were then gzipped. FASTQC was then re-run on the 
trimmed reads to confirm the quality of the reads before alignment to the genome. 
3.4.3 RNA-seq alignments 
All alignments to the respective genomes in each case study were carried out using the 
Spliced Transcripts Alignment to a Reference (STAR) aligner (version 2.3.1x) [127], 
using the two-pass scheme which was conducted using an in-house bash script running 
on a Cray XC30 supercomputer (Magnus, from the Pawsey Supercomputing Centre 
https://www.pawsey.org.au/). Magnus consists of two compute cabinets, each holding 
52 compute blades, with four nodes per blade and each node supporting two 8-core Intel 
Sandy Bridge Xeon E5-2670 processors running at 2.6 GHz, with 64 gigabytes of 
DDR3-1866 per compute node, at 1.6GHz. Each STAR job on the supercomputer was 
assigned 16 cores and 63 GB RAM and ran within a 12 hour walltime. STAR was run 
with 16 threads, and the parameters “genomeSAindexNbases”, “genomeChrBinNbits”, 
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“genomeSAsparseD”, and “limitGenomeGenerateRAM” were set to “7”, “10”, “20”, 
and “63000000000”, respectively (optimised for aligning to particularly larger, highly 
fragmented genomes). The two-pass scheme was implemented by using the splice-
junctions output from the 1st pass, as input for the 2nd pass to improve upon the 
sensitivity of splice junction detection. STAR was chosen by comparison with other 
alignment tools such as TopHat2 [126] due to its improved alignment speed, sensitivity 
and reporting fewer false positives [545]. 
All alignment results from paired end and single end reads were in Sequence 
Alignment/Map (SAM) format, which were then subsequently sorted by coordinate and 
converted to sorted Binary Alignment/Map (BAM) format files using the tool SortSam 
from Picard tools (http://picard.sourceforge.net/). 
3.4.4 Preparation of proteogenomics splice database 
All sorted BAM files from the STAR alignments were then merged together into a 
single BAM file using SamBamba (http://lomereiter.github.io/sambamba/), which is a 
SAM and BAM tool capable of quickly merging many SAM and BAM files into one 
larger file with relatively little memory overhead. The Picard tool MarkDuplicates was 
then run to filter any PCR and optical duplicates from the merged BAM files. In some 
cases, where the BAM files were particularly large with many sequences in the header, 
MarkDuplicates was run before merging the BAM files using Sambamba. The resulting 
BAM files, with redundant read alignments removed, were then converted to a SAM 
file using SAMTools [546]. 
Packaged with Enosi (version 1.0) is a script called BuildSpliceGraph (version 
0.4.11), which takes SAM files and a genome FASTA file. Using the SAM file 
mentioned above, BuildSpliceGraph was run to generate a SpliceInfo file, with a 
maximum peptide length set to 30 aa and a minimum number of spliced reads set to 2. 
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Finally, a splice FASTA file was generated; representing all spliced peptides and 
containing genomic coordinates in the FASTA header. This splice FASTA file was then 
used as a splice database in the proteogenomics analysis. In instances where the genome 
was very large and/or fragmented, resulting in very large numbers of splices to process, 
each splice from the SpliceInfo file was separated out and run in a massively parallel 
manner on Magnus, mentioned previously in Section 3.4.3 for RNA-seq alignment. 
3.4.5 Preparation of six-frame translation database 
A stop-codon-to-stop-codon translation of the genome was generated in all six frames. 
This was undertaken using the Enosi tool, using 30 aa as the minimum Open Reading 
Frame (ORF) size and with the minimum file size for each file set to 500 Mb, unless 
otherwise specified for each specific case study. 
3.4.6 Pre-processing MS/MS spectra and MS/MS database search 
optimization 
In each case study the total set of MS/MS spectra were clustered using MS-Cluster 
[312], thus improving the signal to noise ratio by merging MS/MS spectra and 
removing redundant MS/MS spectra matching the same peptide, which improved the 
overall quality of the MS/MS spectra and reduced the number of aberrant MS/MS 
spectra attributing to false positives. This also reduced the overall dataset size, resulting 
in improved search times. PepNovo [302] was then used to quality filter the clustered 
MS/MS spectra. Due to the limited MS/MS spectral dataset sizes, the level of quality 
filtering was optimised for each dataset to reduce losses. Comparisons using the known 
proteome, were made between the original MS/MS spectra, clustered MS/MS spectra, 
and clustered+quality filtered MS/MS spectra across a range of quality score thresholds 
(PepNovo scores 0.001, 0.005, 0.01, 0.05, 0.1, and 0.2), to ascertain the most 




Often in peptide mass spectrometry users default to around 20 ppm with high 
accuracy Orbitrap, Fourier Transform (FT) and TOF machines, while 2.0 - 4.0 Da is 
often the choice for lower accuracy LTQ machines. Additionally, the accuracy of any 
one machine can alter over time, over different mass ranges (depending on the 
machine), and can also differ from day to day. In keeping with this trend and to keep the 
choice of precursor mass tolerance consistent while assessing quality filtering and 
clustering it is best to default to using a precursor mass tolerance of 20 ppm for high-
accuracy MS/MS spectra and 2.0 Da for low-accuracy MS/MS spectra. Comparisons of 
all results between the original MS/MS spectra, clustered MS/MS spectra, and 
clustered+quality filtered MS/MS spectra, were then made, taking the largest number of 
peptide-spectrum matches (PSMs) <5% peptide false discovery rate (FDR), and the 
most appropriate pre-processing strategy was chosen for further proteogenomics 
analysis.  
For most of the case studies in this thesis, a high accuracy mass spectrometer, 
such as the LTQ Orbitrap and QTOF was used to generate the MS/MS spectral datasets. 
The high accuracy MS/MS spectral datasets are well suited to applying a precursor mass 
tolerance optimization step. The use of high accuracy machines is frequently ignored or 
forgotten when performing MS/MS database searches [161] and it is often prudent to 
optimize MS/MS database search parameters before conducting the analysis proper 
[547]. A similar approach was taken with the proteogenomics analysis, by using the 
high sensitivity and precision of MS-GF+ in conjunction with the choice of an optimal 
precursor mass tolerance to reduce false positives and improve peptide discovery rates, 
while maximizing on the identification sensitivity of proteogenomics annotations. The 
choice of precursor mass tolerance also affects the sensitivity of MS/MS database 
searches. By increasing the error window, particularly for the larger fixed value errors 
in Da often used with low-accuracy mass spectrometers, such as with an LTQ, the 
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search space and search time is essentially increased, which consequently reduces the 
sensitivity of the search (up to a point dependent on the accuracy of the mass 
spectrometer). This fact is reflected in Enosi as outlined in Section 3.3, where Enosi 
purposely restricts the choice of precursor mass tolerances to between 0.0 and 2.0 Da 
when selecting Da as the precursor mass unit. 
Assessment of the optimal precursor mass tolerance for each dataset was 
conducted over a number of ranges (generally 0.5 - 5.0 Da for low-accuracy and 0.5-
150 ppm for high-accuracy) to deduce the optimal precursor mass tolerance for the pre-
processed MS/MS spectral dataset, as before, taking the largest number of PSMs <5% 
peptide FDR. 
MS-Cluster was used to cluster the MS/MS spectra as previously outlined. 
However, in cases where the number of MS/MS spectra was less than 100,000, 
clustering was not performed as this would prove ineffective and it would probably 
result in MS/MS spectral losses. PepNovo on the other hand uses a machine-learning 
approach based on prior MS/MS spectra on which it was trained on during its 
development [314], looking at peak intensities and numbers. The training data were 
likely derived from cell lysates, which would have a higher signal-to-noise ratio, higher 
peak intensities and large numbers of mass peaks compared to samples derived from 1D 
or 2D gel digests. Therefore, any MS/MS spectra derived from similar sources to cell 
lysates, instead of 1D gel digests, would be more suitable for quality filtering. PepNovo 
applies a quality score to each MS/MS spectrum, which is then applied to filter the 
MS/MS spectra. As a result, some case studies with MS/MS spectra derived from 1D 
and 2D gels were not quality filtered, and similarly, when there were a limited number 
of MS/MS spectra, no clustering was performed. 
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 The original MGF files and also the single merged larger MGF file following 
clustering (and quality filtering where applicable) were split up into separate smaller 
files each consisting of 65,000 MS/MS spectra, using an in-house MGF splitting script 
on a local machine or 20,000 MS/MS spectra each, for running on a cluster with a 24 
hour walltime (MS/MS spectral numbers below 1,000 were not recommended as this 
would lead to significantly lower accuracy FDR calculations). The original MGF files 
were also split, as some MS/MS spectral files can be too large for tools like MS-GF+ to 
process effectively or at all. Enosi was designed to run directly on a SGE cluster, where 
it would split up the MS/MS spectral files based on the number of compute nodes 
specified, but when the number of compute nodes is few or is only ever run on a single 
node, each MS/MS spectral file may still remain too large to process effectively. 
To evaluate the different pre-processing strategies and precursor mass 
tolerances, an in-house script was used along with MS-GF+ (version v9949 2/10/2014). 
The in-house script contains parameters as explained in Section 3.3. A decoy database 
was created by reversing the sequences from the target database and then was combined 
with the target database and indexed using a suffix array. This was done automatically 
by MS-GF+ otherwise, depending where the search was run e.g. on a cluster, then the 
generation of decoy sequences and indexing of the databases were performed as 
separate jobs. If running multiple split MS/MS spectra across multiple split databases on 
a cluster, the results were then merged and a 1% PSM FDR applied. This was applied 
using the ComputeFDR function from MS-GF+, with the spectral E-value used as a 
score. Calculations of the peptide FDR and protein FDR were then determined based on 
the method outlined in [411]. In addition, the number of PSMs, number of non-
redundant peptides, and number of non-redundant proteins were then calculated prior to 
and post-FDR filtering. Ultimately, further control on the FDR is employed within each 
case study, either prior to proteogenomics analysis using the more traditional combined 
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FDR strategy (see Section 3.5) or the two-stage FDR strategy (see Section 3.5.2), or 
during proteogenomics analysis by the event probability. 
Other parameters to consider for optimization included post-translational 
modifications (PTMs). The inclusion of PTMs has the effect of also increasing the 
search space and reducing sensitivity. A more prudent approach is to leave the search 
for protein polymorphisms and PTMs to only proteomics searches and focus on what is 
most appropriate for proteogenomics in the context of improving sensitivity by 
maximizing the number of new annotations. As was pointed out by Tsur et al [402], for 
every protein there is likely at least one unmodified peptide, and so by adding further 
modifications to a proteogenomics search will only hamper attempts to discover new 
proteins and novel annotations. As such, the selection of appropriate PTMs for the 
MS/MS database search were kept to the default throughout this thesis: 
carbamidomethylation of cysteine (C+57), oxidation of methionine (M+16) and protein 
N-terminal acetylation (+42). 
3.5 PROTEOGENOMICS PIPELINE 
A proteogenomics pipeline was customized utilizing the proteogenomics tool Enosi 
(version 1.0) [8, 437, 548, 549]. Enosi incorporates the highly sensitive and accurate 
MS/MS database search tool, MS-GF+, and also has the ability to search an RNA-seq 
derived FASTA splice-graph database [549]. 
For all case studies, the appropriate pre-processing strategy and precursor mass 
tolerance were selected based on an evaluation using the known proteome, as outlined 
above in Section 3.4.6. The clustered and quality filtered MS/MS spectra were then split 
using an in-house MGF splitting tool into 65,000 MS/MS spectra when running on a 




The Enosi tool assigns different annotation events to the identified peptide 
clusters: novel genes, identified outside the boundaries of the peptide linkage distance, 
distal events, identified within the boundaries of the peptide linkage distance, but 
outside the boundaries of a gene and proximal events, identified within the boundaries 
of the peptide linkage distance and within the boundaries of a gene. The novel gene 
events consist of novel genes, while distal events consist of gene boundaries, translated 
UTRs and reverse strand events, and proximal events consist of frame-shifts, exon 
boundary, novel exon and novel splice events (when applicable for eukaryote studies). 
The parameters selected for Enosi included a six-frame translation of the 
genome generated as outlined above in Section 3.4.5, a minimum cluster size (total 
peptides per cluster) set to 1, a minimum number of unique peptides per cluster set to 1 
and an initial minimum event probability of 90%, before further manual filtering among 
the different annotation event types. Through MS-GF+, the Enosi tool automatically 
generates a decoy database of reversed sequences with both target and decoy databases 
combined and indexed using a suffix array. As part of the pipeline, the MS/MS database 
search parameters were set as outlined in Section 3.3, with the majority of case studies 
applying a two-pass search approach outlined below in Section 3.5.1. The final MS/MS 
database search results were then either all merged in a combined FDR strategy or split 
into novel and known PSMs, termed a two-stage FDR strategy [439, 474], as outlined 
below in Section 3.5.2. A ≤1% PSM FDR was then applied, with local FDRs for each 
PSM calculated. For the combined FDR strategy, following FDR filtering all identified 
peptides were then grouped into novel peptides and known peptides by comparison to 
the known proteome. 
Using an in-house script, all PSMs identified from the known proteome were 
divided into two confidence levels: all proteins that contained a mapped peptide and all 
proteins that contained ≥2 peptides with 1 unique peptide. This division was done to 
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remove ambiguity due to the protein inference problem and resulted in a list of high 
confidence known protein identifications. All novel peptide identifications were then 
mapped to their genomic coordinates, clustered according to a peptide linkage distance 
with each cluster inferred as a different annotation event, as mentioned previously. All 
annotation events were then screened through a combination of methods; e.g. event 
probabilities, multiple unique peptides, sequence homology to curated proteins, peptides 
mapping to the known proteins being annotated, parsimony and spectral counts, which 
can provide an estimate of protein abundance that correlates well with transcript 
abundance, if high enough protein coverage from the known peptides is achieved. The 
novel events passing screening were then interpreted to infer gene model changes 
(Figure 3.1), which were then visualized in a genome browser, such as IGV, and if a 
eukaryote study, incorporated as hints for gene prediction using the gene prediction tool 





Figure 3.1 Customized proteogenomics pipeline 
In module 1, a MS/MS spectral pre-processing and optimization step was carried out, following a MS/MS 
database search with an optional two-pass search implemented against the six-frame translation of the 
genome, known proteome, and where applicable, a splice graph. In module 2, FDR filtering was applied 
to results, in either a combined FDR strategy (dashed line) or a two-stage FDR strategy (dash dot line), on 
the known results and novel results separately. Identified known proteins were filtered by parsimony (≥2 
peptides) with 1 unique peptide. Novel peptides were mapped to the genome. In module 3, novel peptides 
were clustered within the peptide linkage distance, annotation events inferred, then filtered based on event 
probability, number of unique peptides, sequence homology, presence/lack of multiple peptides mapped 
to the known proteins being annotated, and spectral counts, followed with identification of novel and/or 
refined gene models. 
It should be noted that the current version of Enosi (version 1.0) has some 
inaccessible parameters hard-coded into the tool, such as the number of tolerable 
termini, restricted precursor mass tolerance in the range of 0.0 to 2.0 Da (with precursor 
mass tolerance in ppm being unrestricted), and maximum peptide length. The number of 
reported matches per MS/MS spectra, use of reversed sequence decoy database and 
isotope error range are hidden, but are always on by default, including a restriction on 
the allowed number and types of modifications. Also when selecting Da as the 
precursor mass unit, Enosi purposely restricts the use of a precursor mass tolerance to 
between 0.0 and 2.0 Da. As previously noted, this is to limit the search space and search 
time during proteogenomics searches, as precursor mass tolerances in Da much higher 
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than 2.0 Da would inflate the FDR and significantly reduce the sensitivity of PSM 
identifications, and consequently the number of identified proteogenomics annotations. 
However, in some cases the limit of 2.0 Da was purposely exceeded, as outlined 
previously in Section 3.3. 
The following proteogenomics specific parameters were chosen: 1) annotation 
events were initially filtered based on 1 unique peptide per cluster, 2) a minimum 
cluster size of 1 peptide, 3) a minimum event probability of 90% and 4) the peptide 
linkage distance, which was based on the minimum intergenic distance for particularly 
small compact genomes such as prokaryotes or the size of the majority of genes (>95%) 
in eukaryotes. Other more general parameters included the selection of the MS/MS 
instrument and precursor mass tolerance, which was based on an assessment of the 
MS/MS spectra outlined previously in Section 3.4.6. 
The selection of the peptide linkage distance is important because it impacts 
how annotation events are defined, more so for novel gene and distal events like gene 
boundary and reverse strand events, as these can be identified further afield from the 
peptide cluster, depending on the size of the peptide linkage distance. A larger peptide 
linkage distance would reduce the number of novel genes found, and increase the 
number of distal events, while reducing it would identify more novel genes and fewer 
distal events. As such, the peptide linkage distance was considered carefully. 
Importantly, during proteogenomics annotation any identified distal events such as gene 
boundary and reverse strand events could possibly be novel genes as the peptide linkage 
distance is a fixed variable, unlike reality where the intergenic distances across the 
genome can vary widely. 
Once all peptide clusters were assigned as novel gene, distal events or proximal 
events, they were further filtered manually based on ≥2 unique peptides per cluster 
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and/or event probabilities ≥99.9%, which were considered as high confidence 
annotation events. Any other proximal events were accepted based on a relatively high 
event probability of ≥99.8%. In addition, all annotation events were further screened, 
particularly to validate single unique peptide annotation events by: 1) the presence/lack 
of unique and shared peptides mapping to the known proteins being annotated 
particularly for the proximal events, with consideration of their frame in relation to the 
novel peptides; 2) spectral counts; and 3) sequence homology to protein sequences in 
public protein repositories such as NCBI NR, NCBI RefSeq protein and/or NCBI 
SwissProt, to identify any annotation events already validated within protein 
repositories [439]; and in some cases 4) the peptide length was a consideration which 
would impact significance when searching protein repositories. The presence/lack of 
mapped unique and shared peptides to the reference known proteins being annotated 
were determined using a customized script, with manual checking of the frame of these 
peptides to see if any peptides in close proximity to the novel peptides were in a 
different conflicting frame, which was important for proximal events. 
To improve specificity of annotation event identification and ensure that unique 
loci were identified, peptide clusters with at least 1 unique peptide only were accepted. 
The same principle was applied to improve specificity and remove ambiguity with 
protein identifications. This is a similar concept to using proteotypic peptides as a 
unique signature for a single protein in peptide mass spectrometry [550], often used in 
Selective Reaction Monitoring (SRM) in targeted proteomics [551]. This principle is 
therefore applied by using sequence homology searches of the unique and novel 
peptides, using BLASTP against NR, RefSeq protein and/or SwissProt to reduce the 
ambiguity while screening. Other information found from the sequence homology 
search such as the same chromosome and genomic region identified from the 
proteogenomics analysis, preferably with support from EST, mRNA and/or protein, 
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with 100% coverage and identity particularly for proximal events, was considered as 
conclusive evidence. However, for one early case study in a bacterial genome stringent 
event probabilities alone were used for novel genes, distal events and proximal events, 
with their selection based on cross correlation between different bacterial gene 
prediction tools. 
In each case study the current annotation of the genome was provided as a 
reference. These were provided as GFF file and protein predictions as FASTA 
sequences, and where necessary were modified as outlined in Section 3.4.1. 
For larger proteogenomics studies which required parallel computing, Enosi 
utilizes a Distributed Resource Management Application API (DRMAA) scheduler to 
coordinate each run of MS-GF+. However, throughout the course of this thesis, a 
DRMAA scheduler was not accessible from any of the available clusters provided by 
the Pawsey Supercomputing Centre (http://www.pawsey.org.au/), with PBS Pro and 
SLURM the only installed schedulers. To work around this issue, MS-GF+ searches of 
the six-frame translation, proteome and any splice graph databases were carried out 
using an in-house script which would mimic the initial stages of the Enosi 
proteogenomics pipeline, namely database indexing and the MS/MS database search. 
The Pawsey Supercomputing Centre’s supercomputer Zeus was utilized for this task 
due to its 24 hour walltime and large number of relatively freely available processors 
due to its smaller user base and subsequent shorter queue wait time, and a submission 
limit cap of 96 jobs (although not all running concurrently). The Zeus supercomputer 
has 29 nodes, each with two 8-core Intel Xeon E5-2670 CPUs, and between 128 GB to 
512 GB RAM per node. Enosi is capable of running the proteogenomics workflow from 
any stage in the analysis. This facility was utilised after receiving the MS/MS database 
search results, which were subsequently all merged with 1% PSM FDR applied 
(combined FDR) or merged based on the known proteome search space and novel 
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proteogenomics search space (two-stage FDR), with 1% PSM FDR applied to each 
(Figure 3.1). During FDR filtering each PSM had its local FDR calculated, which was 
run on a different machine and did not require parallel processing. 
In instances where the merged results, using the combined FDR strategy, gave a 
large tab-separated value (TSV) file, upwards of 12 gigabytes (a consequence of 
searching a large six-frame translated genome and/or splice graph database), the files 
were split into smaller result files based on the MS/MS spectral files, as filtering on the 
FDR and calculating local FDR for each PSM on a single large result file extended 
processing time significantly. It was found that the processing time could be reduced to 
around a few days or up to a week per file if the results were merged into 2 (see Section 
6.2.5) or 4 (See Section 5.2.5) TSV files, which differed depending on the dataset. 
Results derived from low-accuracy MS/MS spectra took less time to process than high-
accuracy MS/MS spectral results, as more highly significant PSMs are usually found in 
high-accuracy data. However, such a strategy can result in inaccurate FDR calculations 
and shifts in the eventual event probabilities as the same peptide matches can be 
distributed across multiple different search result files leading to slight biases with some 
results. As a consequence, a balance between processing time versus accuracy of FDRs 
and event probabilities was required, limiting all the results to a few result files at most, 
a necessary compromise if results are to be obtained in any reasonable time frame. For 
results obtained from the two-stage FDR strategy, no splitting of result files was 
necessary, as this strategy implemented a filtering of known and novel PSMs and 
consequently reduced the final result file sizes. This issue indicates a need for new 
processing approaches or algorithms to process larger sets of results, often found from 




As outlined previously [548], a hybrid approach to proteogenomics is often 
suitable for larger more gene-sparse genomes, where a combination of event 
probabilities and unique peptides per cluster are used for different annotation event 
types. In such a case, novel genes and distal events require at least 2 unique peptides per 
cluster with more relaxed event probabilities, while proximal events require 1 unique 
peptide with more stringent event probabilities being applied and with the peptide 
linkage distance set to a distance represented by the majority of genes (generally >95% 
genes). The rationale behind this judgement is that within large intergenic spaces, such 
as in eukaryotic genomes, at least 2 unique peptides are more likely to be found and the 
possibility of finding false positives is much higher. Conversely, within the intragenic 
space, around annotation events such as frame-shifts and exon boundaries, more than 1 
unique peptide is less likely to be found due to the confined region and false positives 
are less likely to occur. When MS/MS spectral datasets are very large such an approach 
would likely correlate well with accepting at least 2 unique peptides for novel gene and 
distal events, but when the MS/MS spectral datasets are small, many annotation events 
may simply lack a second unique and novel peptide due to low coverage. In such 
instances, a single unique peptide could be accepted when other evidence suggests a 
likely valid annotation event, such as was previously described. Within the context of 
the proteogenomics analysis, the peptide linkage distance defines intergenic and 
intragenic spaces. The linkage distance determines how large the peptide clusters can 
become (the intragenic space), while it also defines the distance between peptide 
clusters (the intergenic space). When applying this same principle to smaller, compact 
genomes such as bacteria, it is more prudent to set the number of unique peptides per 
cluster to 1 and apply a more stringent event probability to novel genes and distal 
events, and the same stringency or less for proximal events, while setting the peptide 
linkage distance to a suitably smaller intergenic distance. 
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3.5.1 Two-pass search approach 
A two-pass search approach was applied in a number of case studies, similar to the 
approach demonstrated in [428], to improve the sensitivity and identification rate of 
PSMs and proteogenomics annotations. In the first-pass the six-frame translated genome 
with added protein contaminant sequences was searched against using MS-GF+, with 
parameters as outlined in Section 3.3 and the exception that no decoy database was 
added to the target database and searched. This was repeated for the known proteome 
database and splice graph (if applicable). 
Any PSMs that matched the six-frame translated genome, known proteome or a 
splice graph, were identified, while any PSMs that only identified contaminant 
sequences were discarded. No FDR filtering was applied to any matches during this 
first-pass search. In an earlier bacterial study (Chapter 4) all matches were taken from 
the first-pass. However, in later studies (Chapters 6 and 7), since the MS/MS database 
searches are taking the top 10 matches, it was realized that these could also include very 
low significant matches. These matches were subsequently removed, keeping all PSMs 
below a spectral E-value of 1.0E-05. By comparison, a 1% PSM FDR roughly equals to 
a spectral E-value of 1.0E-10 and so this retains all significant matches, while removing 
all insignificant matches unlikely to be retained below the 1% PSM FDR threshold. The 
choice of a 1.0E-05 spectral E-value was a relatively arbitrary choice, and could be 
adjusted if there was supporting evidence to do so. 
A new MS/MS spectral dataset for each database, and a new target sequence 
database were created from the first-pass search, based on the accepted PSMs and using 
an in-house script. The new MS/MS spectral dataset was then used to search the new 
target databases, along with their decoys in the second-pass search during a normal run 
of the proteogenomics pipeline. 
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3.5.2 Two-stage FDR strategy 
The two-stage FDR strategy was outlined in [439], with similar strategies in [474] and 
[552]. Instead of applying a 1% PSM FDR across all proteogenomics results, the FDR 
was applied across the different search spaces. In [474] this was applied to the known 
proteome and a unified novel set of proteogenomics results, with MS/MS spectral 
identifications in the known set removed from the novel set before MS/MS database 
searching of the proteogenomics search space. However, this can be overly 
conservative, as a MS/MS spectral identification first identified in the known set does 
not necessarily represent the most ‘correct’ identification for that MS/MS spectrum. 
Although when the proteogenomics search space contains a variety of putative variant 
peptides as demonstrated in [474], this can be justifiable to reduce the potential for 
incorrect identifications with Single Amino acid Polymorphisms (SAPs) being 
misidentified as PTMs. Similarly, in [552] prior to MS/MS database searching, the 
sequences from the proteogenomics search space are in silico digested, with the 
peptides identified from the known search space by sub-string matching and 
subsequently removed to create a database of likely novel peptides. However, this does 
not filter out any spurious MS/MS spectra, applying the full MS/MS spectral dataset to 
both known and novel search spaces. This approach also assumes that all MS/MS 
spectra used in a search have no missed cleavages, which would limit coverage 
particular for non-tryptic ended peptides at the proteins N-terminus, and also limiting 
the digestion to a number of well-known proteases and it would also limit the analysis 
to only in vitro protease cleaved peptides, which would miss in vivo proteolytic peptides 
if they were of interest. 
 In this thesis a different approach was taken with PSMs identified after filtering 
the MS/MS spectra through a two-pass search approach, removing spurious MS/MS 
spectra and reducing the search space to high confident matches, where the search space 
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was then divided into novel and known sequences. All PSMs that identified a novel 
peptide had a 1% PSM FDR applied, with the same applied to a separate set of known 
PSMs identifying known proteins. This allowed more accurate FDR calculations for 
both the ‘known’ search space and the ‘novel’ search space. Some MS/MS spectra may 
be interpreted as novel and known, with possibly differing spectral E-values, which this 
method does not account for. However, this method does improve on the accuracy of 
the FDR, and does not make any assumptions of a MS/MS spectrum belonging to 
‘known’ or ‘novel’ peptide sequences, unlike the more conservative approach [474]. 
For Enosi to determine novelty prior to FDR filtering, a different approach to the 
workflow was required. Firstly, the results from the known proteome search had a 1% 
PSM FDR applied. Following this, the results from the six-frame and splice graph 
search are merged and filtered to 100% PSM FDR to identify all possible PSMs in a 
format which is compatible with Enosi’s determine novelty stage. All PSMs identified 
at 100% PSM FDR were then split into known and novel by Enosi. Any PSMs 
identified as a novel PSM are then checked to ensure they fall below a 1.0E-05 spectral 
E-value, after which the identified novel MS/MS spectra and novel sequences were used 
in a novel-only MS/MS database search, followed by the application of a 1% PSM 
FDR. The remainder of the workflow is as normal, which uses a known 1% PSM FDR 
filtered set of PSMs and novel 1% PSM FDR filtered set of PSMs. This essentially 
reduces the size of the proteogenomics search space to only PSMs identified as novel, 
improving the accuracy of the FDR filtering for both the novel and known peptides. 
Some MS/MS spectra can be identified in both the novel and known search 
spaces as a result of different MS/MS spectral interpretations with different spectral E-
values in the top 10 matches. Future work could see the use of a spectral E-value 
comparison between the novel and known PSMs, to more accurately assign a PSM to a 
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novel or known peptide sequence, with any ambiguous matches with the same spectral 
E-values discarded. 
3.5.3 Gene prediction 
Once the novel annotations were filtered and reviewed, the gene prediction tool 
Augustus [102] (version 3.02), was used for studies involving eukaryotic genomes. 
Depending on the study, Augustus was either first trained (generating gene models) or 
ran with the default gene models, the details of which are presented within each chapter. 
Once the novel annotations were filtered and reviewed, the gene predictions 
were improved using the novel peptides as hints. Further hints generated from other 
extrinsic supporting evidence were also generated for some case studies, further 
outlined in their respective chapters. 
The hints generated from EST, RNA-seq and the current annotations were 
designated group name ‘E’ with associated default weighting, and the hints from any 
repeat regions were designated group name ‘RM’ with associated default weighting. All 
novel peptides were designated group name ‘M’, with the default high significance 
weighting to force incorporation of the hints. The hint files were then combined and 
used as hints during the Augustus gene prediction. Augustus was run using the 
parameters listed in Table 3.1. 
It is worth noting that Augustus can predict more genes and proteins than there 
actually are due to two factors: 1) a fragmented genome can cause Augustus to predict 
two or more incomplete genes across contigs and scaffolds and 2) given the available 
evidence, due to possible incomplete coverage, predictions may be split into two or 
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--species Set to the species name 
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Hints file containing novel peptides (group M), any available extrinsic hints, 






4 BACTERIAL PROTEOGENOMICS 
4.1 INTRODUCTION 
Bacteria have long been the dominant form of life on Earth, since they first evolved 
some 3.5 billion years ago. They have since diversified into many forms as they adapted 
across almost all environments across the globe. They are an essential component of our 
biosphere, with some species playing a role in the formation of nitrates in the soil, a task 
that nitrogen-fixing bacteria (rhizobium) perform in the root nodules of host plants, 
others contribute to disease (e.g. Mycoplasma pneumoniae causing pharyngitis, 
bronchitis, and pneumonia), and still others can contribute to a healthy digestive tract 
(e.g. Lactobacillus acidophilus). 
Understanding how different bacteria function is important, so that diseases can 
be treated, soil for agriculture can be improved using nitrogen fixation, and our overall 
wellbeing improved. The biotechnology revolution over the last few decades has 
benefited greatly as a direct result of discoveries from bacteria, such as the use of DNA 
polymerase from thermophilic bacteria used in the DNA polymerase chain reaction 
(PCR) [553], a staple technology used in the amplification of DNA for sequencing. In 
addition, a new technology discovered from bacteria has emerged, called clustered 
regularly interspaced short palindromic repeats (CRISPR) [554], based on the innate 
immune response of bacteria to recognize viruses, which claims to be able to directly 
edit DNA in vivo, potentially allowing for the correction of genetic diseases. 
To better understand the underlying mechanisms that underpin CRISPR, 
nitrogen-fixation, pathogenicity causing disease and others, within bacteria, genome 
sequencing and annotation efforts are required. The throughput and quality of bacterial 
genome sequencing has improved significantly over the years. For example, Illumina 
sequencing technology can now sequence 100 bacterial sequences simultaneously [555]. 
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However, the throughput of genome annotation strategies has not been able to match, 
and bacterial genome annotation strategies often involve the use of ab initio gene 
prediction tools and sequence similarity, which are prone to errors and inconsistencies, 
as was introduced in Section 2.2.2. Therefore, a new methodology, capable of 
maintaining high throughput and quality of genome annotation is needed. 
This study applies a new approach towards genome annotation, termed 
proteogenomics, and also demonstrates the power that repurposing legacy proteomics 
data has for improving the genome annotation of the nitrogen-fixing bacteria 
Bradyrhizobium diazoefficiens. 
Agriculture requires a constant supply of nitrates to the soil to allow crops to 
grow and achieve high yields. This often requires artificial means using fertilizers. 
Unfortunately, fertilizer run-off into water sources such as estuaries causes problems 
with toxic algal blooms resulting in anoxic rivers leading to a large die off of fish 
populations. By understanding the molecular mechanisms underpinning the processes 
for nitrogen-fixation in bacteria such as Bradyrhizobium diazoefficiens, it is highly 
likely that a new strain could be created with higher rates of nitrogen-fixation and 
compatibility with a wider range of host plants, allowing for a more viable, economical 
and natural alternative to fertilisers. 
4.1.1 Outline of this study 
The overall aim of this study was to undertake the genome annotation of 
Bradyrhizobium diazoefficiens, applying a proteogenomics approach using the Enosi 
tool [82] and to compare with the findings from another study which used Genosuite 
[502]. 
B. diazoefficiens is an important agricultural nitrogen-fixing bacterium. The 
genome was first sequenced by Kaneko et al. [556] in 2002, with gene predictions 
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carried out by Glimmer [557] and sequence similarity. It was found that B. 
diazoefficiens had a genome size of 9.1 Mbp and a GC content of 64%. 
The Enosi tool was initially built with a focus on eukaryotic genomes, and the 
latest version incorporates MS-GF+, which applies a combinatorics approach to scoring 
and assignment of significance to peptide-spectrum matches (PSMs). As part of this 
study, a proteogenomics pipeline was employed for B. diazoefficiens, which has not 
been previously demonstrated. 
A customized proteogenomics pipeline incorporated a pre-processing and 
optimization step, using the known proteome to evaluate the MS/MS spectral dataset 
and improve on the PSM identification rate. In addition, a two-pass search approach 
was applied which demonstrated how it could further improve on sensitivity. Two 
additional MS/MS spectral datasets (PRIDE Accessions 10112 and 10113) were also 
included, and with comparisons made between multiple annotations from both methods. 
4.2 MATERIALS AND METHODS 
4.2.1 Proteomics and genomics datasets 
The Bradyrhizobium diazoefficiens USDA 110 (previously B. japonicum) genome 
sequence and gene models [556] in GFF and proteome FASTA file formats were 
downloaded from NCBI BioProject 57599 and further gene models were predicted 
using Prodigal [558] and RAST [134]. Gene models were modified with an in-house 
script to be compatible with the proteogenomics pipeline (Appendix File 4.1). 
Peptide mass spectrometry datasets, totaling 757,807 MS/MS spectra, were 
downloaded from PRIDE [559] as MGF files, using accessions 10099-10104 and 
10112-10116. Initially generated in proteomics studies [4, 5], samples were run on a 1D 
gel, subsequently digested with trypsin and run through an LTQ Orbitrap. The MS1 was 
run on the Orbitrap and MS2 was run on the LTQ. 
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Contaminant proteins were used, as outlined in Section 3.1.1. In addition, three 
sources of plant protein contaminants were also used [4, 5]; Soybean (Glycine max), 
Cowpea (Vigna unguiculata) and Siratro (Macroptilium atropurpureum), obtained from 
Phytozome v9.0 (http://www.phytozome.net/) and UniProt (http://www.uniprot.org/). 
Plant protein databases were merged and redundancy was removed using CD-HIT [560] 
based on 100% homology. These databases were then appended to the reference NCBI 
protein predictions before being used in the MS/MS database search to identify any 
contamination. 
4.2.2 MS/MS database searching  
The MS/MS database search was performed by MS-GF+, as outlined in Section 3.3. In 
this case study, trypsin was used as the protease, instrument was set to low-res LTQ 
(Ion Trap), and the precursor mass tolerance used was set to 6.0 ppm, as determined 
from a preliminary MS/MS spectral dataset assessment, detailed below in Section 4.2.3. 
4.2.3 Dataset processing 
The NCBI predicted protein sequence FASTA file and GFF file required formatting into 
a compatible format for proteogenomics analysis, as outlined in Section 3.4.1. The total 
of all 757,807 MS/MS spectra obtained for this study were first assessed by searching 
against the known proteome, examining the effects of using MS-Cluster to cluster the 
MS/MS spectra, PepNovo to quality filter the MS/MS spectra, and an assessment of 
optimal precursor mass tolerances, as outlined in Section 3.4.6. Since all the MS/MS 
spectra were derived from an LTQ Orbitrap mass spectrometer and of high-accuracy, 
this must be reflected in the search parameters. Thus assessment of the optimal 
precursor mass tolerance involved a range of tolerances: 0.5, 1.0 up to 10.0 in 1.0 ppm 
increments, and then up to 20.0 ppm in 5.0 ppm increments. 
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4.2.4 Proteogenomics pipeline 
The proteogenomics pipeline was used as outlined in Section 3.5, utilizing the Enosi 
tool (version 1.0) and a combined false discovery rate (FDR) strategy. In addition, a 
two-pass search approach was used, similar to the approach demonstrated in [428], and 
which is outlined in Section 3.5.1. Essentially the first-pass MS/MS database search was 
performed to identify matching sequences without a decoy database and no FDR 
filtering, which were then used to define the database for the second-pass MS/MS 
database search, which included a reversed decoy database of the target sequences and a 
1% PSM FDR filtering. The two-pass search approach was used to assess whether any 
improvements could be observed to the sensitivity of the MS/MS database search of the 
six-frame translated bacterial genome. After a preliminary assessment of the MS/MS 
spectra, as outlined above in Section 4.2.3, the choice of clustering the MS/MS spectra, 
but not quality filtering using PepNovo was decided, resulting in 285,344 clustered 
MS/MS spectra and a 6.0 ppm precursor mass tolerance. 
The total 285,344 MS/MS spectra were split into separate MGF files of 65,000 
MS/MS spectra each using an in-house MGF splitting tool, before running each MS/MS 
spectral file through MS-GF+ on a single Ubuntu machine with 40 processors and 64 
GB RAM against the known proteome and a six-frame translation of the genome. The 
two-pass search approach was also applied, according to Section 3.5.1. However, in this 
case study all matches were used to define the search space for the 2nd pass, and not 
those identified with a ≤1.0E-05 spectral E-value, as was demonstrated in later studies, 
which came to light at a later date after this study had been conducted. The combined 
FDR strategy and two-pass search approach are illustrated in Figure 3.1. 
The choice of parameters for the proteogenomics pipeline, as outlined in Section 
3.5, included an initial minimum event probability for novel genes, distal events and 
proximal events of 90%, a peptide linkage distance of 60 bp representing the optimal 
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minimum intergenic space within an operon (see Section 4.3), a minimum cluster size 
of 1 and a minimum of 1 unique peptide per cluster. 
 Further event probability thresholds were applied to the different annotation 
event types based on cross-validation between all of the three gene models (NCBI, 
Prodigal and RAST), with higher stringencies applied to novel gene and distal events. 
The final event probability thresholds applied were 99.5% for novel genes, 99.1% for 
distal events and 99.1% for proximal events. As outlined in Section 3.5, the known 
proteins were identified based on all mapped peptides and also those that contained ≥2 
peptides with 1 unique peptide. 
4.3 RESULTS AND DISCUSSION 
The present study outlined the benefits of the customized proteogenomics pipeline and: 
1) brought awareness to how different -omics platforms can be integrated, e.g. in this 
case genomics and proteomics; 2) demonstrated the differences in sensitivity and 
specificity between Enosi and Genosuite; 3) demonstrated the use of a two-pass search 
approach (Section 4.2.4) to database searching; 4) identified 155 novel genomics 
annotations for B. diazoefficiens and; 5) more broadly identified the power of 
repurposing legacy proteomics data for use in genome annotation. 
4.3.1 Evaluation of pre-processing MS/MS spectra 
Prior to running the proteogenomics pipeline, an evaluation of MS/MS spectra pre-
processing and parameter optimization was conducted (Appendix File 4.2). All 757,807 
MS/MS spectra were clustered by a factor of 2.66. It was found that clustering reduced 
the peptide FDR after an initial 1% PSM FDR filtering from 5.37% to 1.58%, and 
reduced the protein FDR from 31.40% to 9.69% (Appendix figure 4.1A-C). As can be 
seen in Appendix Figure 4.1A, the number of total MS/MS spectra lost after quality 
filtering ranged from 10% at the lowest end to 80% at the most stringent cut-off. 
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Applying scores between 0.05 – 0.1, as recommended by PepNovo (detailed in the Help 
File bundled with the tool), resulted in 50% of the MS/MS spectra being lost. These 
MS/MS spectral losses showed a significant drop in the number of unique peptides 
discovered after FDR filtering (Appendix Figure 4.1D), while showing only a gradual 
drop in the number of PSMs (Appendix Figure 4.1E), with the peptide FDR and protein 
FDR only improving negligibly with quality filtering (Appendix Figure 4.1B-C). Losses 
in MS/MS spectra, resulting in the reduction in the number of unique peptides reported 
without any significant reductions in false positive rates, would indicate the dataset was 
not improving but was losing valuable MS/MS spectra for novel proteogenomics 
discoveries. 
The losses observed were probably attributable to a combination of the 
methodology employed by PepNovo and the source of the proteomics data, which were 
derived from a 1D gel followed by trypsin digestion and LC-MS/MS, as explained in 
Section 3.4.6.  
 These results indicated a clustered MS/MS spectral dataset with the absence of 
PepNovo quality filtering was most suitable for further proteogenomics analysis as this 
resulted in the highest gains in peptide discovery with minimal losses of MS/MS 
spectra, while keeping the peptide FDR below 2%. In addition, the search tool used in 
this analysis, MS-GF+, uses a different approach to quality scoring prior to beginning 
the search, based on log-likelihood ratios [292], and was able to remove poor MS/MS 
spectra in the study with no apparent impact to the search results. 
4.3.2 MS/MS database search parameter optimization 
As outlined in Section 3.4.6, high-accuracy MS/MS spectra are well suited to precursor 
mass tolerance optimization, as tighter tolerances often improve upon the sensitivity of 
PSM identifications. This holds true for this study, which uses high-accuracy MS/MS 
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spectra, generated from an LTQ Orbitrap mass spectrometer. 
A clustered set of MS/MS spectra was used to assess the precursor mass 
tolerances over a range, as outlined previously in Section 4.2.3. From this analysis it 
was determined that 6.0 ppm was the optimal precursor mass tolerance to use 
(Appendix Figure 4.2). After a ≤1% PSM FDR was applied the maximum number of 
PSMs obtainable was 53,349 at 6.0 ppm, while the peptide FDR was 1.69% (Appendix 
File 4.2). 
4.3.3 Effects of preliminary analysis on proteogenomics results 
To determine the effectiveness of pre-processing the MS/MS spectra by clustering/not 
clustering and optimizing the precursor mass tolerance, the different parameters and 
pre-processing steps were compared. It was found that the total run time of the 
unclustered MS/MS spectra took more than 10x longer than the clustered dataset and 
there were 337 more annotations with ≥90% event probability. When these novel 
annotation events were filtered to the same event probability stringency, as outlined in 
Section 4.2.4, the majority of the annotation events were removed leaving 186 
annotation events, 31 more than when clustering and optimizing the precursor mass 
tolerance. Although these results indicate a gain of 31 annotation events by not 
clustering, they most likely include greater numbers of false positives, as was noted 
from the known proteome searches with 5.36% peptide FDR and 31.4% protein FDR 
when using unclustered MS/MS spectra, compared to 1.58% peptide FDR and 9.69% 
protein FDR when clustered. The peptide FDR and protein FDR would likely be further 
inflated by including the six-frame translation, and therefore the confidence applied to 
these annotation events is relatively low. 
Comparing precursor mass tolerances revealed that there were 23 more 
annotation events with a ≥90% event probability using 6.0 ppm, than by using 20.0 
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ppm. However, there were only 16 more annotation events found with a 6.0 ppm 
precursor mass tolerance when more stringent event probability thresholds were 
applied. Therefore, there is a significant advantage to clustering in combination with the 
application of a precursor mass tolerance optimization step with the known proteome. 
Clustering has the advantage of removing many spurious annotation events and 
reducing search and post-processing times. In addition, optimizing the precursor mass 
tolerance improved the number of annotations reported and reduced the error window 
for peptide and protein identifications by removing the potential for incorrect matches. 
A redundant set of MS/MS spectra totaling 757,807 was then clustered by a factor of 3 
and used in the proteogenomics pipeline. 
4.3.4 Proteogenomics pipeline 
There are several key variables in the proteogenomics pipeline to define the number and 
type of accepted annotation events, including: the minimum cluster size (peptides per 
cluster), the minimum number of unique peptides per cluster, the maximum peptide 
linkage distance and the event probability. 
The peptide linkage distance is the most difficult variable to define in bacterial 
genomes. It is usually calculated based on the size of ≥95% of genes, with the same 
value defining the distance between a cluster and a neighbouring gene to include in 
annotation event inference. This would make little sense in prokaryotic genomes due to 
the compactness of the genome, with many genes close together within operons and 
with a large proportion of gene overlap. Therefore the maximum peptide linkage 
distance of 60 bp was chosen because: 1) prokaryotic genomes are often compact with 
overlapping genes; 2) gene overlaps >60 bp may be considered as misannotations [561, 
562]; 3) the maximum distance between genes within an operon is considered to be 
around 50-60 bp [502]; and 4) high GC bacterial genomes often have longer ORFs 
[563], increasing the likelihood of false-positive PSMs across the length of the ORF, 
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which could inadvertently be grouped into the peptide cluster if the peptide linkage 
distance was sufficiently large enough. However, a peptide linkage distance of 60 bp 
may also inadvertently classify novel genes as distal events, such as reverse strand 
annotations, due to a number of truly novel genes on the reverse strand overlapping a 
known gene. As a result, careful consideration is needed when reviewing novel gene 
and distal event annotations. 
Due to the compact nature of the genome and small peptide linkage distance, 
one unique peptide per cluster was used to assign annotation events, particular for novel 
genes and distal events (as opposed to ≥2 unique peptides outlined in [82]), and also due 
to the lower chance of two or more unique peptides appearing within the smaller peptide 
cluster. To avoid potential false positives resulting from the inclusion of only one 
unique peptide, stringent event probabilities were applied, particularly for novel genes. 
The event probability stringency could be adjusted due to the small genome size based 
on calculated annotation event FDRs [82], but tools to determine this adjustment were 
not currently available, therefore to ensure better specificity more stringent event 
probabilities across all annotation events were applied. 
4.3.5 Proteogenomics analysis 
The proteogenomics analysis identified 155 novel annotation events among 145 genes 
from NCBI, with 250 annotation events among 234 genes from the RAST annotation 
and 88 annotation events among 83 genes from the Prodigal predictions (Table 4.1 and 
Appendix Files 4.3 and 4.4). 
From these results, it can be seen that the proteogenomics evidence agreed more 
with the Prodigal predictions and demonstrated the least agreement with the RAST 
annotations, with the NCBI annotations residing in-between these two extremes. 
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Table 4.1 Summary of bacterial proteogenomics annotations 
The results of the proteogenomics pipeline (NCBI reference compared to RAST and Prodigal predictions) 
are compared with the Genosuite analysis [502]. 
Proteogenomics tool Enosi Genosuite 
MS/MS Search tool(s) MSGF+ 
MassWizz/OMSSA/
X!Tandem/InsPecT 
Reference annotation NCBI RAST Prodigal NCBI 
Total NCBI reference genes 8,317 NA NA 8,317 
Total ‘known/predicted’ protein-coding genes 8,317 8,715 8,498 8,317 
Raw MS/MS search ‘known/predicted’ protein matches 
≤1% PSM FDR 
3,123 3,134 3,188 NA 
Proteogenomics mapping: Total 'known/predicted' 
proteins ≤1% PSM FDR 
3,550 3,557 3,617 2,591 
Proteogenomics mapping: Total ‘known/predicted’ 
proteins ≤1% PSM FDR (≥2 peptides with 1 unique) 
2,194 2,182 2,233 NA 
 
Total identified 'novel' peptides ≤1% PSM FDR 330 538 210 221 
Raw MS/MS search ‘known’ peptides ≤1% PSM FDR 15,103 15,061 15,289 NA 
Proteogenomics mapping: Total identified 'known' 
peptides ≤1% PSM FDR 
24,975 24,729 25,088 24,194 
Proteogenomics mapping: Total identified 'known' 
peptides ≤1% PSM FDR (≥2 peptides with 1 unique) 
15,579 15,389 15,684 NA 
 
Frame-shifts 9 47 8 2 
Exon boundaries 22 21 19 48 
Gene boundaries 19 54 17 36 
Reverse strands 45 33 12 21 
Novel genes 60 95 32 36 
 
Total annotation events 155 250 88 107 
Total genes affected 145 234 83 107 
Total novel peptides in affected genes 259 450 144 283 
Findings from [502] were based on ≥2 unique peptides or single peptides with ≥5 significant PSMs ≤1% 
FDR. Due to differences in semantics, the following was assumed: 
 Any identified translation initiation start (TIS) sites in [502] would be considered exon 
boundaries in this study. 
 There was no description of gene boundaries from [502], and are possibly described as novel 
genes. 
NA: Not available 
Note: Some values for the number of identified proteins have been revised since publication [6]. 
4.3.6 Novel gene annotations 
There were a total of 155 novel annotation events from the NCBI predictions, such as 
with gene bll2355 and bll2356 (prp1) where both were annotated as reverse strand 
events as the novel peptides were found within the 60 bp peptide linkage distance of the 
genes. Eight unique peptides, supported by 16 MS/MS spectra (Appendix Figure 4.8), 
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were found to be overlapping gene bll2355 and then aligning across the gene boundary 
into an intergenic region, with an event probability of 100%. There were also no 
peptides that mapped within these NCBI known genes, providing no conflicting 
evidence for the reverse strand annotation. Where this annotation event was identified 
as a reverse strand, the previous study [502], RAST and Prodigal predictions concluded 
differently, identifying a novel gene annotation on the opposite strand. Both RAST and 
Prodigal did not predict the same gene; instead they predicted genes that overlap 
bll2355 on the opposite strand covering the entire region where the 8 novel peptides 
mapped (Figure 4.1). Searching proteins bll2355 and bll2356 against NCBI NR with 
BLASTP revealed no significant matches to bll2355 except to itself and the close 
relative B. japonicum USDA 6, both characterised as hypothetical proteins. However, 
bll2356 matched, both to itself and to several dozen other close relatives, all of which 
are characterised as a metallophosphoesterase protein. Therefore bll2355 should be 
removed or annotated as putative, with a new gene model annotated on the opposite 
strand in line with the Prodigal and RAST gene models (Figure 4.1), with no annotation 
changes to bll2356. As a result from this annotation, it is clear that some reverse strand 
annotations may be novel genes, making the potential true number of novel genes as 
high as 125 (Table 4.1). In conclusion, there is a need to determine how well the peptide 
evidence can fit into heuristically determined gene models. This highlights the need for 
bacterial gene prediction tools such as Prodigal and Glimmer [557] to accept peptide 
level evidence as hints, in a similar way to tools like Augustus [102], in order to remove 
much of the manual annotation and improve throughput. 
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Figure 4.1 Reverse strand or novel gene annotation 
Genome view of potential reverse strand annotation of bll2355 that was probably a novel gene annotation 
on the opposite strand given the supporting evidence. 
Another novel gene discovered in [502] between blr2145 (CYP114) and blr2146 
was identified in this study as a gene boundary event for blr2146. Compared to the 
results in [502], only three of the five peptides identified were also identified in this 
study (Appendix Figure 4.3), with three MS/MS spectra supporting them (Appendix 
Figure 4.10). The other two peptides have probably fallen outside the FDR threshold. 
The annotation of a novel gene was however supported by RAST and Prodigal gene 
predictions (Appendix Figure 4.3). Additionally, known peptides mapped to blr2145 
and blr2146, which have been characterized as cytochrome P450 hydroxylase and a 
dehydrogenase, respectively, by RAST, and which was in agreement with searches 
against NR with BLASTP. Further proteogenomics evidence, with a smaller peptide 
linkage distance would likely annotate this event as a novel gene. This highlights the 
difficulty in assigning a peptide linkage distance for prokaryotes, as the actual 
intergenic distance in this particular case between the Prodigal and RAST predictions 
and blr2146 is only a few base pairs, and with only 38 bp between the most 3’ novel 
peptide and blr2146. 
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A good example of a high confidence novel gene annotation was a novel gene 
located at positions spanning 539,180 to 539,438 containing 7 unique peptides outside 
of the known NCBI predictions with an event probability of 100% (Appendix Figure 
4.4), and supported by eleven MS/MS spectra (Appendix Figure 4.11). This annotation 
was also supported by the RAST annotation and Prodigal predictions. Interestingly, 
RAST annotated the gene as matching a bll3711 protein, which happened to be a 
paralog gene in B. diazoefficiens much further downstream at positions 4,102,260 to 
4,102,625. This was confirmed after searching the RAST prediction against NR with 
BLASTP, which matched bll3711 with an E-value of 1E-81 and query coverage and 
percentage identity of 100%. This novel gene annotation was also confirmed in [502]. 
4.3.7 Sequencing error: A discovery from exon boundary/frame-shift 
annotation 
An example of when annotation events can indicate a potential underlying problem with 
the genome sequence is between two different genes, blr0352 and blr0353. Here the 
unique peptide “IAANPDDVNALYR”, supported by three MS/MS spectra (Appendix 
Figure 4.9), mapped to a region overlapping both genes. This suggested an exon 
boundary for blr0353 and a frame-shift for blr0352. Both genes contain mapped 
peptides, indicating both are being expressed (Figure 4.2A). Both genes were searched 
against NR using BLASTP, with blr0352 shown to contain a Peptidase C14 domain to 
which each known peptide has been mapped, while blr0353 contains a tetratricopeptide 
repeat domain (TPR) that the novel peptide partially overlapped. The Prodigal 
predictions mirror the NCBI annotation, while the RAST annotation indicates one large 
gene and protein product with what appeared to be a change in frame in the middle of 
the gene, and was annotated in agreement with the BLASTP result. The RAST protein 
prediction which spanned both gene regions was searched against NR using BLASTP 
and revealed a number of top matches with ≥90% identity to homologous proteins in 
Japonicum USDA 122, Japonicum S23321 and SEMIA 5079. Multiple sequence 
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alignments of these proteins with the NCBI blr0352, prodigal and RAST prediction, 
using Muscle [564, 565], indicated a greater agreement with the Prodigal predictions 
and the NCBI annotation, except for a region towards the 3’end where a change in 
frame occurred (Figure 4.2B). The genomic nucleotide regions for these homologous 
genes were also aligned using Muscle and identified what appears to be a possible 
sequencing error with the insertion of a guanine (G) at position 370,898, outlining a 
string of guanines (Figure 4.2C) shown previously to induce sequencing errors where 
there are strings of G-C or A-T pairs in the genome [566].  
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Figure 4.2 Exon boundary and frame-shift annotation or sequencing error 
(A) Genome view of potential frame-shift of blr0352 and exon boundary of blr0353. (B) Multiple protein 
sequence alignment of blr0352, RAST, Prodigal and protein homologs, with a sequence discrepancy 
resulting from a possible sequencing error (dashed lines) (C) Multiple nucleotide sequence alignment of 
blr0352 in diazoefficiens USDA 110, japonicum USDA 122, S23321 and SEMIA 507. A “G” insertion at 
position 370,898 (dashed lines). 
 Although the unique peptide did not overlap directly with the possible 
sequencing error, it highlighted a problem with the sequence in this region. Further 
sequencing, PCR or alignment of peptide/protein, mRNA, cDNA or EST sequences to 
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this region are required to confirm the error, as this single nucleotide insertion may 
actually be one of numerous differences between B. diazoefficiens and other closely 
related species. Correction of this sequencing error would re-assign the unique and 
novel peptide as a known peptide. The sequencing error was likely a contribution from 
the presence of the TPR region down-stream to sequencing difficulties of high GC 
content in bacterial genomes. 
4.3.8 Gene boundary annotations 
Another annotation was with genes bll0795 and bll0794 (PhoH), where both were 
annotated as gene boundary events. A unique peptide mapped in between bll0795 and 
bll0794, with an event probability of 99.8% (Appendix Figure 4.6), which was 
supported by one MS/MS spectrum (Appendix Figure 4.14). Only bll0794 contained 
mapped peptides that were in the same frame as the novel peptide, and not the same 
frame as bll0795, so a gene extension to bll0794 and not bll0795 was suggested. 
Interestingly, although this unique peptide has high confidence, it did not agree with the 
RAST annotation or Prodigal predictions (Appendix Figure 4.6). Also the study from 
[502] gave the impression that this unique peptide belongs to gene bll0794, even though 
it clearly falls outside of the gene boundary and in the intergenic region. Searching 
bll0794 against NR with BLASTP revealed the protein matched numerous phosphate 
starvation-inducible proteins (PHOH), within other related species, which was also 
confirmed from the RAST annotation. 
4.3.9 Exon boundary annotations 
An annotation from [502] suggesting an alternative translation initiation start (TIS) site 
was also in agreement with this study, which found an exon boundary event for bll2019 
(NolA). The unique peptide “IGELAEATGVTVR” was detected overlapping NolA at 
the 3’-end, with an event probability of 99.8% (Appendix Figure 4.5A) and was 
supported by three MS/MS spectra (Appendix Figure 4.12). The NolA gene also 
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contained known peptides within the same frame as the novel peptide. Searching the 
NOLA protein against NR with BLASTP revealed that the protein matched numerous 
other nodulation proteins in other related species. In contrast, the novel peptide was 
identified from the RAST annotations as a novel gene, as the NolA gene was not 
predicted by RAST, while Prodigal was able to predict the full length of the NolA gene 
(Appendix Figure 4.5A). Another exon boundary event or TIS from [502] in agreement 
with this study was for gene bll2380. The study from [502] reported four novel peptides 
overlapping and upstream of bll2380. This study confirmed this as an exon boundary 
event (Appendix Figure 4.5B) with an event probability of 100% and was supported by 
fourteen MS/MS spectra (Appendix Figure 4.13), and also supported by the RAST 
annotation and Prodigal predictions. A number of known peptides also mapped to 
bll2380 in the same frame as the novel peptides (Appendix Figure 4.5B). Searching 
bll2380 against NR with BLASTP revealed that the protein matched numerous 
glycosyltransferase proteins in related species, confirming the same RAST annotation. 
4.3.10 Frame-shift annotation 
An example of a high confidence frame-shift annotation was with gene bsr6520. The 
gene bsr6520 and the gene bsr6521 downstream appeared to have swapped names 
according to NCBI Gene (http://www.ncbi.nlm.nih.gov/gene/1053434) and the NCBI 
protein database, which is in contrast to the NCBI annotation and GFF file presented in 
NCBI BioProject 57599. Further references throughout this chapter use the naming 
presented in the NCBI annotation and GFF file during the proteogenomics analysis to 
preclude any confusion. 
The bsr6520 gene has 2 exclusively unique and novel peptides 
“RAGSLGEAGGR” and “QSSEVRPHEGGAVGGGDAR” (Figure 4.3A with two 
supporting annotated MS/MS spectra in Figure 4.3B) mapping to a different frame, both 
contributing to an event probability of 99.99%. The gene bsr6521 down-stream was also 
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in the same frame as the unique peptides. Searching both bsr6520 and bsr6521 against 
NR with BLASTP revealed bsr6520 contained a match to a hypothetical protein with a 
Domain of unknown function (DUF4169), while gene bsr6521 matched to arylsulphate 
sulphotransferase with a Ribbon-helix-helix domain (RHH_4). A previous study [502] 
identified that both unique peptides belonged to bsr6521 and also to bsr6520, so there 
may have be some nomenclature confusion, as mentioned earlier. In addition, the results 
from [502] did not show a report of any frame-shift. This annotation suggests changing 
the frame of bsr6520, while bsr6521 should be extended to position 7,177,733 where a 
methionine initiation start probably resides, fusing with bsr6520, as the new frame of 
bsr6520 contained no stop-codons until the 3’ end of bsr6521 (Figure 4.3A). 
Further evidence is needed in the form of peptide/protein, mRNA, cDNA or 
EST sequences bridging the divide between the genes before any definite conclusions 
can be drawn. Neither the RAST annotations nor the Prodigal predictions agreed with 
the proteogenomics annotation, instead choosing the original frame from NCBI, which 
highlights the caution which needs to be applied when using gene prediction tools such 
as Glimmer, used for the original NCBI annotation of B. diazoefficiens. In addition, 
from the BLASTP results the incorrectly annotated bsr6520 gene can be seen matching 
to a number of homologues in other Bradyrhizobium species, which include species 
Japonicum USDA 124, Japonicum USDA 4, S23321, WSM1743, and URHA0013, all 
containing the DUF4169 domain and all with a percentage identity ≥90%, suggesting 




Figure 4.3 High confidence frame-shift annotation 
(A) Genome view of potential frame-shift annotation of bsr6520. (B) Annotated MS/MS spectra 
supporting the novel peptides suggesting the frame change of bsr6520. 
4.3.11 N-terminal acetylated peptides 
An example of a conflicting annotation from [502] which indicated a potentially over-
predicted gene was with known NCBI gene blr0594 (trxA). N-terminal acetylated 
peptide “TIIDQGNGAAGPAAADLIK” was identified from the study in [502], 
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indicating a GTG instead of an ATG at its N-terminal end, which is known to code for 
the initiator Methionine in high GC genomes and so suggested an alternative TIS site 
and hence indicated that the gene was over-predicted. By searching amongst all peptides 
mapping to known genes it was found that the unique peptide contained no acetylation 
of the N-terminal end (Appendix Figure 4.7 and supporting MS/MS spectrum in 
Appendix Figure 4.15), even though numerous other peptides with N-terminal 
acetylation were found amongst the known peptides. According to MS-GF+ the PSM 
had a spectral E-value of 4.05E-13, an E-value of 1.67E-5 and a Q-value of 0.0, 
indicating a significant identification. The effect of clustering the MS/MS spectra was 
considered as a cause of the missed modification, but it was soon ruled out when 
unclustered MS/MS spectra were searched against the known proteome using MS-GF+ 
(results not shown). Therefore, the cause could be attributed to subtle differences in 
sensitivity in the detection of post-translational modifications between the different 
search tools. In addition, both Prodigal and RAST agreed with the alternative TIS site, 
as the 5’ end of each predicted gene aligned with the coordinates of the unique peptide 
(Appendix Figure 4.7), suggesting agreement with the results from [502]. To follow this 
up all N-terminal acetylated peptides within the NCBI known proteins were explored, 
revealing that each protein they mapped to indicated an agreement with the TIS of each 
gene. 
  Of the 3,550 NCBI known proteins containing 24,975 mapped peptides, 36 
different proteins contained N-terminal acetylated peptides (Appendix File 4.4). While 
out of 2,194 high confidence NCBI known proteins, containing 15,579 mapped peptides 
and at least 2 peptides with 1 unique peptide, there were 20 different proteins containing 
N-terminal acetylated peptides. Thus confirming, as previously indicated in [502], that 
N-terminal acetylation may be more widely utilized in bacteria than previously thought. 
The novel peptides were then screened for N-terminal acetylated peptides, and it was 
 
 134 
found that there were no N-terminal acetylated peptides, except for unique peptide 
“MPMNVPSIAASNMLGMRR” with a low event probability of 93.1%, which was 
subsequently removed from further analysis. The peptide was found mapped within 
gene bll3136 (fdhF) on the reverse strand, which according to the NCBI protein 
database is already well characterized as a formate dehydrogenase alpha subunit, adding 
confidence that this was likely a false positive peptide. 
4.3.12 NCBI vs RAST vs Prodigal annotations 
As a preliminary step before using NCBI, RAST and Prodigal predictions for 
proteogenomics analysis, a comparison was conducted using Mummer [567] to 
determine which protein predictions were in greatest agreement with one another. It was 
found that using NCBI as the reference dataset Prodigal matched to 7,698 genes 
(90.6%) and RAST matched to 7,585 genes (87%), implying that more Prodigal genes 
were in agreement with the NCBI annotations even though there were many more 
RAST annotations. This indicates that RAST contains a number of false positives or 
genes predicted in the wrong frame compared to the other annotations. This is further 
supported from the proteogenomics analysis, which found many more novel annotation 
events with RAST (250) than with Prodigal (88), while NCBI (156) was in-between. 
It was found that the RAST annotation tool incorrectly predicted the CDS phase 
for a number of genes in the GFF output file. Discrepancies are present between the 
predicted protein sequence (not shown) and the gene model for the prediction in the 
GFF file. For example, CDS was in phase 1, when on visual inspection of the predicted 
protein sequence, it should have been 0. This resulted in many incorrect peptide 
coordinates for the known genes amongst the RAST predictions. Consequently, the 
error highlighted the need for highly curated reference datasets before proceeding with 
any proteogenomics annotation, as by definition the mapping to a reference proteome is 
only as good as the reference annotation. 
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4.3.13 Impact of search space  
A total of 3,123 of 8,317 proteins annotated by NCBI were identified during MS/MS 
database searches using MS-GF+, while the total number of proteins mapped by 
proteogenomics was 3,550. Of these, 2,194 high confidence proteins had ≥2 peptides 
with 1 unique peptide. Prodigal predictions showed the largest agreement from the 
proteogenomics analysis, with a total of 3,617 proteins. Of these, 2,233 high confidence 
proteins had ≥2 peptides with 1 unique peptide (Table 4.1). A total of 4,456 proteins 
were identified when the same search was conducted against only the known NCBI 
proteome. Comparisons between proteomics- and proteogenomics-only searches 
revealed a loss of 1,333 proteins out of 4,456, i.e. a loss of 30%, with similar losses 
confirmed in other studies [81, 324, 439]. Based on these results, it is likely that many 
novel annotations derived from the six-frame translation have also been missed due to 
the loss in sensitivity. 
In an attempt to improve on the number of annotations reported, a two-pass 
search approach similar to the approach reported in [428], was applied for the NCBI 
annotations (Appendix Files 4.3 and 4.4). Above an event probability of 90%, from the 
raw MS/MS database search, resulted in the identification of 7 additional novel 
annotation events and 5 known proteins (total 3,128), however no changes were 
observed for all known proteins and high confidence proteins once they were mapped 
by proteogenomics. For the novel annotation events, once filtered to the same 
stringency applied previously, no changes in the number of novel annotation events 
could be seen. Adjusting the stringency of these thresholds would include the additional 
novel annotations at the cost of potentially increasing the false positive rate. A means to 
determine the FDR at the annotation event level or support annotations through 
orthogonal evidence is needed before the thresholds could confidently be lowered to 
include further annotation events. 
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It seems probable that eukaryotic genomes, where the proportion of protein-
coding genes occupy a relatively smaller fraction of the genome and where there are 
relatively fewer sense-antisense gene overlaps, would likely benefit significantly from 
the two-pass search approach. In addition, by combining the accuracy and sensitivity of 
Enosi/MS-GF+ with the two-pass search approach in situations where the genome size 
is large, such as the human genome (~3 Gbp) or even larger in the hexaploid wheat 
genome (~17 Gbp), the likely increase in sensitivity of identifying novel annotation 
events would be worthwhile, and should be incorporated as standard, or at the very least 
as an option, in all proteogenomics pipelines. 
4.4 SUMMARY 
The present study has highlighted the advantages of proteogenomics, the power of 
repurposing legacy proteomics data and has brought awareness to how different –omics 
platforms can be integrated. Primarily, the study has made a significant contribution to 
the genomic annotation of Bradyrhizobium diazoefficiens, identifying 259 novel 
peptides contributing to 155 novel annotation events, consisting of 9 frame-shifts, 22 
exon boundaries, 19 gene boundaries, 45 reverse strands and 60 novel gene events in a 
total of 145 genes. Through the identification of these annotation events a possible 
sequencing error was flagged and further validation is required to resolve some false 
positive annotation events. Some of the lessons learnt from this study include: 1) the 
problems identified when using a fixed peptide linkage distance; 2) the high proportion 
of false positive annotation events with overlapping genes reported by Enosi; 3) the 
relative ineffectiveness of a two-pass search approach in bacterial genomes with a high 
proportion of overlapping genes; and 4) the loss in sensitivity when applying a 




While Enosi benefited greatly from improved sensitivity, improvements were still 
required to deal with overlapping bacterial genes. In contrast, Genosuite was capable of 
distinguishing such features and provided a higher specificity, but a lower sensitivity 
than Enosi. Clustering and the selection of appropriate precursor mass tolerances 
improved efficiency in proteogenomics searches, while the problems with the reduction 
in sensitivity due to six-frame searches resulted in a 30% loss of known proteins when 
using a combined FDR strategy. This was partially overcome using a two-pass search 
approach, however the search space still proved to be an obstacle for bacterial 
proteogenomics. This was probably due to the high level of overlapping genes and the 
relative proportion of coding to non-coding genes compared to larger genomes such as 
human and wheat, where the non-coding portion remained relatively small by 
comparison, and possibly as a result of including very low significant matches from the 
first pass in the second pass. Overall, the methods employed in this study provided a 
means to better understand the field of proteogenomics, thereby identify current gaps in 
understanding and facilitate additional future improvements in the field. 
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5 GRAPE PROTEOGENOMICS 
5.1 INTRODUCTION 
The grapevine industry has successful global market access and large economic support 
worldwide. The genus Vitis is important to the wine industry and as a perennial fruit, 
part of the staple diet in the Mediterranean where there is reduced prevalence of heart 
disease [568]. The putative causative agents reducing the prevalence of heart disease 
may well be derived from grapes, with a number of key candidates being resveratrol, 
quercitin and ellagic acid [569], with resveratrol attracting extensive media attention in 
recent years as a potential life-extending drug [570], and which further adds to the Vitis 
market value and opens up the potential for many unexplored medical benefits. The 
broad spectrum of commercial applications of grapevines challenges the industry to 
improve yields, quality, resistance to diseases and abiotic stress conditions across the 
globe. One particularly important Vitis species is Vitis vinifera, which has recently been 
subjected to sequencing e.g. sequencing of the heterozygous variety Pinot Noir [571], 
and a 93% homozygous Pinot Noir, from genotype PN40024 [572]. The sequencing and 
assembly of the latter variety has since been improved from 8X coverage to 12X 
coverage resulting in a 487.1 Mbp assembled genome. Genomic annotation of the 8X 
and 12X was also undertaken, with the 8X gene prediction being performed using 
GAZE [110], published along with its sequencing [572], while the 12X sequence and 
assembly has since resulted in three different iterative improvements in annotation. The 
first named 12Xv0 was performed using GAZE. The second named 12Xv1 resulted 
from the combination of 12Xv0 and gene predictions by the tool JIGSAW [108], 
undertaken at CRIBI in Padova, Italy [573]. The third improvement named 12Xv2 
(since updated to 12Xv2.1) was undertaken recently, using assembled transcripts from 
RNA-seq, ab initio predictions, proteins, and ESTs [7]. 
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5.1.1 Outline of this study 
The aim of this study was to apply proteogenomics to further improve on genomic 
annotation of the grape genome and to compare the complexity of performing 
proteogenomics annotation in larger plant genomes, in relation to smaller bacterial 
genomes, as was demonstrated in Chapter 4. In addition, the benefits and shortcomings 
of current proteogenomics strategies were outlined. The latest grape Pinot Noir 12X 
genome assembly and 12Xv2.1 genome annotation were obtained from CRIBI, while 
the proteomics data were in the form of 177,174 MS/MS spectra derived from Cabernet 
Sauvignon grape berry skins, used in an earlier proteogenomics study by the 
dissertation author in Chapman et al [8]. In that study an earlier version of the 
proteogenomics pipeline was applied, with 29 annotation events found including; 1 
frame-shift, 3 translated UTRs, 1 exon boundary, 6 novel exons, 9 gene boundaries, 3 
reverse strands and 6 novel gene events. The present study expands on that work by 
using an improved proteogenomics pipeline and an additional 2,701,718 MS/MS 
spectra derived from Cabernet Sauvignon shoot tips, used in a large proteomics study 
on the effects of water deficiency [9]. In addition, RNA-seq data derived from Vitis 
vinifera Corvina cultivar [10] and a large RNA-seq study looking at multiple cultivars 
(unpublished), was used for the identification of splice regions. 
5.2 MATERIALS AND METHODS 
5.2.1 Proteomics and genomics datasets 
The latest assembled grape Pinot Noir 12X genome [572] with the genotype identifier 
PN40024, and the 12Xv2.1 genome annotation and protein predictions [7] were 
downloaded for use from the CRIBI web site (http://genomes.cribi.unipd.it/DATA/) 
(Appendix File 5.1). 
The MS/MS spectra were derived from finely ground shoot tips of Cabernet 
Sauvignon, across 3 biological replicates on 4 different days during water deficit [9]. 
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The samples were digested with trypsin, aided by Lys-C digestion, and were run on a 
LTQ XL mass spectrometer (Thermo), with fractionation performed by HPLC and a 
series of gas-phase fractionation (GPF) steps to further aid in separation. A total of 
2,701,718 MS/MS spectra were downloaded from the ProteomeXchange Consortium 
(http://proteomecentral.proteomexchange.org) via the PRIDE partner repository [574], 
using the identifier PXD000123. An additional 177,174 MS/MS spectra from the 
previous proteogenomics study by the dissertation author in Chapman et al [8] were also 
used, derived from Cabernet Sauvignon berry skins which were finely ground, 
extracted, digested and fractionated in the same way as the shoot tips, with the samples 
running on an LTQ Velos Pro (Thermo) mass spectrometer. 
As outlined in Section 3.1.1, a source of contaminants was appended to protein 
sequence predictions in the 12Xv2.1 annotation before being used in the MS/MS 
database search to identify any contamination. 
5.2.2 RNA-seq datasets 
Illumina RNA-seq datasets were obtained from two sources. One source was from a 
recent study [10], where the transcriptome of V. vinifera cultivar Corvina was 
sequenced, looking at three different developmental time points, i.e. post-fruit set (PFS), 
mid-ripening (MR), and mid-withering (MW), at approximately 2 months post-harvest 
and from different tissues, organs and development time-points. The RNA-seq reads 
were downloaded from the Sequence Read Archive (SRA) 
(http://www.ncbi.nlm.nih.gov/sra) through DNA Nexus (http://sra.dnanexus.com/), 
using identifier SRA055265. The second source of RNA-seq data, which is currently 
unpublished, consisted of grape skins from multiple different cultivars Chardonnay, 
Cabernet Sauvignon, Merlot, Pinot Noir, Semillon, Cabernet Franc and Sauvignon 
Blanc, that had been subjected to different water deficits, time-points and sugar levels. 
This data was obtained from collaborator Ryan Ghan from the University of Nevada 
 
 141 
and who was a co-author to the previous grape proteogenomics study in Chapman et al 
[8]. 
5.2.3 MS/MS database searching  
The MS/MS database search was performed by MS-GF+, as outlined in Section 3.3. In 
this case study trypsin was used as the protease, the instrument was set to low-res LTQ 
(Ion Trap), and the precursor mass tolerance was 2.0 Da and 3.0 Da for two different 
MS/MS database searches, as determined from a preliminary MS/MS spectral dataset 
assessment, detailed below in Section 5.2.4. 
5.2.4 Dataset processing 
The 12Xv2.1 protein sequence FASTA file and GFF file required formatting into a 
compatible format for proteogenomics analysis, as outlined in Section 3.4.1. Many of 
the CDS phase in the 12Xv2.1 annotation were incorrect. The errors were retained for 
the proteogenomics analysis, to highlight corrections to the annotation via 
proteogenomics. However, GenomeTools [542] was used to correct the CDS phase 
errors to be used later as hints for gene prediction, and for visualization, as outlined in 
Section 3.1.1 (Appendix File 5.1). 
The total 2,878,892 MS/MS spectra obtained for this study were first assessed 
by searching against the known proteome, examining the effects of using MS-Cluster to 
cluster the MS/MS spectra, PepNovo to quality filter the MS/MS spectra, and with an 
assessment of optimal precursor mass tolerances, as outlined in Section 3.4.6. Since all 
the MS/MS spectra were of lower accuracy, derived from an LTQ mass spectrometer, 
this factor had to be reflected in the search parameters. Therefore, assessment of the 
optimal precursor mass tolerance involved a range of tolerances, 0.5 up to 5.0 Da, in 0.5 
Da increments (Appendix File 5.2). 
All RNA-seq data were pre-processed for quality and aligned to the 12X grape 
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genome as detailed in Section 3.4.3. The resulting alignment BAM files were then 
merged and used to generate a splice graph FASTA database. A six-frame translation of 
the genome was also generated. The methods used for both splice graph and six-frame 
translation generation are outlined in Section 3.4. 
5.2.5 Proteogenomics pipeline 
The proteogenomics pipeline was used as outlined in Section 3.5, utilizing the Enosi 
tool (version 1.0). This study began before a two-pass search approach with two-stage 
false discovery rate (FDR) strategy was considered, and so a combined FDR strategy 
was applied to all MS/MS search results using a 1% peptide-spectrum match (PSM) 
FDR. However, due to the low-accuracy of the MS/MS spectral dataset, two runs were 
performed using 2.0 Da and 3.0 Da precursor mass tolerances to improve on the number 
of PSMs identified. The choice of these two different precursor mass tolerances were 
based on the preliminary assessment of the MS/MS spectra, detailed previously in 
Section 5.2.4 and later discussed in Section 5.3 (Appendix File 5.2). 
A clustered MS/MS spectral dataset, quality filtered to a PepNovo score of 0.01, 
gave 1,594,076 MS/MS spectra. The MS/MS spectra were then split into 20,000 
MS/MS spectra each using an in-house MGF splitting tool, before running each MS/MS 
spectral file through MS-GF+ on a cluster against the known proteome, two six-frame 
translation files (minimum 500 MB each), and a splice graph FASTA file for each of 
the 2.0 Da and 3.0 Da proteogenomics runs. Each set of results were then merged across 
4 tab-separated value (TSV) files, and further processed through the proteogenomics 
pipeline. It was necessary to merge the results across four different TSV files instead of 
a single TSV file, due to limitations in processing large result files from the combined 
FDR strategy, as was outlined in Section 3.5. 
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The choice of parameters for the proteogenomics pipeline, as outlined in Section 
3.5, included an initial minimum event probability for novel genes, distal events and 
proximal events of 90%, a peptide linkage distance of 18,000 bp representing >95% of 
gene sizes in the current annotation, a minimum cluster size of 1 (total peptides per 
cluster) and a minimum of 1 unique peptide per cluster. Following this, for all 
annotation events which did not have ≥2 unique peptides and/or ≥99.9% event 
probability, screening was performed based on the number of assigned PSMs, sequence 
homology to sequences in NCBI NR, NCBI RefSeq protein and NCBI SwissProt, with 
an emphasis placed on matches to the same chromosome and genomic region, supported 
by EST, mRNA and/or protein evidence, and with all proximal events requiring at least 
100% query coverage and identity. Mapped known peptides matching the protein being 
annotated, and their frame in relation to the novel peptides, were also considered, 
particularly for proximal events (Appendix File 5.3). 
  The results from the proteogenomics analysis at 2.0 Da and 3.0 Da were 
aggregated for the known proteome by providing all FDR filtered results together and 
starting a normal run of the proteogenomics pipeline. For the novel identifications, the 
aggregation of results was undertaken directly through the Enosi tools aggregation 
function, taking the novel peptide locations, known peptides and their locations from 
the 2.0 Da and 3.0 Da results. 
5.2.6 Improving gene predictions 
Once the novel annotations were filtered and reviewed, the gene prediction tool 
Augustus [102], was used to improve the overall gene models of the 12Xv2.1 
annotation. Augustus was first trained using the automated Augustus web server [575], 
by providing ESTs, cDNA (including FL-cDNA) and mRNA downloaded from the 
NCBI nucleotide database and a repeat masked V. vinifera genome, using 
RepeatMasker [576] and Tandem Repeat Finder [577]. Once the Augustus V. vinifera 
 
 144 
gene model parameters were generated, hints in the form of extrinsic evidence to 
improve the gene models were generated. These included ESTs, cDNA, and mRNA, 
generated using the BLAST-like Alignment Tool (BLAT) [122], while intron hints were 
generated using the RNA-seq BAM file (used previously for generation of the splice 
graph) with the Augustus script bam2hints, and repeat masked hints were generated 
from RepeatMasker during previous training. In addition, the current 12Xv2.1 
annotation was used as hints (with the CDS phase corrected using GenomeTools), along 
with the hints from novel peptides reviewed previously from the accepted novel 
annotations. The Augustus gene prediction tool was then run, using parameters as 
outlined in Section 3.5.3. 
5.3 RESULTS AND DISCUSSION 
The present study outlined improvements to the 12Xv2.1 annotation of V. Vinifera, 
demonstrating the benefits of proteogenomics by identifying 341 (103 exclusively) 
novel annotation events, and in particular showed how the use of legacy data from other 
studies can value-add and improve on the gene models. The study was a good example 
of the importance of sharing proteomics and RNA-seq data, to be utilized beyond the 
initial scope of the generation of such data, and provided awareness of how different -
omics platforms, such as genomics, proteomics and transcriptomics can be integrated. 
The study also outlined different strategies towards proteogenomics and the benefits of 
considering and evaluating each parameter and annotation, instead of blindly applying 
thresholds with no reflection of their suitability for the study in question. This study 
further reflects on some of the strategies taken, and considers further improvements. 
5.3.1 Evaluation of pre-processing MS/MS spectra 
Prior to running the proteogenomics pipeline, the MS/MS spectra were evaluated for the 
optimal pre-processing strategy and precursor mass tolerance (Appendix File 5.2). All 
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2,878,892 MS/MS spectra were clustered by a factor of 1.50. It was found that 
clustering reduced the peptide FDR after an initial 1% PSM FDR filtering from 11.70% 
peptide FDR to 4.70% peptide FDR and reduced the protein FDR from 39.30% to 
17.90% (Appendix Figure 5.1A-C). As can be seen in Appendix Figure 5.1A, the 
number of total MS/MS spectra lost after quality filtering ranged from 3.3% at the 
lowest end to 64% at the most stringent cut-off. Applying scores between 0.05 – 0.1, as 
recommended by PepNovo (detailed in the Help File bundled with the tool), resulted in 
around 33% to 45% of the MS/MS spectra being lost. However, at a score of 0.01 only 
17% of MS/MS spectra were lost, while maintaining a peptide FDR of ~3%, as well as 
retaining many PSMs and unique peptides which were lost with higher scores than 0.01 
(Appendix Figure 5.1D-E). Any losses in MS/MS spectra, resulting in a reduction in the 
number of PSMs and the number of unique peptides reported, without any significant 
reductions in false positive rates, would indicate that the dataset was not improving but 
was losing valuable MS/MS spectra for novel proteogenomics discoveries. 
Taken together, the results for this particular MS/MS spectra indicate a clustered 
MS/MS spectral dataset, with a PepNovo quality filtering score cut-off of 0.01 was 
most suitable for further proteogenomics analysis, as this resulted in the best balance 
between keeping the largest number of PSMs and filtering out poor quality MS/MS 
spectra, while keeping the peptide FDR to around 3%. 
5.3.2 MS/MS database search parameter optimization 
Only low-accuracy MS/MS spectra were available for this study, which limited its 
potential for identifying the highest number of PSMs due to a higher false positive rate 
as a consequence of the larger error window. A clustered set of MS/MS spectra, which 
was then quality filtered to a PepNovo score of 0.01, was used to assess the precursor 
mass tolerances (Appendix File 5.2). In this study, in contrast to Chapter 4 (where a 
well-defined optimal precursor mass tolerance could be chosen), due to the larger mass 
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window, the sensitivity of PSM identifications increased the further the mass error 
window was increased, and the peptide FDR after an initial 1% PSM FDR can be seen 
to plateau off after 2.0 to 3.0 Da, remaining under 4.5% (Appendix Figure 5.2). The 
optimal precursor mass tolerance here was not necessarily the highest, which could 
theoretically keep going above the 5.0 Da range looked at in the assessment. However, 
larger precursor mass tolerances would negatively impact the sensitivity of the database 
search as more potential PSMs would be considered in the search, further negatively 
impacting search time and false positive rates. As a result, two different precursor mass 
tolerances were chosen, which gave the best balance between the sensitivity of PSM 
identifications and peptide FDR: 2.0 Da and 3.0 Da, which gave 57,968 PSMs at 3.3% 
peptide FDR and 81,278 PSMs at 3.9% peptide FDR, respectively. 
Using both precursor mass tolerances for proteogenomics analysis by 
aggregating the results together improved the overall identification rate. While the 2.0 
Da precursor mass tolerance identified a slightly different set of novel peptides as a 
result of the smaller search space, identifications which were missed due to the 
restricted mass window were then identified using the 3.0 Da precursor mass window, 
which identified some of the same novel peptides but also included others not 
previously identified (results not shown). In reality, using a much larger range of 
precursor mass tolerances could be selected e.g. 1.0 Da to 4.0 Da, which would identify 
more PSMs than 2.0 Da and 3.0 Da alone. However, to keep the post-analysis simple 
(by keeping the number of time-consuming MS/MS database searches to a minimum), 
and to avoid inflating the FDR further than absolutely necessary, these two were chosen 
which most agreed with the assessment (Appendix Figure 5.2B). 
5.3.3 Proteogenomics pipeline 
A proteogenomics pipeline was customised using Enosi with MS-GF+, as outlined in 
Section 3.5 and illustrated in Figure 3.1, utilizing only the combined FDR strategy with 
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no two-pass search approach, instead improving upon the sensitivity and identification 
rate by performing two proteogenomics runs with two different precursor mass 
tolerances and aggregating the results (Appendix Files 5.3 and 5.4). 
A number of key variables required consideration in this study, just as they were 
considered in Chapter 4. However, in contrast, the peptide linkage distance was easier 
to determine in this study, as the genome was eukaryotic containing much larger 
intergenic distances. The peptide linkage distance was chosen based on the size of 
≥95% of genes in the current genome annotation, which was found to be 18,000 bp. 
For the number of unique peptides per cluster a minimum of 1 unique peptide 
per cluster was applied, with a minimum peptide cluster size of 1. Following this step 
annotation events were accepted based on a number of criteria outlined in Section 5.2.5. 
Such an approach, while laborious in screening large numbers of PSMs, was able to 
identify more novel annotations than simply applying a stringent event probability and 
allowed for annotation events to be validated against proteins previously not considered 
in the original annotation. Based on this approach, the final minimum event 
probabilities were 99.80% for novel genes and 98.374% for distal events and proximal 
events, with a number of other single peptide annotation events removed during 
screening. For example, some single unique and novel peptides, particularly those with 
lower event probabilities, did not match anything significant within the grape family in 
NR, RefSeq protein or SwissProt databases while others only matched bacteria, plant 
mitochondria or chloroplasts, and some proximal events did not have 100% coverage 
and identity with some matches. For a number of proximal and translated UTR events 
in particular, due to their close proximity to the known annotation, there was an overall 
correlation observed between the probability of the annotation event and the number of 
known peptides also mapping to the protein being annotated. A similar observation was 
made with the number of spectral counts and other supporting evidence as the event 
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probabilities increased (Appendix File 5.3). Many of the higher event probability 
annotation events were later found to incorporate into new gene predictions, however, 
this was not consistently the case, as further discussed in Section 5.3.4. 
Many of the novel peptides found to match chloroplasts and mitochondria were 
often accompanied by higher numbers of PSMs compared to the majority of other novel 
peptides. This would be expected due to the larger numbers of such proteins relative to 
the rest of the plant cell, as chloroplasts and mitochondria are numerous, particularly in 
rapidly growing grape shoot tips used in this study. To avoid such contamination, a cell 
component isolation step during sampling could have been applied, but as this dataset 
was legacy data and not originally purposed for proteogenomics, this was not a path that 
could be pursued. The source of the proteomics data can therefore be another source of 
false positives. In this case, due to the source of the genome being the cultivar Pinot 
Noir, with the proteomic data derived from Cabernet Sauvignon and RNA-seq data 
covering various different cultivars, variations between the peptide sequences and target 
genomic and RNA-seq sequences could occur. This could lead to potential 
misinterpretations of the variation as a post-translation modification (PTM) or 
identification of novel peptides in multiple locations where there are none, which would 
negatively impact the final event probability. A means to limit the false positive rate 
could be to limit the MS/MS database search to essential PTMs, limit the search space 
or alternatively by adding known variant peptides to the target database such as that 
demonstrated with splice graphs in [474]. However, the possibility of using variant 
sequences in proteogenomics was not known until late in the study and was 
consequently not explored. 
Future studies utilising data generated solely for proteogenomics could generate 
large amounts of data specifically for one variety, and thus control for these types of 
false positives, with the inclusion of RNA-seq data from other grape varieties, 
 
 149 
conditions and time points to identify variants using the methods demonstrated in [474]. 
Additionally, a source of false positives could be the lack of sequence coverage of the 
genome, with large regions remaining unsequenced. This possibility may be the case 
with the 12X genome assembly in this study, which is fragmented and consists of 19 
chromosomes, a number of which also have random fragment counterparts and also a 
large unassigned chromosome (ChrUn), which can be seen in a relatively recent 
comparative analysis between the 8X and 12X assemblies [578]. A fragmented genome 
can also result in a number of misidentified PSMs, as outlined in Section 2.4.1, which 
highlighted a number of work-around solutions including: the use of de novo 
sequencing tools, searching the interpreted MS/MS spectra against homologous 
sequences, using mutation tolerant search tools, or modifications to approaches such as 
template proteogenomics which align stretches of interpreted MS/MS spectra against 
relatively short homologous sequences for construction of whole proteins in the absence 
of a target genome sequence. However, such approaches were not explored in this 
study, as they would require more algorithmic development for use in proteogenomics 
for whole genomic re-annotation, and as such, have yet to be implemented in tools such 
as Enosi. 
In addition to using the sequence homology approach for the screening of 1 
unique and novel peptide annotation events, the peptide length was also considered; 
with short peptides (<10aa) only considered if the match was to the identical 
chromosome and region identified from the proteogenomics analysis. As in Chapter 4, 
the event FDR could not be calculated to determine which event probability provided an 
acceptable FDR at the annotation event level. Therefore, screening each novel 
annotation event in the manner described above provided another way in which to 
discriminate true from false positives. How effective this was at the annotation event 
level could not, however, be determined. 
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5.3.4 Proteogenomics analysis 
The proteogenomics analysis was performed based on the acceptance of novel 
annotations with preference given to high event probabilities and ≥2 unique peptides per 
cluster accepted. Other annotation events like those with lower event probabilities and 
only 1 unique peptide per cluster, were screened by considering the event probability, 
spectral counts, mapping of unique and shared peptides to proteins being annotated with 
their frame in relation to the novel peptides considered and sequence homology to 
known sequences in the same chromosome and region, containing orthogonal 
supporting evidence. To account for an inflated number of gene boundary and reverse 
strand events for each peptide cluster, due to the use of a fixed peptide linkage distance, 
as was explained in Section 3.5, an exclusive number of annotation events for gene 
boundary and reverse strand events, and their associated genes and proteins was also 
determined to indicate the numbers without the effect of a fixed peptide linkage 
distance, as shown in parenthesis in Table 5.1. 
 This series of screening led to final event probabilities of 99.80% for novel 
genes and 98.374% for distal events and proximal events, which followed with the 
identification of a total of 133 novel peptides and 341 novel annotation events (103 
exclusively) among 216 genes (67 exclusively) from the 12Xv2.1 annotation (Table 5.1, 
Appendix Files 5.3 and 5.4). 
 This study showed a large improvement over the 29 annotation events identified 
during the preliminary study [8] mentioned in Section 5.1.1. The novel annotations 
along with the 12Xv2.1 reference annotation were then used as hints for Augustus gene 
prediction. A total of 84,948 genes and 93,754 proteins (≥66 aa in length) were 
predicted (Appendix File 5.5), and of these, 57 predicted proteins had 110 novel 
peptides incorporated (Table 5.1), of which 94 novel peptides were unique and 
identified in 54 of the 57 predicted proteins (Appendix File 5.6). The number of protein-
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coding genes and proteins predicted by Augustus was far higher than the original 
reference 12Xv2.1 predictions (Table 5.1). In addition to new predictions previously not 
identified, these high numbers could also be attributed to two factors, as was outlined in 
Section 3.5.3. 
The novel peptides incorporated into the predictions ranged in event 
probabilities from 98.374% to 100%, which was within the same range as all resulting 
filtered novel annotation events. However, the majority of the distribution of novel 
annotation events that contained peptides, which were incorporated into the Augustus 
gene predictions, belonged to the higher event probabilities. There were also some 
novel peptides, from high event probability annotation events, which could not be 
incorporated into predictions. This was possibly due to the interpretation of real MS/MS 
spectra derived from contaminants, such as from chloroplasts and mitochondria or 
misidentified variant peptides mistaken as containing PTMs. The event probabilities 
could not discriminate against these types of false positives and could only provide a 
probability of the whole annotation event being correct based on the product and quality 
of all the MS/MS spectra in the annotation event. 
The exclusion of many novel peptides from Augustus gene predictions were also 
observed in the Arabidopsis proteogenomics analysis from [81], however this was not 
discussed in that study. The dissertation author received confirmation that this was the 
case with the Arabidopsis proteogenomics study (S. Payne, personal communication, 
September 29, 2012), and so this should warrant being addressed in the Enosi tool in 
later versions. Because if some accepted novel peptides could not be included into the 
predictions, it is highly probable that some novel peptides that were included should not 
have been, leading to false predictions. This could perhaps be addressed with the 
consideration of other evidence, additional parameters and threshold stringencies before 
defining the final peptide clusters and inferring annotation events, to avoid including 
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what may be spurious novel peptides, instead of mainly relying on parsimony of unique 
peptides within annotation events and their event probabilities. 
The number of novel peptides incorporated into the predictions was quite high at 
110 novel peptides (83%). Of the 110 incorporated novel peptides, 15 were exclusively 
derived from the splice graph, while 7 were identified in both the six-frame translation 
and splice graph, with the remaining 88 novel peptides identified exclusively in the six-
frame translation. 
A BLASTP search was performed, by searching all 93,754 Augustus-predicted 
proteins (Table 5.1) against the 12Xv2.1 proteins, taking the top match with E-value 
≤1E-10. Any sequences that did not match were considered novel predictions, 
sequences that had a query coverage ≥95% with at least 1 mismatch were considered to 
be the same prediction as the reference protein, and the remaining matches were 
considered to be modified predictions, either due to Augustus predicting different gene 
models or modified as a direct result from the supporting evidence. From this analysis 
there were 42,257 non-paralogous novel protein predictions, 32,837 modified 
predictions and 18,660 predictions considered to be essentially the same as the 
reference. 
Searching all 57 protein predictions that had the novel peptide evidence 
incorporated, against the 12Xv2.1 proteins, taking the top match with E-value ≤1E-10, 
identified 49 protein predictions likely to be modified predictions, leaving 3 protein 
predictions, that found no match and were considered as non-paralogous novel protein 
predictions (Table 5.1). 
Based on the annotation events incorporated into the Augustus gene predictions, 
the minimum event probabilities which led to a new Augustus gene prediction were: 
gene boundary, translated UTR, reverse strand and exon boundary event 98.374%, 
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frame-shift event 99.80%, and novel exon event 99.193%. 
Table 5.1 Summary of grape proteogenomics annotations 
The results of the proteogenomics analysis of grape 12Xv2.1 annotation. 
Total 12Xv2.1 genes 31,845 
Total ‘known’ protein-coding genes 31,654* 
Total ‘known’ proteins 55,373* 
Raw MS/MS search ‘known’ protein matches ≤1% PSM FDR 2,773 
Proteogenomics mapping: Total 'known' proteins ≤1% PSM FDR 7,536 
Proteogenomics mapping: Total ‘known’ proteins ≤1% PSM FDR (≥2 peptides with 1 unique) 1,117 
 
Total identified 'novel' peptides ≤1% PSM FDR 325 
Raw MS/MS search ‘known’ peptides ≤1% PSM FDR 7,886 
Proteogenomics mapping: Total identified 'known' peptides ≤1% PSM FDR 11,779 




Translated UTRs 37 
Exon boundaries 16 
Novel splices 1 
Novel exons 9 
Gene boundaries 160 (24) 
Reverse strands 112 (10) 
Novel genes 1 
 
Total annotation events 341 (103) 
Total genes affected 216 (67) 
Total proteins affected 326 (101) 
Total novel peptides in affected genes/proteins 133 
 
Total Augustus protein-coding gene predictions 84,948 
Total Augustus protein predictions 93,754 
Total Augustus gene predictions with incorporated novel peptides 55 
Total Augustus protein predictions with incorporated novel peptides 57 
Total novel peptides incorporated into Augustus protein predictions 110 
Improved protein predictions with incorporated novel peptides 49 
Novel non-paralogous protein predictions with incorporated novel peptides 3 
* The original consisted of 31,845 protein-coding genes coding for 55,564 proteins. A total of 191 
proteins which were <20 aa in length were removed from the analysis. 
Note: Numbers in parenthesis represent the exclusive numbers. The inflationary effect of a large peptide 
linkage distance on gene boundaries and reverse strands was removed by assigning a peptide cluster as 
either a proximal or distal event, not both, with preference placed on proximal events. 
5.3.5 Novel gene annotations 
A single novel gene annotation event was discovered (Table 5.1), located on 
chromosome 14, and spanning positions 14,715,245 to 14,715,284 with an event 
probability of 99.80%. This novel annotation event consisted of a single unique peptide, 
with 2 PSMs assigned (Figure 5.1, and with two supporting annotated MS/MS spectra 
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in Appendix Figure 5.3). Searching the novel peptide against the grape family in NR 
revealed a significant match to a predicted glutathione S-transferase protein 
(XP_002266106.1 with E-value = 3E-07) of 263 aa in size, which was also located on 
chromosome 14, within the same genomic region, with mRNAs, ESTs, and proteins 
supporting the prediction. 
However, the novel peptide could not be incorporated into the Augustus gene 
prediction, although two genes in close proximity were predicted on different strands 
(Figure 5.1). While a BLASTP search of gene g54248 against the grape family in NR 
found no significant matches, gene g54247 in the same frame as the novel peptide, 
further upstream, found a significant match to a hypothetical protein (CAN74624.1 with 
E-value = 0.0). Although as with the BLASTP search, exon and exon_part hints (Figure 
5.1) suggest that there should be an identified gene in this region. Further evidence is 
likely needed to add support to the novel gene event before the weighting of the 
evidence is sufficient to predict a new gene in this region, in line with the supporting 
evidence found in NR. 
 
Figure 5.1 Novel gene annotation 
The novel gene event inferred from a novel and unique peptide flanks Augustus gene predictions, but is 
not incorporated into any new predictions. However, exon_part (EST and cDNA evidence) hints used for 
prediction overlap the novel peptide region before an intron region inferred from the RNA-seq evidence. 
In the last track a repeat region is highlighted. 
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Based on the peptide linkage distance no novel genes were found with ≥2 unique 
peptides, highlighting the importance of screening all annotations to identify valid 
single unique peptide annotation events. With better depth and breadth of sampling 
across many more grape tissues, the identification of annotation events with ≥2 unique 
peptides would likely improve. Regardless, careful screening of all annotations, at least 
with single unique peptides, was still a viable approach to identify potentially missed 
annotations, even if sufficient depth and breadth of sampling was available. 
One of the reasons why only one novel gene event was identified was because 
the proteogenomics approach used categorizes peptide clusters as novel genes when 
they reside outside the peptide linkage distance. This is also similarly true for gene 
boundary events and reverse strand events, which rely on the same peptide linkage 
distance for the assignment of annotation events across the genome, and can result in 
many overlapping annotation events for a single peptide cluster even if they are 
unlikely. A true annotation event assignment is likely to be interpreted correctly for 
peptide clusters in close proximity or directly overlapping the genes, as they cannot be 
refuted, unlike annotation events inferred on genes with peptide clusters possibly many 
thousands of base-pairs away. This is a consequence of applying a general rule (gene 
sizes >95% in size), across all genomic features and as a result there are likely to be 
many more novel genes misidentified as gene boundary events and reverse strand 
events. A good example of where this can occur was with a reverse strand event located 
on chromosome 11, at positions 10,628,861 to 10,628,908, with an event probability of 
99.999%, consisting of 3 novel and unique peptides with 8 PSMs assigned, but on 
inspection appeared more likely to be a novel gene event. In addition Augustus 
predicted a new gene in this location using the novel peptides and exon_part hints 
(Figure 5.2, and with 8 supporting annotated MS/MS spectra in Appendix Figure 5.4). 
Performing a BLASTP search against the grape family in NR revealed all three 
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novel peptides matched 40S ribosomal protein S8 (XP_010646836.1 with E-value 
ranges: 1E-07 – 2E-08) with 100% query coverage and identity, and which had EST and 
mRNA evidence supporting it. The new Augustus gene prediction matched significantly 
but with poor coverage of 29% and identity of 51% to a hypothetical protein 
(CAN81604.1 with E-value 5E-21), which likely indicated a truly novel identification. 
Figure 5.2 Novel gene annotation and prediction misidentified as a reverse strand event 
The novel gene annotation was identified through what was inferred as a reverse strand event, due to the 
peptide linkage distance including a nearby gene. The novel peptides were incorporated into a new 
Augustus gene prediction, which were also supported by exon_part (EST and cDNA evidence) hints. 
5.3.6 Gene boundary annotations 
There were 160 (24 exclusive) gene boundary events identified (Table 5.1). However, 
this could have been artificially inflated as the peptide linkage distance was applied 
evenly across all peptide clusters identified in the genome, as a number of genes from 
the reference annotation could be seen in close proximity to each other, well within the 
18,000 bp peptide linkage distance. 
An example of a gene boundary event is on chromosome 18, spanning positions 
4,109,211 to 4,112,683, with gene VIT_218s0001g04980, consisting of two protein 
isoforms with an event probability of 100% and with 13 PSMs identifying 4 unique 
peptides. In addition, an Augustus gene prediction using the novel peptides and 
reference annotations as hints was able to improve the gene model, incorporating the 
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novel peptides, previous annotations, exon and intron hints, into the new prediction 
(Figure 5.3, and with 13 supporting annotated MS/MS spectra in Appendix Figure 5.5). 
Performing a BLASTP search against the grape family in NR revealed that all 
novel peptides matched acetyl-CoA carboxylase 1-like protein (XP_002285808.2 with 
E-value range: 5E-07 – 3E-16), with 100% query coverage and identity. The two 
reference protein-coding transcripts also matched acetyl-CoA carboxylase 1-like protein 
(XP_002285808.2 both with E-values = 0.0); protein-coding transcript 1 with 100% 
query coverage and protein-coding transcript 2 with 98% query coverage, both with 
100% identity. The new Augustus gene prediction also matched acetyl-CoA 
carboxylase 1-like protein (XP_002285808.2 with E-value = 0.0), with 100% query 
coverage and identity, which showed that the original prediction was under-predicted, 
requiring a further extension of the gene towards the 5’ region on the reverse strand. 
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Figure 5.3 Gene boundary annotation 
The gene boundary event inferred from the novel and unique peptides closely flanked reference gene 
VIT_218s0001g04980 from the 12Xv2.1 annotation. The novel peptides, reference gene 
VIT_218s0001g04980, exon (EST and cDNA evidence) and intron (RNA-seq evidence) hints were 
incorporated into the Augustus gene prediction. A group of peptides were also found mapped to gene 
VIT_218s0001g04980 indicating its expression and adding confidence to this proteogenomic annotation. 
 In the gene boundary annotation event, genes VIT_218s0001g05020 and 
VIT_218s0001g05030 were identified further upstream (based on the peptide linkage 
distance), but the novel peptides were in closer proximity to gene 
VIT_218s0001g04980, which was also the only gene amongst them with known 
mapped peptides. In addition, this peptide cluster also identified a reverse strand 
annotation event for gene VIT_218s0001g04970 further upstream, but this finding was 




As outlined previously in Section 5.3.5, a fixed peptide linkage distance across 
the entire genome is a generalisation of the distribution of genes, inadvertently grouping 
genes into annotation events that do not belong and/or grouping peptides into peptide 
clusters that belong to separate annotation events. 
Numerous other gene boundary events were also discovered with high event 
probabilities and multiple unique peptides, but these findings were also identified as 
translated UTR and reverse strand events, and appeared to agree more with these 
annotation event types than with the gene boundary event type. As such, to identify the 
true number of the different types of annotation events, manual screening of all 
annotation events was needed to see which annotation event was more likely the true 
case, by identifying which peptide clusters from the gene boundary and reverse strand 
events were exclusively identified as only those annotation events (Table 5.1), and were 
not also identified as other annotation events such as proximal events. This can help 
resolve some of the ambiguity when trying to interpret what the location of a peptide 
cluster could actually mean in relation to the surrounding genes instead of automatically 
inferring the annotation event based on its proximity to genes and the peptide linkage 
distance. However, a step of this nature is at odds with one of the aims of 
proteogenomics, i.e. to fast-track genome annotation without any loss in the quality of 
the annotation. 
One way of improving the genomic annotation is to simply ignore classifying 
annotation events and focus on the identified novel peptides as hints towards gene 
prediction in tools such as Augustus, and to filter out any possible false gene predictions 
using orthologous evidence to group genes into low and high confidence sets. However, 
a method of this nature becomes more time-consuming, introduces error and avoids 
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assigning annotation events entirely, and relies heavily on the abilities of the gene 
prediction tool. A better approach to assigning annotation events at the proteogenomics 
level would be to re-define the way in which annotation events are categorized, based 
on additional evidence, such as known mapped peptides and their frame in correlation 
to the nearby novel peptides within the same or overlapping ORF. 
An additional approach could be to determine the peptide linkage distance 
dynamically for each peptide cluster, based on the average size of genes in the 
immediate region in combination with other evidence such as ESTs, RNA-seq and/or 
the distribution of all mapped peptides and applied to machine-learning approaches, 
before annotation event inference, to identify the most likely genes involved in each 
annotation event. For example, a reverse strand annotation event would more likely to 
be defined for a gene when the peptide cluster directly overlaps it and has no 
neighbouring genes, particularly none with mapped known peptides. However, if the 
neighbouring genes have mapped peptides and the genes are in relatively close 
proximity, then the annotation could be defined as a gene boundary event overlapping 
the gene on the opposite strand. Such problems need to be met in a dynamic way, as the 
peptide linkage distance does not discriminate between entities in relatively close 
proximity, and those much further up or downstream of the peptide cluster. 
5.3.7 Reverse strand annotation event leads to a new gene prediction 
There were 112 (10 exclusive) reverse strand annotation events identified (Table 5.1), 
but the majority of these annotation events were also identified as gene boundary and 
translated UTR events due to the peptide linkage distance. However in 8 cases the 
peptide cluster directly overlapped a gene on the opposite strand. An example of one of 
these 8 reverse strand annotations was gene VIT_211s0065g00070 with its single 
protein-coding transcript, which was also identified as a gene boundary annotation for 
gene VIT_211s0065g00060 much further upstream. This annotation was identified on 
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chromosome 11, spanning positions 13,140,580 to 13,147,463, with an event 
probability of 99.960% with 2 PSMs identifying 2 unique and novel peptides. 
Additionally, Augustus predicted a novel gene from one of the novel peptides (Figure 
5.4, and with 2 supporting annotated MS/MS spectra in Appendix Figure 5.6). 
Performing a BLASTP search against the grape family in NR revealed that 
novel peptide “ELSNYMQPIHIHTIYLPILLLIKMEK“ matched a hypothetical protein 
(CAN73713.1 with E-value = 0.030), with 80% query coverage and 56% identity, and 
novel peptide “KVEENLNNEAR” matched a protein transport protein SEC16A 
homolog (XP_010646525.1 with E-value  = 7E-04), with 90% query coverage and 
100% identity. The reference protein-coding transcript from gene 
VIT_211s0065g00070 matched unnamed protein product (CBI24042.3 with E-value = 
0.0), with 100% query coverage and identity. The new Augustus gene prediction 
matched hypothetical protein (CAN82660.1 with E-value = 2E-35), with 57% query 
coverage and 85% identity, indicating novel gene identification on the reverse strand. 
Although the reference protein matched significantly in NR, for unknown reasons it did 
not lead to a new equivalent prediction through Augustus. Further supporting evidence 
is needed before this annotation event and prediction could be accepted with 





Figure 5.4 Novel gene prediction via a reverse strand event 
A reverse strand event inferred from the novel and unique peptides. The novel peptide 
“KVEENLNNEAR” and reference gene VIT_211s0065g00070 used as a hint for Augustus gene 
prediction did not result in a new gene. However, peptide “ELSNYMQPIHIHTIYLPILLLIKMEK” 
contributed to a new Augustus gene prediction, flanking gene VIT_211s0065g00070. The intron (RNA-
seq evidence) hints in this region did not contribute to any new Augustus gene predictions. The region is 
also covered in a number of repeat regions. 
5.3.8 Translated UTR annotation 
There were 37 translated UTR annotations identified (Table 5.1), of which a large 
proportion were also identified as gene boundary and reverse strand annotations due to 
the peptide linkage distance including other genes in close proximity. However, the 
translated UTR annotations by their definition are limited to only directly overlapping a 
UTR gene region. Hence, the reason for just 40 such annotations, compared to the other 
distal events such as reverse strands (112) and gene boundaries (159), which were 
annotated purely on the inclusion of a gene within the peptide linkage distance of a 
peptide cluster. An example was with gene VIT_208s0058g01030, protein-coding 
transcript 1, with the peptide cluster also indicating a gene boundary with genes 
VIT_208s0058g01020, VIT_208s0058g01030 and VIT_208s0058g01040, as well as a 
reverse strand annotation with gene VIT_208s0058g01010, due to the peptide linkage 
distance and close proximity of these genes around gene VIT_208s0058g01030. This 
annotation was identified on chromosome 8, spanning positions 10,371,636 to 
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10,373,023, with an event probability of 100% and with 6 PSMs identifying 4 novel and 
unique peptides. Using the novel peptides, reference annotation and intron hints 
evidence for gene prediction, Augustus predicted two genes (Figure 5.5, and with 6 
supporting annotated MS/MS spectra in Appendix Figure 5.7). 
Performing a BLASTP search against the grape family in NR revealed that all 
novel peptides matched Prosaposin protein (XP_002268581.1 with E-value range: 
0.009 – 1E-11), with 100% query coverage and identity, the reference protein matched 
unnamed protein product (CBI18061.3 with E-value = 0.0), with 100% query coverage 
and identity; described as containing a Saposin-like type B domain. The two new 
Augustus gene predictions, g29772 and g29776, also matched unnamed protein product 
(CBI18062.3 for g29772 and CBI18061.3 for g29776, both with E-values = 0.0), with 
72% query coverage for g29772 and 87% query coverage for g29776, both with 100% 
identity; and both described as containing a Saposin-like type B domain. The two new 
gene predictions matching the same protein, have likely been split into two prediction 
based on the evidence. In addition, the intron evidence (Figure 5.5) indicates splicing 
across the whole length of the region from gene VIT_208s0058g01030, which also 
crosses the regions of both new predictions g29772 and g29776, thus providing further 




Figure 5.5 Translated UTR annotation 
A translated UTR event inferred from the novel and unique peptides. The novel peptides, reference gene 
VIT_208s0058g01030 and exon (EST and cDNA evidence) and intron (RNA-seq evidence) hints were 
incorporated into new Augustus gene predictions, however the predictions were split into two separate 
predictions both matching the same protein. A number of repeat regions were identified upstream of the 
5’ end of gene VIT_208s0058g01030. 
Another interesting translated UTR annotation was for gene 
VIT_207s0031g03000, with the peptide cluster also part of a larger peptide cluster 
indicating a reverse strand annotation for genes VIT_207s0031g02980, 
VIT_207s0031g02990, and VIT_207s0031g03010 further upstream and downstream, 
based on the peptide linkage distance. The gene VIT_207s0031g03000 and its single 
protein-coding transcript also contained a different peptide cluster, indicating an exon 
boundary annotation, which is discussed later in Section 5.3.10. The translated UTR 
annotation for gene VIT_207s0031g03000 was identified on chromosome 7, spanning 
positions 19,731,734 to 19,731,934 with an event probability of 100%, with 90 PSMs 
identifying 4 unique and 5 shared novel peptides. Additionally, using the novel 
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peptides, reference annotations, intron and exon hints, Augustus predicted a new gene 
(Figure 5.6 (translated UTR peptide cluster outlined in dash dotted line), and with a 
sample of 9 of 90 supporting annotated MS/MS spectra in Appendix Figure 5.8). 
Performing a BLASTP search against the grape family in NR revealed that all 
novel peptides matched the ribulose-1,5-bisphosphate carboxylase/oxygenase 
(RuBisCo) large subunit (AFG24212.1 with E-value range: 4E-05 - 8E-14) with 100% 
query coverage and identity. The reference protein matched unnamed protein product 
(CBI21646.3 with E-value = 2E-62), with 100% query coverage and identity; described 
as containing a RuBisCo large chain domain. The new Augustus gene prediction 
matched hypothetical protein (CAN63541.1 with E-value = 5E-166) with 77% query 
coverage and 99% identity; also described as containing a RuBisCo domain. 
All evidence indicated that the identified and refined protein-coding gene was a 
RuBisCo large subunit, which is widely known as a dominant protein in the plant 
kingdom found more abundantly in leaves, a major source of peptides in this study. 
However, the protein, in particular the large subunit, was found exclusively in 
chloroplasts. False identifications such as these would be expected to match randomly 
across the genome by chance alone, but they are distributed across the length of this 
gene. The single protein-coding transcript from gene VIT_207s0031g03000 also 
matched RuBisCo large subunit, as does the new Augustus gene model. This indicated 
that either this was the first likely known case of an actual RuBisCo gene encoded on 
chromosomes in the nucleus, which seems improbable, or there is some over-assembly 
of the reference genome sequence, with chloroplast reads being incorporated into the 
chromosome 7 assembly. Further evidence as to the origin of this gene and the overall 
region in which the gene is found is needed before any further conclusions can be 
drawn. A good indication that over-assembly is the likely cause can be seen from the 
large number of chromosome fragments and the large unassigned chromosome 
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(ChrUn), as pointed out previously in Section 5.3.3, in regards to sources of false 
positives. Highly fragmented genomes with a large number of unassigned chromosomes 
can often indicate an underlying problem with the assembly, either indicating 
unresolved repeat regions at the ends of the scaffolds or co-assembly with nuclear 
chromosome reads and contaminant reads (e.g. incorporating reads from the 
chloroplast) leading to over-assembly; both of which would significantly hamper 
attempts to join scaffolds, leaving the assembly in a disjointed state and fragmented. 
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Figure 5.6 Translated UTR and exon boundary annotation 
An exon boundary (dashed line) and translated UTR (dash dotted line) inferred from the novel and unique 
peptides. The novel peptides, reference gene VIT_207s0031g03000, exon_part (EST and cDNA 
evidence) hints were incorporated into the Augustus gene prediction. A number of repeat regions were 
identified upstream of the 5’ end of gene VIT_207s0031g03000. The new Augustus gene prediction was 
also predicted to be spliced, with GT-AG (U2 spliceosome) donor-acceptor sites, however no other 
evidence indicated splicing across this region. 
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5.3.9 Novel splice annotation 
One novel splice annotation was identified (Table 5.1) for gene VIT_201s0011g05110 
and its single protein-coding transcript. The novel peptide was also identified as a gene 
boundary annotation for a number of other genes in close proximity, including genes 
VIT_201s0011g05082, VIT_201s0011g05090, VIT_201s0011g05100, 
VIT_201s0011g05110, VIT_201s0011g05120, VIT_201s0011g05130, and 
VIT_201s0011g05140. The novel splice annotation event was identified on 
chromosome 1, spanning positions 4,748,591 to 4,761,837, with an event probability of 
99.396% and 1 PSM identifying a single novel and unique peptide. Additionally, using 
the novel spliced peptide to identify a new or revised Augustus gene prediction did not 
lead to any predictions (Figure 5.7, and with 1 supporting annotated MS/MS spectrum 
in Appendix Figure 5.9). 
Performing a BLASTP search against the grape family in NR revealed the novel 
peptide matched hypothetical protein (CAN83049.1 with E-value = 0.012), with 75% 
query coverage and 100% identity. The reference protein also matched the same 
hypothetical protein (CAN83049.1 with E-value = 2E-165), with 100% query coverage 
and identity, described as containing a hydrophobic ligand binding site domain of a 
major pollen allergen. The novel peptide showed only 75% coverage as the N-terminal 
end of the peptide resided within the protein, and the C-terminal resided further 
downstream within an intergenic space. However, there was no evidence to support the 
inferred intron from the proteogenomics analysis, which indicated a GT-GC donor-
acceptor site (U2 spliceosome) at positions 4,748,617 to 4,761,824. To see if this 
putative splice site could be identified via a different strategy, the genomic region 
spanning the exon where the N-terminal end of the novel peptide resided was extracted 
up to 20 bp beyond the C-terminal mapped end of the novel peptide, and was given to 
the NetGene2 splice site prediction web server using Arabidopsis thaliana as a model 
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[579]. No donor or acceptor sites matching those predicted by the proteogenomics 
analysis could be found (Appendix File 5.7). Although the intron hints contained a 
number of introns across the region none spanned the entire length of the region where 
the proteogenomics evidence indicated, which suggested that the novel spliced peptide 






Figure 5.7 Novel splice annotation 
A novel splice annotation inferred from the novel and unique peptide. The novel peptide could not be 
incorporated into the Augustus gene prediction. Only the genes in the region from the 12Xv2.1 annotation 
led to Augustus gene predictions that were supported by mapped known peptides. There were also no 
introns identified among the intron hints from the RNA-seq evidence that spans the entire range inferred 
by the novel spliced peptide. There are also a number of repeat regions dotted across the length of the 
region. 
5.3.10 Exon boundary annotation 
There were 16 exon boundary annotations identified (Table 5.1), a number of which 
were also identified as gene boundary and reverse strand annotations due to the peptide 
linkage distance including other genes in close proximity, as well as a few novel exons 
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identified from different protein isoforms from the same gene. An example of an exon 
boundary annotation was with gene VIT_207s0031g03000, mentioned previously 
containing a translated UTR annotation, with the peptide cluster also part of a larger 
peptide cluster indicating a reverse strand annotation for genes VIT_207s0031g02980, 
VIT_207s0031g02990, and VIT_207s0031g03010 further upstream and downstream. 
The exon boundary annotation for gene VIT_207s0031g03000 and its single protein-
coding transcript was identified on chromosome 7, spanning positions 19,731,614 to 
19,731,721 with an event probability of 100%, and 59 PSMs identifying five novel and 
unique peptides. Using the novel peptides and the current annotation as hints, Augustus 
predicted a new gene model (Figure 5.6 (exon boundary peptide cluster outlined in 
dashed line), and with a sample of 5 of 59 supporting annotated MS/MS spectra in 
Appendix Figure 5.10). 
Performing a BLASTP search against the grape family in NR revealed that all 
the novel peptides matched unnamed protein product (CBI21646.3 with E-value range:  
2E-04 - 8E-20), with 100% query coverage and identity, described as containing a 
RuBisCo large chain domain, which is in agreement with the findings from the 
translated UTR event described previously for the same gene. The reference protein and 
Augustus gene prediction matched unnamed protein product (CBI21646.3) and 
hypothetical protein (CAN63541.1), respectively, as described previously in Section 
5.3.8 for a translated UTR annotation. 
Another interesting exon boundary annotation was for gene 
VIT_206s0004g04440 and its single protein-coding transcript, with the peptide cluster 
also indicating a gene boundary annotation for genes VIT_206s0004g04410, 
VIT_206s0004g04430 and VIT_206s0004g04460, as well as a reverse strand 
annotation for genes VIT_206s0004g04420, VIT_206s0004g04450 and 
VIT_206s0004g04470, due to the peptide linkage distance and close proximity of these 
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genes around gene VIT_206s0004g04440. This annotation was identified on 
chromosome 6 spanning positions 5,401,503 to 5,401,583, with an event probability of 
99.999% and 12 PSMs identifying 2 novel and unique peptides. Using the novel 
peptides and current annotation as hints, Augustus predicted a new gene model (Figure 
5.8, and with 12 supporting annotated MS/MS spectra in Appendix Figure 5.11). 
Performing a BLASTP search against the grape family in NR revealed that the 
novel peptides matched osmotin-like protein (XP_002281193.1 with E-value range: 2E-
19 – 2E-22), with 100% query coverage and identity. The reference protein also 
matched osmotin-like protein (XP_002281193.1 with E-value = 0.0), with 91% query 
coverage and 100% identity and the Augustus gene prediction also matched osmotin-
like protein (XP_002281193.1 with E-value = 0.0), with 94% query coverage and 100% 
identity. The revised gene prediction showed an improvement on the original gene 
prediction of 3% coverage, extending the original exon 1 and merging it with exon 2. In 
addition, the identified osmotin-like protein was also supported by EST and mRNA 





Figure 5.8 Exon boundary annotation 
An exon boundary event inferred from the novel and unique peptides. The novel peptides, reference gene 
VIT_206s0004g04440, exon_part (EST and cDNA evidence) hints were incorporated into the Augustus 
gene prediction. The new Augustus gene prediction was also predicted with a spliced region containing 
GT-AG (U2 spliceosome) donor-acceptor sites. However, no intron (RNA-seq) evidence indicated 
splicing across the region indicated by the prediction. 
5.3.11 Frame-shift annotation 
There were 5 frame-shift annotations identified (Table 5.1), a number of which were 
also identified as gene boundary and reverse strand annotations due to the peptide 
linkage distance including other genes in close proximity. An example of a frame-shift 
annotation was with gene VIT_200s1339g00010 and its single protein-coding 
transcript, with the peptide cluster also indicating a gene boundary annotation for gene 
VIT_200s1343g00010 and a reverse strand annotation for genes VIT_200s1338g00010 
and VIT_200s1338g00020, due to the peptide linkage distance. This annotation was 
identified on chromosome Un, spanning positions 38,615,528 to 38,615,653, with an 
event probability of 99.998% and 3 PSMs identifying 2 novel and unique peptides. 
Frame-shift events can also be identified due to incorrect CDS phase. Numerous CDS 
phase were found to be incorrect throughout the 12Xv2.1 annotation and were not 
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solely limited to those identified in the proteogenomics analysis. All CDS phase in the 
genome annotation were subsequently corrected using GenomeTools [542]. The CDS 
phase corrected reference annotation was then used as hints along with the identified 
novel frame-shift peptides using Augustus to improve the predictions and create a new 
gene model (Figure 5.9, and with 3 supporting annotated MS/MS spectra in Appendix 
Figure 5.12). 
Performing a BLASTP search against the grape family in NR revealed the novel 
peptides matched a hypothetical protein (CAN63109.1 with E-value ranges: 2E-07 – 
5E-21), with 100% query coverage and identity, described as containing a Ribonuclease 
T2 domain. The reference protein matched a hypothetical protein (CAN63794.1 with E-
value = 3.3), with 65% query coverage and 50% identity, described as containing a 
retrotransposon gag protein domain. The Augustus gene prediction matched the same 
hypothetical protein as the novel peptides (CAN63109.1 with E-value = 0.0), with 97% 
query coverage and 98% identity. The BLASTP evidence indicated that the original 
reference protein had a poor match to a hypothetical protein, while the revised Augustus 
gene prediction found a significant match to a hypothetical protein, with a good protein 
alignment that included the novel peptides. In addition, the novel peptides and Augustus 
gene prediction both matched exactly the same protein, described as containing a 
Ribonuclease T2 domain implicated in plant leaf senescence, which correlates well with 
the source of the proteomics data, mainly being derived from plant leaf shoot tips. This 
proteogenomics evidence has led to a significant overall improvement to the annotation 
of this gene. 
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Figure 5.9 Frame-shift annotation 
A frame-shift event inferred from the novel and unique peptides. The novel peptides, gene 
VIT_200s1339g00010, exon and exon_part (EST and cDNA) and intron (RNA-seq) evidence were used 
as hints for the Augustus gene prediction. All hints were incorporated into the prediction except for the 
hints from gene VIT_200s1339g00010, which had a CDS region in a different frame (frame -1) than that 
of the novel peptides (frame -2). A region further downstream contained a number of repeats. 
5.3.12 Novel exon annotation 
There were 9 novel exon annotations identified (Table 5.1), with a number also 
identified as gene boundary, reverse strand and translated UTR annotations, due to the 
peptide linkage distance including other genes in close proximity. An example of a 
novel exon annotation was with gene VIT_217s0000g02480, the same peptide cluster 
was also categorised as a gene boundary annotation for genes VIT_217s0000g02470, 
VIT_217s0000g02490 and VIT_217s0000g02500 due to the peptide linkage distance. 
This annotation was identified on chromosome 17, spanning positions 2,264,427 to 
2,264,591, with an event probability of 99.999% and 15 PSMs identifying 3 novel and 
unique peptides. The novel peptides and the reference annotation were then used as 
hints for Augustus gene prediction, resulting in the incorporation of the novel peptides 
into a new gene model with complete removal of the intron (Figure 5.10, and with 15 
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supporting annotated MS/MS spectra in Appendix Figure 5.13). 
Performing a BLASTP search against the grape family in NR revealed the novel 
peptides matched calcium-binding allergen Ole e 8 (XP_010663678.1 with E-value 
ranges: 2E-07 – 2E-15), with 100% query coverage and identity. The reference protein 
matched unnamed protein product (CBI15562.3 with E-value = 2E-97), with 100% 
query coverage and identity, described as containing an EF-hand calcium-binding 
domain. The Augustus gene prediction matched calcium-binding allergen Ole e 8 
(XP_010663678.1 with E-value = 2E-176), with 100% query coverage and identity. 
Overall, the new Augustus gene prediction had a better match to the calcium-binding 




Figure 5.10 Novel exon annotation 
A novel exon event inferred from the novel and unique peptides. The novel peptides, gene 
VIT_217s0000g02480, exon and exon_part (EST and cDNA) evidence were incorporated into the 
Augustus gene prediction, bridging the two exon/CDS regions in the original prediction into one 
exon/CDS region. 
5.3.13 N-terminal acetylated peptides 
Protein N-terminal acetylation contributes to many functional changes in proteins, from 
signalling, regulation of protein-protein interactions, and transportation of proteins to 
their target, such as embedding in membranes [580]. The identification of any N-
terminal acetylated peptides not at the N-terminal ends of a known protein could 
potentially indicate an over-predicted gene requiring re-annotation, but could also 
indicate an alternative protein isoform with a different translation initiation start (TIS) 
site. 
No N-terminal acetylated peptides were identified from the 133 novel peptides 
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(Table 5.1), however, a total of 192 N-terminal acetylated peptides were identified 
among the known 12Xv2.1 predicted proteins and 80 were identified from 77 high 
confidence proteins (>2 peptides with at least 1 unique). Of the total proteins, 5 shared 
N-terminal acetylated peptides were identified as conflicting with the 12Xv2.1 
annotation (Appendix File 5.8), thus indicating a possible alternative TIS site, while 
none were identified from the high confidence proteins. 
The first of these peptides was shared peptide 
“LQGEAVQDWREIVTYFSYPLR” identified in two different locations: 1) on 
chromosome 4, at positions 19,930,049 to 19,930,316, on gene VIT_204s0023g03370 
with a single protein-coding transcript; and 2) on chromosome 18, at positions 
12,303,451 to 12,304,114 on gene VIT_218s0001g14310 with a single protein-coding 
transcript. The suggestion of an alternative TIS site was not supported by the Augustus 
gene prediction, showing only one protein prediction in agreement with the 12Xv2.1 
annotation, which was true for both predictions on chromosome 4 and 18. An example 
of the mapped peptides including the N-terminal acetylated peptide for chromosome 4 
can be seen in Figure 5.11 (Supported with 1 annotated MS/MS spectrum in Appendix 
Figure 5.14). The N-terminal acetylated peptide was also found to be a spliced peptide 
in both identified locations and the spectral E-value for this identification was ~7.0E-14, 
indicating a significant spectral interpretation. Both proteins were found to share 
extensive sequence homology by Muscle alignment (data not shown). 
Performing a BLASTP search against the grape family in NR, the single protein-
coding transcript from gene VIT_204s0023g03370 was found to match naringenin,2-
oxoglutarate 3-dioxygenase (NP_001268034.1 with E-value = 0.0) on chromosome 4, 
and the single protein-coding transcript from gene VIT_218s0001g14310 was found to 
match flavanone 3-dioxygenase (XP_002275563.1 with E-value = 0.0) on chromosome 
18. Both proteins had their own unique peptides, but both also shared common peptides 
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including the N-terminal acetylated peptide. In addition, both peptides also contained 
unmodified shared peptide “GGFIVSSHLQGEAVQDWREIVTYFSYPLR”, of which 
the N-terminal acetylated peptide was a sub-string, indicating that the N-terminal 
acetylated peptide could have been a representative of an alternative isoform. However, 
the inferred translation initiation codon for both peptide locations on chromosome 4 and 
18 is CAT, which does not appear to be a known alternative translation initiation codon 
in plants [581-584]. In addition, there were no GT-AG, GC-AG (U2 spliceosome) or 
AT-AC (U12 spliceosome) donor-acceptor sites preceding the peptide to use for 
splicing for an initiation codon further upstream. It is possible that other non-AUG TIS 
sites not commonly known of could explain the presence of the N-terminal acetylated 
peptide. Further evidence would be needed to confirm this potential alternative TIS site 




Figure 5.11 Known N-terminal acetylated peptide on chromosome 4 
The known N-terminal acetylated peptide “LQGEAVQDWREIVTYFSYPLR”, was shown to be a 
spliced peptide. However, there was no other evidence to indicate translation begins with this peptide and 
Augustus did not predict isoforms in agreement with it. The same was true for the peptide on 
chromosome 18, with similarly mapped peptides and gene prediction. 
The second of these N-terminal acetylated peptides in conflict with the 12Xv2.1 
annotation was shared peptide “MDTFLFTSESVNEGHPDK”, identified in three 
different locations: 1) on chromosome 6, at positions 17,979,019 to 17,979,072 on gene 
VIT_206s0061g00500 with a single protein isoform; 2) on chromosome 8, at positions 
18,919,477 to 18,919,530 on gene VIT_208s0007g05000 with two protein isoforms; 
and 3) on chromosome 14, at positions 451,155 to 451,208 on gene 
VIT_214s0060g00480 with four protein isoforms. Only the peptide identified on 
chromosome 6 at positions 17,979,019 to 17,979,072 was, however, in disagreement 
with the 12Xv2.1 annotations. Also, the suggested alternative TIS site was not 
supported by the Augustus gene prediction (Figure 5.12, and with 7 supporting 
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annotated MS/MS spectra in Appendix Figure 5.15). The spectral E-values for this 
identification across the different locations range from 1.0E-12 to 1.0E-15, indicating 
significant MS/MS spectral interpretations. All mapped proteins share a number of 
peptides, including the N-terminal acetylated peptide, and they also share extensive 
sequence homology, as indicated by Muscle alignment (data not shown). 
Performing a BLASTP search against the grape family in NR, the single protein-
coding transcript from gene VIT_206s0061g00500 was found to match S-
adenosylmethionine synthase 1 isoform X1 (XP_002273336.1 with E-value = 0.0) on 
chromosome 6. Protein-coding transcripts from gene VIT_208s0007g05000 matched S-
adenosylmethionine synthase 3 (XP_003632745.1 with E-value = 0.0) on chromosome 
8. The four protein-coding transcripts from gene VIT_214s0060g00480 matched S-
adenosylmethionine synthase 4 (XP_010659744.1 with E-value = 0.0) on chromosome 
14. The inferred translation initiation codon is GTG, and is identified as a non-AUG 
translation initiation codon in Arabidopsis thaliana [583] Rhabdopleura compacta 
[585], Ascidian mitochondria [586] and chloroplasts [587]. There were also no splicing 
acceptor sites prior to the peptide, only an AG beginning 4 bp upstream within an 
already identified intron. Due to the validation of the GTG codon being identifiable as a 
known alternative translation initiation codon in plants, this peptide may indicate an 
alternate TIS and/or isoform. However, due to the presence of the peptide in multiple 
similar proteins in other locations, this annotation will remain ambiguous until further 
evidence can be presented. 
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Figure 5.12 Known N-terminal acetylated peptide on chromosome 6 
The known N-terminal acetylated peptide “MDTFLFTSESVNEGHPDK” resides 2 bp into the second 
exon, following a spliced region and the N-terminal end correlates with a known alternative translation 
initiation codon (GTG). However, Augustus did not predict any alternative protein-coding transcripts in 
agreement with it. 
The third of these N-terminal acetylated peptides in conflict with the 12Xv2.1 
annotation was shared peptide “FMIQTGDPLGDGTGGQSIWGREFEDEFHK”, 
identified on chromosome 6, at positions 19,528,020 to 19,528,106 on gene 
VIT_206s0061g01590 with three protein isoforms. Also, the suggested alternative TIS 
site was not supported by the Augustus gene prediction (Figure 5.13, and with 1 
supporting annotated MS/MS spectrum in Appendix Figure 5.16). The spectral E-value 
for this identification is ~9.0E-13, indicating a significant MS/MS spectral 
interpretation. 
Performing a BLASTP search against the grape family in NR the protein-coding 
transcript 1 from gene VIT_206s0061g01590 was found to match unnamed protein 
product (CBI17058.3 with E-value = 0.0), transcript 2 was found to match peptidyl-
prolyl cis-trans isomerase CYP71 (XP_010651713.1 with E-value = 0.0) on 
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chromosome 6, and transcript 3 was found to match a hypothetical protein 
(CAN66191.1 with E-value = 0.0). No other known peptides were found to map to gene 
VIT_206s0061g01590 and the N-terminal acetylated peptide was only identified from 1 
PSM. The inferred translation initiation codon is GGC, however it does not appear to be 
a known alternative translation initiation codon in plants [581-584]. There was also no 
splicing acceptor site, intron region directly prior to the peptide, or intron region 
supported by the hints, only an AG motif beginning 4 bp upstream. There was only 
supporting exon evidence indicating further sites of translation upstream. Although the 
evidence in support of this possible alternative TIS site/protein isoform is lacking, it is 
possible that other non-AUG TIS sites not commonly known of could explain its 
presence. Therefore, more evidence is required, such as in the form of more supporting 
peptides mapped to the gene and preferably with at least 1 unique peptide identified 
from more than 1 PSM, to remove any ambiguity with the identification as well as any 





Figure 5.13 Known N-terminal acetylated peptide on chromosome 6 
The known N-terminal acetylated peptide “FMIQTGDPLGDGTGGQSIWGREFEDEFHK” was located 
in the middle of one of the exons. However, there was no other evidence to indicate translation begins 
with this peptide, no known translation initiation codon or splice acceptor sites prior to the peptide, and 
Augustus did not predict any protein-coding transcripts in agreement. 
The fourth of these N-terminal acetylated peptides in conflict with the 12Xv2.1 
annotation was shared peptide “ANAASGMAVHDDCK”, identified in three different 
locations: 1) on chromosome 6, at positions 5,236,863 to 5,236,904 on gene 
VIT_206s0004g04280, protein-coding transcript 2; 2) on chromosome 8, at positions 
14,331,406 to 14,331,447 on gene VIT_208s0040g03360, protein-coding transcripts 3 
and 4; and 3) on chromosome 13, at positions 2,558,362 to 2,558,403 on gene 
VIT_213s0019g00550, protein-coding transcripts 1, 2 and 3. However, only the peptide 
identified on chromosome 8 at positions 14,331,406 to 14,331,447 was in disagreement 
with the 12Xv2.1 annotations. Also, the suggested alternative TIS site was not 
supported by the Augustus gene prediction (Figure 5.14, and with a sample of 5 of 23 
supporting annotated MS/MS spectra in Appendix Figure 5.17). The spectral E-values 
for this identification across the different locations range from 2.0E-12 to 5.0E-20, 
indicating significant MS/MS spectral interpretations. All mapped proteins share a 
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number of peptides, including the N-terminal acetylated peptide, but none were unique 
which made it impossible to determine if any one or all of them were being expressed 
due to the protein inference problem. In addition, the proteins shared extensive 
sequence homology, as indicated by Muscle alignment (data not shown). 
Performing a BLASTP search against the grape family in NR, protein-coding 
transcript 2 for gene VIT_206s0004g04280 matched actin-depolymerizing factor 2 
(XP_002284292.1 with E-value = 3.0E-100), on chromosome 6. The protein-coding 
transcripts 3 and 4 from gene VIT_208s0040g03360 both matched actin-
depolymerizing factor 1-like (XP_002273958.2 with E-value = 6.0E-138 and 4.0E-99, 
respectively) on chromosome 8. Protein-coding transcripts 1, 2 and 3 from gene 
VIT_213s0019g00550 all matched actin-depolymerizing factor 2-like isoform X1 
(XP_002284029.1 with E-value = 5.0E-100) on chromosome 13.  
Preceding the N-terminal acetylated peptide on chromosome 8 at positions 
14,331,406 to 14,331,447 the inferred initiation codon was CAG, but it does not appear 
to be a known alternative translation initiation codon in plants [581-584]. However, it is 
possible that other non-AUG TIS sites not commonly known of could explain its 
presence. The presence of the peptide could also be explained through the identification 
of AUG translation initiation codons found through splicing. There is a GT-AG or GC-
AG (U2 spliceosome) donor-acceptor site within an already identified intron prior to the 
peptide, with the acceptor AG at position 14,331,404, and further upstream at position 
13,330,577 for GC, and position 13,330,051 for GT. Although the evidence suggested 
that this could lead to an alternative initiation codon since the peptide is backed up by 
23 PSMs, each with significant spectral E-values and potential donor acceptor sites for 
5’ Methionine capping, the peptide could also simply be identified due to the expression 
of the other proteins making the N-terminal acetylated peptide the most abundant form. 
As any one protein could not be identified as being expressed over the others due to the 
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protein inference problem, further evidence is needed before claiming it as an 
alternative TIS site/protein isoform. 
Figure 5.14 Known N-terminal acetylated peptide on chromosome 8 
The known N-terminal acetylated peptide “ANAASGMAVHDDCK” was located at the start of the 
second CDS in 2 out of the 4 protein-coding transcripts. There were no known initiation codons prior to 
the peptide, however there was an AG acceptor site and two possible GT or GC donor sites further 
upstream. In addition, these peptides were shared with other similar proteins in the genome, which had 
annotations in agreement with the N-terminal acetylated peptide. Augustus did not predict any isoforms 
for this gene given the exon, exon_part and intron extrinsic hints. Taken together, this indicated that the 
inferred alternative isoform and TIS site for this gene was ambiguous, requiring further evidence. 
The fifth and final N-terminal acetylated peptide in conflict with the 12Xv2.1 
annotation was shared peptide “ALPNQQTVDYPSFK” identified in four different 
locations: 1) on chromosome 4, at positions 4,517,741 to 4,517,782, on gene 
VIT_204s0008g05020, protein-coding transcript 1; 2) on chromosome 4, at positions 
4,522,707 to 4,522,748 on gene VIT_204s0008g05030, protein-coding transcript 1; 3) 
on chromosome 9, at positions 5,754,839 to 5,754,880 on gene VIT_209s0002g05940, 
with a single protein-coding transcript; 4) on chromosome 11, at positions 4,088,884 to 
4,088,925 on gene VIT_211s0016g04780, with a single protein-coding transcript. Only 
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the peptide identified on chromosomes 9 and 11 at positions 5,754,839 to 5,754,880 and 
4,088,884 to 4,088,925, respectively, were in disagreement with the 12Xv2.1 
annotation. The suggested alternative TIS site was not supported by the Augustus gene 
predictions, showing only one isoform prediction for each gene region in agreement 
with the 12Xv2.1 annotation. An example of the mapped peptides for chromosome 9, 
including the N-terminal acetylated peptide, can be seen in Figure 5.15 (Supported with 
2 annotated MS/MS spectra in Appendix Figure 5.18). The spectral E-values for this 
identification ranged from 6.0E-13 to 6.0E-14, indicating a significant MS/MS spectral 
interpretation. All mapped proteins shared a number of peptides, including the N-
terminal acetylated peptide, but none were unique, making it impossible to determine if 
any one or all of them were being expressed due to the protein inference problem. The 
proteins additionally shared extensive sequence homology, as indicated by Muscle 
alignment (data not shown). 
Performing a BLASTP search against the grape family in NR, protein-coding 
transcript 1 from gene VIT_204s0008g05020 found a match to GTP-binding nuclear 
protein Ran-3-like (XP_002284967.1 with E-value = 3.0E-167) on chromosome 4. 
Protein-coding transcript 1 from gene VIT_204s0008g05030 matched GTP-binding 
nuclear protein Ran-3-like (XP_002284971.1 with E-value = 2.0E-167) on chromosome 
4. Protein-coding transcript 1 from gene VIT_209s0002g05940 matched GTP-binding 
nuclear protein Ran-3-like (XP_002285307.2 with E-value = 0.0) on chromosome 9, 
and protein-coding transcript 1 from gene VIT_211s0016g04780 matched GTP-binding 
nuclear protein Ran-3-like (XP_002285018.2 with E-value = 0.0) on chromosome 11. 
Preceding the N-terminal acetylated peptide on chromosome 9 and 11 at 
positions 5,754,839 to 5,754,880 and 4,088,884 to 4,088,925, respectively, the inferred 
translation initiation codon in each case was TAG, located within the intron, but this is a 
stop codon not an initiation codon, and does not appear to be a known alternative 
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translation initiation codon in plants [581-584]. However, it is possible that other non-
AUG TIS sites not commonly known of could explain its presence. The presence of the 
peptide could also be explained through the identification of an AUG translation 
initiation codon found through splicing. For chromosome 9 there was a GT-AG (U2 
spliceosome) donor-acceptor site within an already identified intron, with the GT donor 
site at position 5,754,701 and the AG acceptor site at position 5,754,837. Similarly, on 
chromosome 11 there was a potential GT donor site at position 4,088,830 and at 
position 4,088,684. The evidence suggested that this could lead to an alternative 
initiation codon, with 2 PSMs, significant spectral E-values, and likely donor-acceptor 
sites for 5’ Methionine capping. However, the peptide could also be derived from the 
other two proteins where the N-terminal acetylated peptide agreed with the annotation. 
Any one protein cannot be identified as being expressed over the others due to the 
protein inference problem, with no proteins identified from any unique peptides to 
pinpoint the most likely expressed protein candidate. Further evidence is therefore 





Figure 5.15 Known N-terminal acetylated peptide on chromosome 9 
The known N-terminal acetylated peptide “ALPNQQTVDYPSFK” was located at the start of the second 
CDS. There appeared to be no known initiation codons prior to the peptide, however there was an AG 
acceptor site at position 5,754,837 and a GT donor site at position 5,754,701. In addition, these peptides 
were shared with other similar proteins in the genome that have annotations in agreement with the N-
terminal acetylated peptide. Augustus did not predict any other protein isoforms for this gene, given the 
extrinsic evidence (exon, exon_part and intron hints). Taken together, this indicated that the inferred 
alternative TIS site/protein isoform for this gene was ambiguous and so required further evidence. The 
same was true for the corresponding peptide on chromosome 11, with similarly mapped peptides and 
prediction. 
From the 5 shared N-terminal acetylated peptides that appeared to conflict with 
the 12Xv2.1 annotation, there was no conclusive evidence, except for peptides 
“ALPNQQTVDYPSFK” and “ANAASGMAVHDDCK”, which could possibly be 
accounted for due to nearby splicing donor and acceptor sites, and peptide 
“MDTFLFTSESVNEGHPDK” which had a known alternative translation initiation 
codon at its N-terminal end. However, due to the protein inference problem and with no 
unique peptides identified to unambiguously identify the most likely protein the N-
terminal acetylated peptides are derived from, further evidence would be needed. 
Interestingly, all 5 shared peptides lacked their 5’ Methionine cap at their N-terminal 
most-end, which 1) indicates that N-terminal Methionine Excision (NME) [248] has 
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likely occurred and 2) that there may be other peptides with retained 5’ Methionine caps 
which are unable to be identified through the current proteogenomics methodology. 
Revisiting the analysis in the future, by generating further MS/MS spectral 
datasets selected only for peptides from the N-terminal end of proteins using N-
terminomics [452], could improve the coverage at the N-terminal end. Particularly in 
combination with multiple replicates and proteases to reduce the ambiguity of which 
protein the N-terminal peptide is represented from, and which could identify non-AUG 
translation initiation codons as well as a variety of non-acetylated N-terminal peptides. 
To account for peptides with a retained 5’ Methionine cap, an additional protein sample 
could be digested, followed by N-terminal peptide enrichment with an addition of 
Methionine aminopeptidase to cleave all N-terminal most Methionine residues in vitro. 
The peptides could then be mapped to their genomic locations and compared to the 
untreated sample. In addition, methods from a proteomics-only context could be applied 
to resolve the protein inference problem, and help with validating the N-terminal end of 
the known proteins, such as those outlined in Section 2.3.7, listed in Table 2.6 and 
further discussed in Section 2.3.9. 
The use of N-terminomics and how best to resolve the protein inference problem 
in proteogenomics remains an open problem. At this time only complete coverage 
through strategies such as top-down proteomics can possibly resolve the ambiguities 
from the protein inference problem to confidently identifying the N-terminal end of 
putative proteins in a proteogenomics analysis. 
5.3.14 Impact of search space 
As highlighted in Section 2.4.2 the search space can have an impact on the sensitivity of 
a proteogenomics search, which was more pronounced in this study due to the larger 
search space of the grape genome. To improve the sensitivity of identifications two 
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different searches using 2.0 Da and 3.0 Da precursor mass tolerances were used, 
however the impact of the inflated search space was still evident using the combined 
FDR strategy. A total of 2,773 out of 55,373 proteins from the 12Xv2.1 annotation were 
identified during MS/MS database searches using MS-GF+, while the total number of 
mapped proteins was 7,536. Of these, 1,117 high confidence proteins had ≥2 peptides 
with 1 unique peptide (Table 5.1). When the same search was conducted against only 
the 12Xv2.1 protein predictions, combining the raw results from the 2.0 Da and 3.0 Da 
database searches, a total of 5,795 proteins were identified. Comparisons between 
proteomics- and proteogenomics-only searches revealed a loss of 3,022 proteins out of 
5,795 or a loss of 52%, which would also infer a significant loss to novel identifications. 
This was significantly higher than the 30% loss found in Section 4.3.13 or outlined in 
previous studies [81, 324, 439], due to the larger sized genome of V. vinifera of 487.1 
Mbp, compared to Arabidopsis thaliana with a genome size of 135 Mbp or 
Bradyrhizobium diazoefficiens with a genome size of 9.1 Mbp. This trend in the loss of 
sensitivity would most likely continue to increase as the genome size increased. This 
subject is addressed later in Chapters 6 and 7, by taking a different approach to MS/MS 
database searching and applying different FDR filtering approaches to improve known 
and novel peptide identification rates and to better discriminate between true and false 
positives. 
5.4 SUMMARY 
This study highlighted a number of advantages, as well as a few caveats in the course of 
conducting proteogenomics analysis, and which has provided a good example of how to 
bring different legacy –omics datasets (e.g. genomics, proteomics and transcriptomics) 
together for the genomic annotation of Vitis vinifera (grape). The proteogenomics 
analysis identified 133 novel peptides contributing to 341 novel annotation events (103 
exclusively), consisting of 5 frame-shifts, 37 translated UTRs, 16 exon boundaries, 1 
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novel splice, 9 novel exons, 160 gene boundaries (24 exclusively), 112 reverse strands 
(10 exclusively) and 1 novel gene event in a total of 216 genes (67 exclusively) and 326 
proteins (101 exclusively). 
Among these annotations, 110 novel peptides directly led to 57 predicted proteins 
via Augustus gene prediction. Through the identification of these annotation events a 
possible over-assembly of the genome was identified, putatively resulting from the 
incorporation of non-nuclear reads into the nuclear chromosome assemblies. In 
addition, a large proportion of the CDS phase throughout the 12Xv2.1 annotation were 
recognised as incorrect, and subsequently corrected for gene prediction. The methods 
employed in this study have identified improvements as well as gaps in the 
understanding of proteogenomics approaches. Specifically, the selection of multiple 
precursor mass tolerances for low-accuracy MS/MS spectra, with an aggregation of 
results, improved coverage, and that using the combined FDR strategy to conduct 
proteogenomics significantly reduced the sensitivity, particularly as the genome size 
increased. This finding indicates a need for a proteogenomics approach with more 
refined control on the search space and FDR filtering stage of analysis. This 
requirement could be achieved by segregating and reducing the search space to only 
necessary sequences for more sensitive identification of novel and known peptides and 
to provide better discrimination between true and false positives, as well as potentially 
reducing the post-processing overhead. 
5.5 CONCLUSIONS 
The present study was able to identify a significantly larger number of proteogenomics 
annotation events than previously reported in Chapman et al [8], by using an improved 
methodology with larger and more diverse datasets. However, the loss in sensitivity due 
to a proteogenomics search continued to be a problem, resulting in a loss of 52% of 
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known proteins when using a combined FDR strategy. The inclusion of a splice graph 
derived from a large RNA-seq dataset contributed to the exclusive identification of 15 
peptides identified in multiple annotation events, however only 1 novel splicing event 
was identified, which was proven to be a false positive and was not incorporated into 
the Augustus gene predictions. As previously demonstrated in Chapter 4, clustering 
MS/MS spectra and selecting the most appropriate precursor mass tolerances proved 
effective for selecting efficient parameters for proteogenomics searches. Applying 
multiple (2.0 Da and 3.0 Da) precursor mass tolerances, and merging the results, proved 
effective at improving the identification rate of PSMs when the mass accuracy of the 
MS/MS spectra was low. 
Annotation events in this study were screened by searching the identified novel 
peptides against NR, manually looking for identifications in known proteins located in 
the same genomic coordinates. Although this approach improved specificity and 
sensitivity, combined with the event probability, it also had a negative impact on 
throughput. Different strategies are needed when identifying outliers from the applied 
event probabilities to determine effective event probability thresholds, in the absence of 
a method to determine the annotation event FDR. These could take the form of 
improving throughput by using automated processes to interrogate unique peptide 
matches found from entries in NR. Or, for example, by increasing the stringencies of the 
match, such as only considering matches of unique peptides with 100% identity and 
coverage to highly curated entries in protein repositories such as RefSeq protein, and 
possibly removing the manual component to analysis entirely by automating checks in 
GenBank entries for genomic coordinates and orthogonal evidence. In addition, 23 
accepted novel peptides could not be included into the predictions. This posed some 
questions: were there any novel peptides included which should not have been 
included? And how could peptides such as these be excluded from peptide clusters and 
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annotation events to prevent similar situations in the future? One possible solution could 
be to apply further filtering steps when selecting novel peptides for inclusion into 
peptide clusters and annotation events using additional sources of evidence. Scenarios 
of this nature should be considered in future versions of the Enosi tool. 
Another caveat of the analysis was the use of a fixed peptide linkage distance 
that resulted in some annotation events being incorrectly categorized, as was previously 
illustrated as a problem in Section 4.3.4. This highlights a need to determine the peptide 
linkage distance for each peptide cluster dynamically. For example, by determining the 
likely distribution and size of genes in the local region and using machine-learning 
approaches, as well as assigning annotation events based on other additional evidence; 
such as known peptide evidence within the same gene being annotated or genes in close 
proximity, particularly those with the same frame located within close proximity. Any 
conflicts between the novel and known peptides from overlapping ORFs, could be 
resolved using parsimony of known versus novel peptides. This approach could remove 
much of the manual interpretation and validation of the annotation events required 
throughout analysis and would also improve the accuracy when assigning annotation 
event types, as well as when applying appropriate event probability thresholds, which 
could, as a result reduce the occurrence of false positive annotation events and 
predictions. 
 In addition, the Enosi tool did not automatically cater for some annotation 
events, such as over-predicted genes. These types of annotation events could be 
identified by N-terminal acetylated peptides located within the gene region not in 
agreement with the TIS site. This is difficult to interpret, primarily due to the protein 
inference problem, however the identification of proteins in the genome containing a 
unique N-terminal acetylated peptide could be used to unambiguously confirm the 
presence of such peptides to correct the annotation, given that the unique status of the 
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N-terminal peptide was accurate. Conversely, the identification of these N-terminal 
acetylated peptides could be used to validate the start sites of already known proteins, as 
was demonstrated in this study. However, it was also found that no TIS sites in the 
known proteins could be confidently identified and so a time-consuming manual 
approach was required. An approach of this type could feasibly be automated to 
improve throughput and could be integrated into the Enosi tool, potentially by 
identifying only unique N-terminal acetylated peptides to avoid ambiguity. A further 
means to resolve the identification of N-terminal acetylated peptides could be to 
perform a proteomics-only analysis and resolve the protein inference problem using 
approaches and tools like those listed in Table 2.6. Another alternative method could be 
to enrich for N-terminal peptides employed in methods such as N-terminomics [452]. 
A problem which became apparent during the analysis was the post-processing 
of large sets of results through the combined FDR strategy, requiring the merging of all 
results into 4 separate TSV files prior to FDR filtering to allow processing within a 
practical time-frame. However this would have negatively impacted on the accuracies 
of the applied FDR threshold and calculated local FDRs for each PSM, and 
consequently the event probabilities. In future studies, ways to limit this impact could 
be applied, such as improvements to the efficiency of the algorithm for FDR filtering 
and reducing the overall MS/MS spectral dataset and database size prior to FDR 
filtering. The benefits of such an approach would lead to improved sensitivity of the 
database searches and, at the same time reduce the overhead for processing the MS/MS 
spectral datasets and databases, thus enabling the results to be processed together and 
reducing or removing the negative impact of FDR and event probability accuracy. 
This study identified a possible over assembly with the 12X genome assembly. 
Some clues indicating that this was the case was with the large number of the 
unassigned chromosome sequences (ChrUn), fragmented chromosomes and the 
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identification of a number of reference proteins, Augustus gene predictions and novel 
peptides finding significant matches to chloroplast and mitochondrial proteins in NR. 
One convincing example was with a reference protein on chromosome 7, with both the 
original reference protein and the Augustus gene prediction matching significantly to 
ribulose-1,5-bisphosphate carboxylase/oxygenase large subunit (RuBisCo large 
subunit), a highly abundant plant protein predominantly confined to the chloroplast 
genome. This prediction contained a high number of PSMs to both unique/shared novel 
and known peptides and highlighted two problems: 1) the genome was most likely over-
assembled due to the presence of contaminant non-nuclear genomic reads, which would 
have hampered proper assembly, and indicating that contaminant reads should have 
been filtered out prior to assembly (or optimally sequenced after chromosome sorting); 
and 2) the proteomics data, which unavoidably was legacy in nature should have been 
filtered by cell component and/or tissue fractionation prior to MS/MS analysis in order 
to improve the depth and breadth of coverage and also reduce contamination from non-
nuclear derived proteins which potentially contributed to false positive identifications. 
Apart from the issues posed by the possible over-assembly there were many 
revised annotations identified, including corrections to incorrect CDS phases that 
conflicted with the appropriate phase inferred from the reference protein prediction. 
This indicated a possible flaw in the method employed for the original reference 
annotation [7]. 
The proteogenomics annotation of grape should be re-visited in the future with a 
much larger MS/MS spectral dataset, preferably obtained from a higher accuracy mass 
spectrometer, such as an LTQ Orbitrap or QTOF, and with sufficient sampling depth 
and breadth of coverage, that tighter stringencies on MS/MS spectral quality thresholds 
could be afforded with little or no negative impact on overall peptide coverage. Such an 
approach was not feasible in the present study due to the relatively limited MS/MS 
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spectral dataset, which necessitated more careful filtering to prevent significant losses. 
The addition of proteomics data derived from Pinot Noir instead of Cabernet Sauvignon 
would keep the analysis consistent between the proteome and genome. Further RNA-
seq data could also be utilised, spanning other cultivars, for sequence variant 
identification, as previously undertaken [474]. Studies of this type would prove even 
more worthwhile once the question of genomic coverage and suspected over-assembly 
have been addressed, to reduce any spurious identifications. In the meantime, the 
assembly and annotation would benefit greatly from a review and assessment using 
tools such as BUSCO [588] to identify and resolve any caveats moving forward with 
improving the assembly and annotation. 
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6 HUMAN PROTEOGENOMICS 
6.1 INTRODUCTION 
The human genome has been the focus of intense study since it was sequenced in 2001 
[35], followed by the final accepted complete draft published in 2004 [49]. In more 
recent years several large scale studies have revealed more about the human genome, 
with one of these studies being the ENCyclopedia Of DNA Elements (ENCODE) 
project, which redefined genes and their transcription [589], leading to additional 
studies to define the coding, non-coding transcripts, transcriptional regulatory regions 
and more [30, 590]. A sub-project of ENCODE, called GENCODE was tasked with 
manually annotating the genome to identify the protein-coding transcripts. However, 
these transcripts were identified from indirect sources such as ESTs, and protein 
sequences available in repositories such as UniProtKB/SwissProt, which, as outlined in 
Section 2.4, only consists of 5% direct protein sequences. In addition, more than 50% of 
the transcripts that were identified have no protein-coding potential [590], and many 
could not be identified as non-coding RNAs either, leaving their interpretation 
ambiguous. 
 A recent proteogenomics study which sheds some light on the hidden protein-
coding regions of the human genome produced proteomics data from a number of 
different human cell lines, including the ENCODE Tier 1 cell lines K562 and GM12878 
[11], and later followed-up with a focus on GM12878, looking at the maternal and 
paternal genomic sequences from the diploid genome NA12878 [449], with both studies 
using the proteogenomics tool Peppy [591]. 
6.1.1 Outline of this study 
The present study improves upon that of previous work [11, 449], increasing sensitivity 
and identifying previously unidentified refinements to the current annotations, and 
highlights that there is still much room for improvement to highly curated data sets like 
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the human genome. The present study utilizes the MS/MS spectra generated from the 
study in [11], from cell line GM12878, the human genome sequence Hg19 (GRCh37 
patch 13), GENCODE v19 reference annotation and the ENCODE spliced alignment 
results for GM12878, to generate a splice graph database. The latest proteogenomics 
tool Enosi [82] was used to perform the proteogenomics analysis. 
As outlined in Section 2.4.2 the search space during a proteogenomics search can 
be a problem, particularly with larger genomes, and as demonstrated in Chapter 5, even 
with a 487.1 Mbp sized genome such as with Vitis vinifera there can be a loss of up to 
52% when looking at the identified known proteins. In the present study with a 3.3 Gbp 
human genome the loss would be significantly more pronounced. This issue is 
addressed using a two-pass search approach, combined with an improved two-stage 
false discovery rate (FDR) strategy over the more conservative strategy used in [474]. 
This enhanced methodology increases the sensitivity of the search, by optimising the 
search space and applying FDR filtering to discrete known and novel search spaces 
separately to improve the separation between true and false positives. 
6.2 MATERIALS AND METHODS 
6.2.1 Proteomics and genomics datasets 
The human genome assembly (Hg19 (GRCh37 patch 13)) and GENCODE v19 human 
genome annotation, which included the protein predictions and GFF file, were obtained 
from GENCODE, downloaded from the web site 
(http://www.GENCODEgenes.org/releases/19.html) (Appendix File 6.1). 
The MS/MS spectra used in the previous studies [11, 449] were generated from 
ENCODE tier 1 cell line GM12878, which is a lymphoblastoid cell line immortalized 
using Epstein Barr Virus (EBV). Proteins from the GM12878 cell line went through a 
series of processes before MS/MS analysis. The proteins first went through subcellular 
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fractionation, GELFREE fractionation [592], filter-aided sample preparation (FASP) 
[593] and finally microwave-assisted tryptic digestion [594] prior to analysis on an LTQ 
Orbitrap Velos mass spectrometer (Thermo Scientific). 
A total of 1,054,278 MS/MS spectra from cell line GM12878 were downloaded 
from The Giddings Lab at Boise State University web site 
(http://giddingslab.org/data/encode/proteome-commons), which in turn were generated 
from different cell component fractions, as outlined in [11]. The cell component 
fractions included cytosol, membrane, nuclear, mitochondria, and a whole cell lysate. 
The cytosol fraction was of poor quality as determined in [11], and was removed from 
that study. However, in the present study all cell component fractions were pooled, 
including cytosol, clustered and quality filtered to improve the overall quality of all 
MS/MS spectra. The benefit of using MS/MS spectra pooled from multiple cell 
component fractions is that it allows for the detection of both low and high abundant 
proteins, improves on the proteome coverage and could potentially increase the novel 
annotation event identification rate. 
As outlined in Section 3.1.1, a source of contaminants was appended to the 
protein sequence predictions from GENCODE v19 before being used in the MS/MS 
database search to identify any contamination. 
6.2.2 RNA-seq datasets 
A source of RNA-seq data to generate a splice graph for proteogenomics analysis was 
used. Instead of obtaining reads from the Sequence Read Archive (SRA) and running 
alignments, alignment results in the form of BAM files from the ENCODE project itself 
were employed. BAM files in the ENCODE project were generated using the spliced 
alignment tool, STAR [127]. The BAM files were obtained from the ENCODE project, 
through NCBI GEO accession GSE30567 and downloaded directly from the University 
 
 201 
of California Santa Cruz (UCSC) Genome Bioinformatics web site 
(http://genome.ucsc.edu/cgi-
bin/hgFileUi?db=hg19&g=wGENCODECshlLongRnaSeq). 
6.2.3 MS/MS database searching  
The MS/MS database search was performed by MS-GF+, as outlined in Section 3.3. In 
this case study trypsin was used as the protease, the instrument was set to low-res LTQ 
(Ion Trap), and the precursor mass tolerance used was 9.0 ppm, as determined from a 
preliminary MS/MS spectral dataset assessment, detailed below in Section 6.2.4. 
6.2.4 Dataset processing 
The GENCODE v19 protein sequence FASTA file and GFF file required formatting 
into a compatible format for proteogenomics analysis, as outlined in Section 3.4.1. 
The total of 1,054,278 MS/MS spectra obtained for this study were first assessed 
by searching against the known proteome, examining the effects of using MS-Cluster to 
cluster the MS/MS spectra, PepNovo to quality filter the MS/MS spectra, and with an 
assessment of optimal precursor mass tolerances, as outlined in Section 3.4.6. Since all 
the MS/MS spectra were of high-accuracy, derived from an LTQ Orbitrap Velos mass 
spectrometer, this factor needed to be reflected in the search parameters. Therefore, an 
assessment of the optimal precursor mass tolerance was needed using a range of 
tolerances, 0.5, 1.0, up to 10.0 in 1.0 ppm increments, and then up to 100.0 ppm in 5.0 
ppm increments (Appendix File 6.2). 
All BAM files from the ENCODE project for cell line GM12878 were merged 
and used to generate a splice graph FASTA database. A six-frame translation of the 
genome was also generated. The steps involved in the generation of both splice graph 
and six-frame translation are outlined in Sections 3.4.4 and 3.4.5, respectively. 
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6.2.5 Proteogenomics pipeline 
The proteogenomics pipeline was used as outlined in Section 3.5, with an included two-
pass search approach, combined with an improved two-stage FDR strategy, which 
reduced the database size and applied discrete 1% peptide-spectrum match (PSM) FDRs 
to the separate known and novel search spaces. This greatly improved the 
discrimination between true and false positives and thus improved on the number of 
known and novel PSMs identified. After a preliminary assessment of the MS/MS 
spectra, as outlined previously in Section 6.2.4, the choice of clustering the MS/MS 
spectra and quality filtering to a PepNovo score threshold of 0.01 was decided, resulting 
in 613,432 clustered MS/MS spectra, and it was determined that the optimal precursor 
mass tolerance was 9.0 ppm. 
The total 613,432 MS/MS spectra were then split into separate MGF files of 
20,000 MS/MS spectra each, using an in-house MGF splitting tool, before running each 
MS/MS spectral file through MS-GF+ on a cluster against the known proteome, six-
frame translation and splice graph, using the two-pass search approach and then the 
improved two-stage FDR strategy as outlined in Section 3.5.1 and 3.5.2, respectively. 
The improved two-stage FDR strategy was applied in this study, as outlined in 
Section 3.5.2 and illustrated in Figure 3.1, to see how it could improve on the 
identification rate in comparison to the more conservative strategy in [474] and the 
more traditional combined FDR strategy. All three methods were compared in this 
study. For the conservative two-stage FDR strategy all MS/MS spectra identified as 
matching the known proteome and protein contaminants were removed. The remaining 
MS/MS spectra, now considered ‘novel’, were then searched against the 
proteogenomics search space, after which the now novel PSMs had a 1% PSM FDR 
applied. With the combined FDR strategy all MS/MS spectra identifying PSMs in both 
the known proteome and proteogenomics search space were used together and all 
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results were merged across 2 TSV files due to the processing limits on large result files 
(See Section 3.5), before a 1% PSM FDR was applied to both resulting TSV files 
(Appendix File 6.3). 
 The choice of parameters for the proteogenomics pipeline, as outlined in Section 
3.5, included a minimum event probability for novel genes, distal events and proximal 
events of 90%, a peptide linkage distance of 150,000 bp representing ≥95% of gene 
sizes in GENCODE v19, a minimum cluster size of 1, and a minimum of 1 unique 
peptide per cluster. 
 The annotation events were further screened, as mentioned in Section 3.5, 
however a number of differences were incorporated.  In Chapter 5, many of the 
accepted annotation events were heavily biased on sequence homology results, and 
manual visual inspection possibly led to higher false positive rates due to human error. 
In the present study novel genes and distal events were first screened with ≥2 unique 
peptides and/or ≥99.9% event probability and proximal events were filtered with an 
event probability of ≥99.8%. Any outliers, such as those derived from single and unique 
peptide annotation events were identified through BLASTP searches against the human 
curated protein repository NCBI RefSeq protein with support from known mapped 
peptides to the genes annotated, particularly for proximal events where the known 
peptides mapped to the same ORF as the novel peptide and spectral counts were also 
often an indication of a likely real annotation event that showed correlation with the 
event probability. In this study, to improve throughput of screening the outlier single 
unique peptide annotation events, the results from sequence homology searches to 
human proteins in RefSeq protein entailed acceptance of matches with 100% query 
coverage and a maximum of 2 mismatches with an E-value of at least 1E-03. 
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The investigation of a number of annotation events in Section 6.3 uses BLASTP 
searches against NCBI NR to broaden the range of evidence supporting the annotation 
during the discussion. Venny (http://bioinfogp.cnb.csic.es/tools/venny/) was used within 
this chapter to illustrate Venn diagrams of identified peptides across different methods. 
6.2.6 Improving gene predictions 
Once the novel annotations were filtered and reviewed the gene prediction tool 
Augustus [102] was used to improve the overall gene models of GENCODE v19. No 
training of Augustus was carried out in the present study, with only the available human 
gene model used from Augustus version 3.02. The novel annotations and GENCODE 
v19 annotations were used as hints for Augustus gene prediction, along with repeat 
region hints generated from the genome using RepeatMasker [576]. The Augustus gene 
prediction tool was then run using parameters as outlined in Section 3.5.3, except that 
only the novel peptides, GENCODE v19 gene models and repeats were used as hints. 
6.3 RESULTS AND DISCUSSION 
The present study outlined improvements to the GENCODE v19 annotation of Homo 
sapiens, demonstrating the benefits that proteogenomics presents by integrating the 
different –omics platforms used from the ENCODE project to contribute to human 
genome annotation and identifying 617 (126 exclusively) novel annotation events. The 
study also improved on the proteogenomics findings from the ENCODE project, by 
using a two-pass search approach with improved two-stage FDR strategy, and which 
was directly compared to previous methods: the combined FDR and ‘conservative’ two-
stage FDR strategy. The improved methodology is particularly useful for larger 
genomes that are accompanied by a reduced sensitivity and a higher false positive rate 
due to their larger proteogenomics search space. 
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6.3.1 Evaluation of pre-processing MS/MS spectra 
Prior to running the proteogenomics pipeline, the MS/MS spectra were evaluated for the 
optimal pre-processing strategy and precursor mass tolerance (Appendix File 6.2). All 
1,054,278 MS/MS spectra were clustered by a factor of 1.54. It was found that 
clustering reduced the peptide FDR after an initial 1% PSM FDR filtering from 4.5% 
peptide FDR to 2.4% peptide FDR and reduced the protein FDR from 25.7% to 13.9% 
(Appendix Figure 6.1A-C). As can be seen in Appendix Figure 6.1A, the number of 
total MS/MS spectra lost after quality filtering can range from 3.2% at the lowest end to 
67.8% at the most stringent cut-off. Applying scores between 0.05 – 0.1, recommended 
by PepNovo (detailed in the Help File bundled with the tool), resulted in around 32.5% 
to 49.6% of the MS/MS spectra being lost, however at a score of 0.01 only 10.3% of 
MS/MS spectra were lost while maintaining a peptide FDR of ~2%, as well as retaining 
many PSMs and unique peptides that were lost when using a higher score than 0.01 
(Appendix Figure 6.1D-E). With higher losses in MS/MS spectra there was a reduced 
number of PSMs and unique peptides reported, and there was only negligible 
improvement in peptide FDR. This observation indicated that the dataset was not 
improving but was losing valuable MS/MS spectra, which could be used to identify 
novel proteogenomics annotations. 
 The results indicated that a clustered MS/MS spectral dataset with a PepNovo 
quality filtering score cut-off of 0.01 was most suitable for further proteogenomics 
analysis, as it resulted in the best balance between keeping the maximum number of 
PSMs and filtering out poor quality MS/MS spectra. 
6.3.2 MS/MS database search parameter optimization 
As outlined in Section 3.4.6 high-accuracy MS/MS spectra are well suited to precursor 
mass tolerance optimization since tighter tolerances often improve the sensitivity of 
PSM identification. This observation also held true for the present study as high-
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accuracy MS/MS spectra were obtained, generated from an LTQ Orbitrap mass 
spectrometer. 
 A clustered set of MS/MS spectra, quality filtered to a PepNovo score of 0.01, 
was used to assess the precursor mass tolerances over a range, as outlined in Section 
6.2.4 (Appendix File 6.2). It was determined from this analysis that 9.0 ppm was the 
optimal precursor mass tolerance to use (Appendix Figure 6.2). After ≤1% PSM FDR 
filtering the maximum number of PSMs obtainable was 97,930 at 9.0 ppm, while the 
peptide FDR was 2.13%. 
6.3.3 Proteogenomics pipeline 
A proteogenomics pipeline was customised using Enosi with MS-GF+, as outlined in 
Section 3.5 and illustrated in Figure 3.1. The pipeline included a two-pass search 
approach with improved two-stage FDR strategy by applying FDR filtering to the 
known and novel search spaces separately. This step reduced the search space and 
improved sensitivity and discrimination between true and false positives. 
The two-pass search approach with improved two-stage FDR strategy reduced 
the overall database size, and as a result the TSV file sizes were significantly reduced in 
size. In addition, the TSV files were split between the known identifications and the 
novel identifications, with a 1% PSM FDR applied to each. This change improved the 
accuracy of the FDR, since the results from the known search space and novel search 
space were aggregated in a separate TSV file for known and novel results as they have 
widely different false positive rates. 
The choice of key variables for the proteogenomics pipeline were chosen as they 
have been in preceding chapters. The peptide linkage distance was chosen based on the 
size of ≥95% of genes in the current genome annotation, which was found to be 150,000 
bp. As previously discussed in Section 5.3.6, the use of a fixed peptide linkage distance 
 
 207 
across the entire genome brings with it the caveat that it inflates the number of gene 
boundary and reverse strand events, thus requiring manual validation and negatively 
impacting throughput, and which could lead to ambiguity with overlapping annotation 
event types. This ambiguity could also in turn lead to an increased false positive rate 
when applying event probability thresholds across the different annotation event types. 
This possibility becomes more of a problem in human, as the peptide linkage distance 
used is the largest used so far within this thesis. Therefore, how the peptide linkage 
distance is defined in Enosi needs to be addressed in future versions of the tool. Until a 
solution is reached manual screening and interpretation of the annotation events and 
also by exclusively assigning peptide clusters to annotation events to negate the impact 
of large peptide linkage distances is necessary to come to a closer value for the true 
number of different annotation event types, as well as the number of genes and proteins 
with inferred annotations. 
 Contamination was not an issue in this study, compared to Chapter 5 and the 
grape genome, where there may have been over-assembly of the genome, with 
chloroplast and mitochondrial reads inadvertently incorporated into the assembly. In 
this study there were no such findings, as would be expected from the human genome, 
which has benefitted from over a decade of sequencing and rigorous manual curation on 
an international level. Additionally, the mitochondrial genome was available in 
GENCODE v19, allowing for a known proteome target for any mitochondrial peptides 
that might have inadvertently been identified as novel within nuclear chromosomes by 
chance in its absence. Also, with the peptide mass spectrometry data being of higher 
accuracy, more specific matches with less error was possible. Additionally, the data 
were generated with proteogenomics in mind and cellular component fractionation 
carried out, thus improving coverage and allowing for the identification of some 
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proteins, which could have otherwise been masked by more abundant proteins from 
other cellular compartments. 
 Further screening of novel events was performed by accepting annotation events 
with high parsimony of unique peptides and/or more stringent event probabilities, with 
any outliers of single unique peptides identified by searching the unique peptides 
against well-curated human RefSeq protein database. This step provided a streamlined, 
faster and more confident approach, compared to screening each annotation event by 
manually checking against a combination of NR, RefSeq protein and SwissProt 
databases that may have resulted in human error. Although the matches were not 
rigorously validated against orthogonal evidence and genomic locations in GenBank, 
the majority of identifications via this method were also found with higher event 
probabilities and parsimony, including those annotation events already accepted at 
higher stringencies. To highlight that the applied method was a valid approach, several 
random annotation events were confirmed manually by checking the GenBank record to 
confirm that the genomic coordinates were often the same, in agreement with the 
proteogenomics analysis (Appendix File 6.3). This proved a viable approach in the 
present study to improve throughput and apply some control on FDR, although there 
was no way to determine how effective it was at the annotation event level as the tools 
to determine the annotation event FDR were not available. However, a more rigorous 
approach could be undertaken by automatically downloading and then screening the 
GenBank records after each BLASTP search to check for orthogonal evidence and 
genomic coordinates to back up the claims from each of the single unique peptide 
annotation events. The final minimum event probabilities after annotation event filtering 




Similar but more powerful methods that could improve the rate of annotation 
event identification and validation could be achieved by spectral library searching to 
validate the identified novel MS/MS spectra, by searching against an already curated 
spectral library using tools such as Tremolo [397]. Which would have much more 
sensitive and specific matches than performing BLASTP searches, or as was previously 
suggested using spectral archives [398]. The spectral archives approach proposes a 
public repository of clustered MS/MS spectra that gradually improves as the public add 
further MS/MS spectra. This resource could then be used to validate annotation events, 
as well as identify truly novel annotation events when an annotation event finds no 
matching or weakly matching MS/MS spectra. These approaches use the MS/MS 
spectra to identify spectrum-spectrum matches (SSMs), which have much higher 
specificity compared to PSMs used in conventional database searches against 
sequences, which often lead to ambiguous identifications depending on the contents of 
the sequence database being searched (e.g. misidentifying variant sequences as 
containing post-translational modifications (PTMs)). 
 As was identified in previous chapters, a source of false positives can be the 
actual MS/MS spectra used in the analysis. For this analysis MS/MS spectra were 
derived from tier 1 cell line GM12878 that was immortalized using EBV. Genetic 
differences between GM12878 and GENCODE v19 may lead to numerous variant 
peptides interpreted from the MS/MS spectra which could further be misinterpreted as 
containing PTMs during the proteogenomics analysis, or lead to the identification of 
novel peptides in locations where none exist. A viable way to account for these variant 
peptide sequences, which may inadvertently lead to false positive identifications, is to 
perform variant call analysis using the same ENCODE alignment results, as previously 
demonstrated [474], to generate variant peptides that could contribute to the splice 
graph. This step could also produce some interesting insights into the genetic changes 
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occurring in GM12878 in becoming an immortalized cell line. However, the approach 
only became known late in the study and was not pursued, but could be re-visited in 
future studies. 
6.3.4 Proteogenomics analysis 
Using the two-pass search approach with improved two-stage FDR strategy, a total of 
593 novel peptides were identified with an event probability of ≥90%, at least 1 unique 
peptide and a minimum cluster size of 1. This is in contrast to the results obtained using 
the combined FDR and conservative two-stage FDR strategies, which resulted in 240 
and 8 novel peptides being identified, respectively. After filtering the novel annotation 
events and applying the same thresholds across all methods, a total of 77, 46 and 5 
novel peptides remained for the two-pass search approach with improved two-stage 
FDR, combined FDR and conservative two-stage FDR strategies, respectively (Figure 
6.1, Table 6.1 and Appendix Files 6.3 and 6.4). Compared to the combined FDR and the 
conservative two-stage FDR strategies, the two-pass search approach with improved 
two-stage FDR strategy was able to identify 35 more novel peptides, while the 
combined FDR strategy identified 4 novel peptides that neither of the other strategies 
were able to identify. Due to the lower FDR accuracy of identifications with the 
combined FDR strategy, these 4 novel peptides may have been false positives, 
incorrectly identified from ‘known’ MS/MS spectra or fallen just below the applied 
thresholds within the other two strategies. By comparison, the conservative two-stage 
FDR strategy only identified 5 novel peptides all of which were identified by both of 
the other strategies. These results indicate a large improvement in the rate of novel 
peptide identifications by restricting to separate known and novel search spaces using 
the two-pass search approach with improved two-stage FDR strategy. 
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Figure 6.1 Comparison of identified novel peptides between three methods 
A comparison between the numbers of identified novel peptides ≥90% event probability, 1 unique peptide 
per cluster and a minimum cluster size of 1, with (A) an unfiltered set with no screening of annotation 
events, and (B) after screening of annotation events using the same thresholds for all methods. 
A side-benefit of reducing the search space and applying FDR filtering on the 
known and novel search spaces separately was a reduced final merged TSV file size for 
each of the search spaces. Previously, in the combined FDR and conservative two-stage 
FDR strategy the final merged TSV files were much larger when using a large MS/MS 
spectral dataset and genome, requiring that they be split into two to four files to be able 
to process the files in a practical time-frame, which resulted in inaccurate PSM and 
local FDRs due to PSMs being distributed across the files. The two-pass search 
approach with improved two-stage FDR strategy reduced the size of the TSV files 
resulting in more efficient and faster processing time with more accurate FDR 
calculations. As pointed out in Section 5.4, a way to resolve this problem was needed. 
This method did resolve the problem with the added benefit of increasing the PSM 
identification rate for both known and novel PSMs. However, the problem may still 
arise if the number of MS/MS spectra and the genome is many times larger than used in 
this study. 
As was applied in the previous Chapter 5, Section 5.3.4, the exclusive number of 
annotation events for each peptide cluster, and their associated genes and proteins, were 
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also determined to account for the inflated number of gene boundary and reverse strand 
events, as shown in parenthesis in Table 6.1. This was more problematic in this study 
due to the much larger peptide linkage distance of 150,000 bp that further inflated the 
number of annotation events identified. 
The 77 novel peptides identified from the two-pass search approach with 
improved two-stage FDR strategy led to 617 annotation events (126 exclusively) 
amongst 147 genes (29 exclusively) and 609 proteins (116 exclusively) from the 
GENCODE v19 annotation. The novel annotations along with GENCODE v19 
reference annotations were then used as hints for Augustus gene prediction. A total of 
29,266 genes and 32,781 proteins (≥66 aa in length) were predicted (Appendix File 6.5), 
and of these, 52 predicted proteins had 66 novel peptides incorporated (Table 6.1), of 
which 48 novel peptides were unique and identified in 37 of the 52 predicted proteins 
(Appendix File 6.6). The number of protein-coding genes predicted by Augustus was 
much higher than the original reference GENCODE v19 predictions (Table 6.1). In 
addition to the new predictions previously not identified, the high number of predictions 
could also be attributed to two factors, as was outlined in Section 3.5.3. 
As previously discussed in Section 5.3.4 the reason why many novel peptides, in 
this case only 11, were not included in the predictions and by extension why peptides 
possibly included should not have been, needs to be addressed in future versions of the 
Enosi tool, to better screen novel peptides before inclusion into peptide clusters and 
annotation events. 
 By comparison with the combined FDR and conservative two-stage FDR 
strategies, the two-pass search approach with improved two-stage FDR strategy directly 
improved the quality of peptide clusters by including more novel peptides, and 
improved the accuracy of the event probabilities, allowing some annotation events to 
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now pass the applied event probability thresholds and identify more annotation events 
as a result. For example, compared to the combined FDR strategy, the number of novel 
gene annotations with ≥2 unique peptides increased from 4 to 5, and compared to the 
conservative two-stage FDR strategy, improved from 0 to 5 novel genes. Similarly, the 
number of proximal events, such as exon boundaries, went from 3 (1 peptide cluster) 
with the combined FDR strategy, 0 with the conservative two-stage FDR strategy to 27 
(7 peptide clusters) using the two-pass search approach with improved two-stage FDR 
strategy, when applying the same stringent thresholds across all methods. 
However, it is worth keeping in mind, the conservative two-stage FDR strategy, 
although limited in sensitivity, is highly specific. It was warranted in the study in which 
it was initially demonstrated, i.e. examining very large datasets of numerous variant 
peptides from cancer, in which the ‘known’ MS/MS spectra likely containing PTMs 
could have misidentified novel variants in the splice graph. 
To further enhance the improved two-stage FDR strategy to provide 
discrimination between novel and known identifications, the spectral E-value could be 
applied. This step could be achieved by comparing the spectral E-values between 
matches to the known sequences and novel peptide sequences, and accepting only the 
MS/MS spectra with better spectral interpretation while discarding matches with 
ambiguous equal spectral E-values, for example, between known protein sequences 
with PTMs versus the variant peptides in the splice graph. Such an approach would 
provide another level of discrimination without compromising on sensitivity, and it 
would not be influenced by the database as the spectral E-value is determined 
independent of the database. 
 The number of novel peptides incorporated into the predictions was reasonably 
high at 66 novel peptides (86%), which was relatively higher, by 3%, than the 
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proportion included in the previous study reported in Section 5.3.4. The higher number 
may be attributed to the differences in applied stringencies and the method of filtering 
single novel unique peptide annotation events between the two studies, as well as 
differences between the number and accuracy of the MS/MS spectra and genomes used 
within each study. Of the 66 novel peptides incorporated into the predictions, 8 were 
exclusively derived from the splice graph, while 2 were identified in both the six-frame 
translation and splice graph, with the remaining 56 identified exclusively in the six-
frame translation. 
As demonstrated previously in Section 5.3.4, BLASTP analysis was performed 
to show how the predictions changed from reference predictions. The analysis was 
performed by searching the 32,781 Augustus predicted proteins (Table 6.1) against the 
GENCODE v19 proteins, taking the top match with E-values ≤1E-10. Any sequences 
that did not match were considered novel predictions, sequences that had a query 
coverage ≥95% with at least 1 mismatch were considered to be the same prediction as 
the reference protein, and the remaining matches were considered to be modified 
predictions, either due to Augustus predicting slightly different models or modified as a 
direct result of the supporting evidence. From this analysis there were 4,620 non-
paralogous novel protein predictions, 12,116 modified predictions and 16,045 
predictions considered to be essentially the same as the reference. 
Searching all 52 protein predictions that had the novel peptide evidence 
incorporated, against the GENCODE v19 proteins, taking the top match with E-value 
≤1E-10, identified 41 protein predictions likely to be modified predictions, leaving 11 
protein predictions, that found no match and were considered as non-paralogous novel 
protein predictions (Table 6.1). 
Based on the annotation events incorporated into the Augustus gene predictions, 
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the minimum event probabilities which led to a new Augustus gene prediction were: 
novel gene event 99.986%, gene boundary, translated UTR, and exon boundary 
98.167%, reverse strand event 95.615%, novel exon 98.236% and frame-shift 99.799%. 
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Table 6.1 Summary of human proteogenomics annotations 
The results of the proteogenomics analysis of GENCODE v19 showing comparisons between the (1) 
combined FDR, (2) conservative two-stage FDR and (3) the two-pass search approach with improved 











Total GENCODE v19 genes 57,820 57,820 57,820 
Total ‘known’ protein-coding genes 20,738 20,738 20,738 
Total ‘known’ proteins 95,309 95,309 95,309 
Raw MS/MS search ‘known’ protein matches ≤1% PSM FDR 6,618 6,607 3,715 
Proteogenomics mapping: Total 'known' proteins ≤1% PSM 
FDR 
27,839 27,796 20,793 
Proteogenomics mapping: Total ‘known’ proteins ≤1% PSM 
FDR (≥2 peptides with 1 unique) 
1,047 1,049 769 
 
Total identified 'novel' peptides ≤1% PSM FDR 667 28 270 
Raw MS/MS search ‘known’ peptides ≤1% PSM FDR 38,191 38,151 21,263 
Proteogenomics mapping: Total identified 'known' peptides 
≤1% PSM FDR 
38,028 37,987 21,170 
Proteogenomics mapping: Total identified 'known' peptides 
≤1% PSM FDR (≥2 peptides with 1 unique) 
9,507 9,512 5,191 
 
Frame-shifts 7 0 0 
Translated UTRs 4 0 3 
Exon boundaries 27 0 3 
Novel splices 0 0 0 
Novel exons 23 0 24 
Gene boundaries 289 (10) 19 (19) 130 (0) 
Reverse strands 262 (50) 9 (9) 77 (8) 
Novel genes 5 0 4 
 
Total annotation events 617 (126) 28 (13) 241(42) 
Total genes affected 147 (29) 8 (3) 62 (11) 
Total proteins affected 609 (116) 28 (13) 240 (41) 
Total novel peptides in affected genes/proteins 77 5 46 
 
Total Augustus protein-coding gene predictions 29,266 NA NA 
Total Augustus protein predictions 32,781 NA NA 
Total Augustus gene predictions with incorporated novel 
peptides 
49 NA NA 
Total Augustus protein predictions with incorporated novel 
peptides 
52 NA NA 
Total novel peptides incorporated into Augustus protein 
predictions 
66 NA NA 
Improved protein predictions with incorporated novel 
peptides 
41 NA NA 
Novel non-paralogous protein predictions with incorporated 
novel peptides 
11 NA NA 
NA: Not available 
Note: Numbers in parenthesis represent the exclusive numbers. The inflationary effect of a large peptide 
linkage distance on gene boundaries and reverse strands was removed by assigning a peptide cluster as 




In the original proteogenomics study from the ENCODE project [11] a total of 
23,085 peptides were identified in both the known and novel search space. In the 
present study 38,028 known peptides and 77 novel peptides were identified, a total of 
38,105 peptides, which was 15,020 more peptides than the ENCODE study was able to 
identify. Of the 77 novel peptides identified, only 18 were also identified in the 
ENCODE study. However, the ENCODE study looked at Hg19 GRCh37 and 
GENCODE v7, while the present study examined Hg19 GRCh37 patch 13 and 
GENCODE v19. While the GENCODE version would unlikely affect the total known 
and novel peptides identified, slight differences between the patch versions of genome 
assembly may have resulted in slightly different numbers of identified peptides, but they 
would unlikely be as striking as 15,020 peptides. These further identifications were 
more likely to be due to the differences between the combined FDR strategy, which the 
ENCODE study used, and two-pass search approach with improved two-stage FDR 
strategy implemented in the present study. This conclusion was drawn, based on the 
observed similarities between the 21,533 identified peptides (Table 6.1) using the 
combined FDR strategy in this study, and the 23,085 peptides identified in the 
ENCODE project. 
6.3.5 Novel gene annotation 
A total of 5 novel genes (Table 6.1) were identified, all on unassigned chromosome 
fragments. An example of one of these novel genes was on unassigned chromosome 
fragment GL000251.1, spanning positions 2,836,635 to 2,837,405, with an event 
probability of 99.999%, consisting of 3 unique peptides with 10 PSMs assigned. In 
addition, Augustus gene predictions were carried out incorporating the novel peptides, 
predicting two new gene models, gene g28537 spanning positions 2,761,309 to 
2,836,886, and gene g28539 spanning positions 2,837,145 to 2,837,411 (Figure 6.2, and 
with 10 supporting annotated MS/MS spectra in Appendix Figure 6.3). 
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Performing a BLASTP search against human in NR revealed novel peptide 
“YFDTAMSR” matched a MHC class I antigen (AAB48498.1 with E-value = 0.045), 
novel peptide “APWIEQEGPEYWDRNTQIFK” matched MHC class I antigen 
(AHA90574.1 with E-value = 7E-17), and novel peptide “YLENGKDTLER” matched 
another MHC class antigen (AGZ87642.1 with E-value = 1E-04), all with 100% query 
coverage and identity. The Augustus gene prediction g28537 matched human leucocyte 
antigen B (CAA10522.1 with E-value = 6E-58), with 15% query coverage and 100% 
identity, also identified as a MHC class I antigen in GenBank, and gene g28539 
matched unnamed protein product (BAG64567.1 with E-value = 9E-60), with 100% 
query coverage and identity, also identified as a MHC class I antigen in GenBank. 
 Novel peptide “YLENGKDTLER” was incorporated into prediction g28537, 
while novel peptides “APWIEQEGPEYWDRNTQIFK” and “YFDTAMSR” were 
incorporated into prediction g28539, with both predictions matching two distinctively 
different MHC class I proteins in NR. However, prediction g28537 appeared to be over-
predicted, with only the first 85 aa (15% query coverage) of the prediction matching 
human leucocyte antigen B (CAA10522.1). The two 5’-most exons and CDS in the 
g28537 prediction, which were not supported by the single novel peptide, found no 
alignment with the human leucocyte antigen B protein, indicating that these two exons 
may be incorrectly predicted. In contrast, gene g28539, which had two novel peptides 
incorporated, found a good alignment to unnamed protein product (BAG64567.1), 
which was also identified as a MHC class I antigen. Therefore, both predictions were 
probably two distinct proteins. Further evidence, beyond that of the 3 novel peptides is 
needed to further refine this prediction. 
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Figure 6.2 Novel gene annotation 
A novel gene annotation event is located on chromosome fragment GL000251.1, leading to two new gene 
predictions on the reverse strand. One novel peptide was incorporated into the large spliced Augustus 
predicted gene g28537 within the genes first exon/CDS, while the two other novel peptides were 
incorporated into the smaller neighbouring Augustus predicted gene g28539. Repeat regions span the 
length of the region, except where the novel peptides were located. 
6.3.6 Gene boundary and novel exon annotations 
There were 289 (10 exclusive) gene boundary and 23 novel exon annotation events 
identified (Table 6.1). An example of a gene boundary and two novel exon events were 
on chromosome 2, spanning positions 69,693,124 to 69,693,567 for the gene boundary 
event and spanning positions 69,693,124 to 69,693,171 and spanning positions 
69,693,190 to 69,693,222 for the two novel exon events, respectively. The gene 
boundary event was identified for genes ENSG00000115977.14, ENSG00000169599.8 
and ENSG00000198380.8, covering protein-coding transcripts ENST00000357308.4, 
ENST00000361060.5, ENST00000410022.2, ENST00000474230.1, 
ENST00000303698.3, ENST00000394305.1, ENST00000462320.1, 
ENST00000450796.2, ENST00000484177.1, ENST00000419370.1, 
ENST00000438184.2, ENST00000409085.4 and ENST00000406297.3, with an event 
probability of 99.999% and 3 PSMs identifying 3 novel and unique peptides. The two 
novel exon events were identified for gene ENSG00000115977.14, with transcript 
ENST00000409068.1, with an event probability of 99.80%, and 1 PSM identifying 1 
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novel and unique peptide for each of the two annotation events. Each of the three novel 
peptides from the gene boundary event was also identified as a novel exon event. Novel 
peptide “TQNNLESDYLAR” spanning positions 69,693,532 to 69,693,567, fell below 
the event probability threshold of 99.80% for proximal events, with an event probability 
of 98.98%, and was therefore removed from further analysis. However, when grouped 
together in a larger peptide cluster as with the gene boundary event it was included, and 
contributed to the higher event probability of the gene boundary event. Interestingly, the 
novel peptides also overlapped the long non-coding RNA (lncRNA) gene 
ENSG00000188971.4. 
Since gene ENSG00000115977.14 was in much closer proximity to the peptide 
cluster, which also annotated protein-coding transcript ENST00000409068.1 with a 
novel exon, it was the best candidate for an annotation event amongst the other genes, 
which were only included due to the large peptide linkage distance. In addition, there 
were known mapped peptides supporting this gene for these annotations: four shared 
known mapped peptides to protein-coding transcripts ENST00000406297.3 and 
ENST00000409085.4, and three shared known mapped peptides to protein-coding 
transcript ENST00000409068.1. Therefore, the three novel peptides were more likely to 
belong to this gene, and may extend the boundaries of transcripts ENST00000406297.3 
and/or ENST00000409085.4, with transcript ENST00000409068.1 being exclusive for 
the identified novel exons. Augustus gene predictions were carried out incorporating the 
novel peptides and reference annotations, predicting a gene model which was an 
extended version of the original reference gene ENSG00000115977.14, protein-coding 
transcript ENST00000409085.4, incorporating the novel peptides (Figure 6.3, and with 
3 supporting annotated MS/MS spectra in Appendix Figure 6.4). 
Performing a BLASTP search against human in NR, revealed that novel peptide 
“SSMAPSQPEESDVFLR” matched unnamed protein product (BAC86877.1 with E-
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value = 2E-09) with 100% query coverage and identity, novel peptide 
“VPNDDMDIFSK” matched alternative protein AAK1 (CCO13666.1 with E-value = 
5E-05) with 100% query coverage and identity, and novel peptide 
“TQNNLESDYLAR” matched an uncharacterised protein (Q6ZSR9.2 with E-value = 
2E-05) with 100% query coverage and identity. All were described as containing a 
BMP-2-inducible protein kinase C-terminus domain. The reference protein 
ENST00000406297.3 matched AP2-associated kinase 1 (AAI04843.1 with E-value = 
0.0) with 100% query coverage and 99% identity, and reference protein 
ENST00000409085.4 and ENST00000409068.1, both matched AP2-associated kinase 1 
(Q2M2I8.3 with E-value = 0.0) with 100% query coverage and identity, and 98% query 
coverage and 99% identity, respectively. The new Augustus gene prediction also 
matched AP2-associated protein kinase 1 (Q2M2I8.3 with E-value = 0.0) with 71% 
query coverage and 100% identity. 
The new prediction showed a 29% reduction in the query coverage compared to 
the original prediction due to the extension of the new protein prediction towards the 
proteins C-terminal end, which may be attributed to a single protein-coding transcript, 
or all transcripts, as evidenced by the known peptides, indicating that each protein 
isoform appeared to be expressed. Since the known peptides were shared, there was a 
concern that they were derived from different proteins, however this is not the case, as 
they were only identified within the same gene across the different protein isoforms 
within that gene. Overall, the prediction improved, extending the C-terminus of the 
protein. But further proteomics evidence is needed to improve the coverage of novel 
peptides across the region, helping to improve the confidence of this annotation event, 
and also to identify any unique known peptides to unambiguously identify at least one 




Figure 6.3 Gene boundary and novel exon annotations 
A gene boundary annotation (dashed lines) and two novel exon annotation events (dash dotted lines) were 
located on chromosome 2. These novel peptides led to a new prediction, extending the region of the 
original transcripts and including a new exon and CDS region previously unknown. Shared known 
peptides were also found mapping to each of the protein-coding transcripts involved in the annotation 
event. Repeats were also dotted across the gene region. 
6.3.7 Reverse strand and frame-shift annotation leads to new gene 
predictions 
There were 262 (50 exclusive) reverse strand annotation events identified (Table 6.1), 
and of these, 27 annotation events directly overlapped a gene/protein-coding transcript 
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(5 exclusively). An example of one of these 27 reverse strand events was on 
chromosome 10, spanning positions 115,609,828 to 115,654,858 for gene 
ENSG00000165806.15 with protein-coding transcripts ENST00000429617.1, 
ENST00000369331.4, ENST00000369321.2, ENST00000345633.4, 
ENST00000369318.3, ENST00000369315.1 and ENST00000452490.2; gene 
ENSG00000148735.10 with protein-coding transcripts ENST00000361048.1, 
ENST00000369312.4, ENST00000369310.3, ENST00000369309.1, 
ENST00000354462.3 and ENST00000448805.1; gene ENSG00000196865.4 with 
protein-coding transcript ENST00000369301.3; gene ENSG00000234631.1 with 
protein-coding transcript ENST00000451472.1; and gene ENSG00000043591.4 with 
protein-coding transcript ENST00000369295.2, with an event probability of 99.996% 
and 3 PSMs identifying 2 unique and 1 shared novel peptide. The majority of these 
genes were included due to the large 150,000 bp peptide linkage distance. The most 
likely gene for this annotation event was gene ENSG00000196865.4 with protein-
coding transcript ENST00000369301.3, which directly overlapped the peptide cluster. 
In addition, there was 1 unique known peptide supporting the original reference protein-
coding transcript ENST00000369301.3, with the unique peptide unambiguously 
indicating its expression. The peptide cluster also overlapped gene 
ENSG00000198924.3 with protein-coding transcripts ENST00000361384.2 and 
ENST00000369305.1, with one of the three novel peptides spanning positions 
115,609,828 to 115,609,857 inferring a frame-shift event, falling outside of the 99.80% 
event probability threshold for proximal events with a 99.799% event probability. This 
novel peptide was saved due to its presence in the reverse strand event, part of the larger 
peptide cluster with a 99.996% event probability. 
Augustus gene predictions were carried out incorporating the novel peptides and 
reference annotations and predicting two genes: one in line with the reference gene 
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ENSG00000196865.4 and protein-coding transcript ENST00000369301.3, and the 
other prediction on the reverse strand, incorporating two of the novel peptides. There 
was also a new prediction, incorporating the novel frame-shift peptide and separate 
from the other two novel peptides in the cluster which split the original reference gene 
ENSG00000198924.3 with protein-coding transcripts ENST00000361384.2 and 
ENST00000369305.1 into two predictions, by changing the frame of exon 2 halfway 
through (Figure 6.4, and with 3 supported annotated MS/MS spectra in Appendix 
Figure 6.5).  
Performing a BLASTP search against human in NR revealed the novel peptide 
“MGVAAHPK” matched protein S100-A8 (NP_002955.2 with E-value = 20) with 
100% query coverage and 88% identity, described as a S100 calcium-binding protein 
A8 (calgranulin A). Novel peptide “FLCTRHCSK” matched hCG1994383 
(EAW52580.1 with E-value = 4.8) with 66% query coverage and 100% identity, 
described as a provisional hypothetical protein, both of which led to the reverse strand 
prediction. The novel peptide which led to the frame-shift event and resulting revised 
prediction was novel peptide “KMMTAVVFLK” which matched SLC35E1 protein 
(AAH14557.1 with E-value = 9.8) with 80% query coverage and 70% identity, 
described as containing a Triose-phosphate Transporter family domain. Many of these 
novel peptides matched proteins in NR with poor significance because all were quite 
short (≤10aa). For the reference proteins and new Augustus gene predictions in which 
the novel peptides were incorporated, the majority of the matches were significant. The 
reference protein ENST00000369301.3 from gene ENSG00000196865.4, for which the 
reverse strand event was identified, matched NHL repeat-containing protein 2 
(NP_940916.2 with E-value = 0.0) with 100% query coverage and identity. Reference 
proteins ENST00000361384.2 and ENST00000369305.1 from gene 
ENSG00000198924.3, for which the frame-shift event was identified, both matched 
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DNA cross-link repair 1A protein (NP_055696.3 with E-value = 0.0) with 100% query 
coverage and identity. The new Augustus gene prediction g13908 on the reverse strand 
matched growth-inhibiting protein 6 (ACA14135.1 with E-value = 0.28) with 20% 
query coverage and 58% identity, indicating what is possibly a truly novel 
identification. Augustus gene prediction g13909 matched NHL repeat-containing 
protein 2 isoform X1 (XP_011538071.1 with E-value = 0.0) with 88% query coverage 
and 100% identity (mostly in line with the original reference prediction on the forward 
strand). The predictions inferred from the novel frame-shift peptide was gene g13906, 
which matched DNA cross-link repair 1A protein (NP_055696.3 with E-value = 0.0) 
with 100% query coverage and identity; and gene g13907 in which the novel frame-
shift peptide was incorporated matched DNA cross-link repair 1A protein 
(NP_055696.3 with E-value = 1E-150) with 76% query coverage and 100% identity. 
 The new gene prediction g13908 on the reverse strand was further supported by 
one of the novel peptides at the N-terminal-most end, which was N-terminal acetylated, 
indicating that the start of translation predicted by Augustus also agreed with the PTM 
presented by the proteomics evidence, thus further supporting the identification of a 
novel gene on the reverse strand (Figure 6.4). Although the peptide cluster identified a 
reverse strand annotation with two of the three novel peptides contributing to a likely 
novel gene prediction on the reverse strand, the single outlying novel peptide that 
instead identified a frame-shift indicated that not all peptides should belong within the 
same peptide cluster. Particularly as this peptide was previously removed as a frame-
shift event due to its lower event probability, possibly as a result of only being a single 
peptide annotation event with a relatively lower intensity MS/MS spectrum when 
compared to the other MS/MS spectra (Appendix Figure 6.5C). Situations such as these 
indicate that more stringent MS/MS spectra quality filtering should be considered, given 
enough MS/MS spectra to tolerate the MS/MS spectral losses with relatively limited 
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negative impact on the identification rate. The other alternative would be to simply 
accept the cost of losing a large proportion of MS/MS spectra from a relatively small 
MS/MS spectral dataset to improve specificity and reduce errors such as these. Another 
alternative could be for a re-consideration to how annotation events are filtered, perhaps 
requiring that all annotation events are further screened to identify unique and novel 
peptides from smaller annotation events within other larger annotation events, which 
have previously been filtered out to reduce ambiguity and keep annotation event 
filtering consistent. 
 The prediction resulting from the frame-shift peptide had its second exon split 
into two different frames resulting in two different predictions, with both matching the 
same protein, DNA cross-link repair 1A protein (NP_055696.3). When looking at the 
proteins corresponding gene DCLRE1A in GenBank, there was sufficient RNA-seq 
coverage across the gene, particularly across the exon that was split in the new 
prediction. Given this evidence, the new prediction as a result of the frame-shift peptide, 
was most likely a false positive. As a result, this particular annotation event should be 
either discarded or at the very least require further evidence before it could be accepted. 
Careful screening of any new predictions which are a direct result of proteogenomics 
annotation should therefore be conducted by comparison with the previous predictions, 
particularly when the previous predictions were manually curated and considered to be 
of high confidence, and supported by numerous types of other orthogonal evidence such 
as RNA-seq and EST. Overall, there were another 7 frame-shift events, derived from 
only 2 peptide clusters, which were above the event probability threshold. However, 
these could not be incorporated into gene predictions indicating the possibility that all 
frame-shift events throughout this particular study were false positives, particularly 
when considering the annotation events directly challenged the highly curated 
predictions that contained multiple sources of orthogonal evidence. 
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Based on this observation, many of the new predictions that were a result of 
dramatic changes (i.e. such as changes in frame) to the current well-curated GENCODE 
v19 annotations, were possibly false positives. The likely exceptions being annotation 
events such as novel genes, translated UTRs, reverse strand and exon boundary events 
that do not drastically conflict with but only add to or extend the annotation. In less 






Figure 6.4 Reverse strand and frame-shift annotation 
A reverse strand annotation event (dashed lines) and a frame-shift annotation event (dash dotted lines) 
were located on chromosome 10. An N-terminal acetylated peptide was also identified within the reverse 
strand event (square dotted lines). These novel peptides led to two new predictions; a novel gene 
prediction on the reverse strand with the incorporated N-terminal acetylated peptide agreeing with the 
genes translation initiation start (TIS) site, and a modified prediction from the frame-shift event, possibly 
a false positive. Repeats were also dotted across the gene regions. 
6.3.8 Exon boundary and translated UTR annotation 
Four translated UTR annotations and 27 exon boundary annotations were identified 
(Table 6.1). An example of an exon boundary and a translated UTR annotation was on 
chromosome 1, spanning positions 45,213,052 to 45,213,121, where a translated UTR 
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annotation was identified for gene ENSG00000142945.8 with protein-coding transcript 
ENST00000372222.3, and an exon boundary was identified for the same gene, with 
protein-coding transcripts ENST00000452259.1, ENST00000372224.4, 
ENST00000372218.4, ENST00000455186.1 and ENST00000372217.1. Both 
annotation events had an event probability of 98.167% with 1 PSM identifying 1 novel 
and unique peptide. In addition, supporting these two annotations, there were known 
mapped peptides, with 9 mapping to protein-coding transcript ENST00000372222.3, 2 
mapping to ENST00000452259.1, 11 mapping to ENST00000372224.4, 9 mapping to 
ENST00000372218.4, 4 mapping to ENST00000455186.1 and 10 mapping to 
ENST00000372217.1. However, none of the known peptides were unique, making it 
impossible to determine which protein-coding transcript was more likely to be 
expressed over the others, and also made it difficult to determine the protein-coding 
transcript to which the annotation event most probably belonged. Additionally, the 
annotation event may be a translated UTR or an exon boundary for one or all of these 
protein-coding transcripts. Augustus gene predictions were carried out incorporating the 
novel peptide and reference annotations, predicting a gene model in line with the 
original reference gene model ENSG00000142945.8, and also with an additional 
protein-coding transcript with a longer exon extended in the 5’ direction incorporating 
the novel peptide (Figure 6.5, and with one supporting annotated MS/MS spectrum in 
Appendix Figure 6.6). 
Performing a BLASTP search against human in NR revealed the novel peptide 
matched kinesin-like protein KIF2C isoform 2 (NP_001284584.1 with E-value = 8E-16) 
with 100% query coverage and 96% identity. The reference protein 
ENST00000372222.3, with which the exon boundary event was identified for, matched 
kinesin-like protein KIF2C isoform 1 (NP_006836.2 with E-value = 0.0), with 100% 
query coverage and identity. The reference proteins which had translated UTR events 
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identified were ENST00000452259.1 which matched kinesin-like protein KIF2C 
isoform 2 (NP_001284584.1 with E-value = 0.0) with 100% query coverage and 
identity; ENST00000372224.4 which matched kinesin-like protein KIF2C isoform 1 
(NP_006836.2 with E-value = 0.0) with 100% query coverage and identity; 
ENST00000372218.4 which matched kinesin-like protein KIF2C isoform 2 
(NP_001284584.1 with E-value = 0.0) with 100% query coverage and identity; 
ENST00000455186.1 which matched mitotic centromere-associated kinesin 
(AAC27660.1 with E-value = 0.0) with 95% query coverage and 99% identity; and 
ENST00000372217.1 which matched kinesin-like protein KIF2C isoform 2 
(NP_001284584.1 with E-value = 0.0) with 100% query coverage and identity. The new 
Augustus gene prediction contained two protein-coding transcripts, the first transcript 
being the altered prediction containing an extended exon, g772 transcript 1, which 
matched kinesin-like protein KIF2C isoform 1 (NP_006836.2 with E-value = 0.0) with 
100% query coverage and 97% identity; and g772 transcript 2 was unaltered, in line 
with the original prediction which matched kinesin-like protein KIF2C isoform 1 
(NP_006836.2 with E-value = 0.0) with 100% query coverage and identity. 
 The novel peptide overlapped the exon in the 5’ direction by 1 aa and led to a 
new transcript prediction g772 transcript 1, which extended the exon by 20 aa in the 5’ 
direction and accounted for the 97% identity with its match to the target sequence in 
NR: kinesin-like protein KIF2C isoform 1. However, the g772 transcript 2 prediction 
reproduced the original reference protein, and showed full alignment with the protein 
with 100% identity. The presence of known peptides around the region of the novel 
peptide improved the confidence of the annotation event by implying that it was being 
expressed. However, the known peptides were shared in multiple other identifications in 
different protein isoforms within the same gene and also found matches in a few other 
paralogous genes making the identification ambiguous. Although the presence of this 
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novel peptide, identified as both a translated UTR and exon boundary, looked 







Figure 6.5 Exon boundary and translated UTR annotation 
An exon boundary annotation event and a translated UTR annotation event for the same novel peptide 
cluster were located on chromosome 1. This novel peptide was incorporated into a new prediction, 
predicting a new transcript in addition to the original transcript from the reference gene, by extending the 
exon region in the 5’ direction (dashed lines). Repeats were also dotted across the gene region. 
There were another 3 translated UTR annotation events identified from a single 
peptide cluster on chromosome 18, spanning positions 3,978,073 to 3,978,145, for gene 
ENSG00000170579.10, with transcripts ENST00000315677.3, ENST00000515196.2 
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and ENST00000581527.1 with an event probability of 99.997%, and with 5 PSMs 
identifying 2 novel and unique peptides. This peptide cluster also happened to overlap 
an already identified pseudogene ENSG00000250933.1, with transcript 
ENST00000509132.1. The pseudogene in question was glyceraldehyde 3-phosphate 
dehydrogenase 66 (GAPDHP66), which is known to be expressed in ENCODE tier 1 
cell line GM12878 probably as a consequence of genetic changes during 
immortalization of the cell line using EBV. Since the reference proteome used in the 
present study was GENCODE v19, this expressed pseudogene was not accounted for 
among the known proteins and was misinterpreted as a translated UTR in this instance. 
This finding outlines a need for caution when using datasets to perform proteogenomics 
annotations, due to the differences in various cell lines. At the very least, if available, 
the known proteome for that cell line should complement the target known proteome to 
remove any inconsistencies between the proteomics data source and target genome 
annotation. The finding also outlined the lack of any support from the Enosi tool, with 
the identification of expressed pseudogenes or non-coding RNA genes, which could 
have identified the annotation event instead of it being misinterpreted as a translated 
UTR and requiring further manual parsing of the results for correct interpretation. 
Continuing the theme of expressed pseudogenes: one identified pseudogene, 
ENSG00000257907.2, with transcript ENST00000547505.2 and classified as 
translation elongation factor 1 alpha 1 pseudogene 17, contained unique and novel 
peptide “SGDAAIVDMVPGKPMCVESFSVYPPLSR” on chromosome 12, spanning 
positions 44,054,701 to 44,054,784. The novel peptide was primarily identified by 
proteogenomics analysis as a gene boundary and reverse strand event with an event 
probability of 98.167% for a number of genes in the region. However, no other novel 
peptides were in close proximity to indicate a gene spanning this region, possibly 
indicating a misidentified annotation event, solely based on the peptide linkage distance. 
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A BLASTP search of the novel peptide revealed a match to a protein-coding gene 
translation elongation factor 1 alpha 1 (NP_001393.1 with E-value = 4E-19) with 100% 
query coverage and 93% identity on chromosome 6, however the alignment contained 2 
mismatches. It is quite possible that the peptide was derived from an actual protein-
coding translation elongation factor 1 alpha 1 from cell line GM12878 elsewhere in the 
genome and, due to sequence variation, found a match to identified pseudogene 
ENSG00000257907.2. Further novel peptides mapping to the pseudogene would need 
to be identified before it would be feasible to re-annotate this pseudogene as a 
functional protein-coding gene. 
6.3.9 N-terminal acetylated peptides 
Protein N-terminal acetylation is known to contribute to many functional changes in 
proteins and the identification of such changes in conflict with the known proteome can 
potentially indicate over-predicted genes requiring re-annotation, but could also indicate 
an alternative protein isoform with a different translation initiation start (TIS) site. A 
total of 729 N-terminal acetylated peptides were identified amongst 2,949 proteins in 
the GENCODE v19 annotation and 136 were identified from 131 high confidence 
proteins (≥2 peptides with at least 1 unique), using the two-pass search approach with 
improved two-stage FDR strategy. 
Many of the N-terminal acetylated peptides appeared to agree with the TIS sites 
of the reference proteins, whereas others did not. These conflicts could not be accounted 
for because the N-terminal acetylated peptides were shared with other proteins, which 
supported their TIS sites. Due to the large number of these peptides a thorough manual 
validation was not practical, requiring a way to automate the process. However, even if 
this were done, numerous N-terminal acetylated peptides would still be shared between 
many other proteins due to the protein inference problem, with the problem amplified in 
this case by the presence of numerous isoforms in GENCODE v19. Thus making any 
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findings that have conflicts with the annotation ambiguous, as found in Section 5.3.13. 
Therefore, to improve the specificity of any findings only unique known N-terminal 
acetylated peptides were identified, as these could more confidently be assigned as 
alternate TIS sites. Alternatively, as discussed in the previous chapter (Section 5.3.13), 
N-terminomics [452] and other methods, such as heuristic approaches and top-down 
proteomics, could be used in the future to resolve such ambiguous analysis. 
From the 729 N-terminal acetylated peptides, 132 were found to be unique 
amongst 123 proteins, all of which did not conflict with the GENCODE v19 annotation. 
Of the 77 novel peptides identified (Table 6.1), 4 were found to be N-terminal 
acetylated (Appendix File 6.7). Of these, 3 were found to be unique, 2 of which were 
incorporated into different gene predictions at the N-terminal most-end, and one could 
not be incorporated into the prediction. The fourth peptide was a shared peptide, found 
in a peptide cluster consisting of two other novel peptides, but it was also mapped to 76 
other genome locations. In one of these other locations within the same chromosome, 
the novel peptide was incorporated into a new gene prediction. 
The first of the novel N-terminal acetylated peptides was unique peptide 
“LTNQDCPGRER“, spanning positions 19,524,186 to 19,524,218, on chromosome 8, 
identified within a gene boundary event and reverse strand event with an event 
probability of 99.927%, and with 1 annotated MS/MS spectrum in Appendix Figure 6.7. 
This particular peptide could not be incorporated into any gene prediction. 
 The second novel N-terminal acetylated unique peptide was “MGVAAHPK”, 
spanning positions 115,654,835 to 115,654,858 on chromosome 10, identified within a 
gene boundary event and reverse strand event with an event probability of 99.996%, 
with 1 annotated MS/MS spectrum (Appendix Figure 6.5A). This peptide was 
incorporated into Augustus gene prediction g13908 at the N-terminal-most end, 
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highlighted previously as an example of a reverse strand annotation, also shown in 
Figure 6.4, further supported by N-terminal proteomics evidence. 
 The third novel N-terminal acetylated unique peptide was “MTLRGCNQK”, 
spanning positions 16,027,267 to 16,027,293, on chromosome 6, identified within a 
gene boundary event and reverse strand event with an event probability of 99.995% and 
with 1 annotated MS/MS spectrum in Appendix Figure 6.8. This peptide was 
incorporated into Augustus gene prediction g8234 at the N-terminal-most end, spanning 
positions 16,027,267 to 16,100,195, which found no known matches to proteins in NR, 
indicating the identification of a truly novel gene, further supported by N-terminal 
proteomics evidence. Interestingly, the protein sequence of g8234 contains a long chain 
of arginine, lysine and glutamic acid residues, all of which are highly charged, 
potentially indicating an important role in ligand binding and protein-folding. 
 The fourth and final novel N-terminal acetylated shared peptide was 
“PGDSIRSHR”, spanning positions 16,165,749 to 16,165,775 on chromosome 6, 
identified within the same gene boundary event and reverse strand event as peptide 
“MTLRGCNQK”, with 2 annotated MS/MS spectra in Appendix Figure 6.9. The 
peptide was not incorporated into a gene prediction at this location; however, the 
peptide was found with 76 other genomic locations. At one of these locations, 
specifically spanning positions 83,808,134 to 83,808,160 on the same chromosome 6, 
residing within an intron region of gene ENSG00000083097.10 with protein-coding 
transcripts ENST00000349129.2, ENST00000237163.5, ENST00000536812.1, and 
ENST00000369739.3, there was a possible novel exon event. This particular annotation 
event was not formally identified because it was filtered out as it only contained shared 
peptides. At this location the novel peptide was incorporated into Augustus gene 
prediction g8936 within exon 2 and CDS 2, shared by two transcripts, which spanned 
positions 83,806,697 to 83,877,886. 
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Performing a BLASTP search of the two protein-coding transcripts from gene 
g8936 against human in NR revealed that protein-coding transcripts 1 and 2 matched 
protein dopey-1 isoform b (NP_001186871.1 with E-value = 0.0) with 100% query 
coverage and 99% identity and 100% query coverage and 98%, respectively, within the 
same chromosome 6 and within the same genomic region. However, the region where 
the novel peptide was incorporated did not show complete homology with the protein, 
indicating a potential new gene structure or isoform for this protein. Because the peptide 
was also located in another 75 locations, it was likely that the N-terminal acetylated 
status of the peptide agrees more with one of the other locations, and due to the protein 
inference problem the true location of this particular peptide will remain ambiguous 
until further evidence becomes available. 
6.3.10 Impact of search space 
The impact that an inflated search space has on proteogenomics analysis has often been 
a challenge, as outlined previously in Chapters 4 and 5. The combined FDR strategy has 
been shown to be limited in its sensitivity and reduces the identification rate in both 
known and novel search spaces. While the conservative two-stage FDR strategy 
outlined in [474] showed improved identification rate of known proteins, it was overly 
conservative for the novel identifications and did not take advantage of improved 
sensitivity using a two-pass search approach such as that mentioned in [427]. The 
enhanced method of controlling FDR by implementing the use of a two-pass search 
approach with improved two-stage FDR strategy demonstrated better balance of FDR 
control, improved the discrimination between true and false positives in the known and 
novel search spaces, and allowed for more peptides and proteins to be identified when 
compared to the combined FDR and conservative two-stage FDR strategies (Table 6.1). 
This was accomplished by reducing the impact that the proteogenomics search space 
has on analysis, through a reduction in the size of the search space to only sequences 
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containing likely matches to either the known or novel search spaces, prior to 1% PSM 
FDR filtering. 
At the known protein level protein identification rates during MS/MS database 
search changed from 3.9% of all proteins with combined FDR, to 6.93% with the 
conservative two-stage FDR, and 6.94% with the two-pass search approach with 
improved two-stage FDR strategy. Overall, there were 44% more known proteins 
identified with the two-pass search approach with improved two-stage FDR strategy 
than compared with the combined FDR strategy. At the novel peptide level, 
identification rates during MS/MS database search changed from 270 with combined 
FDR, down to 28 with the conservative FDR (a 10x drop in sensitivity), with an 
increase to 667 with the two-pass search approach with improved two-stage FDR 
strategy (a 2.5x improvement over the combined FDR strategy) (Table 6.1). This new 
method resulted in improvements in sensitivity, where previous losses were towards 
30% of the known proteins demonstrated in Chapter 4 and 52% of the known proteins 
demonstrated in Chapter 5. Using the new method, no losses of known proteins were 
observed. Instead, slight gains in the identification of known proteins could be seen 
using the two-pass search approach when compared to the conservative two-stage FDR 
strategy, which did not implement a two-pass search approach. However, the opposite 
was true for the high confidence protein identifications, although this was a negligibly 
small difference. Future algorithmic improvements will likely result in better 
identification rates and provide a means of reducing the impact that the proteogenomics 
search space has on analysis. 
6.4 SUMMARY 
This study integrated different –omics platforms: genomics, proteomics and 
transcriptomics, available from a previous proteogenomics study which was part of the 
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ENCODE project, and identified an improved methodology for conducting 
proteogenomics. This new methodology, which improves on the sensitivity and 
specificity of a proteogenomics search, was directly compared to two previous methods: 
the combined FDR and ‘conservative’ two-stage FDR strategy. In addition, this study 
identified 15,020 more peptides when compared to the previous ENCODE 
proteogenomics study. 
 The present study made a significant contribution to the annotation of the human 
genome, identifying 77 novel peptides contributing to 617 novel annotation events (126 
exclusively), consisting of 7 frame-shifts, 4 translated UTRs, 27 exon boundaries, 23 
novel exons, 289 gene boundaries (10 exclusively), 262 reverse strands (50 
exclusively), and 5 novel gene events, amongst a total of 147 genes (29 exclusively) and 
609 proteins (116 exclusively). 
Of these annotations 66 novel peptides directly led to 52 predicted proteins via 
Augustus gene prediction. The two-pass search approach with improved two-stage FDR 
strategy proved that after filtering it was able to identify 35 more novel peptides than 
either the combined FDR or conservative two-stage FDR strategies, and as a result it 
identified more annotation events, thus reducing the negative impact of the inflated 
proteogenomics search space and reducing the overhead for the post-processing of raw 
results. 
The number of annotation events identified in this study was far higher than the 
relatively few peptides identified, and more pronounced than found in the previous 
study in Chapter 5, due to the much larger peptide linkage distance used in this study, as 
was explained in Section 6.3.4. Although this caveat was accounted for by also 
providing the number of exclusive annotation events and associated genes and proteins, 
the problem still remains and should be addressed appropriately in future studies by 
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applying a novel way to determine the most appropriate peptide linkage distance for 
each peptide cluster. Other identified caveats included misidentified annotation events 
due to the lack of proper annotation event coverage; such as the absence of a way to 
identify expressed pseudogenes and non-coding RNAs, discrepancies between the 
proteome of GENCODE v19 and cell line GM12878 and overlapping annotation events 
causing ambiguities when annotation events were filtered, leading to false positive 
predictions. 
6.5 CONCLUSIONS 
The implementation of a two-pass search approach with improved two-stage FDR 
strategy proved highly effective at improving the PSM identification rate, and which 
reduced losses of known proteins as the searches were conducted separately and did not 
impact on the sensitivity of known and novel peptide sequence identification within 
their respective searches. This can be seen when comparing the identified known 
proteins between the two-stage FDR strategy and the combined FDR strategy (Table 
6.1), as well as from the proteomics-only searches during the precursor mass tolerance 
optimization step from Section 6.4.1. As a result, this led to improvements in the 
discrimination of true and false positives and also reduced the overhead needed to 
process the results for FDR filtering. 
As in the previous studies presented in Chapters 4 and 5, clustering MS/MS 
spectra and selecting the most appropriate precursor mass tolerances was also effective, 
particularly with the high-accuracy MS/MS spectra utilized in the present study. 
Although higher stringency MS/MS spectral quality filtering may have improved 
specificity and reduced the occurrence of some identified false positives found during 
analysis, this would have been at the cost of impacting true positive identifications. 
Much larger MS/MS spectral datasets may afford such higher MS/MS spectral quality 
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stringencies with a relatively limited negative impact on the identification rates. 
 The present study was compared to the ENCODE study from [11]. In this study, 
a total of 38,105 peptides were identified, of which 77 were novel peptides. Compared 
to the original ENCODE study, an additional 14,961 known peptides and 59 novel 
peptides were identified. 
 In the absence of a method to determine the annotation event FDR to identify 
appropriate event probability thresholds, the screening of annotation events by applying 
tighter stringencies when searching against RefSeq protein proved an effective way of 
identifying more annotation events outside of the applied stringent event probability 
thresholds. 
 An issue arose in Section 6.3.7 where a frame-shift peptide with an event 
probability below the applied threshold was incorporated into a larger peptide cluster 
with a higher event probability, identified as a reverse strand event. Because the single 
frame-shift peptide was still retained, this led to a probable false positive prediction. 
Suggestions to resolve this issue could be that, when applying filtering, an additional 
level of filtering should be applied to further remove any single unique and novel 
peptide annotation events that have been previously filtered out. This step could be 
achieved by also filtering from larger annotation events, thus reducing ambiguity, 
improving specificity and ensuring consistency across all annotation event filtering, as 
well as avoiding the occurrence of false positive annotation events being included in the 
revised annotation. 
 Another issue arose in Section 6.3.8, with the identification of a false positive 
translated UTR event, which was really a protein-coding pseudogene, namely 
glyceraldehyde 3-phosphate dehydrogenase 66 (GAPDHP66), identified as only a 
protein-coding gene in GM12878. This finding highlighted two problems: 1) the 
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proteome from GENCODE v19 did not reflect the proteome of cell line GM12878, 
which should be appended, if possible; and 2) the Enosi tool did not accommodate the 
identification of possible coding pseudogenes and/or non-coding RNA genes, and 
instead misidentified an annotation event, which required further manual curation of all 
identified annotation events. The ability to identify such annotation events automatically 
is important, as it removes the possibility of misidentifications and ambiguity, and time 
spent manually interpreting the results. Enabling such a feature could be relatively 
simple as interpreting the reference annotations and creating a new annotation event 
type, or running the analysis in parallel with other proteogenomics tools, such as 
PGTools [496], which can handle such annotation events. 
 Another caveat of the analysis, which was highlighted in the previous two 
chapters, was how annotation events could be better defined using other evidence, such 
as known peptides in close proximity, and dynamically defined peptide linkage 
distances across the genome for each peptide cluster. 
Another consideration for improving how annotation events could be defined 
came to light during the analysis in Section 6.3.7 with the application of N-terminal 
acetylated peptides, by examining the location of unique N-terminal acetylated peptides 
in the context of the peptide cluster, to define the cluster boundaries. However, this 
tactic would be conditional on the fact that the provided genome was near complete 
with little fragmentation, in order to reduce as much as possible the unambiguity when 
assigning an N-terminal acetylated peptide as unique. 
 Four N-terminal acetylated novel peptides were identified in this study, with 
three being unique, of which, two were included in Augustus gene predictions at the N-
terminal-most end, while there were numerous known N-terminal acetylated peptides, 
with 132 found to be unique among 123 proteins, none of which conflicted with the 
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GENCODE v19 annotation. 
 Besides the use of unique peptide parsimony, other methods to identify these N-
terminal acetylated peptides in the context of known proteins and novel annotations are 
needed, e.g. in a proteomics-only context using tools such as those listed in Table 2.6, 
top-down proteomics and N-terminomics [452]. 
 Future studies on the human genome could further expand on this work by 
including other cell lines, besides GM12878, e.g. K562: an immortalized cell line 
produced from a female patient with chronic myelogenous leukaemia (CML); A549: an 
adenocarcinomic human alveolar basal epithelial cell line; H1 human embryonic stem 
cell line: H1-neuron cell line from neurons derived from H1 embryonic stem cells; and 
A431: a human vulvar cancer cell line. All of these cell lines are publically available 
from ENCODE and other sources. In addition, much larger comprehensive data sources 
could be obtained from previous proteogenomics studies, such as the recent human 
proteome mapping study [450, 451], which mapped the proteome from multiple cell 
lines and tissues. Sources of RNA-seq data could be obtained from large comprehensive 
studies, such as those conducted in the 1,000 Genome Project [65], a large international 
project to sequence 1,000 genomes and identify genomic variants. Such studies would 
greatly benefit from using comparable proteomics data from the same biological 
samples to be truly meaningful, thus providing a means of confidently identifying 
variant peptides between different individuals. 
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7 WHEAT PROTEOGENOMICS 
7.1 INTRODUCTION 
Bread wheat (Triticum aestivum) is a major food crop for human consumption, 
contributing to a large proportion of our staple diet, comprising approximately 20% of 
calories consumed, being a good source of protein, vitamins and minerals, and also as a 
good livestock feed. Originally derived from a cross-hybridization of cultivated 
tetraploid emmer wheat (AABB, Triticum dicoccoides) and diploid goat grass (DD, 
Aegilops tauschii) approximately 8,000 years ago, the net result was a allohexaploid 
genome (6x), consisting of an A, B and D genome with a combined genome size of 17 
Gbps, making it one of the largest known plant genomes around [595, 596]. 
Recently, the International Wheat Genome Sequencing Consortium (IWGSC) 
sequenced and assembled the genome of Triticum aestivum cultivar Chinese Spring 
done on a per chromosome arm basis, by isolating and sorting each chromosome arm 
prior to sequencing [12]. A total of 124,201 gene loci were identified, evenly distributed 
across the chromosomes and subgenomes. In the same study, the dissertation author 
contributed towards proteogenomics analysis, which validated 50 high confidence 
genes, and identified 16 novel peptides which contributed to 33 novel annotations in 13 
genes: 4 frame-shifts, 3 translated UTRs, 2 exon boundaries, 13 novel exon events, 4 
gene boundary events, 2 reverse strand events and 5 novel gene events. However, the 
proteogenomics study was limited in scope with only 11,334 MS/MS spectra and 
implementing an earlier version of the Enosi tool, with no splice graph to define the 
splice junction search space, and with no method employed to address the huge loss in 
sensitivity resulting from searching a six-frame translation of the 17 Gbp genome [12]. 
7.1.1 Outline of this study 
The present study re-visited the proteogenomics annotation and addressed the 
limitations from the earlier study by the dissertation author within the study by Mayer 
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and colleagues [12] by adding an additional sources of MS/MS spectra: 1) Wheat flour 
from cultivar Butte 86 under three different digest protocols (Trypsin (as per the same 
as the previous proteogenomics study in [12]), chymotrypsin, and thermolysin [13]); 
and 2) meiotically developing anthers from a cross between rye (Secale cereale cultivar 
Petkus) and wheat (Triticum aestivum cultivar Chinese Spring), digested with trypsin 
and AspN [14]. The analysis utilised an improved Enosi tool, with incorporated MS-
GF+ MS/MS database search tool and a splice graph derived from a large source of 
RNA-seq data. The splice graph included RNA-seq data used in the study from [12], 
RNA-seq data derived from maturing grain in a related study [15], as well as a selection 
of four publically available datasets from the Sequence Read Archive (SRA). The loss 
in sensitivity was also addressed by applying a two-pass search approach with improved 
two-stage false discovery rate (FDR) strategy, which aimed to improve the sensitivity 
and discrimination between true and false positive identifications. In addition, due to the 
complexity of the allohexaploid wheat genome combined with the highly fragmented 
draft assembly, the difficulties of performing proteogenomics annotation and accurately 
predicting genes with such a dataset were highlighted. 
7.2 MATERIALS AND METHODS 
7.2.1 Proteomics and genomics datasets 
The latest version of the assembled Triticum aestivum genome sequence and Wheat 
MIPS version 2.2 annotations as GTF file and protein FASTA file from the study by 
Mayer and colleagues [12] were downloaded from the URGI web site 
(https://urgi.versailles.inra.fr/download/iwgsc/). The GTF file was subsequently 
converted to GFF, using the gtf2gff perl script supplied with the Augustus gene 
prediction tool (Appendix File 7.1). 
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The MS/MS spectra for this study were derived from a number of different 
sources. The first source was from the study in [13], totalling 42,909 MS/MS spectra 
from trypsin (11,334), thermolysin (16,776) and chymotrypsin (14,799) digests. The 
proteins were extracted from finely ground Triticum aestivum wheat flour cultivar Butte 
86 and run on a 2D electrophoresis gel, with 233 spots excised and separately digested 
with trypsin, chymotrypsin and thermolysin. The resulting digests were then run on a 
QSTAR Pulsar i quadrupole time-of-flight mass spectrometer (QTOF) (Applied 
Biosystems/MDS Sciex), with attached nano-electrospray source and nano-flow HPLC. 
The MS/MS spectra were kindly provided and downloaded from Susan Altenbach and 
William Vensel at USDA (California), co-authors of a prior proteomics study [13]. 
The second source of MS/MS spectra was derived from meiotic tissue from the 
anthers of a wheat-rye hybrid with Ph1 deletion (Ph-) from the study in [14], totalling 
42,528 MS/MS spectra from a trypsin digest, with a sub-fraction of 5,392 MS/MS 
spectra digested with trypsin and AspN. The wheat-rye hybrid came from a cross 
between rye (Secale cereale cultivar Petkus) and wheat (Triticum aestivum cultivar 
Chinese Spring). Protein extracts from the anthers, were run on a 1D gel, 8 bands were 
excised and digested using trypsin with 1 band digested with trypsin and AspN. The 
samples were then run on an LTQ Orbitrap (Thermo Scientific) mass spectrometer with 
attached nano-flow HPLC. The MS/MS spectra was kindly provided and downloaded 
from Ali Pendle and Graham Moore, co-authors of a prior proteomics study [14]. 
The protein sequence predictions from the Wheat MIPS version 2.2 annotations 
were appended to a source of contaminants before being used in the MS/MS database 
search as outlined in Section 3.1.1, to identify any contamination. In this study, for the 
thermolysin and AspN specific searches, thermolysin and AspN contaminant sequences 
downloaded from UniProtKB/Swiss-Prot were also added to account for the protease 
used in both cases. 
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7.2.2 RNA-seq datasets 
Illumina RNA-seq datasets were obtained from six different sources. One source was 
obtained from the Triticum aestivum cultivar Chinese Spring study [12], derived from 
five tissues (root, leaf, stem, spike and grain) of 5 different pooled conditions (SE 
library). In addition, RNA-seq data that was not used in the study from [12] were used, 
which included the same five tissues from 5 different conditions and 3 different 
developmental stages (PE library). These datasets were downloaded from URGI 
(http://wheat-urgi.versailles.inra.fr/Seq-Repository/RNA-Seq). 
The second source of data was obtained from a different study [15], which ran in 
parallel with [12], derived from the aleurone layer of developing endosperm tissue at 
different time points from the Triticum aestivum cultivar Chinese Spring. These datasets 
were kindly provided by Odd-Arne Olsen one of the co-authors from the studies [12, 
15]. 
The third to sixth sources of data were obtained from the Sequence Read 
Archive (SRA) (http://www.ncbi.nlm.nih.gov/sra) via the DNA Nexus 
(http://sra.dnanexus.com/). The identifiers used were: SRA053323 (a study which 
looked at the alueurone layer and starchy endosperm layer at different developmental 
time points); SRA048049 (a study which examined different tissues from cultivar 
Kukri); SRA059240 (a study which surveyed various cultivars for variation, including 
AC_Barrie, Alsen, Baxter, Chara, Excalibur, Kukri, Pastor, RAC875, Westonia, 
Xianyon54, Volcani, Yitpi, Steele, Stephens, Truman, Caledonia, Grandin, ID0444, 
Jaypee, and Jupateco); and SRA071558 (a study which looked at heat stress of cultivar 
HD2985 (thermotolerant) and HD2329 (thermosusceptible)). 
7.2.3 MS/MS database searching  
The MS/MS database search was performed by MS-GF+, as outlined in Section 3.3. In 
this case study, trypsin, chymotrypsin, thermolysin and AspN were used as the 
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proteases for the different sources of MS/MS spectra. For the wheat flour dataset 
digested with protease trypsin, chymotrypsin and thermolysin, the instrument was set to 
TOF (QTOF) and for the meiotic tissue dataset, digested with trypsin, with one sub-set 
dataset digested with trypsin and AspN, the instrument was set to low-res LTQ (Ion 
Trap). MS-GF+ does not have thermolysin as an option for protease and therefore 
‘unspecific cleavage’ as the protease was chosen, based on evidence where MS-GF+ 
has previously been shown to identify peptides from unspecified proteases, such as αLP, 
outperforming Mascot [292]. The MS-GF+ results from unspecified cleavage 
(thermolysin), were then screened for peptides which contained >1 missed cleavage 
sites, based on the enzyme chemistry for thermolysin according to the Expasy peptide 
cutter tool (http://web.expasy.org/peptide_cutter/peptidecutter_enzymes.html). The R 
package ‘cleaver’ [597] from Bioconductor was used to identify which peptides 
contained >1 missed cleavage, and these peptides were then removed from further 
downstream analysis. 
7.2.4 Dataset processing 
The Wheat MIPS version 2.2 protein sequence FASTA file and GFF file required 
formatting into a compatible format for proteogenomics analysis, as outlined in Section 
3.4.1. In particular, the exon coordinates in the GFF file were in the wrong orientation 
on the reverse strand, in a 5’ to 3’ direction, and were subsequently corrected to a 3’ to 
5’ orientation using an in-house script. 
The total 85,437 MS/MS spectra from all datasets obtained for this study, were 
first assessed by searching against the known proteome, examining the effects of using 
MS-Cluster to cluster the MS/MS spectra, PepNovo to quality filter the MS/MS spectra, 
and an assessment of optimal precursor mass tolerances, as outlined in Section 3.4.6. 
Since all the MS/MS spectra were of high-accuracy, derived from a QTOF and also an 
LTQ Orbitrap mass spectrometer, this factor needed to be reflected in the search 
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parameters. Therefore, assessment of the optimal precursor mass tolerance, involved 
using a range of tolerances, 0.5, 1.0, up to 10.0 in 1.0 ppm increments, and then up to 
150.0 ppm in 5.0 ppm increments (Appendix File 7.2). 
All RNA-seq data were pre-processed for quality and aligned to the wheat 
genome as detailed in Section 3.4.3. The resulting alignment BAM files were then 
merged and used to generate a splice graph FASTA database. A six-frame translation of 
the genome was also created for proteogenomics analysis. The methods used for both 
splice graph and six-frame translation generation are outlined in Sections 3.4.4 and 
3.4.5, respectively. When running a MS/MS database search using the larger precursor 
mass tolerances for trypsin and chymotrypsin digests, as outlined below in Section 
7.2.5, smaller file sizes for the six-frame translation, of around 50 MB, were needed to 
keep the MS/MS database search within the walltime. 
7.2.5 Proteogenomics pipeline 
The proteogenomics pipeline used a two-pass search approach, combined with an 
improved two-stage FDR strategy as outlined in Section 3.5. The choice of not 
clustering the MS/MS spectra and not quality filtering with PepNovo was selected due 
to the small dataset size and the significant loss of MS/MS spectra when quality 
filtering. Based on the preliminary assessment outlined in Section 7.2.4, 75.0 ppm, 
110.0 ppm, 5.0 ppm, 10.0 ppm and 5.0 ppm precursor mass tolerances were chosen for 
the wheat flour trypsin digest, chymotrypsin digest, thermolysin digest, meiotic tissue 
trypsin digest, and meiotic tissue AspN digests, respectively. 
Using MS-GF+ on a cluster, the MS/MS spectra from each dataset were 
searched against the known proteome, six-frame translated genome and splice graph, 
and further processed using the two-pass search approach, and then the improved two-
stage FDR strategy as outlined in Section 3.5.1 and 3.5.2, respectively. 
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The choice of parameters for the proteogenomics pipeline, as outlined in Section 
3.5, included a minimum event probability for novel genes, distal events and proximal 
events of 90%, a peptide linkage distance of 8,500 bp representing ≥95% of gene sizes 
in the Wheat MIPS version 2.2 annotation, a minimum cluster size of 1, and a minimum 
of 1 unique peptide per cluster. 
The annotation events were further screened, as outlined in Section 3.5 and 
taking the same approach as in Section 6.2.5, accepting novel gene and distal events 
with ≥2 unique peptides and/or ≥99.9% event probability and proximal events filtered 
with an event probability of ≥99.8%. Single unique peptide annotation events identified 
outside these thresholds were screened against a protein repository before acceptance. 
However, the protein repository used in this study was NCBI NR, instead of NCBI 
RefSeq protein as was used in the previous chapter, because no wheat proteins (apart 
from mitochondrial and chloroplast) were represented in the highly curated RefSeq 
protein repository. Therefore, the NR protein repository was used to screen against with 
a higher level of specificity to account for the lack of a curated protein database. The 
outliers were identified through BLASTP searches against bread wheat in NR, with 
100% query coverage, no mismatches, and an E-value of at least 1E-03, with any 
peptides matching required to have a length of >10aa. The findings outlined later in 
Section 7.3 also used BLASTP searches against bread wheat in NR to identify 
supporting evidence for discussion. 
7.2.6 Improving gene predictions 
Once the novel annotations were filtered and reviewed, the gene prediction tool 
Augustus [102], was used to improve the overall gene models of the Wheat MIPS 
version 2.2 annotation. Augustus was first trained with 6,137 filtered FL-cDNA from 
Komugi-TriFLDB (http://trifldb.psc.riken.jp/download.pl) and 1,286,040 EST 
sequences from NCBI to generate a base gene model. The training was kindly 
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conducted by Stefanie Koenig, from Mario Stanke’s group (http://bioinf.uni-
greifswald.de/bioinf/group/), the developer of Augustus. The novel annotation events, 
reference Wheat MIPS version 2.2 annotations and other additional extrinsic hints were 
then used as hints during gene prediction. Stefanie generated the additional extrinsic 
hints by: 1) masking the wheat genome using RepeatMasker [576] and generating 
repeat hints; 2) aligning 6,137 filtered FL-cDNA from Komugi-TriFLDB and all 
available EST sequences from NCBI, to the masked wheat genome using BLAT [122]; 
and 3) aligning all RNA-seq reads available from the URGI web site (http://wheat-
urgi.versailles.inra.fr/Seq-Repository/RNA-Seq) using Bowtie2/Tophat2 [126]. The 
Augustus gene prediction tool was then run on a compute cluster, as mentioned in 
Section 3.4.3, across all chromosome fragments, split into 10 MB sizes to improve 
throughput in a highly parallel manner, and using parameters as outlined in Section 
3.5.3, except that Augustus version 3.03 was used, and parameters “UTR” and 
“singlestrand” were set to on and off, respectively. The need to change some of the 
applied parameters arose due to a different version of Augustus (v3.03), which allowed 
for UTR predictions in this instance but not on both strands independently, which may 
have also been due to specific features of the Augustus wheat gene model prepared by 
Stefanie.  
7.3 RESULTS AND DISCUSSION 
The present study outlined improvements to the Wheat MIPS version 2.2 annotation of 
Triticum aestivum cultivar Chinese Spring, demonstrating the benefits of 
proteogenomics by integrating –omics datasets from genomics, proteomics and 
transcriptomics. Primarily, the study identified 189 (187 exclusively) novel annotation 
events, value-adding to the previous proteogenomics annotation by the dissertation 
author [12], outlining the benefits of performing a two-pass search approach with two-
stage FDR strategy, suitable for very large plant genomes, and also highlighting the 
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challenges for proteogenomics with fragmented genomes. 
7.3.1 Evaluation of pre-processing MS/MS spectra 
Prior to running the proteogenomics pipeline the MS/MS spectra were evaluated for the 
optimal pre-processing strategy and precursor mass tolerance (Appendix File 7.2). It 
was decided that clustering should not be used due to the small dataset size, with 
>100,000 MS/MS spectra being ideal, while quality filtering negatively impacted on 
each of the MS/MS spectral datasets, resulting in the majority of the MS/MS spectra 
being filtered out, which would have resulted in very few or no annotation events being 
identified in the downstream analysis. 
For the trypsin-digested wheat flour dataset, quality filtering reduced the peptide 
FDR after an initial 1% peptide-spectrum match (PSM) FDR filtering from 2.99% to 
1.88%, and the protein FDR from 11.59% to 3.8%, at the most stringent PepNovo 
quality score of 0.2 (Appendix Figure 7.1B-C). However, as can be seen in Appendix 
Figure 7.1A, the total number of MS/MS spectra lost after quality filtering ranged from 
15.52% at the lowest end to 62.33% at the most stringent cut-off. Applying scores 
between 0.05 – 0.1, as recommended by PepNovo (detailed in the Help File bundled 
with the tool), resulted in around 43.57% - 52.73% of the MS/MS spectra being lost. 
Approximately half of the MS/MS spectra were lost when using a mid-range score 
threshold, while the peptide FDR was maintained at around 2% - 3% with no 
improvements noticed. In addition, the number of MS/MS spectra, PSMs, and unique 
peptides dropped dramatically from 11,334 to 4,270, from 1,667 to 213, and from 535 
to 106, respectively, at the highest stringency (Appendix Figure 7.1A, D-E). 
For the chymotrypsin-digested wheat flour dataset, quality filtering reduced the 
peptide FDR after an initial 1% PSM FDR filtering from 2.44% to 0.00%, probably due 
to inaccuracies because of the small peptide numbers, and the protein FDR from 5.55% 
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to 0.00%, also likely due to inaccuracies with small protein numbers, at the most 
stringent PepNovo quality score of 0.2 (Appendix Figure 7.2B-C). However, as can be 
seen in Appendix Figure 7.2A, the total number of MS/MS spectra lost after quality 
filtering ranged from 10.61% at the lowest end to 74.49% at the most stringent cut-off. 
Applying scores between 0.05 – 0.1, as recommended by PepNovo, resulted in around 
53.56% - 64.36% of the MS/MS spectra being lost. Approximately half of the MS/MS 
spectra were lost when using a mid-range score threshold, while the peptide FDR was 
seen to vary widely. In addition, the number of MS/MS spectra, PSMs, and unique 
peptides dropped dramatically from 14,799 to 3,775, from 213 to 53, and from 41 to 6, 
respectively, at the highest stringency (Appendix Figure 7.2A, D-E). 
For the thermolysin-digested wheat flour dataset, which required MS/MS 
searching with ‘unspecific cleavage’, quality filtering reduced the peptide FDR after an 
initial 1% PSM FDR filtering from 6.98% to 3.30%, and the protein FDR from 19.51% 
to 7.14%, at the most stringent PepNovo quality score of 0.2 (Appendix Figure 7.3B-C). 
However, as can be seen in Appendix Figure 7.3A, the total number of MS/MS spectra 
lost after quality filtering ranged from 11.77% at the lowest end to 71.88% at the most 
stringent cut-off. Applying scores between 0.05 – 0.1, as recommended by PepNovo, 
resulted in around 51.35% - 61.56% of the MS/MS spectra being lost. Approximately 
half of the MS/MS spectra were lost when using a mid-range score threshold, while the 
peptide FDR was seen to increase and then drop significantly at the higher quality score 
cut-offs. In addition, the number of MS/MS spectra, PSMs, and unique peptides 
dropped dramatically from 16,776 to 4,718, from 1,036 to 183, and from 129 to 30, 
respectively, at the highest stringency (Appendix Figure 7.3A, D-E). 
 For the trypsin-digested wheat meiotic tissue dataset, quality filtering reduced 
the peptide FDR after an initial 1% PSM FDR filtering from 1.25% to 0.8%, and the 
protein FDR from 2.6% to 0.97%, at the most stringent PepNovo quality score of 0.2 
 
 255 
(Appendix Figure 7.4B-C). However, as can be seen in Appendix Figure 7.4A, the total 
number of MS/MS spectra lost after quality filtering ranged from 63.43% at the lowest 
end to 94.42% at the most stringent cut-off. Applying scores between 0.05 – 0.1, as 
recommended by PepNovo, resulted in around 88.74% - 91.78% of the MS/MS spectra 
being lost. More than three quarters of the MS/MS spectra were lost when using a mid-
range score threshold, while the peptide FDR was maintained at around 1%, with no 
improvements noticed. In addition, the number of MS/MS spectra, PSMs, and unique 
peptides dropped dramatically from 42,528 to 2,371, from 5,324 to 258, and from 4,250 
to 243, respectively, at the highest stringency (Appendix Figure 7.4A, D-E). 
For the AspN-digested wheat meiotic tissue dataset, a small sub-set of the 
trypsin digest dataset, quality filtering reduced the peptide FDR after an initial 1% PSM 
FDR filtering from 0.91% to 0.00%, probably due to inaccuracies because of the small 
peptide numbers, and the protein FDR from 1.25% to 0.00%, also likely due to 
inaccuracies associated with small protein numbers, at the most stringent PepNovo 
quality score of 0.2 (Appendix Figure 7.5B-C). However, as can be seen in Appendix 
Figure 7.5A, the total number of MS/MS spectra lost after quality filtering ranged from 
66.64% at the lowest end to 95.73% at the most stringent cut-off. Applying scores 
between 0.05 – 0.1, as recommended by PepNovo, resulted in around 90.28% - 92.97% 
of the MS/MS spectra being lost. Almost all of the MS/MS spectra were lost when 
using a mid-range score threshold, while the peptide FDR was essentially 0% due to the 
small number of peptides. In addition, the number of MS/MS spectra, PSMs, and unique 
peptides dropped dramatically from 5,392 to 230, from 116 to 8, and from 110 to 8, 
respectively, at the highest stringency (Appendix Figure 7.5A, D-E). 
These results indicated that the datasets were not improving as further MS/MS 
spectra were removed. Also, any apparent improvements, such as reduced peptide FDR, 
were inaccurate because the small numbers made any statistical analysis difficult, and 
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any numbers that appeared to improve were likely due to the significant losses of 
MS/MS spectra on such small datasets. Additionally, if any quality filtering was to be 
applied to these datasets, very few or no annotations would likely be identified further 
downstream in analysis due to the FDR inaccuracies from such small datasets. 
The results indicated no clustering and no PepNovo quality filtering should be 
applied as clustering was not suitable for small MS/MS spectral datasets, and quality 
filtering reduced the dataset sizes significantly, resulting in too many lost MS/MS 
spectra and as a result poor accuracy of the statistical calculations required to ascertain 
any improvements to the dataset. Although no quality filtering was applied, as 
mentioned in Section 4.3.1, MS-GF+ applied a level of quality filtering based on log-
likelihood ratios [292], and so sufficiently poor MS/MS spectra would still have been 
removed from the analysis to reduce potential false positives. 
7.3.2 MS/MS database search parameter optimization 
As outlined in Section 3.4.6, high-accuracy MS/MS spectra are well suited to precursor 
mass tolerance optimization. This held true for the present study, as high-accuracy 
MS/MS spectra were generated from a QTOF and LTQ Orbitrap mass spectrometer. 
The original MS/MS spectra, with no clustering and quality filtering, were used 
to assess the precursor mass tolerances over a range, as outlined in Section 7.2.4 
(Appendix File 7.2). From this analysis it was determined that for the trypsin-digested 
wheat flour, chymotrypsin-digested wheat flour, thermolysin-digested wheat flour, 
trypsin-digested meiotic tissue and the AspN-digested meiotic tissue, that the optimal 
precursor mass tolerance should be 75.0 ppm, 110.0 ppm, 5.0 ppm, 10.0 ppm, and 5.0 
ppm, respectively (Appendix Figures 7.6, 7.7, 7.8, 7.9 and 7.10). After ≤1% PSM FDR 
filtering the following number of PSMs and peptide FDRs were obtained for each 
dataset. For the trypsin-digested wheat flour the maximum number of PSMs obtainable 
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was 2,755 at 75.0 ppm, while the peptide FDR was 3.5%. For the chymotrypsin-
digested wheat flour the maximum number of PSMs obtainable was 713 at 110.0 ppm, 
while the peptide FDR was 4.49%. For the thermolysin-digested wheat flour the 
maximum number of PSMs obtainable was 274 at 5.0 ppm, while the peptide FDR was 
4.08%. For the trypsin-digested meiotic tissue the maximum number of PSMs 
obtainable was 5,352 at 10.0 ppm, while the peptide FDR was 1.2%. For the AspN-
digested meiotic tissue the maximum number of PSMs obtainable was 126 at 5.0 ppm, 
while the peptide FDR was 0.8%. 
7.3.3 Proteogenomics pipeline 
A proteogenomics pipeline was customised using Enosi with MS-GF+, as outlined in 
Section 3.5, and illustrated in Figure 3.1. As in Chapter 6, for each MS/MS spectral 
dataset that was processed a two-pass search approach with improved two-stage FDR 
strategy was used. 
As was similarly applied in previous chapters, key variables for the 
proteogenomics pipeline were chosen. The peptide linkage distance was chosen based 
on the size of ≥95% of genes in the Wheat MIPS version 2.2 genome annotation, which 
was found to be 8,500 bp. As previously determined, a fixed peptide linkage distance 
brings with it problems when defining annotation events. However, in this study, due to 
the highly fragmented genome the peptide linkage distance now overshot the size of 
many smaller scaffolds containing genes, which could further contribute to 
misidentified annotation event types. 
Contamination was also not an issue in this study, as compared with Chapter 5, 
with no noticeable over-abundance of peptides matching chloroplast and/or 
mitochondrial proteins. In all MS/MS spectral datasets, digests were obtained from 1D 
and 2D gels, acting as a filtering step and improving the abundance of target proteins 
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within a given mass range. No fractionation of samples by tissue or cellular components 
was conducted, except for filtration by 1D and 2D gels. However, this filtration resulted 
in significant losses, as shown from the limited number of MS/MS spectra obtained, but 
was partially compensated for by using different tissues (flour and meiotic tissue) and 
proteases in an attempt to improve the peptide coverage. 
As applied previously in Section 7.2.5, the screening of novel and unique 
peptides in the novel annotation events was performed by accepting annotation events, 
that contained ≥2 unique peptides, and/or more stringent event probabilities, with single 
unique peptide outliers identified from homology searches against bread wheat in NR 
(Appendix Files 7.3 and 7.4). It was found that many accepted annotation events above 
the event probability/parsimony threshold also matched well to wheat proteins in NR. 
The majority of the outliers were found to just fall outside the event 
probability/parsimony thresholds applied, implying that for some annotation event 
types, further refinement of the applied thresholds could improve annotation event 
identification rates without relying so much on homology searches for their 
identification. This method is thus a viable approach to help define appropriate event 
probability thresholds when lacking a direct method to determine the annotation event 
FDR for a given event probability. The final minimum event probabilities after the 
applied filtering were 95.284% for novel genes, 95.615% for distal events and 98.167 
for proximal events. 
Similarly, as outlined in Chapter 6, due to the multiple sources of MS/MS 
spectra and RNA-seq data used in this analysis, with some being derived from different 
cultivars, there was the possibility of a number of variant sequences being 
misinterpreted as post-translational modifications (PTMs), or the false identification of 
novel peptides in incorrectly identified locations, both of which would affect the 
calculated event probabilities. These possibilities could be accounted for by including 
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and identifying known variants in the splice graph, as was previous demonstrated [474]. 
However, as mentioned in previous chapters, this approach only became known late in 
the study and so it was not pursued. The approach could, however, be used in a later 
wheat proteogenomics studies to compare variants from different cultivars that could 
account for differences in traits and gene expression profiles. Another source of false 
positives could be derived from the poor coverage of the assembly, which was more of 
an issue in this study, and could be addressed via a number of possible approaches, as 
previously mentioned in other chapters. For example: de novo sequencing, matching 
MS/MS spectra against closely homologous sequences, or modifications to approaches 
such as template proteogenomics. 
Another caveat was that due to the highly fragmented nature of the wheat 
genome, a number of genes probably span across multiple scaffolds in the assembly, 
thus artificially inflating the number of identified gene regions, which could also 
hamper attempts to identify novel and unique coding regions. Therefore, revisiting a 
proteogenomics annotation as the draft assembly improves is an important consideration 
in future studies, as the status of unique/shared peptides and the peptide linkage distance 
of annotation events and consequently their event probabilities may well change. 
Additionally, in the future, adding a larger source of MS/MS spectra and RNA-seq data 
with a focus on a single cultivar, as well as specifically targeting the identification of 
variants between cultivars, will further improve the annotation and improve the event 
probabilities of annotation events that fell below the set thresholds in the present study. 
 During the screening of annotation events containing single novel and unique 
peptides no obvious correlation could be found with spectral counts as the event 
probability increased. This was probably due to the relatively small number of MS/MS 
spectra used. A number of novel and unique peptides had very high spectral counts 
compared to other annotation events (Appendix File 7.3) and so were considered as 
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possible contaminants from chloroplast and/or mitochondria, as was found in Chapter 5. 
However, after screening of a number of these particular unique and novel peptides, no 
evidence could be found to indicate that these were indeed peptides derived from 
chloroplasts and/or mitochondria. The novel peptides with high spectral counts were 
mostly distributed amongst the novel gene and distal events, where false positive rates 
are often higher and may also be due to the draft genome being highly fragmented, with 
a higher proportion of MS/MS spectra being misinterpreted to the same sequence, due 
to the limited coverage and also possibly because no MS/MS spectral quality filtering 
was applied. 
7.3.4 Proteogenomics analysis 
A total of 6,834 novel peptides were identified with an event probability of ≥90%, at 
least 1 unique peptide per cluster and a minimum cluster size of 1, using the two-pass 
search approach with improved two-stage FDR strategy. After filtering the novel 
annotation events as detailed in Section 7.2.5, there were a total of 290 novel peptides 
remaining (Table 7.1 and Appendix Files 7.3 and 7.4). 
 The final 290 novel peptides led to 189 novel annotation events (187 
exclusively) in total amongst 96 genes (96 exclusively) and 189 proteins (187 
exclusively) from the Wheat MIPS v2.2 annotation. The novel annotations along with 
the Wheat MIPS v2.2 reference annotation, and the extrinsic hints as generated by 
Mario Stanke’s group outlined in Section 7.2.6, were then used as hints for Augustus 
gene prediction. A total of 413,587 genes and 426,007 proteins (≥66 aa in length) were 
predicted (Appendix File 7.5), and of these, 70 predicted proteins had 180 novel 
peptides incorporated (Table 7.1), of which 80 novel peptides were unique and 
identified in 49 of the 70 predicted proteins (Appendix File 7.6). The number of protein-
coding genes and proteins predicted by Augustus was far higher than the original 
reference Wheat MIPS v2.2 predictions (Table 7.1). In addition to the new predictions 
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previously not identified, the high number of predictions could also be attributed to two 
factors, as outlined in Section 3.5.3. 
 The number of novel peptides incorporated into the predictions was reasonably 
high at 180 novel peptides (62%), but relatively lower compared to the previous two 
chapters by about 20%, probably due to some genes which were unable to be predicted 
within short scaffolds, as well as the relatively lower number of MS/MS spectra due to 
the limited dataset size and absence of MS/MS spectra quality filtering. Of the 180 
incorporated novel peptides 20 were exclusively derived from the splice graph, 62 were 
identified in both the six-frame translation and splice graph, with the remaining 98 
identified exclusively in the six-frame translation. 
As demonstrated previously in Section 6.3.4, BLASTP analysis was performed 
to show how the predictions changed from the reference predictions. This was 
undertaken by searching all 426,007 Augustus predicted proteins (Table 7.1) against the 
Wheat MIPS v2.2 proteins, taking the top match, with E-value ≤1E-10. Any sequences 
that did not match were considered novel predictions, sequences that had a query 
coverage ≥95% with at least 1 mismatch were considered to be the same prediction as 
the reference protein, and the remaining matches were considered to be modified 
predictions, either due to Augustus predicting slightly different models or as a direct 
result of the supporting evidence. From this analysis, there were 257,341 non-
paralogous novel protein predictions, 111,004 modified predictions and 57,662 
predictions considered to be essentially the same as the reference. 
Searching all 70 protein predictions that had the novel peptide evidence 
incorporated, against the Wheat MIPS v2.2 proteins, taking the top match with E-value 
≤1E-10, identified 46 protein predictions likely to be modified predictions, leaving 24 
protein predictions, that found no match and were considered as non-paralogous novel 
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protein predictions (Table 7.1). 
Based on the annotation events incorporated into the Augustus gene predictions, 
the minimum event probabilities which led to a new Augustus gene prediction were: 
novel gene event 98.785%, gene boundary 99.639%, reverse strand event 99.899%, 
translated UTR and frame-shift 99.8%. No filtered annotation events from exon 
boundaries and novel exons could be incorporated into the Augustus gene predictions. 
Of the 290 novel peptides identified in this study, 127 were derived from the 
trypsin-digested wheat flour, of which 86 were included in new predictions, with 41 
unique peptides. A total of 97 peptides were derived from chymotrypsin-digested wheat 
flour, of which 68 were included in new predictions, with 19 unique peptides. A total of 
3 peptides were derived from thermolysin-digested wheat flour, of which 2 were 
included in new predictions, 1 of which was a unique peptide. A total of 55 peptides 
were derived from trypsin-digested meiotic tissue, of which 20 were included in new 
predictions, 16 of which were unique. A total of 9 peptides were derived from AspN 
digested meiotic tissue, of which 4 were included in new predictions with 3 unique. One 
novel peptide was identified in both trypsin-digested wheat flour and trypsin-digested 
meiotic tissue. 
In the initial study 16 novel peptides were identified in 33 novel annotation 
events [12]. Of these 5 novel peptides were re-identified from the 290 identified in this 
study, 127 of which were from the trypsin-digested wheat flour. This demonstrated that 
the present study was able to significantly improve upon the previous work, even 
though in this study tighter event probability stringencies were applied. Including the 
novel peptides derived from the trypsin-digested wheat flour which were not re-
identified in this study, overall this new study demonstrated a ~8x improvement in the 
novel peptide identification rate. Overall, compared to the initial study, a total of 156 
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additional novel annotation events were identified. 
 The reason why an additional 122 novel peptides were identified from the 
trypsin-digested wheat flour in this study was probably due to a number of factors: 1) 
the use of MS-GF+ over InsPecT; 2) a tighter precursor mass tolerance (75.00 ppm 
versus 2.0 Da); 3) the two-pass search approach with improved two-stage FDR strategy 
versus the combined FDR strategy; and 4) the application of a later version of the 
Wheat MIPS annotation (November 2013 version used in the previous proteogenomics 
study [12] versus July 2014 (v2.2) for this study). 
 The previous study [12] validated 50 high confidence proteins, consisting of 152 
peptides, whereas in this study 107 high confidence proteins were identified consisting 
of 557 peptides (Table 7.1). Of the 557 peptides that were mapped to 107 high 
confidence proteins, 174 peptides were derived from trypsin-digested wheat flour, and 
of these 54 peptides were re-identified from the 50 validated proteins from the previous 
study. The differences in identification could be attributed to the same reasons for the 
novel peptides mentioned above, as well as the difference in method used to identity 
high confidence proteins. In the previous study, the protein probability was used based 
on the product of the local FDR of mapped peptides, whereas in this study the use of 
protein probability was discarded from the proteogenomics pipeline in favour of simply 
identifying proteins containing at least 2 peptides with at least 1 unique peptide. 
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Table 7.1 Summary of wheat proteogenomics annotations 
The results of the proteogenomics analysis of the Wheat MIPS v2.2 annotation, using the two-pass search 
approach with improved two-stage FDR strategy. 
Total Wheat MIPS v2.2 genes 99,386 
Total ‘known’ protein-coding genes 99,386 
Total ‘known’ proteins 293,053 
Raw MS/MS search ‘known’ protein matches ≤1% PSM FDR 1,970 
Proteogenomics mapping: Total 'known' proteins ≤1% PSM FDR 16,635 
Proteogenomics mapping: Total ‘known’ proteins ≤1% PSM FDR (≥2 peptides with 1 unique) 107 
 
Total identified 'novel' peptides ≤1% PSM FDR 14,151 
Raw MS/MS search ‘known’ peptides ≤1% PSM FDR 4,471 
Proteogenomics mapping: Total identified 'known' peptides ≤1% PSM FDR 4,474 
Proteogenomics mapping: Total identified 'known' peptides ≤1% PSM FDR (≥2 peptides with 1 unique) 557 
 
Frame-shifts 46 
Translated UTRs 9 
Exon boundaries 17 
Novel splices 0 
Novel exons 39 
Gene boundaries 17 (15) 
Reverse strands 24 (24) 
Novel genes 37 
 
Total annotation events 189 (187) 
Total genes affected 96 (96) 
Total proteins affected 189 (187) 
Total novel peptides in affected genes/proteins 290 
 
Total Augustus protein-coding gene predictions 413,587 
Total Augustus protein predictions 426,007 
Total Augustus gene predictions with incorporated novel peptides 67 
Total Augustus protein predictions with incorporated novel peptides 70 
Total novel peptides incorporated into Augustus protein predictions 180 
Improved protein predictions with incorporated novel peptides 46 
Novel non-paralogous protein predictions with incorporated novel peptides 24 
Note: Numbers in parenthesis represent the exclusive numbers. The inflationary effect of a large peptide 
linkage distance on gene boundaries and reverse strands was removed by assigning a peptide cluster as 
either a proximal or distal event, not both, with preference placed on proximal events. 
7.3.5 Novel gene annotation 
A total of 37 novel genes (Table 7.1) were identified. An example of one of these novel 
genes was on chromosome 5BL, fragment 5BL10923515, spanning positions 6,935 to 
8,434, with an event probability of 100%, consisting of 5 unique and 3 shared peptides 
and with 24 PSMs assigned, derived from trypsin-digested wheat flour protein. In 
addition, an Augustus gene prediction was carried out incorporating the novel peptides, 
exon, exon_part and intron hints, predicting 1 new gene model (Figure 7.1, and with a 
sample of 14 of 24 representative MS/MS spectra supporting annotated MS/MS spectra 
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in Appendix Figure 7.11). 
Performing a BLASTP search against bread wheat in NR revealed that novel 
peptide “AFLQPSHYDADEIAFVR” matched an unnamed protein product 
(CDM82143.1 with E-value = 1.6), with 35% query coverage and 100% identity; novel 
peptide “ALAFPQQAR” matched gamma-gliadin (AGZ20266.1 with E-value = 1.6) 
with 88% query coverage and 75% identity; novel peptide “AQPESVFVAGPQQQR” 
matched globulin 3B (ACJ65515.1 with E-value = 0.17) with 53% query coverage and 
88% identity; novel peptide “EGDVFVIPAGSIVYSANTHR” matched storage protein 
(AAA34269.1 with E-value = 6E-04) with 90% query coverage and 72% identity; novel 
peptide “EGEGVLVLLR” matched unnamed protein product (CDM83362.1 with E-
value = 1.3) with 80% query coverage and 88% identity; novel peptide 
“GGGGGSGSEKEDIQPR” matched homeobox protein (BAH03543.1 with E-value = 
0.96) with 50% query coverage and 100% identity; novel peptide “IYIVVEGR” 
matched CBL-interacting protein kinase 23 (AFR90218.1 with E-value = 5.0) with 75% 
query coverage and 83% identity; and novel peptide “SLTGEKPR” matched 
phenylalanine ammonia-lyase (AAA50849.1 with E-value = 6.5) with 87% query 
coverage and 86% identity. The Augustus gene prediction g265543 matched to storage 
protein (AAA34269.1 with E-value = 1E-54) with 94% query coverage and 38% 
identity. The most significant novel peptide “EGDVFVIPAGSIVYSANTHR” and the 
Augustus gene prediction g265543 both matched a storage protein. Many of these 
matches were also of low coverage, identity and E-value, indicating that the new gene 




Figure 7.1 Novel gene annotation 
A novel gene annotation event was located on chromosome 5BL, fragment 5BL10923515, and led to a 
new gene prediction. The novel peptides were incorporated into the Augustus predicted gene g265543. 
Extrinsic hints from EST, cDNA and RNA-seq evidence indicate exon, exon_part and intron hints, in 
agreement with the novel peptides and new prediction. 
7.3.6 Gene boundary annotation event leads to a new gene prediction 
There were 17 (15 exclusive) gene boundary annotation events identified (Table 7.1). 
An example of a gene boundary annotation event was on chromosome 1AL, fragment 
1AL3923345, spanning positions 10,484 to 12,796, with an event probability of 100%, 
consisting of 8 unique and 14 shared peptides, and with 50 PSMs assigned, 38 derived 
from trypsin-, 11 derived from chymotrypsin- and 1 derived from thermolysin-digested 
wheat flour protein. The gene boundary event was identified for gene 
Traes_1AL_52FE5D716, protein-coding transcripts 2 and 3. In addition, an Augustus 
gene prediction was carried out incorporating the novel peptides, reference gene 
Traes_1AL_52FE5D716 and exon_part and intron hints, predicting two new gene 
models. One gene was an identical prediction to the reference gene 
Traes_1AL_52FE5D716, whereas the other gene was a completely novel prediction in 
close proximity to the reference gene Traes_1AL_52FE5D716 prediction (Figure 7.2, 
and with a sample of 25 of 50 supporting annotated MS/MS Appendix Figure 7.12). 
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Performing a BLASTP search against bread wheat in NR revealed the 22 novel 
peptides matched to a high molecular weight (HMW) glutenin (CAC84119.1, P02861.1, 
CAC84121.1, CAC40684.1, CAC83002.1, AAA62315.1, CAE00624.1 and 
BAN29068.1 with E-value range: 0.086 – 2E-24) with 100% query coverage and 
identity. The two reference protein-coding transcripts 2 and 3 matched a protein kinase 
(ABG68041.1 with E-value = 0.0) with 100% query coverage and 95% identity, and an 
unnamed protein product (CDM85023.1 with E-value = 3.3) with 30% query coverage 
and identity, respectively. The Augustus gene prediction g4797 matched a HMW 
glutenin (AHZ62762.1 with E-value = 0.0) with 100% query coverage and 96% 
identity, and gene g4798 matched a protein kinase (ABG68041.1 with E-value = 0.0) 
with 100% query coverage and 96% identity. 
The novel peptide “QPGYYSTSPQQLGQGQPR” (Figure 7.2), which matched 
a HMW glutenin (BAN29068.1) was not incorporated into the prediction and was a 
shared peptide, probably derived from a different genomic region, and also probably 
from a HMW glutenin gene. The novel peptide and hints evidence (Figure 7.2) 
indicated that the gene boundary annotation identified was actually a novel gene 
annotation, and probably a HMW glutenin. No known peptides were identified for the 
reference gene Traes_1AL_52FE5D716, and both gene predictions g4797 and g4798 
matched to two different proteins in NR, indicating that it was unlikely that these two 
genes were simply a fragmented Augustus gene prediction. 
The misidentification of this annotation as a gene boundary event also 
highlighted again the difficulty of using a fixed value peptide linkage distance to 
conduct proteogenomics analysis. If the peptide linkage distance were significantly 
shorter (i.e. the distance between the peptide cluster and the neighbouring reference 
gene), this annotation would have been identified correctly as a novel gene instead of a 
gene boundary annotation. To improve the accuracy of the assignment of annotation 
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event types such as these, the determination of a peptide linkage distance through a 
dynamic approach using additional sources of evidence could be used. 
Figure 7.2 Novel gene annotation misidentified as a gene boundary event 
A gene boundary annotation event that led to two gene predictions; g4798 in line with the original 
reference gene Traes_1AL_52FE5D716 and gene g4797 a new gene prediction in close proximity to the 
reference gene on chromosome 1AL, fragment 1AL3923345. The novel peptides and exon_part hints led 
to a novel gene prediction, while the reference Traes_1AL_52FE5D716 gene, exon_part, and intron hints 
led to a similar prediction to the reference. No known peptides were identified for the reference gene 
indicating that both gene predictions were unlikely to be simply fragmented predictions. 
7.3.7 Reverse strand annotation 
There were 24 (24 exclusive) reverse strand annotation events identified (Table 7.1). An 
example of a reverse strand annotation event was on chromosome 3AL, fragment 
3AL4447768, spanning positions 2,753 to 2,968, with an event probability of 99.90%, 
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consisting of 1 unique and 2 shared peptides, and with 3 PSMs assigned, derived from 
trypsin-digested meiotic tissue. The reverse strand event was identified for gene 
Traes_3AL_8EF777719, and its single protein-coding transcript. In addition, an 
Augustus gene prediction was carried out, incorporating the novel peptides, reference 
gene Traes_3AL_8EF777719 and exon_part hints, predicting a new gene model on the 
opposite strand and removing the previous reference prediction. This indicated that the 
original reference gene was predicted on the wrong strand (Figure 7.3, and with 3 
supporting annotated MS/MS spectra in Appendix Figure 7.13). 
Performing a BLASTP search against bread wheat in NR revealed that the three 
novel peptides matched to an unnamed protein product (CDM87003.1 with E-value 
range: 1.1 – 6E-07) with 100% query coverage and percentage identity ranging between 
92% and 100%. The single reference protein-coding transcript matched to wall-
associated kinase-like 1 (AAY34779.1 with an E-value = 0.47) with 25% query 
coverage and 34% identity. The Augustus gene prediction g50683 matched unnamed 
protein product (CDM87003.1 with E-value = 3E-86) with 90% query coverage and 
89% identity. This evidence indicated that the novel peptides and the new prediction 
found a better match to a Triticum aestivum protein than the reference protein from the 






Figure 7.3 Reverse strand annotation 
A reverse strand annotation event, located on chromosome 3AL, fragment 3AL4447768, where the 
original Traes_3AL_8EF777719 prediction was predicted on the forward strand. An Augustus gene 
prediction on the reverse strand was suggested with incorporated novel peptides and exon_part hints. 
7.3.8 Translated UTR annotation hides an exon boundary event 
There were 9 translated UTR annotation events identified (Table 7.1). An example of a 
translated UTR annotation event was on chromosome 1DL, fragment 1DL2289899, 
spanning positions 56 to 2,161, with an event probability of 100%, consisting of 3 
unique and 16 shared peptides, and with 34 PSMs assigned, 5 derived from trypsin- and 
14 derived from chymotrypsin-digested wheat flour protein. The translated UTR event 
was identified for gene Traes_1DL_757719220 and protein coding transcript 4, which 
also directly overlapped protein coding transcripts 2 and 3, both of which had a 41 bp 
region of ambiguous X amino acid residues at the 5’ end of their protein predictions 
(Appendix File 7.1). In addition, an Augustus gene prediction was conducted 
incorporating the novel peptides, reference gene Traes_1DL_757719220 and exon_part 
and intron hints, predicting a gene model, and revised from the original reference 
prediction, replacing the intron from the reference gene with an exon region by 
incorporating the novel peptides (Figure 7.4, and with a sample of 25 of 34 supporting 
annotated MS/MS spectra in Appendix Figure 7.14). 
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Performing a BLASTP search against bread wheat in NR revealed that the novel 
peptides matched to a HMW glutenin (AAS67321.1, ABB05179.1, AEF32781.1, 
AEL99901.1, AHI62992.1, BAH96595.1, CAC40684.1 and P02861.1 with E-value 
range: 0.003 – 7E-21) with 100% query coverage and identity. The reference protein-
coding transcript 4 matched protein kinase (ABG68032.1 with E-value = 2E-13) with 
71% query coverage and 93% identity, while reference protein-coding transcripts 2 and 
3 matched HMW glutenin (AAS67319.1 with E-value = 9E-55 and AAS67320.1 with 
E-value = 1E-46, respectively) with 46% query coverage and 100% identity, and 66% 
query coverage and 96% identity, respectively. The Augustus gene prediction g307507 
matched HMW glutenin (P08489.1 with E-value = 0.0) with 99% query coverage and 
identity, with the 1% coverage in disagreement located at the 5’-most end of the 
prediction. 
The novel peptides, reference protein-coding transcripts 2 and 3, and the revised 
prediction all matched HMW glutenin in NR, while the reference protein-coding 
transcript 4, which was identified specifically for this annotation event, matched protein 
kinase. In addition, all novel peptides and the 7 identified known peptides were within 
the same frame as transcripts 2 and 3 (frame +2), while transcript 4 was in a different 
frame (frame +3) (Figure 7.4). The revised prediction failed to predict the exon/CDS 
region of transcript 4, which also lacks support from the extrinsic exon_part and intron 
hints (Figure 7.4). Additionally, the 5’ region of the gene prediction appeared truncated, 
with a different exon in an alternate frame (frame +1) and an intron, which conflicted 
with all the evidence, including the BLASTP results, which found inconsistencies with 
the 5’ end of the match to a HMW glutenin. This is because there was only one 
Methionine translation initiation codon (ATG) located at the 5’ end of the scaffold, in 
agreement with the Augustus gene prediction. The absence of any more translation 
initiation sites further upstream was probably because the actual gene overlapped the 
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edge of the scaffold. This could also explain why the original reference protein-coding 
transcripts 2 and 3 were truncated at the 5’ end with a 41 bp ambiguous X protein 
sequence in their protein predictions, because the available evidence used for the Wheat 
MIPS v2.2 predictions overlapped the end of the scaffold and, instead of producing half 
a protein sequence, X residues were used instead to indicate incompleteness. 
Although this annotation event was identified as a translated UTR event for 
transcript 4, it was also unreported by Enosi as an exon boundary event for transcripts 2 
and 3. The annotation event did not completely agree with the hints evidence, however 
it is worth noting that many of the extrinsic hints were also originally used for the 
Wheat MIPS v2.2 annotation, and so should not be considered as complete evidence. 
An exon boundary event was never identified for transcripts 2 and 3 because the only 
identified unique peptides within the peptide cluster mapped within their 5’ regions 
which, as described previously, contained a 41 bp region with ambiguous X amino acid 
residues and so were never identified as known peptides belonging to those transcripts. 
This is because, as described in Section 3.5, this analysis only accepts peptide clusters 
with at least 1 unique peptide. However, if the unique peptides were identified mapping 
to transcripts 2 and 3, they would have been identified as known peptides and therefore 
the annotation event would not have been identified. If, to allow detection of this 
annotation event, the analysis was to accept all annotation events with a minimum of 
zero unique peptides, then the annotation event would have been identified in this case. 
However, all possible events would have also been identified, including many which are 
ambiguous due to multiple locations across the genome, which would have inflated the 
FDR at the annotation event level. 
Overall, the evidence was in agreement with transcripts 2, 3 and the revised 
Augustus gene prediction, but required a correction to exon 1 and further extension to 
the 5’ region of the gene. Further extending the scaffold towards the 5’ region would 
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improve the prediction and also resolve the 41 bp ambiguous X amino acid residue 
region of the original transcript 2 and 3 protein predictions, which should then reach full 





Figure 7.4 Exon boundary annotation via a translated UTR event 
An exon boundary annotation identified via a translated UTR event, located on chromosome 1DL, 
fragment 1DL2289899. The novel peptides appeared within the untranslated UTR region of transcript 4 
but within a different frame and they also appeared as an exon boundary for transcripts 2 and 3, within the 
same frame. Known peptides appeared mapped to both transcripts 2 and 3, within the same frame as the 
novel peptides. The evidence indicates an annotation event more in line with transcripts 2 and 3. There 
was also no hints evidence for many of the novel peptides spanning the intron region. The four 5’-most 
novel peptides map to a 41 bp ambiguous X amino acid region at the 5’ end of transcripts 2 and 3 
indicating incompleteness of the prediction. The revised Augustus gene prediction agrees with transcripts 
2, 3 and the novel peptides. 
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7.3.9 Exon boundary annotation 
There were 17 exon boundary annotation events identified (Table 7.1). An example of 
an exon boundary annotation event was on chromosome 6AL, fragment 6AL2841856, 
spanning positions 6 to 71, with an event probability of 99.899%, consisting of 1 unique 
and 1 shared peptide, and with 2 PSMs assigned, derived from trypsin-digested meiotic 
tissue. The exon boundary event was identified for gene Traes_6AL_895062375 and its 
single protein-coding transcript. In addition, an Augustus gene prediction was carried 
out incorporating the novel peptides, reference gene Traes_6AL_895062375 and 
exon_part hints. However, no Augustus gene prediction could be generated, regardless 
of the proteogenomics evidence and hints supplied. This was likely due to the small 
fragment size of 6AL2841856 which was just 315 bp in size, with only 3 Methionine 
translation initiation codons across the entire length of the fragment, and no translation 
initiation codons towards the 5’ region of the original Traes_6AL_895062375 gene 
where the novel peptides were mapped. Also, in the absence of a suitable translation 
initiation codon, Augustus probably penalises any evidence and resulting prediction. 
Extending this fragment length further given the supporting evidence would probably 
see a prediction along the length of this chromosome fragment (Figure 7.5, and 2 
supporting annotated MS/MS spectra in Appendix Figure 7.15). 
Performing a BLASTP search against bread wheat in NR revealed the novel 
peptides matched to a putative pyruvate dehydrogenase (ADD73514.1 with E-value 
range: 0.002 – 2E-08) with 100% query coverage and identity. The single reference 
protein-coding transcript matched putative pyruvate dehydrogenase (ADD73514.1 with 
E-value = 1E-55) with 100% query coverage and 99% identity. The 1% discrepancy in 
identity was attributed to a region missing from the original prediction, of around 77 bp 
according to a BLASTP alignment to the putative pyruvate dehydrogenase in NR. All 
other exon boundary events identified in this study could not be incorporated into 
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Augustus gene predictions, some probably due to their small fragment sizes and/or 
missing appropriate translation initiation start (TIS) sites, while others were possibly 
due simply to false positive peptide identifications. 
As pointed out with this annotation event, and the translated UTR event 
previously discussed in Section 7.3.8, the fragmented nature of the genome can be a 
limiting factor for gene prediction. In addition, many scaffolds making up the genome 
were smaller than the peptide linkage distance. This size constraint further limited the 
approach to recruit more genes and peptide clusters into annotation events, reducing the 
upper bounds for the identification of novel annotation events and also further 
increasing the chances of misidentifying an annotation event. As a result, it is important 
to revisit the proteogenomics analysis as future versions of the wheat genome assembly 
become available. 
Figure 7.5 Exon boundary annotation 
An exon boundary annotation event, located on chromosome 6AL, fragment 6AL2841856. Two novel 
peptides overlapped the exon boundary of gene Traes_6AL_895062375, which was supported by 
exon_part hints. This evidence, as well as the reference gene was used as hints for gene prediction. 
However, no prediction resulted, probably due to the short fragment length of 315 bp, resulting in a 
missing TIS site from further upstream needed for Augustus gene prediction. Later extensions of his 
fragment on chromosome 6AL will likely allow for a prediction, given the supporting evidence that is 
already available. 
7.3.10 Frame-shift annotation 
There were 46 frame-shift annotation events identified (Table 7.1). An example of a 
frame-shift annotation event was on chromosome 1AL, fragment 1AL3886502, 
spanning positions 4,108 to 4,197, with an event probability of 99.80%, consisting of 1 
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unique peptide, and with a single PSM assigned, derived from trypsin-digested meiotic 
tissue. The frame-shift event was identified for gene Traes_1AL_C8971FBEE and its 
single protein-coding transcript. In addition, an Augustus gene prediction was carried 
out incorporating the novel peptide, reference gene Traes_1AL_C8971FBEE, exon_part 
and intron hints, which predicted a gene model revised from the original reference 
prediction, by splitting the original prediction with 1 exon/CDS into a gene prediction 
with 2 exons/CDS, with the novel peptide incorporated into the first exon/CDS in a 
different frame to that that of the original (Figure 7.6, and a single supporting annotated 
MS/MS spectrum in Appendix Figure 7.16). 
Performing a BLASTP search against bread wheat in NR revealed the novel 
peptide matched to an unnamed protein product (CDM84219.1 with E-value = 6.3) with 
53% query coverage and 57% identity. The single reference protein-coding transcript 
matched unnamed protein product (CDM82578.1 with E-value = 1.5) with 16% query 
coverage and 29% identity. The Augustus gene prediction g2008 matched unnamed 
protein product (CDM81340.1 with E-value = 0.026) with 36% query coverage and 
41% identity. 
The novel peptide, reference protein-coding transcript and gene prediction 
g2008 all matched different unnamed protein products. However, of significant note 
was that the E-value, query coverage and percentage identity of gene prediction g2008 
were better than that found with the reference protein-coding transcript. One shared 
known peptide was mapped to the reference protein-coding transcript and also appeared 
in the g2008 gene prediction. Additionally, as can be seen in Figure 7.6, many of the 
hints appeared located around the two new exons, more so around exon 2 which can be 
seen when the exon_part hints are not stacked on one another indicating potential 
splicing patterns, even though there were no intron hints to indicate definitive evidence. 
Many of the other 45 frame-shift events also contained single unique peptides, all with 
 
 278 
the same event probability and most with the same or similar number of PSMs 
identified. 
Of the remaining 45 frame-shift events, 27 were incorporated into predictions. 
These were visually inspected and appeared to conflict with the available hints. Also, in 
some instances a number of known peptides mapped to the same region as the frame-
shift novel peptide, indicating a direct conflict within the proteogenomics evidence 
itself. This demonstrated that careful consideration of all the provided evidence, 
particularly with the frame of mapped peptides, is needed before acceptance of a new 
annotation and the inferred prediction, and that the acceptance of an annotation event 
should never solely rely on the confidence of the event probability alone, particularly 
when the evidence is only in the form of a single unique peptide. 
Figure 7.6 Frame-shift annotation 
A frame-shift annotation event located on chromosome 1AL, fragment 1AL3886502. A novel and unique 
peptide was identified in a different frame to reference gene Traes_1AL_C8971FBEE. The novel peptide, 
reference gene Traes_1AL_C8971FBEE, and exon_part and intron hints were incorporated into new 
prediction g2008, which consisted of two exons in two different frames, in agreement with the novel 
peptide, and also the single supporting known mapped peptide. 
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7.3.11 Novel exon annotation 
There were 39 novel exon annotation events identified (Table 7.1). An example of a 
novel exon annotation event was on chromosome 1DS, fragment 1DS1899380, 
spanning positions 5,423 to 5,449, with an event probability of 99.80%, consisting of 1 
unique peptide, and with a single PSM assigned, derived from chymotrypsin-digested 
wheat flour. The novel exon event was identified for gene Traes_1DS_947F6918F, 
protein-coding transcript 1, 2 and 3. In addition, an Augustus gene prediction was 
carried out using the novel peptides, reference gene Traes_1DS_947F6918F and 
exon_part and intron hints. However, the Augustus gene prediction did not incorporate 
the novel peptide, only the reference gene, exon_part and intron hints (Figure 7.7, and a 
single supporting annotated MS/MS spectrum in Appendix Figure 7.17). 
Performing a BLASTP search against bread wheat in NR revealed that the novel 
peptide matched to an unnamed protein product (CDM83565.1 with E-value = 2.2) with 
88% query coverage and 75% identity. The three reference protein-coding transcripts 
matched chloroplast MDAR6 protein (AKA43771.1 with E-value range: 2E-06 – 4E-
07) with ~48% query coverage and 32% identity. 
The three reference protein-coding transcripts appeared to be poorly annotated, 
with no entries in NR, since they found no matches with significant coverage. However, 
the proteins did have 11 shared peptides mapped, supporting their prediction, ranging in 
lengths from 7 aa to 24 aa. By comparison, the novel peptide only found poor 
significant matches to known proteins in NR, with a relatively short peptide of only 9 aa 
and with little supporting evidence, indicating that the annotation event may be a false 
positive. 
None of the other 38 novel exon annotations identified in the proteogenomics 
analysis led to new predictions, with the majority of novel exon annotations appearing 
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to conflict with the extrinsic EST, cDNA and RNA-seq evidence from the exon, 
exon_part and intron hints. However, in a few novel exon annotation events, including 
this example novel exon event for gene Traes_1DS_947F6918F, there appeared be to 
intron and exon_part hints across the same region (Figure 7.7), which may account for 
the single novel exon peptide identified. Until further evidence comes to light in support 
of these novel exon annotation events, it is assumed that all novel exon annotation 
events in the present study are likely false positives. 
Figure 7.7 Novel exon annotation 
A novel exon annotation event located on chromosome 1DS, fragment 1DS1899380. A novel and unique 
peptide was identified in the middle of an intron from gene Traes_1DS_947F6918F. The reference gene, 
novel peptide, exon_part and intron hints were used for gene prediction. All but the novel peptide could 




7.3.12 N-terminal acetylated peptides 
As applied in previous chapters and the overall study, N-terminal acetylation was used 
as a variable modification to infer the location of TIS sites, in order to further validate 
novel annotation events and identify potentially over-predicted known genes, or identify 
alternative protein isoforms with different TIS sites. A total of 87 N-terminal acetylated 
peptides were identified among 348 genes (795 protein isoforms) in the Wheat MIPS 
v2.2 annotation (Appendix File 7.7), and 10 were identified from 10 high confidence 
proteins (≥2 peptides with at least 1 unique). Of the total 348 genes there were 208 
genes (~60%) that had N-terminal acetylated peptides in agreement with their TIS sites, 
and the other 140 genes (~40%) had N-terminal acetylated peptides in disagreement 
with their TIS sites. Due to the protein inference problem only unique N-terminal 
acetylated peptides were considered and these were found to map to 11 genes (11 
protein isoforms), all of which were in agreement with their TIS sites. 
 Among the 290 novel peptides identified (Table 7.1), 12 were found to be N-
terminal acetylated (Appendix File 7.7). Of these, 11 were unique and 1 was shared, 
with 10 of the unique peptides not incorporated into any Augustus gene predictions. The 
two remaining novel N-terminal acetylated peptides incorporated into gene predictions 
were not incorporated at the N-terminal-most end of the predictions, but instead resided 
towards the C-terminal or the middle of the predictions. 
The one unique N-terminal acetylated peptide “RRGGQGIWRRH” was 
incorporated into Augustus gene prediction g151373, located at positions 18,926 to 
24,839, inferred by a novel gene annotation event, on chromosome 2BL, fragment 
2BL8085194, spanning positions 18,334 to 21,094. The N-terminal acetylated peptide 
was located well within the prediction at positions 21,062 to 21,094, conflicting with its 
suggested TIS site. The ambiguity that the locations of these N-terminal acetylated 
peptides presents could probably be attributed to the level of fragmentation of the 
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genome, with the large number of missing sequence regions causing misrepresentation 
of the majority of truly unique and shared peptides within the genome. 
The single shared N-terminal acetylated novel peptide “RWERRPR” was 
identified within a gene boundary event on chromosome 1AS, fragment 1AS3271894, 
spanning positions 3,166 to 3,186, for gene Traes_1AS_16ED0B5C3 and its two 
protein-coding transcripts, as well as gene Traes_1AS_70E8717D0 and its single 
protein-coding transcript. The N-terminal acetylated peptide was, however, incorporated 
into two Augustus gene predictions: g12834 and g320082, located on chromosome 
1AS, fragment 1AS3271894, and spanning positions 3,094 to 3,715, in line with the 
proteogenomics evidence, and on chromosome 2DL, fragment 2DL9871754, spanning 
positions 1 to 785, respectively. The location of the peptide from gene g320082 on 
chromosome 2DL was not reported within any novel annotation events, due to the lack 
of at least a single unique and novel peptide within the peptide cluster at that genomic 
location. 
There were only 11 unique and known N-terminal acetylated peptides identified 
amongst the known proteins and only 1 unique and 1 shared novel N-terminal 
acetylated peptide identified amongst the novel annotation events, probably due to the 
high level of fragmentation of the genome. As a result, the ability to identify all of these 
N-terminal acetylated peptides as unique and thus provide a level of unambiguity to 
reliably identify alternative TIS sites is sorely lacking. Moving forward, this would 
require the genome to be further assembled before any enhanced interpretation of the 
locations of these N-terminal acetylated peptides. 
Methods to further assist in identifying the N-terminal ends of proteins to help 
validate the known proteins and improve the identification of novel annotation events 
could be implemented through the use of N-terminomics [452], and other methods such 
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as heuristic and database techniques, as well as top-down proteomics, as was outlined in 
the preceding two chapters (Sections 5.3.13 and 6.3.9). 
7.3.13 Impact of search space 
Applying the two-pass search approach with two-stage FDR strategy, as previously 
demonstrated in Chapter 6, significantly reduced the impact that the search space had on 
the proteogenomics analysis. Using the same strategy in the present study 1,970 of 
293,053 proteins from Wheat MIPS v2.2 annotation were identified during the MS/MS 
database searches using MS-GF+, while the total number of proteins mapped by 
proteogenomics was 16,635. Of these, 107 high confidence proteins had ≥2 peptides 
with 1 unique peptide. 
7.4 SUMMARY 
This present study has highlighted the advantages of proteogenomics and how different 
legacy –omics datasets from genomics, proteomics and transcriptomics can be 
repurposed for genomic annotation. Primarily, the study made a significant contribution 
to the genome annotation of Triticum aestivum (Bread wheat), specifically the Wheat 
MIPS v2.2 annotation, and which further contributed to the dissertation author’s 
previous proteogenomics study [12]. The present study identified 290 novel peptides 
contributing to 189 novel annotation events (187 exclusively), consisting of 46 frame-
shifts, 9 translated UTRs, 17 exon boundaries, 39 novel exons, 17 gene boundaries (15 
exclusively), 24 reverse strands (24 exclusively), and 37 novel gene events, among a 
total of 96 genes (96 exclusively) and 189 proteins (187 exclusively). Among these 
annotations, 180 novel peptides directly led to 70 predicted proteins via Augustus gene 
prediction. This study, which implemented a new methodology, benefitted from 
utilising MS/MS spectra over a range of proteases and tissues and contributed a large 
RNA-seq dataset as a splice graph, which will become a valuable resource for further 
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wheat proteogenomics studies in the future. This study also identified some key 
highlights for consideration in future proteogenomics analysis: 1) the high level of 
fragmentation of the genome caused problems with annotation event identification and 
gene prediction; 2) the large fixed peptide linkage distance caused misidentified 
annotation events, as has been found to be the case in previous chapters, which also 
impacted the identification of annotation events where the scaffolds are much shorter 
than the peptide linkage distance used; and 3) the spectral datasets used were small and 
derived from gels which prevented clustering and quality filtering and probably resulted 
in retained spurious spectra. 
7.5 CONCLUSIONS 
In this study, as in Chapter 6, a two-pass search approach with improved two-stage FDR 
strategy was used. This approach greatly benefitted the study; given the further inflated 
search space of the 17 Gbp wheat genome and it’s much larger proteogenomics search 
space. 
Due to the small MS/MS spectral datasets, and being derived from 1D and 2D 
gel, clustering and quality filtering were not feasible. This decision may have 
inadvertently impacted the false positive rate, possibly resulting in a number of 
misidentifications due to spurious partially fragmented MS/MS spectra as a result of the 
absence of clustering, and retained poor quality MS/MS spectra because of the absence 
of any quality filtering. However, the use of multiple proteases probably offset these 
drawbacks to a degree, by reinforcing the identification of numerous annotation events 
derived from different sources. In addition, selection of the most appropriate precursor 
mass tolerances for each of these datasets proved effective, particularly with the high-
accuracy MS/MS spectra. This approach, in combination with the various proteases 
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used to improve coverage, provided an effective method to achieve sufficient coverage 
and deliver an informative proteogenomics analysis. 
The study was able to significantly improve the novel peptide identification rate 
from the trypsin-digested wheat flour by comparison with the initial study by the 
dissertation author [12], by an additional 122 novel peptides, demonstrating a ~8x 
improvement in sensitivity and with similar improvements observed in the identification 
of known proteins. 
The merging of multiple search results from the various protein extracts and 
tissues digested with different proteases resulted in a number of annotation events 
containing multiple different sources of MS/MS spectra from different digests, while 
others consisted of only one source of MS/MS spectra from a single digest. This 
demonstrated that, by using multiple proteases, the coverage within an annotation event 
could be significantly increased and as a result could improve the event probability. 
The MS/MS spectra and RNA-seq data sources in the present study were limited 
to reported findings obtainable as legacy data at the time. Due to the apparent 
differences between proteomics data and RNA-seq data obtained from the different 
tissues, cultivars and wheat-rye hybrids, there was a real potential for increasing the 
FDR, which needed to be taken into consideration when identify any annotation events 
and new predictions. Future studies, with a focus solely on obtaining MS/MS spectra 
and RNA-seq data for proteogenomics analysis, could concentrate on the Chinese 
Spring cultivar and generate sufficient depth and breadth of sampling to reduce the 
occurrence of any false positives. Additionally, when different sources of MS/MS 
spectra, genomic and RNA-seq data are included from different cultivars, the addition 
of variant calls in the splice graph could identify and account for the different sequence 
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variations, allowing for informative side studies with a focus on identifying these 
variants. 
The total number of predicted genes and proteins in this study were probably 
overestimated due to the fragmented nature of the genome, with some longer genes 
spanning scaffolds being identified two or more times. The number of genes could also 
be overestimated due to Augustus splitting the prediction based on the evidence. 
Revisiting the genomic annotation in the future as knowledge of the genome improves 
would likely see these numbers drop. Another problem related to the highly fragmented 
nature of the genome would be the application of the peptide linkage distance, which 
probably would be larger than many chromosome fragments, and which would have 
resulted in a number of annotation events being misidentified, particular on the 
boundaries of a scaffold where a locus may span two or more scaffolds. 
As mentioned in previous chapters, a dynamic way to determine the peptide 
linkage distance was needed. The problem with using a fixed peptide linkage distance 
was clearly illustrated in Section 7.3.6, where a novel gene event was misidentified as a 
gene boundary event due to its close proximity to the neighbouring gene. One 
possibility would be to determine the peptide linkage distance dynamically through 
machine-learning approaches, considering the distribution of genes in the local region 
as well as considering the distribution of all mapped peptides, protein, EST and RNA-
seq alignment evidence. 
Another problem that arose in this study as a result of the fragmented genome 
was the occurrence of partially predicted genes in the reference annotation. In one 
example, detailed in Section 7.3.8, a partially predicted gene caused problems with an 
assigned annotation event that contained a 41 bp ambiguous stretch of amino acid X 
residues, because the reference prediction overlapped the end of the chromosome 
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fragment. This resulted in confusion with the annotation event, as the only unique and 
novel peptide identified in this peptide cluster resided in the ambiguous, supposedly 
known coding part of the prediction, and therefore would not have been identified if 
sufficient coverage of the reference prediction had been available. 
The Enosi tool could be improved to recognise annotations containing 
ambiguous protein sequences and flag these as problems prior to annotation event 
inference, or discard them from the analysis to prevent misinterpretation of annotation 
events. At the very least, the reference predictions used for analysis should be complete 
predictions, either full predictions or truncated, with the GFF and protein prediction in 
complete agreement and with no ambiguous regions confusing the assignment of the 
annotation event. 
Overall, the fragmented wheat genome was a problem when identifying 
annotation events accurately and the final gene predictions were often erroneous or 
incomplete due to a gene overlapping the end of the chromosome fragment. As 
mentioned in previous chapters, possible methods which could be used to overcome 
such limitations in the future could be de novo sequencing of unassigned MS/MS 
spectra, matching the MS/MS spectra against closely homologous sequences, or 
approaches such as template proteogenomics, which could be used to build up complete 
coverage of proteins given closely homologous sequences to use as the genomic 
template and enough MS/MS spectra to provide complete coverage. However, such a 
method has only ever been used for small niche studies, looking at single genes, such as 
antibody genes, but it feasibly could be modified to work on the scale of an entire 
genome. Moving forward, tools such as BUSCO [588], as suggested in Chapter 5, 
Section 5.4, could be applied to conduct an assessment of the genome assembly and 
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8 GENERAL CONCLUSIONS 
Proteogenomics has evolved greatly over the last decade, holding promise for 
improving genome annotation to match the accelerating rate of genome sequencing 
technologies. However, a number of computational challenges remain, many of which 
have been addressed throughout this thesis, including: how to address the reduction in 
sensitivity due to an inflated search space; how to accurately identify various annotation 
events; how to define the search space; how best to control the false discovery rate 
(FDR); and how best to define the parameters for a MS/MS database search. 
 This thesis identified a bioinformatics framework for conducting 
proteogenomics analysis, defined in a methodology that was iteratively improved and 
demonstrated across four case studies using the Enosi proteogenomics tool. During the 
time Enosi was being further developed, since its publication in [81], the dissertation 
author provided the developers with extensive input through debugging and suggested 
features, while conducting early preliminary studies for grape [8] and wheat [12], which 
were later expanded on within the thesis.  
The dissertation author made further contributions to methodology development 
by adding an evaluation of search parameters, FDR filtering approaches, the screening 
of annotation events to improve the number of annotation events identified, and 
modifications to the search space to improve sensitivity and discrimination between true 
and false positives. 
Finally, the thesis draws conclusions and provides further insight into 
proteogenomics, and highlights a number of considerations for the future of this new 





8.1  CASE STUDIES 
Throughout the thesis a proteogenomics methodology was applied to a number of 
different case studies and it was understood that each case study would highlight the 
benefits and caveats of the applied methodology in an iterative improvement. The 
identified known proteins and numerous novel annotation events identified in each of 
these case studies are illustrated below in Table 8.1. 
 Table 8.1 Summary of proteogenomics annotations across four case studies 
 Bacteria Grape Human Wheat 
Known proteins 3,550 11,779 27,849 16,635 
High confidence known proteins 2,194 5,048 1,047 107 
 
Frame-shifts 9 5 7 46 
Translated UTRs NA 37 4 9 
Exon boundaries 22 16 27 17 
Novel splices NA 1 0 0 
Novel exons NA 9 23 39 
Gene boundaries 19 160 (24) 289 (10) 17 (15) 
Reverse strands 45 112 (10) 262 (50) 24 (24) 
Novel genes 60 1 5 37 
Total annotation events 155 341 (103) 617 (126) 189 (187) 
Annotated genes 145 216 (67) 147 (29) 96 (96) 
 
Augustus gene predictions NA 84,948 29,266 413,587 
Augustus gene predictions as a 
direct result of proteogenomics 
NA 55 49 67 
Note: Numbers in parenthesis represent the exclusive numbers. The inflationary effect of a large peptide 
linkage distance on gene boundaries and reverse strands was removed by assigning a peptide cluster as 
either a proximal or distal event, not both, with preference placed on proximal events. 
In light of these findings, there were a number of problems encountered during 
proteogenomics analysis, which included: the underlying quality of the reference 
annotation; the quality of the genome assembly; the limitation of the available MS/MS 
spectra; and/or the different shortcomings of the applied proteogenomics approach. 
A common challenge across all studies was the use of a fixed peptide linkage 
distance, which was an over-simplification of gene sizes and intergenic distances. The 
use of a fixed peptide linkage distance likely contributed to misidentified annotation 
events due to the many varying degrees of gene overlap, gene size and intergenic 
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distances across genomes the size of bacteria to larger, eukaryotic genomes. The use of 
a fixed peptide linkage distance was a significant problem and was resolved in part by 
identifying the exclusive annotation events, as highlighted in Figure 8.1, however, a 
more robust solution will be needed in future methodologies and/or later versions of 
Enosi, to more accurately identify the annotation events and by extension perform more 
accurate annotation event level filtering for more confident gene predictions. 
The majority of case studies were able to utilise MS-Cluster to improve the 
overall quality of the MS/MS spectra, by clustering and merging and with PepNovo to 
remove any lower quality MS/MS spectra. However, there were two case studies, 
namely the bacterial and wheat studies, where this was not entirely possible. In the 
bacterial case study, the MS/MS spectra were suitable for clustering. However, the 
spectra were derived from 1D gels, and had relatively few peaks and lower peak 
intensities, resulting in relatively high spectral losses when using PepNovo. In the wheat 
case study, there were too few spectra per dataset, which did not allow for clustering, 
and the spectra were derived from 1D and 2D gels, which led to relatively fewer peaks 
and peak intensities and again resulted in higher spectral losses when using PepNovo. 
Therefore, there may have been a higher level of false positives derived from these 
datasets, particularly with the wheat case study, as both clustering and quality filtering 
were not possible. Nevertheless, the multiple sources of protease digests for the wheat 
study may have partially compensated, by providing higher coverage and thus 
reinforcing some identifications with multiple different sources of MS/MS spectra. 
Revisiting these studies in the future with larger MS/MS spectral datasets, 
optimally derived from whole cell lysates, would alleviate these problems. While the 
outcomes from the pre-processing steps were not always consistent across all case 
studies, the use of a precursor mass tolerance optimization step greatly improved on the 
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sensitivity of peptide-spectrum match (PSM) identification, while keeping the peptide 
FDR low, which in particular was useful for high-accuracy MS/MS spectra. 
8.1.1 Bacterial 
In Chapter 4, proteogenomics analysis was applied to the nitrogen-fixing bacteria 
Bradyrhizobium diazoefficiens, identifying 155 novel annotation events (Figure 8.1). 
One particular major finding and a number of challenges were identified, as detailed 
below. 
1) Major finding 
One of the novel annotation events identified was found to be an ambiguous annotation 
event, which hinted at a possible sequencing error. The possible sequencing error was 
further assessed and successfully validated, through the identification of a guanine 
insertion indicated from multiple sequence alignment of closely related species. 
Through this identification another avenue for proteogenomics has been highlighted: a 
means to assess the quality of the genome sequence itself within protein-coding regions. 
2) Challenges encountered 
During analysis a number of caveats were also identified, such as the inability to utilise 
the identified annotation events, at least for bacteria, in heuristic gene prediction tools, 
apart from simply validating predictions and performing manual curation. The 
dissertation author is currently unaware of any prokaryotic gene prediction tools that 
consider external peptide evidence as hints during gene prediction. This challenge could 
be addressed by applying modifications to well-known and highly accurate prokaryotic 
gene prediction tools, such as GeneMark [598] and GeneMark.Hmm [599], Prodigal 
[558] and Glimmer [557]. Applying such an approach to accept external peptide hints as 
evidence, during gene prediction, would accelerate bacterial proteogenomics annotation 
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pipelines, such as with the use of Augustus [101, 102], a predominantly eukaryotic gene 
prediction tool demonstrated within Chapters 5 to 7. 
 Another caveat of this analysis was the high proportion of overlapping genes, 
the high proportion of coding to non-coding genes, and relatively small intergenic 
spaces in bacterial genomes. This caveat, which was more commonly identified in this 
study, resulted in a number of novel gene events being misinterpreted as reverse strand 
events, as genes also present on the reverse strand, were not considered by Enosi when 
inferring annotation events. The high proportion of overlapping genes also made the 
two-pass search approach less effective in choosing the most appropriate stop-to-stop 
ORFs from the six-frame translation to reduce the database size and improve sensitivity. 
A way to improve upon the selection of ORFs was later demonstrated in Chapters 6 and 
7; by accepting only relatively significant matches to ORFs and hence likely spurious 
PSMs were removed from the second-pass search. The use of a combined FDR strategy 
within this study reduced sensitivity and proved less effective at accurately 
discriminating true and false positives from within the known and novel search spaces. 
This was later rectified in Chapters 6 and 7 with the improved two-stage FDR strategy, 
but this case study could not be later revisited to utilise the new methodology due to 
time constraints. To account for the high proportion of overlapping genes in this type of 
study, in future the use of stranded RNA-seq analysis [600] could be performed during 
sampling. Possibly in combination with Ribo-seq [464], previously mentioned in 
Section 2.4.1, to confidently identify the expressed gene on either strand and to select 
the most appropriate ORF, if any, prior to peptide mapping and clustering. 
 Although a number of caveats were identified in the present study, the use of 
orthologous gene prediction, demonstrated with predictions sourced from NCBI, 
Prodigal and RAST, proved an effective way to compare the accuracy of different 
prediction approaches. This method also provided an orthogonal approach to validating 
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predictions from the reference, and assist with determining suitable event probability 
thresholds, given there was no means of determining the annotation event FDR at any 
chosen event probability. 
8.1.2 Grape 
In Chapter 5, proteogenomics analysis was applied to Vitis vinifera (grape), identifying 
341 novel annotation events (103 exclusively) that led to 57 Augustus protein 
predictions (Figure 8.1). A number of major findings and challenges were identified, as 
detailed below. 
1) Major findings 
One of the novel annotation events identified hinted at the possibility of an over-
assembly of the genome, particularly on chromosome 7.  The over-assembly was 
inferred after the reference protein, identified novel peptides, and the Augustus gene 
prediction all matched significantly to a RuBisCo protein in NCBI NR, which is 
normally found exclusively in the chloroplast genome. The presence of a RuBisCo gene 
on chromosome 7 is probably a result of reads derived from the chloroplast genome 
being incorporated into the assembly of chromosome 7. The conclusion of an over-
assembled genome is also backed up by the already fragmented nature of the genome, 
with unresolved chromosome fragments, which can fail to resolve into complete 
chromosomes when scaffolds in the assembly contain either long repeat regions and/or 
an over-assembly. Future proteogenomics analysis of the grape genome should 
therefore not proceed until this over-assembly issue can be resolved to prevent such 
occurrences happening in future proteogenomics studies. 
In addition, the original reference annotation was found to contain numerous 
CDS phase errors within the GFF file, which conflicted with the predicted reference 
protein sequences and required correction prior to Augustus gene prediction. This 
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brought into question the employed method used for the original reference annotation. 
Ultimately for the grape genome, many improvements will be required to improve the 
assembly and annotation. Therefore, an in-depth review of both the completeness of the 
assembly and annotation should be considered to identify all of the caveats moving 
forward. For example, the level of completeness of the genome assembly and 
annotation could be determined using tools such as BUSCO [588], which utilises 
single-copy orthologs to assess the completeness of conserved genomic regions, as was 
mentioned in Sections 5.4 and 7.4. 
2) Challenges encountered 
A number of caveats were identified throughout this study, such as the use of low-
accuracy MS/MS spectra, which limited the PSM identification rate and, as a result, 
required larger precursor mass tolerances. Additionally, only a combined FDR strategy 
was implemented, with no two-pass search approach with improved two-stage FDR 
strategy, which was later developed and employed in Chapters 6 and 7, but which could 
not be revisited in this case study due to time constraints. As a direct result from using 
the combined FDR strategy and the larger grape genome translated in six-frames, there 
was also a resultant loss of sensitivity, with 52% fewer known proteins identified when 
performing a proteogenomics search, which also equated to a loss in sensitivity with the 
identification of novel peptides to infer novel annotation events. 
In an attempt to negate the impact of low-accuracy MS/MS spectra and improve 
the sensitivity of novel annotation event identifications, the results from two 
proteogenomics runs with two different precursor mass tolerances of 2.0 Da and 3.0 Da 
were used, which provided 3.3% peptide FDR and 3.9% peptide FDR at the known 
proteome level respectively. The identified annotation events from both of the 
proteogenomics analysis runs were aggregated thus improving the coverage. Given 
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additional sources of MS/MS spectra of higher accuracy and sourced from multiple 
proteases, this same approach towards aggregating proteogenomics results could be 
applied to further improve coverage, as was later demonstrated in Chapter 7. 
 In this study, annotation events with only a single unique and novel peptide 
which were identified outside the applied annotation event thresholds, were accepted 
based on the consideration of other evidence, such as sequence homology to proteins in 
NR with considerations of the genomic coordinates, as well as known peptides, spectral 
counts, and peptide length. This approach provided a means to validate the annotation 
events from other orthogonal protein evidence, not considered in the original 
annotation, as well as provided a means to improve sensitivity, at the same time 
retaining relatively good specificity, as no method to determine the annotation event 
FDR was available. Due to the requirement to manually check matches for entries in 
GenBank for genomic coordinates and orthogonal evidence, the throughput of the 
approach was negatively impacted, making the approach particularly unruly for much 
larger studies. To improve the throughput of annotation event screening a modification 
was later considered and applied in Chapters 6 and 7. 
 Utilizing N-terminal acetylated peptides in both the novel annotation events and 
known proteins to identify translation initiation start (TIS) sites was not a trivial task to 
accomplish in this study, particularly in a relatively larger genome, and required manual 
searching to interpret potential conflicts within the annotation. Results from this 
analysis identified numerous ambiguous identifications due to the protein inference 
problem. A method to resolve this issue to reduce ambiguity and improve throughput 
could have been to consider only unique N-terminal acetylated peptides, as was later 
applied in Chapters 6 and 7. To further assist in resolving the N-terminal end of proteins 
and annotation events, the use of N-terminomics in combination with multiple proteases 
and replicates, top-down proteomics and other more heuristic methods to resolve the 
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protein inference problem, from a proteomics-only context (Chapter 2, Table 2.6), could 
be applied. 
Many of the identified novel and known N-terminal acetylated peptides 
appeared to have undergone N-terminal Methionine Excision (NME) [248], due to the 
lack of their 5’ Methionine cap. In instances where the 5’ Methionine cap is retained 
and an alternative translation initiation codon is used, the peptide would not be able to 
map to its genomic coordinates and would go undetected in the current proteogenomics 
methodology. The most practical approach to identifying such peptides would be to 
supply another protein sample, digest, perform N-terminal peptide enrichment and then 
add Methionine aminopeptidase in vitro to cleave off all N-terminal Methionine 
residues, and then map the resulting peptides. The locations of peptides with 5’ 
Methionine caps and alternative translation initiation codons could then be identified by 
comparison to the same samples without treatment with Methionine aminopeptidase. 
 The processing of overly large result files during PSM FDR filtering, from 
combined FDR results, proved problematic, requiring the processing of subsets of the 
search results to achieve filtered results in a reasonable time-frame. But this led to 
reduced accuracy with PSM FDRs and event probabilities. This problem was later 
resolved in Chapters 6 and 7 with the two-pass search approach with improved two-
stage FDR strategy, which essentially provided a multiple step filtering process to 
reduce the final dataset size prior to the final PSM FDR filtering while also improving 
sensitivity and discrimination between true and false positives.  
8.1.3 Human 
In Chapter 6, proteogenomics analysis was applied to Homo sapiens (human) and 617 
novel annotation events (126 exclusively) were identified that led to 52 Augustus 
protein predictions (Figure 8.1). A number of major findings and challenges were 
identified, as detailed below. 
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1) Major findings 
This case study was the first to apply a new methodology in FDR filtering for 
proteogenomics, using a two-pass search approach by accepting only significant 
matches for the second-pass search and the use of an improved two-stage FDR strategy, 
by performing PSM FDR filtering on separated known and novel identified sequences. 
This method was demonstrated to outperform the combined FDR approach and 
conservative two-stage FDR strategies, by identifying 44% more known proteins and 35 
more novel peptides. In addition, the new methodology resulted in reduced search result 
file sizes, allowing for a reduction in the overhead needed to process the files for PSM 
FDR filtering, which was problematic in Chapter 5. This strategy was also later 
employed in Chapter 7. In addition, as a direct result from the improved methodology, 
the identification of an additional 15,020 peptides compared to the ENCODE project 
[11] was realised. 
2) Challenges encountered 
A number of caveats were identified throughout this study, such as the identified 
discrepancy between the proteome of cell line GM12878 and the proteome from 
GENCODE v19. The discrepancy was realised when an expressed pseudogene 
ENSG00000250933.1 also known as glyceraldehyde 3-phosphate dehydrogenase 66 
(GAPDHP66) was identified. This pseudogene is known to be protein-coding in cell 
line GM12878 and non-protein coding in GENCODE v19. As a result, the novel 
peptides identified from the expressed pseudogene were misinterpreted as a translated 
UTR. This highlighted the effect that a lack of support by Enosi to identify expressed 
pseudogenes and non-coding RNAs has on the accuracy of annotation event 
identification, as well as the time it takes to manually and correctly interpret the 
annotation events. This delay could have been avoided by Enosi adding the additional 
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annotation event types by first parsing the known annotation. In addition, future studies 
could identify the known protein-coding pseudogenes and/or RNA genes from the 
different sources being studied, such as cell line GM12878 and supplement the known 
proteome to avoid further false identifications. 
 In comparison to the previous grape study in Chapter 5, in this study an 
improvement was made to the throughput of screening single peptide annotation events. 
The same event probability and peptide parsimony thresholds were applied, and instead 
of using NCBI NR for sequence homology searches, NCBI RefSeq protein was used 
instead at higher stringency to improve the specificity. Due to its impact on throughput, 
with minimal exception, no screening of each match in GenBank for genomic 
coordinates and orthogonal evidence was performed, as was done previously in Chapter 
5 with grape. However, this could be resolved in later studies by automating the process 
by parsing GenBank entries downloaded from NCBI. Other similar concepts to quickly 
and efficiently validate annotation events in a highly specific manner could be via the 
use of spectral library searching or with the use of spectral archives [398]. 
The selection of only unique and known N-terminal acetylated peptides proved 
to be a viable approach to the identification of TIS sites to improve throughput by 
reducing the number to a manageable size, in contrast to Chapter 5 with the grape study 
where every N-terminal acetylated peptide was manually checked and validated. 
The identification of one particular unique and novel N-terminal acetylated 
peptide indicated the TIS site of a new Augustus prediction inferred from a reverse 
strand annotation event, which identified a novel gene on the reverse strand (Section 
6.3.7). This brought to the dissertation author’s attention the fact that unique N-terminal 
acetylated peptides could be used to define the boundaries of annotation events by their 
specific position within the annotation event to avoid including the wrong peptides from 
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other clusters in close proximity. However, this would be highly dependent on the level 
of fragmentation of the genome, with a fragmented genome making the identification of 
any unique peptide highly ambiguous, due to missing genomic regions, and would not 
account for some genes encoding multiple protein isoforms, with multiple TIS sites, and 
which may be expressed concurrently. Further methodologies could also be applied to 
improve the identification of the N-terminal end of proteins, as mentioned previously in 
Section 8.1.2. 
8.1.4 Wheat 
In Chapter 7, a proteogenomics analysis was applied for Triticum aestivum (Bread 
wheat) and 189 novel annotation events (187 exclusively) were identified that led to 70 
Augustus protein predictions (Figure 8.1). A number of major findings and challenges 
were identified, as detailed below. 
1) Major findings 
The same methodology, using the two-pass search approach with improved two-stage 
FDR strategy and annotation event-screening method as employed in Chapter 6, was 
also used in this study, which provided the benefit of increasing the sensitivity of 
annotation event identification, given the much larger 17 Gbp genome. Compared to the 
initial study by the dissertation author with Mayer and colleagues [12], that only utilised 
a small wheat flour tryptic-only MS/MS spectral dataset, 156 additional novel 
annotation events were identified. The use of multiple sources of MS/MS spectra from 
different tissues and multiple different protease digests provided higher coverage than 
using a single protease, and after aggregation resulted in more peptides identified within 
annotation events with improvement of the event probabilities. In addition, the inclusion 
of multiple proteases probably offset some negative effects from not clustering or 
quality filtering each of the MS/MS spectral datasets. 
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2) Challenges encountered 
A number of caveats were identified throughout this study, such as the annotation event 
screening which was done previously in Chapter 6 using RefSeq protein, but in this 
study due to the lack of wheat protein entries, it was necessary to use NR, filtered at 
much higher stringencies to account for the higher redundant and un-curated protein 
repository. The requirement to use NR may have inadvertently introduced false 
positives and suffered from reduced sensitivity in identifying the correct corresponding 
proteins. The inaccuracies introduced from this approach could be negated if spectral 
library/archive approaches were developed, as was suggested in Section 8.1.3. 
 Another caveat that occurred in other studies but was more common in this 
study was the appearance of unique N-terminal acetylated peptides incorporated into the 
middle region of new Augustus predictions. This error was most likely a direct result of 
the highly fragmented genome causing a misidentification of the unique and shared 
status of all identified novel peptides. Further methodologies to improve the 
identification of N-terminal ends of proteins could be applied, as was outlined in 
Section 8.1.2, although what benefits, if any, will be gained by applying these methods 
to a highly fragmented genome in this study is unknown. In addition, due to the small 
size of many chromosome fragments the peptide linkage distance was often much larger 
causing some annotation events to be misidentified, such as novel genes, which may be 
gene boundary events to genes on another chromosome fragment. 
 Another caveat that was a result of a highly fragmented genome was the 
inflation in the number of predicted genes and proteins, due to many genes and proteins 
spanning across chromosome fragments. Additionally, many genes could not be 
predicted due to small scaffolds and missing translation initiation sites off the end of the 
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scaffold, even though proteogenomics evidence, as well as other evidence from the 
reference and orthogonal hints evidence was available. 
Further improvements to the genome assembly and annotation are needed before 
any additional proteogenomics analysis is conducted, which could be assisted using 
tools such as BUSCO [588], as was previously highlighted in Section 8.1.2. 
 A unique issue that was only identified in this study was the misidentification of 
a translated UTR event, revealed as a probable exon boundary event for two different 
protein isoforms within the same gene. The exon boundary event was not primarily 
identified by the Enosi tool, due to two protein isoforms containing an ambiguous X 
amino acid region, where the novel peptides should have been identified as known but 
were instead identified as novel. Resolving the ambiguous sequences would have 
resulted in the novel annotation event not being identified, as the single unique peptide 
was identified within the ‘known’ ambiguous region of the protein. The dissertation 
author drew two conclusions from this observation: 1) if possible, ambiguous X amino 
acid protein sequences in protein predictions should not be included in analysis, 
however this is often difficult due to partial reference predictions with first draft 
genomes; and 2) using all mapped peptides during clustering with at least 1 unique 
peptide, followed by removal of all known peptides would identify many more 
annotation events at a high specificity. Using all peptides during peptide clustering 
would be superior to using only novel peptides, as many more valid peptide clusters 
could be identified containing a unique peptide. Even as the annotation improved the 
sensitivity of novel annotation event identification could remain high as the number of 
identified unique and novel peptides diminished. 
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8.2 FUTURE DIRECTIONS 
Over the course of this thesis an improvement to how proteogenomics could be 
conducted was realised, in terms of further expanding on the case studies outlined 
within this thesis and the field of proteogenomics as a whole.  
8.2.1 Future directions for case studies 
In terms of how any specific case study could be improved in the future, the use of the 
two-pass search approach with improved two-stage FDR strategy, which was developed 
and utilised in the human (Homo sapiens) and wheat (Triticum aestivum) case studies in 
Chapters 6 and 7, respectively, could be applied to the nitrogen-fixing bacteria 
(Bradyrhizobium diazoefficiens) case study in Chapter 4 and the grape (Vitis vinifera) 
case study in Chapter 5. 
To further expand on the case studies, more evidence could be utilised, such as 
larger MS/MS spectral datasets and of higher mass accuracy, preferably from multiple 
different proteases and also comparably suitable large RNA-seq datasets, all of which 
could be provided with high depth and breadth of coverage. In addition, the large 
datasets could also be tailored with other studies in mind, hence value-adding to its use. 
For example, once the datasets have contributed to improving the genome annotation, 
the new predictions could be used in a proteomics-only analysis, examining the 
differences between environmental conditions such as stress, time-points, tissues, 
protein expression levels, and peptide variants between individuals and/or closely 
related species. 
 An example of such a large-scale proteogenomics study could be the human 
genome. As one of the most studied research areas, there is now a plethora of additional 
datasets to choose from, one of the better known being the 1,000 Genome Project [65]. 
This large dataset could provide a resource of RNA-seq data that, when converted to a 
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splice graph, could help identify the complement of variant peptides within a 
population, in a similar manner to the cancer peptides in the study from [474], but from 
1,092 individuals. However, for the study to be comprehensive, proteomics data would 
also need to be obtained representing these individuals. There is currently one large 
resource of MS/MS spectral data for human, from recent proteogenomics studies which 
amassed an impressive 25 million MS/MS spectra from a diverse range of tissues and 
cell lines [450, 451], and which could be further mined for information using the 
methodologies outlined within this thesis to identify more novel annotations which 
previously have been missed. 
 Considering the above-mentioned human studies, a much larger and more 
ambitious undertaking would be to conduct a systems biology study, where the 
genomes, transcriptomes and proteomes of 1,000 individuals would be sampled from a 
wide variety of tissues and multiple ethnicities. This would account for protein-coding 
variants across the global human population at the genomics, transcriptomics and 
proteomics levels, and could form a new standard for identifying variations across 
human populations. To take this one step further and to value-add to such a study, the 
whole epigenome and metabolome could also be mapped from the global population. 
8.2.2 Methodology improvements 
In general terms of future directions for proteogenomics methodologies, huge room 
exists for improvement, with many of these avenues for improvement identified 
throughout this thesis and which are now discussed in detail in the following eleven 
points. 
1) Expanding on event types 
To reduce the occurrence of misinterpreted annotation events, further annotation event 
types could be added to the Enosi tool. The addition of further annotation events could 
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include expressed pseudogenes, for example, the two pseudogenes manually identified 
in Section 6.3.8 and long non-coding RNAs (lncRNAs), which are employed in tools 
such as PGTools [496] (previously discussed in Section 2.4.4). Other types of 
annotation events could include over-predicted genes, N-terminal methionine excision 
(NME) and signal peptides inferred from the presence of non-tryptic N-terminal peptide 
ends, and alternative TIS sites within the known proteins [492]. The identification of 
potential over-predicted genes and TIS sites was conducted manually throughout the 
thesis looking at only unique N-terminal acetylated peptides due to the large numbers 
and ambiguity from the protein inference problem. In addition, sequence variant events 
could also be considered, such as mutation, insertion and deletion, achieved through the 
use of RNA-seq alignments and common variant-calling tools such as the Genome 
Analysis Toolkit (GATK) [473], which could then be converted into a splice graph to 
supplement the standard splice graph. The variant splice graph could then be used to 
answer questions such as differences in the types of variants between samples, to 
identify potential causes of changes in protein function, and to account for physiological 
responses and/or underpin specific phenotypes. 
2) Resolving the negative impact of fragmented genomes 
During the proteogenomics analysis of grape (Chapter 5) and wheat (Chapter 7), the 
level of fragmentation of these respective genomes was quite high, with wheat being the 
most fragmented and grape appearing to be also over-assembled, with numerous 
identifications from chloroplasts and mitochondria. Future proteogenomics studies of 
these genomes could either implement a methodology to utilise sequences of close 
homology to account for the missing genomic regions, such as implementing template 
proteogenomics using a tool similar to GenoMS [481]. The alternative could be to wait 
until they have been assembled sufficiently and accurately, devoid of over-assemblies 
until re-analysis is conducted, to avoid any false positive identification. In order to 
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utilise template proteogenomics, another closely related genome could be added to the 
analysis. Regions of the genome that do not have homology to any of the fragmented or 
partially assembled target genome could be identified, and then selected to use with a 
tool such as GenoMS, which could be modified to handle larger genomic sequences. 
Any MS/MS spectra identified as unassigned to the target genome could be run against 
the homologous genomic fragments to identify missed protein-coding genes. The 
identified proteins could then possibly assist with validating the genome assembly as it 
further improves. 
3) Impact of inaccurate annotation events and filtering prior to gene prediction 
Many novel peptides could not be included into Augustus gene models, as was first 
pointed out in Chapter 5, Section 5.3.4, and found to be the case throughout Chapters 6 
and 7. This had been confirmed to be the case in a previous study [81], even with an 
applied annotation event FDR of 5%, as was communicated to the dissertation author 
(S. Payne, personal communication, September 29, 2012). Based on this information, it 
is not unreasonable to assume that numerous novel peptides, which were not 
incorporated into predictions by chance, could have also been incorporated into the 
predictions, leading to false positives. This was observed to be the case throughout the 
thesis, with some probable spurious peptides within annotation events leading to what 
appeared to be false positive predictions, and in some cases conflicting with other 
evidence. This was at odds with what was suggested in the original study that led to the 
development of Enosi [482]. According to the author of that study, acceptance of novel 
peptides at the PSM and annotation event identification levels was allowed to be more 
tolerant for final filtering of false positives at the gene prediction level with Augustus 
(N. Castellana, personal communication, April 15, 2014). 
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However, as observed from examples throughout this thesis, using Augustus as 
a final false positive peptide-screening tool was not without its problems, particularly 
when the actual FDR at the gene prediction level is not known. To improve the quality 
and throughput of genome annotation the quality of the final gene products need to be 
improved, and therefore the quality of the proteogenomics data provided to Augustus 
prior to gene prediction needs to be improved to reduce the occurrence of false positive 
predictions. 
A number of methods could be employed to reduce the occurrence of false 
positives at the peptide, annotation event and prediction level, as further detailed below. 
4) Defining the peptide cluster prior to annotation event inference 
A method to reduce the occurrence of false positives reaching the annotation event 
inference and gene prediction stage is to change the way peptide clusters, and therefore 
annotation events, are defined by considering other evidence during clustering. One 
variable which most influences the peptide cluster is the peptide linkage distance, which 
defines how peptides are clustered, and the distance between a gene and a cluster, and 
which by extension, directly influences the assignment of events. In particular, the novel 
gene, gene boundary and reverse strand events. 
In Enosi, the peptide linkage distance is currently a fixed value and, at least for 
eukaryotic genomes, is determined based on the majority of gene sizes across the 
genome, unlike in reality where gene sizes often vary widely and can often appear in 
close proximity or with large intergenic distances. A more intuitive approach would be 
to define the peptide linkage distance for each peptide cluster in a dynamic way, looking 
at additional evidence such as: 1) the distribution of all peptides across the genome; 2) 
considering evidence from aligned EST, protein and RNA-seq sequences within the 
region; and 3) the average size of genes in the local region. All of this evidence could be 
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used to build a model of likely gene distribution across the genome using a machine-
learning approach. However, it is unreasonable to assume that the correct peptide 
linkage distance would be chosen every time for every peptide cluster, as it may not 
always be easy to determine due to the level of fragmentation of the genome and the 
available evidence in proximity to the identified peptide clusters. In cases where 
evidence is lacking to build a reliable model, a default peptide linkage distance, 
determined by the user, could be assigned. 
Another method would be to redefine the way peptide clusters are generated. 
Currently in Enosi, all known peptides are removed and then the remaining novel 
peptides are clustered together based on the peptide linkage distance, which may 
include other spurious peptides or peptides that should belong to other nearby clusters. 
Each unique or shared novel peptide is identified in the context of the proteogenomics 
search space (six-frame translated genome and if applicable, splice graph) and whether 
the peptide is absent from the known proteome and the respective genomic coordinates. 
The known peptides are only labeled as either unique or shared in the context of the 
known proteins. Since only novel peptides are used in peptide clustering, with 1 unique 
peptide per cluster, prior to annotation event inference, this highlights a potential 
oversight for the use of the known peptides to identify valid annotation events. 
As was briefly introduced in Section 8.1.4, and will now be expanded on here, a 
better suggestion would be to first perform clustering prior to discriminating between 
known and novel peptides, which would improve the sensitivity of annotation event 
identification when selecting for at least 1 unique peptide per cluster. 
Since the genome annotation will improve over time, the pool of unique novel 
peptides will ultimately be reduced until most peptide clusters only consist of shared 
novel peptides. To avoid this and improve on the sensitivity of annotation event 
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identification, all peptides, including those that are identified to map to known proteins, 
could also be mapped to the six-frame translated genome, and if applicable, splice graph 
and used for peptide clustering, with subsequent removal to leave only novel peptide 
clusters. This would ensure that the sensitivity of annotation event identification would 
not diminish, even as the genome annotation improved. After filtering out all known 
peptides, the remaining peptide clusters with at least 1 unique novel peptide, as well as 
only shared novel peptide clusters (which previously contained at least 1 unique known 
peptide), could be used for annotation event inference. This approach came to light 
when considering the annotation event identified in Section 7.3.8, where a unique novel 
peptide was identified in an ambiguous protein sequence region. Such an approach 
could be implemented into the Enosi tool in future versions, however it would require 
some major reworking of a number of core functions. 
To further expand on this approach, after peptide clustering the included 
peptides could be screened based on other evidence. For example, peptides could be 
excluded to their own peptide clusters if they to do not have the same frame as the 
majority of other peptides (if any) and do not cluster within the same exon/CDS and 
ORF(s). Considerations such as these, if neglected, could lead to ambiguous and likely 
false positive frame-shift events and other proximal events such as translated UTRs and 
exon boundaries, as was identified to be the case in Section 6.3.7. 
Further evidence, which could also be considered, includes the location of 
unique and novel N-terminal acetylated peptides. For example, in Section 6.3.7 a unique 
and novel N-terminal acetylated peptide was identified on the boundaries of a peptide 




As was demonstrated in Section 6.3.7, peptide clusters may sometimes 
inadvertently incorporate other groups of peptides that should not belong together. 
Improvements could be achieved by considering any identified unique N-terminal 
acetylated peptides in the peptide cluster, and then splitting the peptide cluster at the 
location of the N-terminal acetylated peptide. This could be done provided that the 
unique status of the N-terminal acetylated peptide was not incorrectly assigned due to a 
fragmented genome and that multiple protein isoforms have not concurrently been 
expressed containing multiple different TIS sites across the same gene, which would be 
ambiguous due to the protein inference problem and lead to incorrectly splitting peptide 
clusters. However, by identifying the expression of multiple isoforms for a single gene, 
the larger peptide cluster assigned to that gene could be retained to avoid the ambiguous 
splitting of the peptide cluster or peptides could be assigned to the different protein 
isoforms and their respective peptide clusters more coherently. The identification of 
multiple protein isoforms for a gene and the intelligent assignment of peptides to 
different split peptide clusters could be achieved by first using traditional proteomics 
means, using tools such as those listed in Table 2.6, prior to proteogenomics analysis to 
identify the most likely protein isoforms being expressed. Such an approach would, 
however, only be of use for the known proteins used in the proteomics analysis, with 
later interpretation of any novel gene protein isoforms performed post-proteogenomics 
analysis. 
The use of N-terminomics [452] in combination with multiple proteases and 
sample replicates could also be used to improve coverage and assist with the resolution 
of ambiguity by assigning N-terminal acetylated peptides within peptide clusters and 
annotation events, to help define their boundaries and also validate the TIS sites of 
known proteins. This approach could also include the identification of non-AUG 
translation initiation codons and a variety of non-acetylated N-terminal peptides. 
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5) Filtering peptide clusters and annotation events 
Throughout this thesis, during annotation event filtering it was observed that many 
smaller annotation events that were filtered out with lower event thresholds often 
overlapped with larger annotation events with higher event thresholds and were 
erroneously retained as a result. Which contributed to false positives at the peptide, 
annotation event and prediction levels. An example of one such annotation event where 
this occurred was identified in Section 6.3.7, where a single novel peptide was inferred 
as a frame-shift event. It was previously filtered out with a lower event probability, but 
was retained in a larger reverse strand event with a higher event probability, and 
ultimately led to a probable false gene prediction that conflicted with RNA-seq 
evidence in GenBank. 
Many of these caveats could be addressed to improve the final peptide clusters 
and annotation events by identifying and then filtering out these erroneously included 
peptides and annotation events. This would keep the filtering of all annotation events 
consistent, improve specificity and reduce false positives, as well as removing much of 
the manual annotation and screening. 
A further method to improve how novel annotation events can be defined is by 
being more selective in how a PSM and, by extension, the identified peptide is defined 
as known or novel prior to peptide clustering and inference. This approach would 
further improve the discrimination between true and false positives. Currently the Enosi 
tool simply identifies a peptide as known by parsing the known proteome coordinates, 
with all peptides not identified considered as novel. This, like the peptide linkage 
distance, is overly simplistic in its approach. In many instances a spectrum matches the 
proteogenomics search space as well as the known search space due to overlap with 
their respective genomic coordinates, particularly in the combined FDR approach, 
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which makes the search space redundant and reduces sensitivity when applying PSM 
FDR to all known and novel results. The ‘conservative’ two-stage FDR approach 
applied from the study in [474], and examined in detail in Chapter 6, goes to the other 
extreme by completely removing any PSMs identified as known. These problems were 
addressed in this thesis with the improved two-stage FDR strategy, by creating separate 
known and novel search spaces prior to PSM FDR filtering. However, even though this 
was appropriately addressed, there are still a number of spectra which can match both 
the novel and known search spaces and which can be further confounded when the 
search performed by Enosi accepts the top 10 matches, increasing the potential overlap 
between known and novel identifications. 
To further differentiate the novel and known PSMs, the results between the 
known identifications and novel identifications could be compared. Any PSMs 
identified in one search space which have a lower spectral E-value compared to the 
corresponding PSM in the other search space should be retained, while the other PSM is 
discarded. In cases where the spectral E-value is identical in both novel and known 
search spaces, both PSMs should be discarded to avoid ambiguous identifications. This 
method to utilize the spectral E-value provides a convincing approach, as the spectral E-
value is independent of the database size and would allow a simple comparison between 
the likelihood of one spectral interpretation over another. 
6) Increase stringency and specificity at cost of sensitivity 
Lacking the means to apply any other methodology improvements as has been detailed 
elsewhere, an alternative means to reduce the incidence of false positives could be 
achieved by applying much higher stringencies on the quality of the MS/MS spectra by 
only using large clustered MS/MS spectral datasets which could tolerate quality filtering 
at the highest stringencies to reduce false positive rates. In addition, only the highest of 
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event thresholds with the higher event probability (>99.9%) with ≥2 unique peptides per 
peptide cluster could be accepted across all annotation event types. Another approach 
could be to increase the stringency at the PSM level by using a PSM FDR lower than 
1% or by filtering the search results directly using a spectral E-value, which would be 
more suitable for smaller genomes [492]. Multiple different PSM level filtering 
methods could be integrated into Enosi to allow for more flexible approaches for 
filtering. Although these methods would significantly reduce the incidence of false 
positives, they may also negatively impact sensitivity with the loss of many real 
annotation events. The impact of increasing stringencies at the PSM level and/or 
annotation event level could be determined in future studies to ascertain acceptable 
thresholds across different studies using the best balance between sensitivity and 
specificity to achieve the lowest possible false positive rate. 
7) Defining further search spaces for refined control on FDR 
To improve control on FDR the final filtered peptide clusters and annotation events as 
well as the different types of annotation events need to have their boundaries well 
defined, then they can be used to split the proteogenomics search space based on their 
propensity for false positives, for example annotation events from intergenic spaces 
versus intragenic spaces. Referring back to point 1) above, by expanding on the 
repertoire of annotation event types the proteogenomics database could be further split 
into annotation event-specific sequences to define a search space for each annotation 
event and thus improve the identification rate of novel PSMs and the distinction 
between true and false positives. This approach would prove highly beneficial when 
using a higher diversity of proteomics and RNA-seq data. 
The idea to apply PSM FDR filtering on each of the different types of annotation 
events was first mentioned by Nesvizhskii [439], who suggested that each class of novel 
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PSM (i.e. novel PSMs belonging to different annotation event types), could have their 
class or annotation event-specific PSM FDR calculated. For example, the false positive 
rate of the novel gene and distal events, such as gene boundary, translated UTR and 
reverse strand, is much higher than other annotation event types. The number of false 
positives in the intergenic space for novel genes would be highest, and lower for 
translated UTR which is very close to the reference coding region. Furthermore, for 
proximal events the false positive rate would tend to be lower than novel gene and distal 
events, with novel exons and frame-shifts likely to have higher false positive rates than 
novel splice, which would be higher still, compared to exon boundary events. In 
consideration of these varying false positive rates, a multi-stage FDR strategy could be 
applied, as opposed to a two-stage FDR strategy which only implements FDR filtering 
on the known and entire novel search space. 
 Based on the above information, a correlation can be seen with the number of 
expected false positives within certain novel annotation events among the three 
categories of annotation events; novel gene, distal events, and proximal events, and the 
degree of change required for re-annotation. Further work could map the false positive 
rates of each annotation event in a range of different case studies and datasets with a 
variety of different genomic sizes. After improvements to the proteogenomics 
methodology, as previously envisioned, the annotation event FDR could be determined 
within a number of case studies and across the various types of annotation events. From 
such a study, a general rule could be deduced for an applied event probability for each 
annotation event type depending on the size of the genome (within a given range of 
magnitudes), allowing for more appropriate control on the proteogenomics analysis and 
to reduce the false identifications of annotation events and predictions in the future. A 
side-benefit afforded by applying PSM FDR filtering to each of the annotation events 
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would be a further reduction in the processing overhead for FDR filtering, which could 
be particularly advantageous when the datasets used in a study are particularly large. 
8) Improving proteogenomics throughput 
The analysis of large genomes in proteogenomics is often hampered by poor 
throughput, however a means around this issue would be the utilization of high-
performance computing (HPC) resources. There are currently two throughput 
bottlenecks in a proteogenomics workflow: 1) the MS/MS database search and 2) 
applying PSM FDR filtering and local FDR calculations on proteogenomics results. 
As was detailed in Section 2.4.2, a number of methods can be employed to 
improve the throughput of an MS/MS database search, with one such method being the 
splitting of the database into smaller parts, which is employed by the Enosi tool and 
which was employed throughout this thesis. Another method that could efficiently 
utilize HPC resources would be an MS/MS database search tool developed with 
Message Passing Interface (MPI), allowing for searches to be performed across multiple 
nodes in a cluster, such as MassMatrix [601]. However, the large majority of search 
tools, like MS-GF+ [292] and others, only use multi-threading, forcing the user to either 
split databases or use search tools with faster but less sensitivity algorithms, such as the 
sequence tag approach employed by InsPecT [326], and other approaches as highlighted 
in Section 2.4.2. Ultimately, this lack of broad support for MPI in the proteomics 
community relegates MPI to only specialty cases. 
To the best of the dissertation author’s knowledge there is no way to improve 
the throughput of PSM FDR filtering and local FDR calculation. However, by splitting 
the result file and processing each file separately the throughput can be improved at the 
cost of reduced PSM FDR accuracies and conversely to improve accuracies iterative 
searches can be applied to reduce the database size using the two-stage FDR strategy, at 
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the cost of throughput. Therefore, for this stage of the proteogenomics workflow, a 
trade-off between throughput and FDR accuracy needs to be decided, until more 
efficient algorithms are developed or which could possibly implement strategies 
utilizing MPI. 
9) Added functionality to proteogenomics 
Another viable improvement to proteogenomics would be further functionality, by 
adding multiple other pre-processing, post-processing and analysis tools to the 
workflow. For example, PGTools [496] has multiple functionality, such as: 1) allowing 
switching between proteomics- and proteogenomics-only analysis; 2) merging multiple 
search results from multiple search tools to improve sensitivity; 3) a file conversion 
module for handling conversion of multiple spectral data formats into MGF format for 
processing; 4) visualization modules for the generation of Venn diagrams to display 
unique and overlapping peptides; 5) chromosome distribution and Circos plots of 
identified mapped novel peptides; 6) the generation of a treemap to show protein 
grouping; 7) protein annotation; 8) customization of genome databases to suit the type 
of analysis; 9) the ability to port into genome browsers such as the UCSC Genome 
Browser and IGV; and finally 10) generating a summary report. 
These types of additional functions could be integrated into tools, like Enosi, by 
the developers or more easily and much more quickly added by the user with little or no 
assistance by a developer, within a workflow environment such as Yabi, previously 
discussed in Section 2.5. Yabi could run an entire proteogenomics or proteomics 
workflow from beginning to end, with multiple branching inputs and outputs, allowing 
for very powerful workflows that could run on HPC resources. 
Other tools which could be utilized in a workflow environment to enable further 
functionality for proteogenomics and proteomics analysis include pre-processing tools 
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for deconvolution, such as Zscore [293], deisotoping, such as LASSO [294], quality 
filtering, such as PepNovo [302] and/or clustering, such as MS-Cluster [312]. In 
addition, post-processing tools to automate the filtering of annotation events using 
additional information, such as was manually conducted throughout this thesis, as well 
as further post-processing tools such as Cytoscape [602] and STRING [603] for 
functional protein-protein interaction studies, and functional annotation analysis using 
tools like DAVID [604] and AutoFACT [139], could process the final gene and protein 
products for further genomic annotation. 
10) Post-proteogenomics: Integration of multi-stage peptide identification 
In addition, methodologies such as the multi-stage peptide identification strategy [426], 
could also be integrated into such workflow environments. The use of multi-stage 
peptide identification was outlined previously in Section 2.3.9, and aims to assign each 
and every spectrum to a peptide, by iteratively searching conventional databases, 
spectral libraries, identifying common post-translational modifications (PTMs) through 
a “blind” search and finally any remaining unassigned MS/MS spectra searched against 
a translated genome database, as is done in proteogenomics analysis. This method is 
akin to the ‘conservative’ two-stage FDR strategy [474], which was outlined and 
compared in Section 6.3.4, identifying its pitfalls and as previously discussed in terms 
of the ambiguities which can result with the overlap between MS/MS spectra identified 
as both known and novel.  
A modification to the above mentioned multi-stage peptide identification 
strategy could be to first apply a proteogenomics analysis (with splice graph if 
applicable) using the methodologies demonstrated within this thesis, as well as the 
above suggested improvements, followed by gene prediction and validation. Following 
this strategy, any unassigned MS/MS spectra not matching the known proteome or 
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leading to an annotation event, which identified a new or improved gene prediction, 
could then be used in multi-stage peptide identification. This strategy could identify 
further peptide sequences and possibly their genomic coordinates; 1) with unaccounted 
for PTMs; 2) from different database; 3) identified from raw translated reads or 
transcripts de novo assembled from any un-aligned RNA-seq reads not included in the 
initial splice graph; and 4) spectral libraries. Any remaining spectra, by process of 
elimination, may likely be false positives due to poor quality/partial fragmentation. The 
unassigned MS/MS spectra, which would now be accounted for and identified, could 
then re-enter the proteogenomics analysis, with new considerations for adding 
additional PTMs and/or further sequences such as missing genomic regions, splicing 
regions from RNA-seq evidence or derived from particularly small ORFs in the six-
frame translation, missed in the first proteogenomics run. A strategy of this nature could 
be implemented within a workflow environment, such as Yabi, which would enable the 
user to capture meta-data, share workflows and parameters with other collaborators to 
assist within large national or international research efforts. 
11) Integration of ortho-, meta and comparative proteogenomics 
Another improvement to proteogenomics could be an automated approach towards 
applying comparative proteogenomics [446, 448], ortho-proteogenomics [79, 445] and 
metaproteogenomics [503], previously discussed in Section 2.4.3. In comparative 
proteogenomics, given two or more closely related species with proteomics, genomics 
and transcriptomic datasets for each, the identification of annotation events could be 
validated in each of the parallel analyses within the same genomic coordinates. Such an 
approach could help confirm that the identification is real, particularly for single peptide 
annotation events, often referred to as “one-hit-wonders”, which would also do away 




Although the use of event probabilities is touted as a viable solution to salvaging 
single hit peptides for the identification of proximal events [82], the most appropriate 
thresholds needed to be applied to the various annotation events to achieve a high level 
of sensitivity and specificity while keeping the false positive rate low is still unclear. A 
more direct form of validation with the use of two or more confirmed annotation events 
in similar parallel comparative proteogenomics analyses could resolve the ambiguities. 
In ortho-proteogenomics any identifications from a single proteogenomics study 
could be used to further identify genes and proteins in other highly similar genomes [79, 
445], which was highlighted with a few examples in the bacterial study from Chapter 4, 
particularly for the frame-shift event identified in Section 4.3.10. 
Given the complexity of higher eukaryotes, analyses such as these using 
comparative proteogenomics may only be viable for closely related species of bacteria, 
or sub-species or different varieties of higher eukaryotes, which may only differ with 
subtle variations in sequence. Such an approach could be automated to perform analyses 
across different proteogenomics runs in a workflow environment, which when 
comparing the analyses could apply a scoring scheme for the identification of 
annotation events across species. Such an approach would vastly improve sensitivity 
and resolve ambiguous annotation events, as well as fast-track analysis. 
In metaproteogenomics, since many of the species within the bacterial 
communities are likely unknown, an initial step towards a comprehensive analysis could 
be a metaproteomics step for identification of suspected known proteins in the sample 
already represented in public repositories such as GenBank. Through the 
proteogenomics pipeline, these identified MS/MS spectra could then be searched 
against the six-frame translation of the metagenome, mapped, genomic coordinates 
determined, peptides clustered and novel gene events inferred. All the identified novel 
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protein-coding regions could then be annotated and gene models predicted, followed 
with functional annotation based on comparative genomics analysis. The full set of 
MS/MS spectra and the now identified “known” proteome could then be used during a 
full and more thorough metaproteogenomics analysis of the metagenome using the two-
pass approach with improved two-stage FDR strategy, as outlined within this thesis, and 
with potentially some additional improvements suggested throughout this chapter. 
Given sufficient depth of metagenome sequencing, coverage and assembly, the 
identification of unique peptides within a metaproteogenomics analysis would likely 
indicate the identification of proteins unique to a particular bacterial species, and which 
may indicate a unique role within the bacterial community. 
8.2.3 Application of new MS technologies 
Up until now, much has been discussed on how to improve upon the current 
implemented methodologies for proteogenomics, with adjustments to already 
established methods, inherited from developments in proteomics over the last few 
decades. Many of these methods are reflected in the proteogenomics tools listed in 
Section 2.4.4. A quick PubMed search reveals an explosion of new proteogenomics 
tools within the last 12 months of this thesis, all with slight variations compared to the 
Enosi tool used throughout this thesis, which provides a good indication that the future 
of proteogenomics will evolve more rapidly with time. However, there are three new 
technologies into which proteogenomics has yet to tap and predictably will evolve to 
become the gold standard in proteogenomics in the coming years. These tools are: top-
down proteomics, multiplexed data-independent acquisition (DIA) and spectral 
archives. 
 Top-down proteomics, as outlined previously in Section 2.3.2, would be suitable 
for complementing bottom-up proteomics, due to its limitation to provide global 
coverage but powerful ability to provide full coverage of a limited number of proteins, 
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including a full range of their PTMs, due to solubility and ionization problems with 
some large proteins. The technique has improved in throughput over the last decade 
making it a viable tool for large-scale studies, where it is important to identify the N-
terminal end of proteins and to identify sites of potential signal peptide cleavage and 
full coverage of PTMs. This makes the technology a suitable candidate for 
implementation into proteogenomics, allowing further coverage to infer many more 
annotation events both confidently and without ambiguity, resolving the protein 
inference problem, resolving multiple co-expressed protein isoforms, and identifying 
annotation events amongst other paralogous genes and proteins. There are not to the 
dissertation author’s knowledge, currently any proteogenomics tools or strategies 
available that utilize top-down proteomics data. Such tools would require algorithmic 
improvements for handling and interpreting the data, over traditional bottom-up 
approaches. As the mass spectrometry technology improves to generate, interpret and 
handle such data, this will become an important resource to complement current 
bottom-up proteogenomics approaches and in combination with approaches such as N-
terminomics [452]. 
 Multiplexed DIA, as outlined previous in Section 2.3.3, is another technology 
gaining much more traction in recent years, as the rate of technological advancement of 
mass spectrometry has improved, allowing for better speeds of data acquisition, 
interpretation and management. This technology allows for an unprecedented level of 
depth and breadth of coverage by considering all precursor ions (including multiple 
precursor ions from multiplexed MS/MS spectra) and their MS/MS spectra in a sample 
instead of pre-selecting the precursor ions in DDA. Multiplexed DIA also allows for all 
the data from the sample to be stored for further data mining without the need to re-
sample. By incorporating multiplexed DIA into proteogenomics, much more coverage 
would be attainable, and with sufficient control on FDR would allow much higher rates 
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of annotation event discovery. Coupling this technology with top-down proteomics 
would require reconsideration on proteogenomics algorithmic design to accommodate 
the data. This arrangement would ultimately provide near-complete coverage of the 
proteome for proteogenomics analysis, resolving ambiguities with assigning annotation 
events and significantly reducing the occurrence of annotation events with single 
peptides, as well as resolving ambiguities when trying to identify TIS sites. 
 Spectral archives, as outlined previously in Section 2.3.8, is another technology 
that promises to change the landscape for spectral interpretation in MS-based 
proteomics completely, and predictably will have wide sweeping implications for 
proteogenomics in the years to come. In essence, the use of spectral archives would 
allow a higher level of specificity in identification and also discrimination between 
known and novel spectra by matching to a large archive of clustered spectra, both 
identified and unknown. Each spectrum in the archive would improve and be further 
validated each time further spectra are added. This level of enhancement would 
eliminate the ambiguity of assigning matches, since a SSM compared to a PSM, 
provides a much higher sensitivity and specificity. Any spectra from a proteogenomics 
study could contribute to the archive and in return the archive could assist with 
validating known proteins and identifying novel annotation events with confidence. The 
spectral archive would also remove the need to cross-validate matches against curated 
protein databases, as performed manually throughout this thesis, which was identified as 
an important consideration when performing proteogenomics analysis [439]. 
 A possible method which could be used to integrate spectral archives with 
proteogenomics, to identify the type of annotation events and their genomic locations, 
would be to first cluster the spectra by adding it to the spectral archive and contribute 
towards the growing archive. Following this step, sequences from the stop-to-stop 
ORFs of the six-frame genomic translation and sequences from a splice graph could be 
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split into known and novel sequences, based on the known reference annotation. The set 
of known and novel sequences could then be digested in silico to peptide sequences, 
based on different proteases and cleavage specificities and converted into simulated 
spectra using tools such as Mspire [605], all the while keeping track of their genomic 
coordinates. The known simulated spectra derived from the reference annotation could 
be validated against the spectral archive, to see if it matches only known spectra 
identified as belonging to a curated protein within the same genomic coordinates. The 
novel simulated spectra derived from the novel search space could be validated against 
the spectral archive to determine if they happen to match any known spectra already 
identified from a curated protein or un-identified spectra currently not assigned any 
annotation to validate its novelty. All the SSMs could be processed by the 
proteogenomics pipeline with both the identified novel and known spectra (with any 
PTMs) interpreted back into peptide sequences with retained genomic coordinates. The 
peptide sequences could then be clustered and annotation events inferred in context to 
the reference annotation. 
This approach is in contrast to previous methods of spectral identification, as the 
query and target have been inverted during the search stage. However, using this 
approach can provide an unparalleled level of specificity and sensitivity and, if event 
probabilities could be incorporated, the large spectral support provided by the spectral 
archive could be leveraged to improve the discrimination between true and false 
positive annotation events further, with few or no ambiguous annotation events. 
Overall, there is much promise for proteogenomics moving forward, with many 
possible approaches in its application, or a combination of approaches, such as the latest 
considerations with top-down proteomics, multiplexed DIA and spectral archives, to 
truly bring proteogenomics on a par with the latest next generation sequencing 
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technologies. The time when proteogenomics will herald the extinction of the non-
model organism is fast approaching [3]. 
8.2.4 Guidelines for proteogenomics 
To bring proteogenomics into the future, based on the findings from this thesis, some or 
all of the following seven points (Figure 8.1), should be considered in order to better 
contribute to genome annotation efforts: 
1) The use of the latest “next-generation” fast, accurate and sensitive MS/MS search 
tools such as MS-GF+ [407] should be used, or improved proteogenomics 
approaches utilizing multiplexed-DIA spectra and associated search tools, top-down 
proteomics methods and/or highly specific approaches, such as spectral library 
searching e.g. with tools like Tremolo [397] or the spectral archives approach [398, 
399]. In addition, these tools should include methods to improve throughput, such as 
multi-threading and/or MPI support. 
2) The workflow should include a two-pass search approach using significant matches 
in the second-pass and some form of two-stage PSM FDR for the known and then 
all novel sequences. Alternatively, multi-stage PSM FDR to the known sequences 
and then novel sequence from each annotation event type (novel annotation event-
specific PSM FDR) could be applied. To improve the discrimination between the 
known and novel identifications, a probabilistic approach that is independent of the 
database (e.g. spectral E-value) should be used. 
3) Regardless of the proteogenomics approach adopted, to improve the rate and 
accuracy of the assignment of annotation events the workflow should accurately 
cluster peptides using all identified peptides and use of a dynamically and machine-
learned peptide linkage distance, considering other evidence. Peptide clusters should 
have known peptides removed and the novel peptide clusters should be filtered to 
remove any ambiguity introduced from incorrectly clustered peptides, based on 
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other evidence, such as the frame of the majority of peptides within exon/CDS and 
ORF(s). These steps would achieve consistency and reduce ambiguity across all 
identified peptides and annotation events. 
4) In any proteogenomics approach there should be a very broad variety of novel 
annotation event types to account for all different types of search spaces that have 
varying levels of false positive rates. Not only those annotation event types 
identified by Enosi throughout this thesis, but also annotation events such as over-
predicted genes, NME, signal peptides, expressed pseudogenes, expressed non-
coding RNAs, and variants such as insertions, deletions and mutations. Only then 
can better control be applied to the false positive rate throughout the analysis, as 
each annotation event will have its own specific false positive rate. 
5) The identified genomic and RNA-seq derived sequences from the different novel 
annotation events should then feed back into point 2) above, to define the novel 
annotation event-specific search space to apply an annotation event-specific PSM 
FDR and/or apply filtering with unique peptide parsimony and event probability 
thresholds with an annotation event level FDR determined for each annotation event 
type. 
6) After the annotation events have been accepted from point 5) above, they should be 
further filtered for any incorrectly included overlapping peptide clusters, to keep the 
applied thresholds consistent and unambiguous at both the peptide and annotation 
event level, which could otherwise lead to false positive annotation events and 
predictions. 
7)  Finally, heuristic methods of gene prediction, such as Augustus should be used to 
improve the predictions given the proteogenomics evidence as well as any other 
orthogonal evidence. The predictions should be annotated and validated through a 
variety of means, such as an automated annotation pipeline as well as through ‘wet’ 
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lab validation. Any unassigned spectra could be validated through a modified 
template proteogenomics approach and/or a multi-stage peptide identification 
strategy to be identified in a second adjusted run of the proteogenomics pipeline to 
cater for the missed PSMs. All identified predicted novel and modified gene 
products should assist with the identification of orthologous genes in closely related 
species, where applicable, in an ortho-proteogenomics approach. In addition, the 
whole proteogenomics run could be performed in parallel with a closely related 
species, where applicable, with a cross-validation of identified annotation events 
and novel PSMs to improve sensitivity and specificity. Additionally, filtering 
stringencies at the PSM level and annotation event level should be optimized to 
reduce false positives and any identified peptides that were not incorporated into 
validated gene predictions should be investigated to see how to further improve the 
methods employed within points 1) through 6). 
Figure 8.1 Seven guidelines for proteogenomics 
 
8.3 CONCLUSIONS 
This thesis identified and developed a bioinformatics framework for proteogenomics, 
defined within a new methodology, which was demonstrated in a number of case 
studies through which its viability was tested. A number of caveats were identified as 
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the methodology was implemented and, as a result, the methodology evolved through a 
series of modifications and future improvements. In addition, significant contributions 
were made towards the genomic annotations of bacteria, grape, human and wheat, 
highlighting important discoveries and caveats. Overall, the thesis identifies and brings 
to light considerations for future proteogenomics strategies, by suggesting the 
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Appendix Figure 4.1 Pre and post clustering with and without PepNovo quality filtering 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 
filtering. (E) Total number of PSMs after 1% PSM FDR filtering.  
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Appendix Figure 4.2 Precursor mass tolerance optimisation 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 





Appendix Figure 4.3 Gene boundary of blr2146 or novel gene 
The gene blr2146 had a gene boundary event, while the study in [502], Prodigal and RAST suggested a 






Appendix Figure 4.4 High confidence novel gene annotation 







Appendix Figure 4.5 Exon boundaries of gene bll2019 and bll2380. 
(A) The gene bll2019 (NolA) had an exon boundary event, in agreement with the study from [502]. RAST 
did not predict bll2019, resulting in a novel gene event, while Prodigal predicted bll2019, and is in 
agreement with the exon boundary annotation event. (B) The gene bll2380 had an exon boundary event, 
which was in agreement with the study from [502],  RAST annotation and Prodigal predictions. 
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Appendix Figure 4.6 Gene boundary annotation 
The gene bll0794 (PhoH) and bll0795 both had gene boundary annotations. The evidence from known 
peptides, suggested a gene extension to bll0794, however there was no supporting evidence from the 






Appendix Figure 4.7 Known peptide mapping to blr0594 (trxA) 
The unique peptide “TIIDQGNGAAGPAAADLIK” mapped to gene blr0594 (trxA). The study from 
[502] identified the unique peptide as being N-terminal acetylated indicating an alternative translated 
initiation start (TIS) site. However, according to the MS-GF+ search results in this study, the peptide was 













Appendix Figure 4.8 Supporting MS/MS spectra for reverse strand or novel gene event 
Sixteen MS/MS spectra (A-P) supporting the eight novel peptides annotating the reverse strand or novel 













Appendix Figure 4.9 Supporting MS/MS spectra for exon boundary and frame-shift annotation 
event or sequencing error 
Three MS/MS spectra (A-C) supporting the novel peptide annotating the exon boundary and frame-shift 







Appendix Figure 4.10 Supporting MS/MS spectra for gene boundary or novel gene annotation 
event 
Three MS/MS spectra (A-C) supporting the three novel peptides annotating the gene boundary event of 

















Appendix Figure 4.11 Supporting MS/MS spectra for a novel gene event 
Eleven MS/MS spectra (A-K) supporting the seven novel peptides annotating a novel gene event 





Appendix Figure 4.12 Supporting MS/MS spectra for exon boundary event of gene bll2019 (NoIA) 
Three MS/MS spectra (A-C) supporting the novel peptide annotating the exon boundary event of bll2019 












Appendix Figure 4.13 Supporting MS/MS spectra for exon boundary event of gene bll2380 
Fourteen MS/MS spectra (A-N) supporting the four novel peptides annotating the exon boundary event of 
bll2380 illustrated in Appendix Figure 4.5B. 
Appendix Figure 4.14 Supporting MS/MS spectrum for gene boundary event of gene bll0794 
(PhoH) 
One MS/MS spectrum supporting the novel peptide annotating the gene boundary event of bll0794 
(PhoH) illustrated in Appendix Figure 4.6. 
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Appendix Figure 4.15 Supporting MS/MS spectrum for peptide “TIIDQGNGAAGPAAADLIK”, 
indicating no N-terminal acetylation 
One MS/MS spectrum supporting a known peptide with no N-terminal acetylation, in contrast to the 
study from [502], illustrated in Appendix Figure 4.7. 
 
Appendix File 5.1 Reference predictions are in zip file ‘AppendixFile5.1.zip’ on the DVD provided. 
Appendix File 5.2 Clustering, quality filtering and precursor mass tolerance optimization results 
are in excel file ‘AppendixFile5.2.xlsx’ on the DVD provided. 
Appendix File 5.3 Processed proteogenomics results are in excel file ‘AppendixFile5.3.xlsx’ on the 
DVD provided. 
Appendix File 5.4 Raw proteogenomics results are in zip file ‘AppendixFile5.4.zip’ on the DVD 
provided. 
Appendix File 5.5 Augustus gene predictions are in zip file ‘AppendixFile5.5.zip’ on the DVD 
provided. 
Appendix File 5.6 Augustus gene predictions with incorporated novel peptides are in excel file 
‘AppendixFile5.6.xlsx’ on the DVD provided. 
Appendix File 5.7 NetGene2 splice site prediction results are in zip file ‘AppendixFile5.7.zip’ on the 
DVD provided. 





Appendix Figure 5.1 Pre and post clustering with and without PepNovo quality filtering 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 





Appendix Figure 5.2 Precursor mass tolerance optimisation 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 
filtering. (C) Peptide FDR at equivalent 1% PSM FDR across precursor mass tolerances. 
 
Appendix Figure 5.3 Supporting MS/MS spectra for a novel gene event 








Appendix Figure 5.4 Supporting MS/MS spectra for a novel gene annotation misidentified as a 
reverse strand event 
Eight MS/MS spectra (A-H) supporting novel peptides annotating a novel gene event via a reverse strand 










Appendix Figure 5.5 Supporting MS/MS spectra for a gene boundary annotation event 
Thirteen MS/MS spectra (A-M) supporting novel peptides annotating a gene boundary event illustrated, 
in Figure 5.3. 
Appendix Figure 5.6 Supporting MS/MS spectra for a novel gene annotation via a reverse strand 
annotation event 
Two MS/MS spectra (A-B) supporting novel peptides annotating a novel gene event via a reverse strand 












Appendix Figure 5.7 Supporting MS/MS spectra for a translated UTR annotation event 







Appendix Figure 5.8 Supporting MS/MS spectra for a translated UTR annotation event 
Nine representative MS/MS spectra (A-I; from a total of 90), supporting novel peptides annotating a 




Appendix Figure 5.9 Supporting MS/MS spectra for a novel splice annotation event 




Appendix Figure 5.10 Supporting MS/MS spectra for an exon boundary annotation event 
Five representative MS/MS spectra (A-E; from a total of 59) supporting novel peptides annotating an 






Appendix Figure 5.11 Supporting MS/MS spectra for an exon boundary annotation event 
Twelve MS/MS spectra (A-L) supporting novel peptides annotating an exon boundary event, illustrated 
in Figure 5.8. 
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Appendix Figure 5.12 Supporting MS/MS spectra for a frame-shift annotation event 










Appendix Figure 5.13 Supporting MS/MS spectra for a novel exon annotation event 




Appendix Figure 5.14 Supporting MS/MS spectrum for a N-terminal acetylated peptide suggesting 
a conflict with the reference annotation 
A single MS/MS spectrum supporting an N-terminal acetylated peptide in a known reference protein, 






Appendix Figure 5.15 Supporting MS/MS spectra for an N-terminal acetylated peptide suggesting a 
conflict with the reference annotation 
Seven MS/MS spectra (A-G) supporting an N-terminal acetylated peptide in a known reference protein, 
illustrated in Figure 5.12. 
 
Appendix Figure 5.16 Supporting MS/MS spectrum for an N-terminal acetylated peptide 
suggesting a conflict with the reference annotation 
A single MS/MS spectrum supporting an N-terminal acetylated peptide in a known reference protein, 
illustrated in Figure 5.13. 
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Appendix Figure 5.17 Supporting MS/MS spectra for an N-terminal acetylated peptide suggesting a 
conflict with the reference annotation 
Five representative MS/MS spectra (A-E; from a total of 23), supporting a N-terminal acetylated peptide 
in a known reference protein, illustrated in Figure 5.14. 
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Appendix Figure 5.18 Supporting MS/MS spectra for an N-terminal acetylated peptide suggesting a 
conflict with the reference annotation 
Two MS/MS spectra (A-B) supporting an N-terminal acetylated peptide in a known reference protein, 
illustrated in Figure 5.15. 
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Appendix Figure 6.1 Pre and post clustering with and without PepNovo quality filtering 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 
filtering. (E) Total number of PSMs after 1% PSM FDR filtering. 
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Appendix Figure 6.2 Precursor mass tolerance optimisation 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 






Appendix Figure 6.3 Supporting MS/MS spectra for a novel gene event 




Appendix Figure 6.4 Supporting MS/MS spectra for a gene boundary and novel exon annotation 
events 
Three MS/MS spectra (A-C) supporting novel peptides annotating a gene boundary and novel exon 
events, illustrated in Figure 6.3. 
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Appendix Figure 6.5 Supporting MS/MS spectra for a reverse strand annotation event and 
erroneously included frame-shift annotation event 
Three MS/MS spectra (A-C) supporting novel peptides annotating a reverse strand event, and a likely 
erroneous frame-shift event from peptide “KMMTAVVFLK”, with its lower intensity MS/MS spectrum, 
illustrated in Figure 6.4. 
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Appendix Figure 6.6 Supporting MS/MS spectrum for an exon boundary and translated UTR 
annotation event 
A single MS/MS spectrum supporting a novel peptide annotating an exon boundary and translated UTR 
event, illustrated in Figure 6.5. 
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Appendix Figure 6.7 Supporting MS/MS spectrum for a novel and unique N-terminal acetylated 
peptide 
A single MS/MS spectrum supporting a novel and unique N-terminal acetylated peptide, identified in a 




Appendix Figure 6.8 Supporting MS/MS spectrum for a novel and unique N-terminal acetylated 
peptide 
A single MS/MS spectrum supporting a novel and unique N-terminal acetylated peptide, identified in a 
gene boundary and reverse strand event, and which was incorporated into an Augustus gene prediction. 
Appendix Figure 6.9 Supporting MS/MS spectra for a novel and shared N-terminal acetylated 
peptide 
Two MS/MS spectra supporting a novel and shared N-terminal acetylated peptide, identified in a gene 
boundary and reverse strand event, which was not incorporated into the Augustus gene prediction at that 






Appendix File 7.1 Reference predictions are in zip file ‘AppendixFile7.1.zip’ on the DVD provided. 
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are in excel file ‘AppendixFile7.2.xlsx’ on the DVD provided. 
Appendix File 7.3 Processed proteogenomics results are in excel file ‘AppendixFile7.3.xlsx’ on the 
DVD provided. 
Appendix File 7.4 Raw proteogenomics results are in zip file ‘AppendixFile7.4.zip’ on the DVD 
provided. 
Appendix File 7.5 Augustus gene predictions are in zip file ‘AppendixFile7.5.zip’ on the DVD 
provided. 
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Appendix Figure 7.1 Pre and post PepNovo quality filtering for trypsin-digested wheat flour 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 





Appendix Figure 7.2 Pre and post PepNovo quality filtering for chymotrypsin-digested wheat flour 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 
filtering. (E) Total number of PSMs after 1% PSM FDR filtering. 
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Appendix Figure 7.3 Pre and post PepNovo quality filtering for thermolysin-digested wheat flour 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 
filtering. (E) Total number of PSMs after 1% PSM FDR filtering. 
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Appendix Figure 7.4 Pre and post PepNovo quality filtering for trypsin-digested meiotic tissue 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 
filtering. (E) Total number of PSMs after 1% PSM FDR filtering. 
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Appendix Figure 7.5 Pre and post PepNovo quality filtering for AspN-digested meiotic tissue 
(A) Total spectral counts independent of database search. (B) Peptide FDR at equivalent 1% PSM FDR. 
(C) Protein FDR at equivalent 1% PSM FDR. (D) Total number of unique peptides after 1% PSM FDR 
filtering. (E) Total number of PSMs after 1% PSM FDR filtering. 
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Appendix Figure 7.6 Precursor mass tolerance optimisation for trypsin-digested wheat flour 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 
filtering. (C) Peptide FDR at equivalent 1% PSM FDR across precursor mass tolerances. 
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Appendix Figure 7.7 Precursor mass tolerance optimisation for chymotrypsin-digested wheat flour 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 
filtering. (C) Peptide FDR at equivalent 1% PSM FDR across precursor mass tolerances. 
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Appendix Figure 7.8 Precursor mass tolerance optimisation for thermolysin-digested wheat flour 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 
filtering. (C) Peptide FDR at equivalent 1% PSM FDR across precursor mass tolerances. 
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Appendix Figure 7.9 Precursor mass tolerance optimisation for trypsin-digested meiotic tissue 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 
filtering. (C) Peptide FDR at equivalent 1% PSM FDR across precursor mass tolerances. 
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Appendix Figure 7.10 Precursor mass tolerance optimisation for AspN-digested meiotic tissue 
(A) Total number of PSMs before 1% PSM FDR filtering. (B) Total number of PSMs after 1% PSM FDR 









Appendix Figure 7.11 Supporting MS/MS spectra for a novel gene annotation event 
Fourteen representative MS/MS spectra (A-N; from a total of 24), supporting novel peptides annotating a 















Appendix Figure 7.12 Supporting MS/MS spectra for a novel gene annotation misidentified as a 
gene boundary annotation event 
Twenty-five representative MS/MS spectra (A-Y; from a total of 50) supporting novel peptides annotating 
a gene boundary event, which was actually a novel gene annotation, illustrated in Figure 7.2. 
Appendix Figure 7.13 Supporting MS/MS spectra for a reverse strand annotation event 
















Appendix Figure 7.14 Supporting MS/MS spectra for an exon boundary annotation via a translated 
UTR annotation event 
Twenty-five representative MS/MS spectra (A-Y; from a total of 34) supporting novel peptides annotating 
a translated UTR event, which was more likely an exon boundary annotation, illustrated in Figure 7.4. 
Appendix Figure 7.15 Supporting MS/MS spectra for an exon boundary annotation event 




Appendix Figure 7.16 Supporting MS/MS spectrum for a frame-shift annotation event 




Appendix Figure 7.17 Supporting MS/MS spectrum for a novel exon annotation event 
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